


























Thesis submitted for the degree of Doctor of Philosophy awarded by the 












 II  
Acknowledgements 
 
There are a number of people I wish to thank for their support during the completion of this 
thesis.  
 
First and foremost I thank my supervisors Dr Paul Ke ly and Dr Harry Olverman for their 
guidance and direction throughout the whole three yar PhD process. In particular I would 
like to thank Paul for his expert tuition in all practical aspects of the work completed in this 
thesis, as well as for his intellectual guidance and continual support. I also thank Harry for 
his expert advice about all things pharmacological and his enduring patience while teaching 
me all things mathematical. More importantly, I wish to thank them both for their friendship. 
 
I thank Dr Linda Ferrington who worked closely with me in many of the studies completed 
in this thesis. Her friendship and support during the completion of this thesis has been 
invaluable and her ability to keep me dancing until the early hours of the morning more than 
slightly unnerving. 
 
I also wish thank Dr Megan Holmes and Mrs Karen French for their expertise and help with 
the in situ hybridisation studies and Dr Paula Brunton for her advice on the use of 
immunoassays. 
 
I thank my Mam, Brian, Dad and Val for their support and encouragement. I also thank 
Kelly, Kris, Robyn and my all of my nephews and nieces for always managing to cheer me 
up when the going gets tough. So many good friends also deserve a special mention for 
being there for me over the last few years; Rachael, Eva, Fiona, John, Naomi, Kat and Davie 
to name a few.  
 
Finally, last but by no means least, I would like to thank Gregor who has provided 
unshakable support during the last couple of years. Thank you for keeping me calm and 
focused, especially during the last year. Your smile always manages to cheer me, even at the 




 III  
Declaration of Originality 
 
I declare that the composition of this thesis and the work presented herein is my own, unless 












































 IV  
Abstract 
 
The affective disorders (anxiety and depression) are common psychiatric disorders that 
primarily involve disturbances in mood and represent the second leading source of disease 
burden world-wide. A wide base of evidence supports a significant genetic contribution to 
these disorders. Polymorphic variation in the promoter region (5-HTTLPR) of the human 
serotonin transporter (hSERT) gene, which leads to a life-long alteration in serotonin 
transporter (SERT) expression and functioning, has been implicated in the aetiology of both 
anxiety and depression. Despite the strong evidence implicating a role for this polymorphism 
in affective psychopathology the underlying mechanism by which genetically determined 
SERT bioavailability influences affective functioning are not understood.  
 
In these studies I attempt to elucidate the alterations in cerebral, serotonin (5-HT) system and 
hypothalamo-pituitary-adrenal (HPA) axis functioning which may relate to the effect of the 
5-HTTLPR on affective functioning by characterising these parameters in an animal model 
of genetically increased SERT expression (hSERT over-expressing mice; hSERT OVR). 
Furthermore, as gender influences both the likelihood f developing affective disorders and 
the impact of the 5-HTTLPR on affective functioning, with a greater effect being observed in 
females than in males, we characterise these parameters in mice of both genders. 
 
The data presented in this thesis demonstrate that the life-long increase in SERT 
bioavailability present in hSERT OVR mice produces profound alterations in cerebral, 
serotonin system and HPA axis functioning. Furthermore, the influence of increased SERT 
expression upon cerebral and serotonin system functioning is greater in females than in 
males. Additionally, a number of sexually dimorphic variations in serotonin system 
functioning were identified. Thus this thesis extends the currently available information 
regarding the underlying mechanisms by which gender and a life-long alteration in SERT 
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MAPK   mitogen-activated protein kinase 
MDD   major depressive disorder 
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mPFC   medial prefrontal cortex 
MR   mineralocorticoid receptor 
MRN   median raphé nucleus 
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NA   noradrenaline 
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NO   nitric oxide 
 VIII  
NSB   non-specific binding 
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OD   optical density 
Paroxetine 3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4fluorophenyl)-piperidine 
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PD   panic disorder 
PTSD   post-traumatic stress disorder 
PKC   protein kinase C 
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SAD   social anxiety disorder 
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SERT   serotonin transporter 
SNAT   5-hydroxytryptamine N-acetyl transferase 
SNP   single nucleotide polymorphism 
SQ 2-DG  semi-quantitative 2-deoxyglucose autoradiography 
SSRI   selective serotonin reuptake inhibitor 
TB   total binding 
TCAs   tricyclic antidepressants 
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Chapter 1 – Introduction 
1. Affective disorders: Epidemiology and Aetiology  
 
Affective disorders are common psychiatric disorders that primarily involve disturbances in 
mood. They are a major cause of disability and represent the second largest source of global 
disease burden (Collier et al., 1996). The most comm n affective disorder major depressive 
disorder (MDD, or unipolar depression) has a lifetim  risk of between 15-20% in the general 
population with women having twice (~21%) the preval nce of men (~12%) (Blazer et al., 
1994; Fava abd Kendler, 2000). MDD is characterised by a major depressive episode lasting 
two or more weeks with symptoms such as depressed mood, anhedonia, disturbed sleep, 
inability to concentrate, psychomotor alterations ad suicidal thoughts. In contrast to MDD, 
bipolar disorder (BPD, manic depression) is characterised by depressive episodes with 
intermittent periods of extreme elation, often accompanied by psychotic disturbances. The 
lifetime risk of BPD at approximately 1% is lower than that of MDD (Rees et al., 1997). The 
anxiety disorders (panic disorder (PD), social anxiety disorder (SAD), generalized anxiety 
disorder (GAD), obsessive-compulsive disorder (OCD) and post-traumatic stress disorder 
(PTSD)) which are characterised by excessive fearfulness are also common (~4% lifetime 
risk of any anxiety disorder). Again these disorders a e more prevalent in females than in 
males (~5% v ~2%) (Schuckit et al., 1997) and anxiety disorders also display a high level of 
co-morbidity with the depressive disorders being present in ~11% to ~65% of depressed 
patients (Pini et al., 1997). The dramatic impact of depressive and anxiety disorders on the 
individual sufferer, their families and society as  whole emphasises the importance of 
further elucidating the underlying neurobiology and physiology of these disorders in order to 
improve treatment and possibly develop prevention strategies. 
 
Although affective disorders are clinically heterogeneous with complex aetiologies there is 
considerable evidence in support of there being a significant genetic component in the 
development of these disorders. For example, studies have shown that the concordance of 
MDD between genetically identical,  monozygotic twins s around 50% (Oswald et al., 2004) 
and meta-analysis suggests that the overall heritability of MDD is approximately 33% 
(Sullivan et al., 2000). Genetic factors also appear to be important in BPD where data show a 
75-80% risk of developing the disorder in the co-twins of affected monozygotic twins, as 
compared to the 1% risk in the general population (Rees et al., 1997). Similarly, meta-
analysis of anxiety disorders indicates that their estimated heritability is approximately 40%-
50% (Hettema et al., 2001).  
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Genome-wide linkage surveys have only recently been applied to identify the chromosomal 
loci of the genes that are involved in depressive and nxiety disorders (Boomsa et al., 1999; 
Nash et al., 2004; Zubenko et al., 2003). However, as affective disorders are highly 
multigenic in their aetiology, with each gene contributing a relative small increase in the 
risk, the power of linkage analysis studies to detect g netic effects is limited. An alternative 
approach has been to use genetic association studies to investigate the possible role of 
genetic variants (polymorphisms) in affective disorders, and a number of these have been 
completed. Because of the proposed central role for the monoamines in affective functioning 
(Bunney Davis, 1965; Carlsson et al., 1969; Lapin and Oxencrug, 1969), these association 
studies have largely focused on polymorphisms present in those genes involved in the 
regulation of monoaminergic neurotransmission. To date a role for several monoaminergic-
related genetic polymorphisms have been identified in the aetiology of the affective 
disorders, but despite the high co-morbidity of anxiety and depressive disorders few studies 
have identified a role for the same genetic polymorphism in both of these disorder types. 
Nevertheless, there is compelling evidence in support of a role for polymorphic variation in 
the promoter region (5-HTTLPR) of the serotonin transporter gene, which leads to a life-
long alteration in serotonin transporter (SERT) expr ssion and function, in the aetiology of 
both anxiety and depressive disorders (see section 6.3). However, despite this strong 
evidence implicating the 5-HTTLPR in affective disorders, the exact mechanistic link 
between genetically-regulated SERT activity and affective functioning is not understood, but 
it is likely to involve changes to the central serotonergic system. 
 
In this thesis I have examined indices of activity in the central serotonin (5-HT) system and 
hypothalamo-pituitary-adrenal (HPA) axis in an animal model of genetically increased 
SERT function. The meaningful interpretation of these data in relation to the effect that the 
5-HTTLPR may have upon on affective function in the uman brain requires a sound 
understanding of the anatomy of the central 5-HT system, the physiological and 
pharmacological processes of 5-HT neurotransmission, and the functional roles of 5-HT, 
with particular attention paid to the involvement of the 5-HT system in psychopathology and 






2. Neuroanatomy of Central Serotonergic System  
 
Twarog and Page (1953) were the first to detail the presence of 5-HT in the CNS, noting also 
that concentrations of 5-HT varied between different brain areas. The anatomical localisation 
of the cell bodies and terminal fields of 5-HT-contai ing neurones within the CNS (rat) was 
not detailed, however, until over 10 years later following the development of fluorescent 
histochemical techniques (Dahlstrom and Fuxe, 1964a,b; 1965). These original 
classifications identified nine discrete clusters (B1 to B9) of 5-HT-containing cell bodies in 
the raphé region of the midbrain and were found to be analogous to those previously 
identified some 54 years earlier by Ramon y Cajal (1911) as “large multipolar neurones with 
unknown projections”. It was later shown that the 5-HT system consisted of two 
subdivisions, with the most caudal groups of cells in the medulla (B1-B3) giving rise to 
axons that descend to innervate the ventral and dorsal horns and the lateral spinal cord, while 
the more rostral groupings in the dorsal and median raphé project to the forebrain (Ungerste, 
1971). More recently the anatomy of the 5-HT system has been more precisely characterised 
using both autoradiographic and immunohistochemical methods (Riad et al., 2001; 
Steinbusch et al., 1981) and these studies have indicate  that this neurotransmitter system 
represents the most expansive and complex neurochemi al system in the mammalian CNS.   
 
2.1 Ascending (Rostral) Serotonergic Projections  
 
Cell bodies of the rostrally-projecting 5-HT system are found in the dorsal (DRN; B6 and 
B7) and median raphé nuclei (MRN; B5 and B8), the caudal linear nucleus (CLN; B8) and 
group B9 (Jacobs and Azmitia, 1992; Tork 1990). Six ascending pathways from these nuclei 
innervate anatomically and functionally diverse regions of the forebrain, including many 
components of the limbic system. The DRN gives rise to four pathways (the arcuate, cortical, 
periventricular and forebrain tracts) whose targets include neocortex, basal ganglia, thalamic 
and hypothalamic nuclei, amygdala and the suprachiasmatic nucleus (SCN). Two pathways 
arise from the MRN (median raphé forebrain tract and raphé medial tract) that innervate the 
SCN, preoptic area, olfactory bulb, hippocampus, entopeduncular nucleus and the mamillary 
body. Despite its close proximity to the MRN the efferents of the CLN most closely match 
those of the DRN (Imai et al., 1986). Although the DRN and MRN each preferentially 
innervate different forebrain regions, their anatomical arrangement is such that most areas of 
the brain receive input from both. Moreover, it must also be noted that 5-HT neurones are 
highly collateralised which means that a single 5-HT neurone may innervate several 
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projection fields (Deolmos and Heimer, 1980; Vanderkooy and Hattori, 1980; Waterhouse et 
al., 1986) and this anatomical arrangement allows the potential for 5-HT neurones to co-
ordinate the activity of several functionally-relatd nuclei. In addition to the differences in 
the topographic distribution of innervation between the DRN and MRN the fibres arising 
from these two nuclei are also morphologically distinct. DRN (D) fibres have fine axons 
(<1µM diameter) with irregularly spaced varicosities that branch frequently, whereas, MRN 
(M) fibres are thin and have large spherical variscosities (typically 2-5µM diameter) (Kohler 
et al., 1980; Kosofsky and Molliver, 1987; Mamounas and Molliver, 1988; Mulligan and 
Tork, 1988). It is the ascending 5-HT systems arising from the DRN and MRN that are of 
primary interest in this thesis.  
 
 
Figure 1.1 Serotonin System Neuroanatomy F1 
 
Diagram illustrating the distribution of the major clusters of serotonergic neurones 
and pathways in the rat CNS. Ext. capsule= external capsule, N. caudate = caudate 
nucleus, Stria. term= stria terminalis, MFB= median forebrain bundle. (Derived from 







2.2 Descending (Caudal) Serotonin Projections  
 
5-HT cells with their cell bodies in the nucleus raphé pallidus (NRPa), nucleus raphé 
obscurus (NRO) and the nucleus raphé magnus (NRM), corresponding to B1,B2 and B3 
respectively, give rise to the descending 5-HT system (Dahlstrom and Fuxe, 1964). 5-HT 
fibres of the descending system innervate both sensory and motor nuclei of the autonomic 
system at every spinal level. A more detailed review of the descending system, however, is 
out-with the scope of this thesis as the involvement of these systems in the following studies 
is extremely limited. Jacobs and Azmitia (1992) provide a comprehensive review detailing 
descending serotonergic neuroanatomy. 
 
2.3 Afferent Innervation of Raphé Nuclei  
 
The activity of raphé neurones is modulated by a number of neurotransmitters and 
neuromodulatory peptides, and the raphé nuclei receiv  a range of afferent input from a 
number of other neurotransmitter systems. The most extensive innervation of the raphé 
nuclei, however, comes from the nuclei themselves. Thus, extensive connections have 
previously been shown to link the DRN, MRN and B9 cell groups to each other (Mosko et 
al., 1977; Stratford and Wirtshafter, 1988). Innervation of the raphé by the other 
monoaminergic neurotransmitter systems has also been found, with afferents from the locus 
coeruleus providing noradrenergic (NA) innervation (Aghajanian and Wang, 1977; Swanson 
and Hartman, 1975) and afferents from the substantia igra and ventral tegmental area 
(VTA) providing dopaminergic (DA) innervation to the raphé (Kalen et al., 1988; Lira et al., 
2003). These innervations provide neuroanatomical evidence of the reciprocal interactions 
that exist between 5-HT and the other neurotransmitter systems as all of these regions 
receive dense innervation from 5-HT raphé neurones. 
 
Interestingly, an increasing body of evidence suggests that the raphé receive functional 
afferent inputs from a number of other forebrain regions, including afferents from the medial 
prefrontal cortex (mPFC) (Peyron et al., 1998; Sesack et al., 1989). These afferents appear to 
activate GABAergic interneurones localised within the raphé resulting in the inhibition of 5-
HT neuronal firing (Hajos et al., 1999; Varga et al 2001; 2003). A similar mechanism of 
action has been proposed for afferent innervation of the raphé arising in the lateral habenula 




3. Serotonergic Neurotransmission  
 
3.1 Biosynthesis and Metabolism of Serotonin  
 
5-HT is synthesised in a two step reaction from the essential dietary amino acid L-tryptophan 
and availability of this amino acid is rate-limiting in 5-HT synthesis. L-tryptophan is 
transported across the blood brain barrier (BBB) by the large neutral amino acid carrier, 
responsible for the transport of all of the large neutral amino acids into the CNS (tyrosine, 
leucine, isoleucine, valine and phenylalanine). Competition between these amino acids for 
the transporter, therefore, determines L-trytophan availability in the CNS. In neurones the 5-
position of the indole ring of L-tryptophan is hydroxylated by the cytoplasmic enzyme 
tryptophan hydroxylase, which is specifically express d only in 5-HT neurones (Lovernberg 
et al., 1968). The resulting 5-hydroxytrytophan (5-HTP) from this reaction is then rapidly 
decarboxylated by non-specific L-aromatic amino acid decarboxylase, forming 5-HT.  
 
In most cells 5-HT is metabolised by monoamine oxidase (MAO) located on the 
mitochondrial outer membrane. MOA-A, one of two isoforms of the enzyme, deaminates 5-
HT to the intermediate 5-hydroxyindole acetaldehyde. This is then metabolised by NAD+-
sensitive aldehyde reductase to form the major metaboli e 5-hydroxyindole acetic acid (5-
HIAA). Further metabolism of 5-HIAA to 5-hydroxytryptanol can also occur, although this 
accounts for only 1% of 5-HT metabolite levels present in the brain (Cheifetz and Warsh, 
1980). Additionally, alternative metabolic pathways can result in the production of other 
neuroactive substances from 5-HT. For example, melatonin is synthesised from 5-HT in the 
pineal gland (Klein and Weller, 1970) and evidence also suggests that 5-HT may be 
biotransformed by cytochrome P450 resulting in the generation of nitric oxide (NO) 














Abbreviations: Monoamine oxidase (MAO), Aldehyde reductase (AR), Aldehyde 
dehydrogenase (ADH), 5-hydroxylindole 0-methyltransferase (HIOMT), 5-hydroxytryptamine 









3.2 Storage and Release  
 
Following neuronal synthesis, 5-HT from the cytoplasm is sequestered into terminal storage 
vesicles by the vesicular monoamine transporter (VMAT). Of the two VMAT isoforms 
(VMAT1 and VMAT2) VMAT2 is predominantly responsible for vesicular transport of all 
monoamines in the CNS, having similar affinities for NA, DA and 5-HT (Liu and Edwards, 
1997; Masson et al., 1999). Vesicular transport of 5-HT is driven by the electrochemical 
gradient created as a result of vesicular H+ ion uptake by an ATP-driven pump. In the 
process of 5-HT translocation two internalised H+ ions are exchanged for one molecule of 
cytoplasmic 5-HT by VMAT (Parsons, 2000; Schuldiner, 1994). Within the vesicle 5-HT is 
bound by a specific binding protein which increases the concentration of 5-HT that can be 
stored in the vesicle. 
 
The arrival of an action potential at the nerve terminal causes 5-HT release from vesicular 
stores by Ca2+-dependent exocytosis. A review of the molecular mechanisms of this process 
are out-with the scope of this thesis but several comprehensive reviews are available 
(Burgoyne and Cheek, 1995; Sollner, 2003). Once released into the extracellular space 5-HT 
activates a number of post-synaptic and pre-synaptic 5-HT receptors.  
 
3.3 Serotonin Receptors  
 
In 1957 Gaddum and Picarelli first identified two pharmacologically distinct 5-HT receptors, 
termed M and D, responsible for the 5-HT-induced contractile response of the guinea pig 
ileum. Over 20 years later subtypes of the 5-HT receptors were further confirmed using 
radioligand-binding studies (Peroutka and Snyder, 1979). The first attempt to classify 5-HT 
receptors was completed by Bradley et al. (1986) on the basis of receptor pharmacology and 
the functional responses elicited by the receptors. These studies led to the identification of 
three families of 5-HT receptor (5-HT1-3), comprising five distinct receptor binding sites. 
With some prescience the authors suggested that the future identification of other receptor 
subtypes was highly likely. Of the three families, the 5-HT1 receptor subtype were found to 
represent a heterogeneous group of receptors at which 5-HT displayed high affinity, while 5-
HT2 receptors were identified as being analogous to the D receptor and 5-HT3 receptors were 
analogous to the M receptor previously identified by Gaddum and Picarelli (1957).  
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Since this initial classification advances in radioligand-binding and molecular biological 
techniques have lead to the discovery of many more 5-HT receptor subtypes. At present 
these are classified into seven receptor families (5-HT1-7) compromising a total of 14 
structurally and pharmacologically distinct receptor subtypes (Hoyer et al., 2002). 
Comprehensive reviews of all known 5-HT receptor subtypes are available (Barnes and 
Sharp, 1999; Hoyer et al., 1994), and Table 1 provides a brief summary of the CNS 
distribution of each receptor subtype, its effector mechanism, behavioural functions and the 
neurochemical effects of receptor activation. A more detailed analysis of the pharmacology 
and function of every 5-HT receptor subtype is out with the scope of this thesis, but those 
receptors with a putative role in the psychopathology f affective disorders, namely 5-HT1A, 






Table 1.1 Serotonin Receptor Subtypes T1 
Overview of 5-HT receptor subtype localisation, behavioural functions and neurochemical effects. ↑indicates increased activity/availability whereas 
↓indicates decreased activity/availability. Abbreviations: AC: adenylate cyclase, Amyg: amygdala, Anx: anxiety, Caud: caudate, CTX: cortex, Cogn: 
cognitive, C.V: cardiovascular, Dep: depression, DS: dorsal subiculum, GP: globus Pallidus, GPCR: G-protein coupled receptor, HP: hippocampus, Hypo: 
hypothalamus, LGIC: ligand gated ion channel, Loco: locomotion, Migr: migraine, N.Acc: nucleus accumbens, PLC: phospholipase C, SCN: 
suprachiasmatic nucleus, SNR: substantia nigra pars reticulata, Thermo: thermoregulation. a denotes autoreceptor effect. Developed from (Barnes and 
Sharp, 1999; Bonaventure et al., 2007; Bonsi et al., 2007; Diaz-Mataix et al., 2005; Hirst et al., 2003; Matsuyama et al., 1997; Nelson, 2005).
Neurotransmitter Effects 
Receptor Mechanism CNS high density 
Behavioural 
Functions 5-HT NA ACh Glut DA GABA 
5-HT1A Raphé, HP, Septum, CTX 
Anx., Dep., Aggr., Loco., Thermo., 
Hyperphagia 
↓a ↑ ↑ ↓ ↑ ↓ 
5-HT1B SNR, GP, DS 
Anx., Dep., Aggr., Sex., Loco., Rotation, 
Hypophagia, Migr. 
↓a ↓ ↓ ↓  ↓ 
5-HT1D SNR, GP Anx., Dep., Migr. ↓
a   ↓  ↓ 




CTX, HP, Caud. Migr. Unknown, lack of selective ligands 
5-HT2A N.Acc., HP, CTX, Caud. 
Anx., Dep., Apetite, Thermo., Sleep, 
Hallucination ↓ ↓ ↓  ↓ ↓ 
5-HT2B CTX, Sept, Amyg., Hypo. Anx.       
5-HT2C 
Choroid plexus, N.Acc., Amyg., 
HP 




HP Unknown, lack of selective ligands 
5-HT3 LGIC 
Entorhinal CTX,  
Dorsal Vagal Complex 




HP, Colliculi, Mesolimbic, 
Nigrostriatal 








Thal., Hypo., Amyg., SCN 
Anx., Dep., Learning and Memory, 
Circadian rhythm, Sleep ↓  ↓    
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3.4 5-HT1 Receptor Family  
 
The 5-HT1 receptor family consists of five receptors subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-
HT1E and 5-HT1F) defined by their high degree of amino acid sequence homology. All of 
these receptors are G-protein coupled receptors (GPCRs) that couple negatively to adenylate 
cyclase (AC) via pertussis toxin-sensitive G-proteins (Gi/Go). Therefore, activation of these 
receptors results in decreased intracellular cyclic adenosine-3’,5’-monophosphate (cAMP) 
levels. 
 
3.4.1 5-HT1A Receptors  
 
Following identification of two distinct 5-HT1 binding sites, termed 5-HT1A and 5-HT1B 
(Middlemiss and Fozard, 1983; Pedigo et al., 1981), understanding of the pharmacology and 
function of the 5-HT1A receptor subtype progressed quickly due in no small part to the 
development of the selective 5-HT1A agonist 8-OH-DPAT and synthesis of its tritiated 
analogue ([3H]-8-OH-DPAT), although it is now apparent that 8-OH-DPAT also displays 
moderate affinity for the 5-HT7 receptor subtype (Lovernberg et al., 1968; Shen et al., 1993). 
A number of selective 5-HT1A antagonists, of which WAY 100,635 is the most selectiv , 
have also been developed (Johansson et al., 1997), and both radiolabelled [3H]-8-OH-DPAT 
and [3H]-WAY 100,635 have been used with autoradiographic imaging to map the 
distribution of the 5-HT1A receptor in the mammalian CNS (Castro et al., 2003; Khawaja, 
1995). The highest density of 5-HT1A binding sites are found in limbic brain regions, 
particularly in subregions of the hippocampus, the lat ral septum, cortical regions (including 
cingulate and entorhinal) and also the dorsal raphé. Lower levels are found in the median 
raphé, amygdala regions and some hypothalamic and thalamic nuclei. These findings have 
been replicated by in vivo binding studies in humans, primates and mice with few differences 
in the pattern of distribution reported between species (Farde et al., 1997; Laporte et al., 
1994; Pike et al., 1995).  
 
5-HT1A receptors are predominantly somatodendritic and they are located post-synaptically 
in forebrain areas receiving 5-HT projections and as autoreceptors on raphé 5-HT neurones 
(Kia et al., 1996; Miquel et al., 1991; Pompeiano et al., 1992). In forebrain regions 5-HT1A 
receptor expression has been detected in cortical pyramidal (glutamatergic) neurones, 
hippocampal granular and pyramidal (glutamatergic) neurones and cholinergic neurones in 
the septum (Burnet et al., 1995). 5-HT1A receptors are also expressed by corticotrophin 
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releasing factor-containing (CRF) neurones in the paraventricular nucleus (PVN) of the 
hypothalamus, an area which contributes to the regulation of neuroendocrine components of 
the stress response (see section 5.2).  In addition, 5-HT1A receptors are localised on 5-HT cell 
bodies and processes and GABAergic interneurones in the raphé (Day et al., 2004). The 
somatodendritic localisation of autoreceptors on 5-HT raphé neurones has been confirmed by 
the observation that levels of raphé 5-HT1A binding sites are maintained following 5,7-
dihydroxytryptamine (5,7-DHT) lesion, which is selectively neurotoxic to 5-HT nerve 
terminals (Radja et al., 1991). Activation of these somatodendritic 5-HT1A autoreceptors by 
extracellular 5-HT inhibits raphé efferents and leads to a reduction in the synaptic release of 
5-HT in the forebrain. In addition to this local mechanism of 5-HT1A-receptor-mediated 
negative feed-back on 5-HT neuronal activity, evidence also suggests that “long-loop” 
negative feed-back mechanisms exist that also involve the post-synaptic 5-HT1A receptor. 
For example, activation of post-synaptic 5-HT1A receptors in the medial prefrontal cortex is 
proposed to inhibit the activity of glutamatergic (excitatory) neurones which provide 
reciprocal, descending innervation of the raphé. Inhibition of this normally excitatory 
innervation of the raphé is proposed to result in decreased 5-HT neuronal activity (Celada et 
al., 2001; Hajos et al., 1999). 
 
In addition to their neuronal localisation there is al o evidence that 5-HT1A receptors are 
expressed by astroglial cells (Whitaker-Azmitia et al., 1993). At present the function of these 
glial 5-HT1A receptors is unknown. However, the localisation of 5-HT1A receptors to glia of 
the hippocampal dentate gyrus (DG) and the finding that 5-HT1A receptor stimulation 
promoters the secretion of pro-survival factors by glia (Jacobs and Azmitia, 1992), can 
activate pro-survival signalling cascades (Cowen, 2007) and stimulates neurogenesis and 
progenitor survival in this region (Huang and Herbert, 2005) suggests a putitative role for 
glial 5-HT1A receptors in the regulation of hippocampal neurogenesis. 
 
Neuronal 5-HT1A receptors signal via coupling to Gi/ o proteins to inhibit cAMP formation, 
inactivate calcium channels and activate potassium channels (Lemonde et al., 2003). These 
actions are inhibitory, reducing neuronal activity and neurotransmitter release. However, in 
hippocampal tissue, positive coupling to adenylate cyclase has also been reported (Markstein 
et al., 1986; Shenker et al., 1983) although this may ultimately be attributed to 
pharmacological activation of the 5-HT7 receptor. Furthermore, even if positive coupling to 
adenylate cyclase does occur in hippocampal neurones then it would appear that the negative 
coupling mechanisms of 5-HT1A receptor signalling may predominate. Electrophysiology 
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studies confirm that post-synaptic 5-HT1A receptor activation does indeed decreases neuronal 
activity in the hippocampus, in part as a result of p tassium channel activation (Graeff et al., 
1996; Tada et al., 1999). Further support for the importance of non-cAMP mediated 
signalling mechanisms in 5-HT1A-receptor mediated inhibition of neuronal activity is evident 
from studies on raphé 5-HT neurones. 5-HT1A receptor activation does not alter cAMP levels 
in raphé membranes (Clarke et al., 1996) but isolated DR neurones have been shown to 
display inwardly rectifying potassium currents and an inhibition of calcium currents in 
response to 5-HT1A autoreceptor activation (Lemonde et al., 2003; Penington et al., 1991; 
1993; Williams et al., 1988).  
 
The pre- and post-synaptic localisation of 5-HT1A receptors and their diverse 
neuroanatomical localisation contribute to the wide-spread alterations in extracellular 
neurotransmitter levels observed following their activation and also the diverse behavioural 
and physiological functions associated with this receptor (See table 1). The relative 
importance of pre- versus post-synaptic 5-HT1A receptors is often unclear and highly 
contentious, although there is good evidence that both are implicated in anxiety and 
depression. Thus, there are many studies that support a r le for reduced post-synaptic 5-HT1A 
receptors expression, binding and function in depression (Adlersberg et al., 2000; Drevets et 
al., 2000; Lopez-Figueroa et al., 2004; Sargent et al., 2000), while an important role for 
altered 5-HT1A autoreceptor function in depression is also supported by observations of 
increased 5-HT1A autoreceptor binging in depressed patients (Stockmeier et al., 1998). 
Furthermore, the selective desensitisation of 5-HT1A autoreceptors by chronic antidepressant 
treatment has been proposed as central to their therapeutic effect in depressed patients 
(Hervas et al., 2001; Lemonde et al., 2003; Riad et al., 2001). Despite a relative paucity of 
data investigating 5-HT1A binding in anxiety diosorde s patients decreased post-synaptic 
and autoreceptor binding has been reported in both PD and social anxiety disorder 
(Lanzenberger et al., 2005; Neumeister et al., 2004). A role for the 5-HT1A receptor in the 
regulation of affective functioning is also supported by evidence from preclinical studies 
showing that animals in which 5-HT1A function is ablated (5-HT1A receptor knock-out mice) 
display increased anxiety-like behaviour (Heisler et al., 1998; Zhuang et al., 1999; Ramboz 
et al., 2002). As conditional rescue of 5-HT1A receptor function in the forebrain of these 
animals during the early postnatal period, but not i  adult-hood, is able to reverse the 
anxiogenic effect of 5-HT1A receptor knock-out (Gross et al., 2002) this suggests that post-
synatpic 5-HT1A receptors may play an important role in regulating anxiety through 
developmental mechanisms. In addition to this developmental role the level of 5-HT1A 
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receptor activation in the adult brain also appears to regulate anxiety with a differential role 
for the autoreceptors (anxiolytic) and post-synaptic (hippocampal, anxiogenic) receptors 
supported (File et al., 1996). 
 
3.4.2 5-HT1B Receptors  
 
The 5-HT1B receptor subtype was originally identified in rodent brain tissue as a [
3H]-5-HT 
binding site with low affinity for spiperone (Pedigo et al., 1981). Later, the observation that 
this binding site also displayed low affinity for the specific 5-HT1A agonist 8-OH-DPAT 
further established the pharmacological difference between the two receptors. It was 
originally thought that the 5-HT1B receptor was species-specific to rodents (rat, mouse, 
hamster) (Hamon et al., 1986; Pedigo et al., 1981). However, further pharmacological 
characterisation and sequencing studies have shown that rodent 5-HT1B receptor is 
homologous to the human 5-HT1Dβ receptor (Adham et al., 1992). The same nomenclature is 
now recommended for this receptor subtype in all mam lian species with the human 5-
HT1Dβ receptor now known as h5-HT1B and the rodent as r5-HT1B (Hartig et al., 1996; Sari, 
2004). Distinct pharmacological differences between these receptor homologues, such as 
higher affinity of r5-HT1B for (-)propranolol than the h5-HT1B, are the result of a single 
amino-acid difference between these receptors (Hamblin et al., 1992; Metcalf et al., 1992) in 
which there is otherwise 97% homology. 
 
A number of radioligands have been used in order to map the distribution of the 5-HT1B 
receptor in autoradiographic studies. These include the use of non-specific ligands such as 
[3H]-5-HT in the presence of blocking concentrations of 5-HT1A and 5-HT2C ligands 
(Peroutka, 1986) and more recently the use of more 5-HT1B selective ligands such as [
3H]CP 
93,129 (Koe et al., 1992) and [3H]GR 125,743 (Varnas et al., 2001). In such studies a high 
density of 5-HT1B binding has been identified in basal ganglion regions, including the 
substantia nigra, globus pallidus (GP) and entopeduncular nucleus in the rodent brain. These 
results have been confirmed, and the distribution of the 5-HT1B receptor expanded, by use of 
antibodies specific to the receptor. In these studies high levels of the 5-HT1B receptor were 
also confirmed in the dorsal subiculum (DS), with lower levels identified in the caudate-
putamen, cerebral cortex and peri-aqueductal grey (PAG) (Sari, 2004).   
 
Both radioligand binding and immunocytochemical techniques have demonstrated that 5-
HT1B receptors localise to axons and axon terminals (Boulenguez et al., 1996; Sari, 2004). 
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An increasing body of evidence suggests that 5-HT1B receptors function as both 
autoreceptors modulating the release of 5-HT from 5-HT nerve terminals (Buhlen et al., 
1996; Middlemiss, 1990) and heteroreceptors on non-serotonergic terminals regulating the 
release of other neurotransmitters including glutamate (Li and Bayliss, 1998), GABA 
(Johnson et al., 1992; Stanford and Lacey, 1996) and acetylcholine (Maura and Raiteri, 
1986). 5-HT1B receptors are GPCRs that mediate their inhibitory effect on neurotransmitter 
release by coupling negatively to adenylate cyclase via Gi/Go proteins (Sari, 2004). 
 
A role for the 5-HT1B receptor has been suggested in multiple physiological functions, 
behaviours and psychiatric disorders including locomotion, migraine, drug abuse 
reinforcement and aggression. A wealth of evidence from preclinical studies also suggests a 
role for 5-HT1B receptors in anxiety, depression and the response t  antidepressant treatment. 
For example, 5-HT1B knock-out mice display reduced anxiety-like behaviour in a number of 
paradigms (Brunner et al., 1999; Zhaung et al., 1999; Malleret et al., 1999). Furthermore, 
pharmacological activation of 5-HT1B receptors is anxiogenic (Lin and Parsons, 2002) and 
also produces antidepressant-like effects (O’Neil; et al., 1996; O’Neill and Conway, 2001). 
With regard to antidepressant treatment, a down-regulation or desensitisation of 5-HT1B 
autoreceptors is proposed to be central to their the apeutic effect and the combined 
administration of 5-HT1B antagonist with SSRI antidepressants may potentiat their efficacy 
(Sari, 2004). Despite considerable preclinical evidnce implicating 5-HT1B in anxiety and 
depression there is a paucity of data on CNS binding and function from clinical studies. This 
may be due to the lack of selective 5-HT1B ligands available until recently. However, one 
study has reported an increase in 5-HT1B receptor mRNA levels in the hippocampus of 
depressed suicide victims (Lopez-Figueroa et al., 2004), suggesting that 5-HT1B may be 
altered in depression. 
 
3.5 The 5-HT2 Receptor Family   
 
The 5-HT2 receptor family consists of three receptor subtypes (5-HT2A, 5-HT2B and 5-HT2C) 
which possess very similar molecular structures and couple to the same signal transduction 
pathways. All 5-HT2 receptors stimulate phospholipase C (PLC) activity a Gαs protein 
activation resulting in an increased accumulation of the second messangers inositol 
phosphate (IP3) and diacylglycerol (DAG), which in turn lead to increased intracellular 
calcium and increased protein kinase C (PKC) activity respectively (Barnes and Sharp, 
1999). 
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3.5.1 5-HT2A Receptors  
 
The 5-HT2A receptor is analogous to the D receptor previously defined by Gaddum and 
Picarelli (1957) in the guinea pig ileum. In the CNS this receptor subtype also corresponds to 
the classical 5-HT2 binding site defined by Peroutka and Synder (1979) as having high 
affinity for [3H]spiperone and [3H]LSD but a low affinity for [3H]5-HT. The use of 
[3H]spiperone and the discovery, and subsequent tritiation, of the selective 5-HT2A antagonist 
ketanserin which displays >1000 fold selectivity for the 5-HT2A over the 5-HT2B and 5-HT2C 
receptors, were central in mapping the distribution of this receptor in the CNS (Castro et al., 
2003; Leysen et al., 1982). A number of other radiol belled ligands including [125I]DOI and 
more recently [3H]MDL 100,907 have also been used to map 5-HT2A receptor distribution 
(Li et al., 2003; Lopez-Gimenez et al., 1997). These studies show that 5-HT2A receptors are 
expressed widely throughout the rodent CNS including the caudate nucleus, nucleus 
accumbens, the hippocampus and many cortical regions. The distribution of this receptor in 
rodents is closely matched in humans, as detected by [11C]MDL 100,907 in PET and other 
ligands in post-mortem studies (Forutan et al., 2002; Hinz et al., 2007; Pandey et al., 2002). 
The high concordance between 5-HT2A binding sites, immunoreactivity and the mRNA 
distribution for the receptor in the CNS suggests that the receptors are located post-
synaptically. Indeed, 5-HT2A expression has been identified on cortical interneu ones 
(GABAergic) (Burnet et al., 1995; Lira et al., 2003; Morilak et al., 1993) and pyramidal 
(glutamatergic) neurones (Wright et al., 1995).  
 
5-HT2A activation results in excitatory neuronal responses in a variety of brain regions 
including the cortex and hippocampus. This has been shown electrophysiologically in 
cortical neurones by the application of the 5-HT2A agonists DOI and LSD (Marek and 
Aghajanian, 1996; 1999) and by the blockade of 5-HT-evoked neuronal activation by the 
specific 5-HT2A antagonist MDL 100,907 in both the cortex and hippocampus (Marek and 
Aghajanian, 1994; Piguet and Galvan, 1994). Alterations in potassium conductance are, in 
part, responsible for these depolarisations but the contribution of the phosphoinositide 
signalling pathway in this effect is not certain (Aghajanian et al., 1990). 
 
Initially, a central role for the 5-HT2 receptors in depression and anxiety disorders was 
supported by the finding of altered 5-HT2 receptor binding (with non-selective 5-HT2 
ligands) in the brains of depressed suicide victims (Arango et al., 1992; Cheetham et al., 
1988; Yates et al., 1990). More recently, due to the availability of more selective ligands, 5-
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HT2A receptor binding and function have been shown to be altered not only in post-mortem 
brains of depressed suicide victims (Rosel et al., 2004) but also in the living brains of 
depressed patients (Mintun et al., 2004; Sheline et al., 2004) and OCD sufferers (Adams et 
al., 2005). In preclinical studies the anxiolytic-like effects of the mixed 5-HT2A/2C agonist 
DOI have also been shown to be mediated specifically by the 5-HT2A receptor (Dhonnchadha 
et al., 2003a). In addition, mice lacking the 5-HT2A receptor (genetic knock-out) display 
decreased anxiety-like behaviour in conflict paradigms, an effect which can be reversed by 
the cortical rescue of 5-HT2A receptor function during early brain development (Weisstaub et 
al., 2006). These results suggest that cortical 5-HT2A receptors may play a role in 
determining anxiety through developmental mechanisms. Overall the pre-clinical and 
clinical data support the suggestion that 5-HT2A receptors play a role in both anxiety and 
depressive disorders. 
 
3.5.2 5-HT2C Receptors  
 
The 5-HT2C receptor was initially identified as a binding site in the choroid plexus that could 
be labelled by [3H]mesulergine and [3H]LSD but not by [3H]ketanaserin (Castro et al., 2003). 
Autoradiographic studies have utilised a number of radioligands, including [3H]LSD, 
[3H]mesulergine and [125I]DOI to characterise the distribution of 5-HT2C receptors in the 
CNS. In addition to the very high levels of expression detected in the choroid plexus 5-HT2C 
receptors are widely distributed in areas of limbic system (nucleus accumbens, amygdala, 
hippocampus), the basal ganglia (caudate nucleus, substantia nigra) and many cortical 
regions (Castro et al., 2003; Li et al., 2003; Radja et al., 1991). In general there is good 
concordance between the distribution of 5-HT2C mRNA expression and 5-HT2C binding sites 
and immunohistochemistry (Mengod et al., 1990; Sharma et al., 1997). These observations, 
along with the fact that 5-HT2C immunoreactivity is upregulated following 5,7-DHT lesion, 
supports a post-synaptic localisation for the 5-HT2C receptor. However, in the lateral 
habenula 5-HT2C mRNA has been detected whereas 5-HT2C binding in this region is very 
low suggesting a possible pre-synaptic location for these receptors on lateral habenula 
projections (Barnes and Sharp, 1999). This has yet to be confirmed. 
 
In line with the functional responses of the other 5-HT2 receptors, 5-HT2C receptors have 
been shown to increase phopholipase C activity via a G-protein dependent mechanisms 
(Boess and Martin, 1994; Sandersbush et al., 1988). This mechanism may contribute to the 
excitatory role of the 5-HT2C receptor on neurones in several brain regions. 5-HT2C receptors 
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have, for example, been shown to directly excite cortical pyramidal cells (Sheldon and 
Aghajanian, 1991) and to be involved in the 5-HT mediated excitation of GABAergic (dorsal 
raphé) (Boothman et al., 2003) and cholinergic interneurones (Bonsi et al., 2007) 
. 
Evidence supporting a role for the 5-HT2C receptor subtype in depression and anxiety largely 
comes from preclinical studies showing that antagonists of the receptor are anxiolytic 
(Kuznetsova et al., 2006; Martin et al., 2002) and that the anxiogenic-like effects of mCPP in 
mice are blocked by administration of 5-HT2C antagonists (Hackler et al., 2007). In the 
future, as mCPP is also known to be anxiogenic in humans, co-administration of specific 5-
HT2C antagonists with mCPP may further confirm the role f the 5-HT2C receptors in 
anxiety. The role of the 5-HT2C receptor in anxiety is also supported by the observation that 
animals in which 5-HT2C function is ablated, by genetic knock out, display decreased 
anxiety-related behaviours (Heisler et al., 1999; Heisler et al., 2007; Tecott et al., 1996). A 
role for the 5-HT2C receptor in determining compulsive behaviour is alo supported by 
observations made in 5-HT2C receptor knock-out mice (Chou-Green et al., 2003). To date 
there are no studies assessing the binding levels or function of central 5-HT2C receptors in 
anxiety disorder or depressed patients. However, recent analysis of 5-HT2C pre-mRNA in the 
post-mortem brains of suicide victims suggests thatpre-mRNA editing of 5-HT2C mRNA 
was altered in the brains of suicide victims in such a way as to alter the efficacy of 5-HT2C 
signalling (Gurevich et al., 2002b). In the future it is likely that studies in humans will 




















 Schematic representation of components of neurotransmission at a serotonergic 
synapse. (1) 5-HT (solid circles) is synthesised from its amino acid precursor 
(tryptophan). (2) 5-HT is then packaged into vesicles by VMAT. (3) 5-HT is released 
into the synaptic cleft following depolarisation of the presynaptic neurone. (4) 
Extracellular 5-HT activates pre- and post-synaptic neuronal 5-HT receptors and 
possibly glial 5-HT receptors. (5) 5-HT is cleared from the synapse by the serotonin 
transporter (SERT). In the cytoplasm 5-HT is either re-packaged into vesicles or 
metabolised by monoamine oxidase (MAO). Note the presence of the Na+/K+ 
ATPase in the plasma membrane, which maintains the ionic gradients used to drive 
5-HT reuptake by SERT. Also note on the enlarge synaptic vesicle the H+-ATPase 
which provides the driving force for 5-HT transport into the vesicle. Figure from 







3.6 Serotonin Reuptake  
 
The activity of 5-HT at its receptors is terminated by its removal from the synaptic cleft. 
Reuptake of 5-HT into the presynaptic terminal by the serotonin transporter (SERT) is the 
principle mechanism by which 5-HT is removed from the cleft. SERT belongs to a family of 
structurally and pharmacologically distinguishable transporter proteins known as the plasma 
membrane monoamine transporters (Amara and Kuhar, 1993; Torres et al., 2003). Other 
members of this family include the dopamine transporter (DAT) and the noradrenaline 
transporter (NAT), responsible for the reuptake of DA and NA respectively.  
 
3.6.1 The Serotonin Transporter (SERT)  
 
SERT is made up of 630 amino acids arranged into 12 α-helical transmembrane domains 
(TMDs) with a predicted 5 intracellular and 6 extracellular loops with both the carboxy- and 
amino-termini located intracellularly (Masson et al., 1999; Rudnick and Clark, 1993). 
Multiple sites for N-linked glycosylation are located on the large extracellular loop between 
TMDs 3 and 4, whereas consensus sequences for possible phosphorylation by a range of 
kinases exist at different intracellular sites (Hoffman et al., 1998). N-glycosylation of the 
transporter appears to be essential for the transport and cell surface expression of the 
transporter while the phosphorylation state of SERT plays a role in regulating the availability 
of the transporter at the membrane to allow 5-HT reuptake (Blakely et al., 1998; Qian et al., 
1997). Although most models of transporter function have assumed that transporters function 
as single units, an increasing body of evidence suggests that SERT may function as an 
oligomer as it displays activity as both a dimer (2 units) and tetramer (4 units)(Jess et al., 
1996; Kilic and Rudnick, 2000; Qu et al., 2003).  
 
Inwardly-directed Na+ and Cl- gradients and outwardly directed H+ and K+ gradients provide 
the driving force for 5-HT transport across the plasm  membrane by SERT. These 
electrochemical gradients are created and maintained by the plasma membrane Na+/K+ 
ATPase (Kanner and Schuldiner, 1987; Rudnick and Clark, 1993) and allow for the 
accumulation of 5-HT concentrations in the nerve terminal to several hundred-fold that 
observed in the extracellular space. The ionic dependence has been established and 5-HT 
transport by SERT involves the internalisation of one Na+ and one Cl- ion with the 
externalisation of one K+ ion (Gu et al., 1994). This means that 5-HT transport is 
electrochemically neutral. However, in addition to this substrate transport mechanism it is 
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suggested that the monoamine transporters also exhibit channel-like activity as they all 
demonstrate ionic conductances that can not be accounted for by the fixed stoichiometry of 
substrate translocation (Galli et al., 1996; Mager et al., 1994; Sonders et al., 1997).  
 
3.6.2 SERT Localisation  
 
Characterisation of the anatomical and cellular localisation of SERT in the CNS has been 
possible due to the availability of specific radioligands for the transporter, including 
[3H]paroxetine and [3H]citalopram, the development of SERT antibodies and the advent of 
RNA sequencing, which has allowed for detection of SERT mRNA expression (Qian et al., 
1995; Sur et al., 1996). There is good concurrence between SERT expression as detected by 
radioligand autoradiography and immunocytochemistry. SERT is present and functional on 
the surface of every component of the 5-HT neurone including dendrites, peikarya, axons 
and nerve terminals. Evidence also suggests that SERT may be expressed and functional on 
glial cells (Bel et al., 1997; Inazu et al., 2001), which may also play an important role in the 
regulation of extracellular 5-HT availability. SERT mRNA expression is highest in the raphé 
nuclei with lower levels detectable in some projection terminal fields such as the cortex, 
hippocampus and striatum but there are clear parallels between SERT mRNA expression in 
regions outside the raphé and high densities of serotonergic innervation suggesting that 
SERT mRNA detected in these regions may be associated wi h 5-HT neurones. 
 
3.6.3 Regulation of SERT function  
 
SERT expression and function is regulated by multiple factors at different levels, from that 
of gene transcription to post-translational modification. Despite increasing knowledge of the 
mechanisms involved in the regulation of SERT the full nature of these mechanisms is yet to 
be fully elucidated.  
 
Regulation of SERT function at the genetic level is produced by coding variations present in 
the SERT gene. To date several single nucleotide polymorphisms (SNPs) have been 
identified in the human SERT gene (hSERT) (Cargill et al., 1999). Recently two non-
synonymous SNPs, nucleotide codons that code for diferent amino acid insertions, were 
found to alter basal 5-HT transport capacity by altering the expression levels of SERT (Kilic 
et al., 2003; Prasad et al., 2005). Furthermore, five other SNPs were found to alter the 
regulatory effects of protein kinase G (PKG) and p38 mitogen-activated protein kinase 
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(MAPK) signalling on SERT functioning (Prasad et al., 2005). However, two other 
polymorphisms in the human SERT gene have received the most attention because they have 
been directly implicating in affective disorders. One, a variable nucleotide tandem repeat 
sequence (VNTR) in intron 2 of the SERT gene confers higher transcriptional activity when 
12 copies of the VNTR are present in comparison to lower copy numbers (Fiskerstrand et al., 
1999; MacKenzie and Quinn, 1999). The second polymorphism, a common promoter variant 
in the 5’ flanking region located ~1.4kb upstream of the transcription start site, termed the 5-
HTT gene-linked polymorphic region (5-HTTLPR) also c nfers higher expression and 
SERT function when composed of sixteen (“long” or “L” allele, 44 base pair insertion) as 
compared to fourteen (“short” or “S” allele, 44 base pair deletion) repeated elements 
(Greenberg et al., 1999; Lesch et al., 1996; Little e  al., 1998).  
 
Figure 1.5 Organisation of the SERT gene and protei n F4 
 
Schematic diagram showing organisation of the human SERT gene and protein. (A) Diagram 
of SERT gene organisation showing coding exons (red) and non-coding introns (blue). Note 
the location of the 5-HTTLPR upstream of the first exon and the location of the VNTR near 
exon 2. (B) Schematic of amino acid sequence in SERT protein with amino acids coded by 
single nucleotide polymorphisms (SNPs) in the gene shown. Some result in altered amino 
acids (red) insertions while others (blue) do not. Note also the 12 transmembrane helices, 
internal carboxy and amino termini and intracellular and extracellular loops. Figure from 
Murphy et al (2004). 
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In addition to the chronic regulation of SERT function dictated by the polymorphisms 
present in the hSERT gene, evidence also supports a role for several m chanisms involved in 
the acute regulation of SERT functioning, including those that regulate gene transcription 
and post-translational modification. For example, chronic elevation of cAMP has been 
shown to increase SERT-encoding mRNA (Ramamoorthy e al., 1993) suggesting that 
signalling pathways linked to intracellular cAMP may play a role in the regulation of SERT 
function by altering the rate of transcription. Theoretically, this mechanism could provide a 
link between 5-HT autoreceptor activation and altertions in SERT transcription. In turn, this 
pathway may play a part in the observed transcriptional regulation of SERT function 
following chronic antidepressant treatment, which decreases SERT-encoding mRNA 
expression (Lesch, 1993). However, others have found no effect of chronic antidepressant 
treatment on SERT transcription (Benmansour et al., 1999). Modified SERT functioning 
resulting from transcriptional alterations are likely to occur after a significant time delay 
(hours). However, evidence also suggests that SERT function can be regulated over a shorter 
time frame by mechanisms involving the activation of multiple GPCRs, including the 5-
HT1B receptor (Daws et al., 2000), as well as by several p otein-kinase and protein-
phosphatase linked pathways. Several studies have shown that activation of protein kinase C 
(PKC) and protein kinase G (PKG), or inhibition of protein phosphatase 2Ac (PP2Ac) and 
p38 mitogen-activated protein kinase (MAPK), decreases SERT activity in a number of 
systems (Jayanthi et al., 1994; Prasad et al., 2005; Qian et al., 1997; Ramamoorthy and 
Blakely, 1999; Samuvel et al., 2005). Evidence from PKC studies largely suggests that the 
phosphorylation state of SERT dictates whether it is expressed at the cell surface or whether 
it is redistributed to intracellular compartments (Ramamoorthy and Blakely, 1999; Torres et 
al., 2003). However, the observation that down-regulation of the transporter by PKC 
activation is not prevented by removal of the PKC consensus phosphorylation sites from 
SERT suggests that direct phosphorylation of SERT may not be the primary mechanism of 
SERT regulation by PKC (Sakai et al., 1997). In contrast, modification of SERT function by 
PKG is dependent upon the direct phosphorylation of threonine residue 276 in SERT 
(Ramamoorthy et al., 2007) and the effect of MAPK and PKG activation on SERT function 
is altered by genetically determined variation in the amino acid sequence of SERT (Prasad et 
al., 2005). These findings suggest that the regulation of SERT by different protein-
phosphorylation and protein-phosphatase linked pathways is likely to involve diverse 
mechanisms. Additionally, protein-kinase linked pathways may be central to the acute 
regulation of SERT function by extracellular 5-HT levels, as down-regulation of SERT by 
PKC activity is sensitive to 5-HT (Ramamoorthy and Blakely, 1999) suggesting a possible 
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4. Functional Roles of Serotonin  
 
In the CNS 5-HT neurones innervate components of all functional systems and regulate the 
neuronal activity of sensory, motor, autonomic and enteric neurones. Therefore 5-HT is 
implicated in a diverse range of functions including appetite, sleep, learning and memory, 
temperature regulation, motor behaviour, endocrine regulation and affective functioning.  
 
4.1 Psychopathology of Serotonin  
 
Due to its involvement in the regulation of numerous f nctional systems and behaviours, 
dysfunction of 5-HT neurotransmission has been implicated in a multitude of 
psychopathologies including aggression, impulsivity, schizophrenia, obsessive compulsive 
disorder (OCD), attention deficit hyperactivity disorder (ADHD) and Autism. A prominent 
role has also been suggested in a number of neurodegenerative diseases such as Alzheimers 
and Parkinsons. However, most research to date has been dedicated to further elucidating the 
role of 5-HT in the affective (depression and anxiety) disorders. 
 
The monoamine hypothesis of depression was initially put forward to explain the 
antidepressant effects of iproniazid, a monamine amine oxidase inhibitor (MAOIs), and 
imipramine, a tricyclic antidepressant (TCA) (Bunney and Davis, 1965; Schildkraut, 1965). 
The hypothesis suggested that depression resulted from a functional deficit in 
monoaminergic (5-HT and/or NA) neurotransmission in key brain areas while mania was the 
result of a functional excess of transmission. Therefore, TCAs and MAOIs were proposed to 
elicit their antidepressant effect by increasing extracellular monoamine concentrations. This 
hypothesis stimulated much research into the role of these monoamines in depressive 
disorders and has dominated the biological approach to depression since its proposal. Later, 
the observation that the ranked affinity of imipramine-related drugs for the inhibition of 5-
HT reuptake correlated well with their mood-elevating efficacy, lead to the suggestion that 
5-HT may be the most important neurotransmitter in the antidepressant effects of TCAs 
(Carlsson et al., 1969). This knowledge, along with the observation that 5-HT and 5-HIAA 
concentrations are reduced in both the cerebrospinal fluid (CSF) of depressed patients 
(Ashcroft et al., 1966; Dencker et al., 1966) and the post-mortem brains of depressed suicide 
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victims (Pare et al., 1969; Shaw et al., 1967) lead to the development of the indoleamine 
hypothesis of depression (Carlsson et al., 1969; Lapin nd Oxenkrug, 1969), placing even 
more importance on 5-HT in depressive disorders. At this time the indolemine hypothesis 
was also supported by the observation that supplementing the diet of depressed patients with 
the amino acid precursor for 5-HT, tryptophan, was also antidepressant (Coppen et al., 1967; 
Hertz and Sulman, 1968). To date a multitude of studies have also reported on the 
depressogenic effects of acute tryptophan depletion, a dietry challenge which decreases 
central 5-HT neurotransmission, in depression susceptibl  individuals (Klaassen et al., 1999; 
Moreno et al., 1999) and remitted depressed patients (Leyton et al., 2000; Moreno et al., 
1999). It was the development of the selective serotonin re-uptake inhibitors (SSRIs) such as 
paroxetine and citalopram in the 1980s and their establi hment as highly effective 
antidepressants, however, that truly cemented a central role for 5-HT in the aetiology 
depression. 
 
Although there is much evidence supporting a role fr the monoamine and indoleamine 
hypotheses in depression they do not explain the reason for the delay in the mood elevating 
effects of TCA, MAOI or SSRI treatment in comparison to their rapid enhancement of 
extracellular monoamine levels. Furthermore, these hypotheses do not explain the 
effectiveness of antidepressants in the treatment of anxiety disorders (Vaswani et al., 2003; 
Zohar and Westenberg, 2000). In contrast to the proposed mechanism of 5-HT function in 
depression, 5-HT is classically viewed as being anxiogenic (Iversen, 1984; Wise et al., 1972) 
and anxiety disorders are thought to be associated with enhanced 5-HT neurotransmission. 
As anxiety and depression often display co-morbidity, both being present in the same patient, 
it is hard to reconcile the two conflicting hypothesis of 5-HT functioning in these disorders. 
It has been suggested, however, that these differenc s may be due to the involvement of 
differential serotonin receptor subtypes and/or neural substrates in these disorders (Graeff et 
al., 1996). 
 
Despite the conflicting theoretical role for 5-HT in depressive and anxiety disorders, 
however, there remains considerable evidence for convergent alterations (genetic and 
molecular) in the 5-HT system in both of these disorders. For example, functional 
polymorphisms in a number of 5-HT receptor gene subtypes have been found to increase the 
risk of developing both anxiety and depressive disor ers (5-HT1A: Lemonde et al., 2003; 
Maron et al., 2005, 5-HT2A: Bonnier et al., 2002; Gorwood et al., 2002; Inada et l., 2003; 
Little et al., 1998, 5-HT2C: Gutierrez et al., 1998; Lerer et al., 2001). Furthe more, consistent 
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alterations in 5-HT1A receptor binding have been reported in both anxious and depressed 
patients. Post-synaptic 5-HT1A binding has been reported to be decreased in depression 
(Drevets et al., 1999; Lesch et al., 1992b; Lopez et al., 1998) panic disorder (Neumeister et 
al., 2004) and social anxiety disorder (Lanzenberger et al., 2005). In contrast 5-HT1A 
autoreceptor function has been reported to be increased in depression and panic disorder 
(Drevets et al., 1999; Neumeister et al., 2004b; Stockmeier et al., 1998). In addition to 5-
HT1A receptor findings a decrease in the density of SERT binding has been reported in the 
brains of both living depressed patients (Bremner et al., 1997; Staley et al., 1998) and those 
suffering from panic disorder (Maron et al., 2003). However, while SERT density was found 
to be reduced on the platelets of patients with GAD (Hernandez et al., 2002; Iny et al., 1994) 
reduced binding in the brain was not confirmed (Maron et al., 2004). These data suggest that 
common genetic and molecular events in the 5-HT system play a role in both anxiety and 
depressive disorders. However, future research dedicated to elucidating alterations in the 
other receptor subtypes in both anxiety and depressive disorders is required. From the studies 
already completed, however, it is interesting to note that while alterations in 5-HT1A and 
SERT binding are consistent in directionality in both anxiety and depression the 
neuroanatomical localisation of these alterations is different. These findings give some 
credence to the proposal by Graeff et al. (1996) that alterations in differential neural 
networks may be central to depression and anxiety. 
 
Extensive pre-clinical data also support a role for 5-HT in the regulation of affective 
functioning as modification of 5-HT system functioning results in altered affective-related 
behaviours in animal models. While pharmacological challenge studies targeting specific 5-
HT receptor subtypes have been informative on the regulation of affective-related behaviours 
for some of the 5-HT receptor subtypes, a lack of specific ligands for other receptor subtypes 
has limited the usefulness of pharmacological studies in determining the role of these 
receptors in affective behaviour. Studies in transge ic animals with targeted disruption 
(knock-out; KO) of specific 5-HT receptor subtypes, however, have been particularly useful 
in investigating the role of specific 5-HT receptor subtypes in affective-related behaviours. 
Serotonin receptor KO animals have been used to investigate the role of the specific 5-HT 
receptor subtypes investigated in this thesis in affective-related behaviours (see relevant 
study introduction sections for more detailed information). In addition, evidence from 
transgenic animals also supports a role for the 5-HT3 (Bhatnagar et al., 2004) and 5-HT7 
(Guscott et al., 2005; Hedlund et al., 2005) in depressive and/or anxiety-related behaviours. 
The availability of animals with targeted disruption f the other 5-HT receptor subtypes, 
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including the 5-HT4 (Conductier et al., 2006) and 5-HT6 receptor (Bonasera et al., 2006) 
subtypes, may allow for the further elucidation of the possible role of these receptors in 
affective functioning. Furthermore, producing conditional KO animals for the specific 5-HT 
receptor subtypes in the future may be able to further elucidate the relative importance of the 
developmental role versus the adult level of 5-HT receptor functioning in determining 
affective-related behaviour. In this way, the use of 5-HT1A receptor conditional KO animals 
has already shown that the developmental mechanisms regulated by cortical 5-HT1A 
receptors may be particularly important in determining anxiety-related behaviours (Gross et 
al., 2002).   
 
4.2 5-HT regulation of hypothalamo-pituitary-adrena l (HPA) axis 
function  
 
4.2.1 Anatomy of the hypothalmo-pituitary-adrenal ( HPA) axis  
 
Activation of the hypothalamo-pituitary-adrenal (HPA) axis is a major component of the 
stress response and leads to behavioural and physiological adaptations that attempt to restore 
homeostasis and ensure survival. Parvocellular neuro s of the paraventricular nucleus 
(PVN) located in the hypothalamus are responsible for the release of corticotrophin releasing 
hormone/factor (CRH/ CRF) and arginine-vasopressin (AVP) at the median eminence into 
the portal system of the anterior pituitary. Activaon of CRF receptors on corticotroph cells 
present in the anterior pituitary causes them to secret  adrenocorticotropic hormone (ACTH) 
into the peripheral blood system. Simultaneous activ tion of AVP receptors on the same 
cells acts synergistically to enhance CRH secretion while AVP alone has little ACTH 
secretagogue activity (Lamberts et al., 1984; Liu et al., 1983).  At the adrenal cortex 
circulating ACTH regulates the secretion of glucocorti ids (cortisol in humans, 
corticosterone in rodents) into the circulation. Glucocorticoids are the final effectors of the 
HPA axis and are involved in a multitude of responses that contribute to the control of whole 
body homeostasis. Under non-stressful conditions CRH and AVP are secreted into the portal 
system in a pulsatile fashion with a frequency of approximately 3 secretory episodes per 
hour (Engler et al., 1989b). This secretion also displays a circadian rhythm, with the 
amplitude of CRH and AVP secretions being greater upon waking resulting in higher ACTH 
and cortisol concentrations (Antoni, 1986; Horrocks et al., 1990). During stressful 
experiences the rate and amplitude of pulsatile CRH and AVP secretion is increased 
(Charmandari et al., 2005) resulting in increased circulating glucocorticoid levels. 
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Schematic of the hypothalamo-pituitary-adrenal (HPA) axis. Parvocellular neurones of the 
PVN produce CRF and AVP. These factors stimulate the synthesis and release of ACTH 
from anterior pituitary corticotroph cells into the systemic circulatory system. At the adrenal 
cortex ACTH simulates the release of glucocortiocoids. Glucocortioids act at multiple loci 
within the body to maintain homeostasis and also act in the CNS to modify behaviour. In the 
CNS glucocorticoids also act at glucocorticoid (GR) and mineralocorticoid (MR) receptors to 
















Glucocorticoids exert their affects through their ubiquitous cytoplasmic receptors, the 
mineralocorticoid (MR; type I) and glucorticoid (GR; type II) receptors. Within the CNS MR 
expression is highest within the septo-hippocampal (McEwen et al., 1986) complex whereas 
the GR receptor is more widely distributed with high levels present in the dentate gyrus, 
lateral septum, PVN, the thalamus and cortical regions (DeKloet et al., 1984). When bound 
to their ligands these receptors translocate to the nucleus where they form homodimers to 
interact with specific glucocorticoid-responsive elments (GREs) present within the DNA to 
activate the transcription of specific hormone-responsive genes (Pratt, 1990). In addition to 
this classical genomic pathway evidence also suggests that rapid, non-genomic mechanisms 
also play a part in mediating the more immediate eff cts of glucocorticoids. For example, the 
rapid effect of corticosterone on neuronal activity is proposed to involve possible alterations 
in membrane properties by non-genomic mechanisms governed by the classical receptors or 
by activation of a putative G-protein linked membrane receptor (Tasker et al., 2005; 2006). 
 
Glucocortiocoids also play a central role in the regulation of HPA axis activity by a negative 
feedback mechanism, acting at extrahypothalamic sites (such as the hippocampus), the 
hypothalamic PVN and pituitary gland to limit the scretion of CRH and ACTH. Occupancy 
of the MR receptor, which has a very high affinity for the glucocorticoids, is involved in the 
tonic control of corticosterone secretion. GR occupancy is involved in termination of the 
stress axis response when high levels of glucocorticoids are present, as this receptor has 
lower affinity for glucocortiocoids and is only significantly occupied at higher glucocorticoid 
concentrations (DeKloet and Reul, 1987; Reul et al., 2000). 
 
5-HT plays a role in modulating the function of the HPA axis through two different 
mechanisms, it both regulates the feed-forward activ tion of the HPA axis and affects the 
feed-back mechanisms that regulate HPA axis activity. 
 
4.2.2 5-HT involvement in HPA axis feed-forward dri ve 
 
With regard to feed-forward regulation, Liposits et al. (1987) were the first to demonstrate 
that CRH containing neurones in the PVN received direct synaptic innervation from 5-HT 
neurones. These connections are proposed to represent functional 5-HT inputs into the PVN 
as 5-HT directly stimulate the release of CRH from hypothalamic explants (Calogero et al., 
1989) and the destruction of 5-HT nerve terminals within the PVN, by 5,7-DHT injection, 
significantly attenuates the ACTH response to numerous stressors (Feldman et al., 1984). 
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Therefore, the ability of 5-HT precursors (tryptophan) and the releasing agent fenfluramine 
to stimulate ACTH release in vivo was proposed to result, in part, from direct activation of 
PVN CRH-containing neurones (Heninger et al., 1984; O’Keane and Dinan, 1991). With the 
development of more specific pharmacological probes it was possible to determine which 5-
HT receptor subtypes were responsible for the activting effect of 5-HT on the HPA axis. 
Thus, a central role for 5-HT1A and 5-HT2A/C was identified by the ability of their selective 
agonists, 8-OH-DPAT and DOI, to increase in vivo CRH and ACTH release (Lesch et al., 
1990; Rittenhouse et al., 1994; Yatham and Steiner, 1993). As these studies involved 
systemic injection of the serotonergic agonists, however, the localisation of their action 
within the CNS could not be determined. Furthermore, th  possible contribution of other 
neurotransmitter systems to their effects on the HPA axis could not be ruled out. However, 
as direct electrical stimulation of the dorsal raphé has been shown to excite neuronal activity 
within the PVN (Saphier and Feldman, 1989), and CRH neurones express 5-HT1A and 5-
HT2A/C receptors (Li et al., 1997b) the direct activation of these receptors could certainly be 
responsible, in part at least, for the increases in ACTH induced by systemic injection of their 
respective agonists (Little et al., 1998; Pan et al., 2001). Nevertheless, the contribution of 
other 5-HT receptor subtypes and the involvement of other 5-HT-mediated feed-forward 
pathways in the regulation of the HPA axis under both basal and stress conditions must not 
be underestimated. Indeed, the observation that 5-HT1 and 5-HT2 receptor antagonists, alone 
and in combination, can not completely inhibit the effect of endogenously released 5-HT on 
CRH and ACTH secretion suggests that other pathways and 5-HT receptor subtypes are of 
importance (Fuller and Snoddy, 1990). There is some evidence supporting a role for the 5-
HT1B and 5-HT7 receptor subtypes in HPA axis activation (Jorgensen et al., 2002) and 
injection of the 5-HT2A antagonist ketanserin directly into the amygdala attenuates the HPA 
axis response to photic stress (Feldman et al., 1998). These findings indicate the importance 
of alternate neuronal pathways to that of the direct activation of PVN CRH neurones by 5-
HT, and specifically for 5-HT2A receptors, in the feed-forward regulation of HPA axis 
activity. Evidence also suggests that 5-HT may play a role in regulating the output of ACTH 
by acting directly at the level of the pituitary as5-HT, DOI and 8-OH-DPAT all elicit 
increased secretion of ACTH from primary rat anterior pituitary cell cultures (Calogero et 
al., 1993), as does 5-HT3 and 5-HT4 receptor activation (Calogero et al., 1995). In addition to 
these central mechanisms of activation, 5-HT may also ct as a paracrine regulator in the 
adrenal cortex to stimulate corticosterone secretion v a activation of 5-HT2, 5-HT4 (human) 
or 5-HT2 and 5-HT7 (rat) receptors on adrenocortical cells (Alper, 1990; Contesse et al., 
2000; Lefebvre et al., 1992). 
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Despite the multitude of studies implicating a role f r 5-HT in the feed-forward regulation of 
HPA axis functioning its true role in the stress reponse is yet to be fully elucidated. For 
example, while it has been reported that 5-HT1 and 5-HT2 receptor antagonists are able to 
attenuate the HPA axis response to specific stressos, including restraint, ether stress and 
immune activation (with LPS endotoxin), they do not at enuate the response to other 
stressful stimuli, such as cold-swim stress (Jorgensen et al., 2002; Saphier et al., 1995). This 
suggests that these receptor subtypes, or even the 5-HT system as a whole, is involved in 
modulating the effects of some stressors upon HPA axis activity but not others. 
 
In addition to the acute regulation of HPA axis activation by altering neuronal activity and 
acute CRH, AVP and ACTH secretion, evidence also suggests that 5-HT may regulate the 
rate of CRH and ACTH synthesis through transcriptional mechanisms. 5-HT1A, 5-HT1B and 
5-HT2A/C receptors have all been implicated in the control of CRH and ACTH synthesis, as 
administration of their selective agonists increases the expression of CRH mRNA in the 
PVN and that of the ACTH pre-cursor pro-opiomelanocortin (POMC) in the anterior 
pituitary (Jorgensen et al., 2002). Only 5-HT2A/C receptors, however, have been shown to 
regulate AVP mRNA expression (Jorgensen et al., 2003). The exact role of 5-HT in the 
regulation of CRH, AVP and POMC expression in response to stress, remains unclear as 5-
HT depletion by p-chlorophenylalanine does not attenuate LPS stress-induced alterations in 
CRH mRNA expression (Condo et al., 1998; Harbuz et al., 1993). Furthermore, 5-HT 
depletion enhances POMC expression in the pituitary in response to restraint stress, 
suggesting that the 5-HT system may inhibit POMC expr ssion during stress (Garcia-Garcia 
et al., 1997). An inhibitory role for 5-HT on POMC expression is further supported by the 
observation than chronic SSRI treatment, which increases extracellular 5-HT, mediates a 
down-regulation in POMC mRNA expression (Jensen et al., 1999; 2001). 
 
4.2.3 5-HT regulation of HPA axis feed-back mechani sms  
 
A role for 5-HT in the regulation of glucocorticoid feedback on HPA axis activity is 
supported by the observation that lesioning of the 5-HT system, or 5-HT depletion, reduces 
the ability of dexamethasone (GR agonist) to suppress corticosterone secretion (Lowy et al., 
1990; Mcintyre et al., 1984). In addition, lesioning of central 5-HT pathways has been shown 
to decrease [3H]corticosterone and [3H]dexamethasone binding in CNS regions known to be 
involved in the negative feedback regulation of the HPA axis (Lovenberg et al., 1993; Stith 
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and Weingarten, 1979), and to reduce mRNA levels for both the GR and MR (Yau et al., 
1994). Furthermore, studies using chronic SSRI treatm nt paradigms, which chronically 
increase extracellular 5-HT levels, have shown that glucocorticoid feedback to the HPA axis 
is enhanced (Pariante and Miller, 2001; Pariante et al., 2004). In human studies, this 
enhanced feedback can only be attributed to alterations in GR function as the ligands used to 
detect this (dexamethasone and prednisolone) only target the GR receptor. However, pre-
clinical and in vitro data suggests that chronic SSRI treatment up-regulates both MR and GR 
function in central structures known to be involved in the negative feedback of 
glucocorticoids (Bjartmar et al., 2000; Okugawa et l., 1999; Pariante et al., 2001; Seckl and 
Fink, 1992). Despite these observations limited research has been directed towards 
elucidating the role of specific 5-HT receptor subtypes in the regulation of MR and GR 
expression although one recent study has highlighted th  involvement of 5-HT7 receptors in 
the regulation of hippocampal GR receptor expression (Laplante et al., 2002). Overall, the 
data suggests that 5-HT signalling regulates GR and MR expression as a contributory 
mechanism to the regulation of glucocorticoid-mediated feed-back inhibition of the HPA 
axis. 
 
4.2.4 Reciprocal 5-HT system-HPA axis Interactions  
 
In addition to widespread evidence supporting a role f r 5-HT in the regulation of the HPA 
axis functioning a multitude of studies also suggest that the HPA axis, through both CRH 
and glucocortiocoid release, regulates the function of the 5-HT system. For example, 
increased glucocorticoid levels have been shown to i crease central 5-HT turnover (DeKloet 
et al., 1982; Singh et al., 1990), induce a down-regulation of 5-HT1A autoreceptor expression 
or desensitize their function (Bagdy et al., 1989; Fairchild et al., 2003a,b), increase 
postsynaptic 5-HT1A expression in the hippocampus (Frankfurt et al., 1993; Takao et al., 
1995), increase the number and sensitivity of postsynaptic 5-HT2 receptors (Kuroda et al., 
1992; Takao et al., 1995) and increases 5-HT1B binding (Frankfurt et al., 1993). Additionally, 
5-HT1A and 5-HT1B receptors, but not 5-HT2 receptors, appear to be tonically regulated by 
glucocorticoid levels as adrenalectomy decreases both 5-HT1A and 5-HT1B receptor 
expression but does not alter that of the 5-HT2 receptors (Chaouloff et al., 1995; 1993; 
Kuroda et al., 1992a,b). This may be related to the known regulatory role of MR but not GR 
signalling on 5-HT1A receptor expression (Kuroda et al., 1994) and that of GR signalling on 
the 5-HT2 receptors (Kuroda et al., 1993). 
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In addition to glucocorticoid-mediated regulation of the 5-HT system evidence also suggests 
that CRF may be involved in the integration between the stress-response and 5-HT system 
functioning. In addition to its neuroendocrine role, c ntrally released CRF may also act as a 
neuromodulator or neurotransmitter. CRF-immunoreactive terminals are widespread 
throughout the CNS and are present within the raphé (Sakanaka et al., 1987; Swanson et al., 
1983) as are the CRF receptors (DeSouza et al., 1987). Furthermore, acute central 
administration of CRF reduces extracellular 5-HT concentrations in the forebrain (Price and 
Lucki, 2001) and CRF inhibits dorsal raphé neuronal activity when administered locally 
(Price et al., 1998). This suggests that CRF may represent another mechanism by which 
stress-related systems influence the activity of the 5-HT system. 
 
4.2.5 Psychopathology of the HPA axis  
 
Activity of the HPA axis is tightly regulated by complex feed-forward and feed-back 
mechanisms that are designed to limit the duration of HPA axis activation in times of stress. 
The time-limited nature of the HPA axis renders its physiological and behavioural effects, 
including its anti-reproductive, catabolic and immunosuppressant effects, beneficial to 
survival. Dysregulation of HPA axis function, however, is likely to result in a number of 
alterations that are damaging. Indeed, substantial evidence suggests that HPA axis 
dysfunction may be central in the aetiology of a number of disorders including obesity, 
diabetes mellitus, rheumatoid arthritis and the affective disorders where altered HPA axis 
function has been reported in patients suffering from major depressive disorder (Gibbons and 
Mchugh, 1962; Gold et al., 1986; Rubin et al., 1987), bipolar disorder (Cervantes et al., 
2001; Middlemiss et al., 2002), panic disorder (Abelson and Curtis, 1996), obsessive 
compulsive disorder (Gehris et al., 1990; Monteleone et al., 1994), generalised anxiety 
disorder (Nutt, 2001) and post-traumatic stress disor er (Marshall et al., 2002). 
 
Altered HPA axis function is most commonly reported and has been most extensively 
characterised in MDD patients. An increase in basal HPA axis activity, as reflected by an 
increase in plasma cortisol secretion throughout the 24 hour circadian cycle, is found in 
approximately 50% of MDD patients (Halbreich et al., 1985; Pfohl et al., 1985; Rubin et al., 
1987) and evidence suggests that alterations in both the feed-forward and feed-back 
mechanisms regulating HPA axis function are present in depression. An increase in feed-
forward drive is supported by observations of increase cerebrospinal fluid (CSF) CRF levels 
(Carroll et al., 1976), an increase in CRF and AVP co-localised expression in the PVN 
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(Raadsheer et al., 1994), a marked enhancement of the synergistic effect of AVP on CRH 
stimulated ACTH release (Dinan, 2004; Dinan et al., 2004) and increased plasma ACTH 
levels (Anisman et al., 1999). Although adrenal gland hypertrophy is commonly reported in 
depressed patients the sensitivity of the adrenal gland to ACTH is not altered (Amsterdam et 
al., 1989; Carroll, 1980; Carroll et al., 2007; Fang et al., 1988; Kalin et al., 1987; Rubin et 
al., 1995). The increased size of the adrenal gland in the presence of enhanced plasma ACTH 
secretion is likely to contribute to the increased basal plasma cortisol secretion observed in 
some depressed patients. 
 
Evidence also suggests that the negative feed-back regulation of HPA axis function by 
glucocorticoids is attenuated in depression. Numerous studies that have reported the inability 
of dexamethasone, in the classic “dexamethasone suppression test” (DST), or hydrocortisone 
to suppress plasma ACTH and corticosterone levels in depressed patients (Carroll, 1980; 
Maes et al., 1991; Young et al., 1991). As dexamethasone only has agonist activity on GR 
receptors in vivo and not on the MR receptor (Reul et al., 2000) this suggests that the GR 
receptor system is deficient in depression (for review see (Pariante and Miller, 2001). In 
keeping with this suggestion, levels of GR mRNA were found to be decreased in the post-
mortem brains of depressed patients (Lopez et al., 1998; Webster et al., 2002) while in 
contrast, evidence suggests that MR receptor functio  is maintained or even increased in 
depressed patients (Lopez et al., 1998; Webster et al., 2002). As increased 5-HT 
neurotransmission is associated with enhanced GR and MR expression (Pariante and Miller, 
2001; Pariante et al., 2004) a deficit in 5-HT neurotransmission in depression may be central 
to the decreased glucocorticoid feedback found in this disorder. Therefore, altered balance in 
GR-MR receptor signalling is likely to contribute to he aberrant HPA axis functioning in 
depression. 
 
The observation that the alterations in mood experienced by depressed patients treated with 
antidepressants were temporally associated with normalisation of HPA axis function has lead 
to the hypothesis that antidepressants regulate mood in depressed patients, in part, through 
their long-term effects on HPA axis function (Holsboer and Barden, 1996; Holsboer et al., 
1982; Nikisch et al., 2005). In depressed patients the e normalisations include a reduction in 
plasma ACTH and cortisol (Inder et al., 2001), a reduction in CSF levels of CRF and AVP 
(Debellis et al., 1993) and a reduction in adrenal size (Rubin et al., 1995). 
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Numerous clinical and preclinical studies have attempted to characterise the mechanisms that 
underlie HPA axis normalisation in depressed patients following chronic antidepressant 
treatment. Evidence from studies using both TCAs and SSRIs suggest that modification 
occurs in both the feed-forward and feed-back mechanisms regulating HPA axis activity. 
Evidence for reduced feed-forward drive following chronic anti-depressant treatment 
includes reduced CRF mRNA expression levels in the PVN (Brady et al., 1991), reduced 
POMC mRNA expression in the pituitary (Jensen et al., 1999) and a reduction in CRF 
stimulated ACTH secretion (Heuser et al., 1994) following chronic antidepressant treatment.  
 
However, the modification of feed-back mechanisms regulating HPA axis functioning has 
received the most attention. A primary role for altered GR receptor function in mediating the 
effects of antidepressant treatment on HPA axis functio  was first suggested following the 
observation that dexamethasone suppression of plasma corticosterone was re-established in 
antidepressant-treated, remitted depressed patients (Greden et al., 1983; Peselow and Fieve, 
1982). A multitude of preclinical studies have confirmed that long-term antidepressant 
treatment can upregulate both GR mRNA and binding i key regions involved with 
glucocorticoid feedback to the HPA axis (for review see (Pariante and Miller, 2001). 
Initially, it was suggested that only TCAs and not SSRIs altered HPA axis feedback by 
altering GR receptor levels, but several recent studies support the ability of SSRIs to modify 
GR receptor expression in key regulatory brain regions (Uys et al., 2006; Yau et al., 2002). 
In addition to the regulation of GR by anti-depressant  there is also evidence for increased 
MR function following chronic treatment with both te TCAs and SSRIs (Pariante et al., 
2004; Seckl and Fink, 1992). 
 
4.3 Serotonin and brain development  
 
5-HT, like the other monoamine neurotransmitters, has been shown to play a role in 
regulating brain development prior to the time it assumes its role as a 
neurotransmitter in the mature brain. The early expr ssion of the 5-HT 
neurotransmitter system and its widespread distribution are proposed to be central to 
its known diverse effects upon brain development. 5-HT has been shown to be 
mitogenic for both neurones and other cell types (Lauder, 1993) and is also 
implicated in a multitude of other developmental events including neuronal 
differentiation, synaptogenesis and dendritic refinement. Through these mechanisms 
5-HT influences the development and maturation of terminal areas but in addition 5-
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HT has been shown to influence the development of 5-HT projections themselves, 
through a process known as autoregulation (Whitaker-Azmitia 2001). 
 
In vivo pharmacological manipulations during development have shown that 5-HT 
depletion or 5-HT receptor activation during critical developmental periods can 
influence neurogenesis (Lauder et al., 1976), neuronal differentiation (Lauder et al., 
1987) and neurite outgrowth (Haydon et al., 1987; Lotto et al., 1999). As SERT plays 
a primary role in the regulation of 5-HT availability t is likely that any manipulation 
which alters SERT function during these periods may also impact upon brain 
development. The observation that the temporal expression of SERT during brain 
development closely mirrors that of 5-HT (Bruning et al., 1997; Zhou et al., 2000) 
supports the contention that SERT may indeed regulate 5-HT availability at this time. 
Furthermore, the complete ablation of SERT function ( n SERT knock-out mice) has 
been shown to result in subtle alterations in the brain proposed to be related to the 
role of 5-HT in development. This includes a decrease in 5-HT cell number (Lira et 
al., 2003) and altered barrel field formation in the somatosensory cortex (Persico et 
al, 2001; Salichon et al., 2001). Furthermore, as the alterations present in the barrel 
formation of SERT KO mice can be overcome by removal f the 5-HT1B receptor 
(by genetic knock-out) this supports the suggestion hat it is the regulation of 
extracellular 5-HT concentrations by SERT and the subsequent elevation of 5-HT1B 
receptor activation, which results in altered barrel formation (Salichon et al., 2001). 
Pharmacological manipulation of 5-HT availability during the prenatal period has 
also been shown to alter the function of specific serotonin receptor subtypes in the 
brain of the adult animal (Whitaker-Azmitia et al., 1987). As the work presented in 
this thesis involves the investigation of brain and serotonin system function in an 
animal model with a life-long increase in SERT function it is important to recognise 
that developmental mechanisms are likely to contribu e to some of the altered 
endophenotype found in these animals. Furthermore, the altered regulation of 5-HT 
in these animals during development, as a result of increased SERT function, may 
also contribute to the anxiolytic behavioural phenotype of these animals as 
pharmacological manipulation of SERT function restricted to the perinatal period 
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have also been shown to produce altered anxiety-like behaviour in the adult animal 
(Ansorge et al., 2004). 
 
 
5. Animal model used in thesis  
 
5.1 Generation of hSERT over-expressing ( hSERT OVR) mice  
 
Mice over-expressing the human serotonin transporter gene (hSERT OVR) were generated at 
the University of Edinburgh from C57BL/6xCBA wild-type (Wt) mice by Loder et al. 
(2000).  
 
In brief, the transgene was a 500-Kb yeast artificial hromosome (YAC35D8) containing the 
hSERT gene flanked by 150kb of 5’ and 300 kb 3’ sequence, with the ‘short’ allele of the 5-
HTTLPR in the promoter region and the 10-repeat allele of the VNTR in intron 2. The YAC 
was modified to include a hemagglutinin epitope tag at the C-terminus of the 5-HTT protein 
and the lacZ reporter gene downstream of an internal entry ribosome site using placZSERT 
and pYAM4 (Connor et al., 2000). The vector placZSERT was generated by:- 
 
(i)  inserting a fragment of hSERT genomic DNA extending 5kb upstream from the stop 
codon (obtained by PCR using the forward primer 5’-
ACTGCATAGCGGCCGCATCTTTCATTTGCATCCC-3’ and the revers  primer 5’-
TGTGCTCGAGAGCATTCAAGCGGATGT-3’) into the Notl-Xhol sites of pYIV3. 
 
(ii)  inserting a sequence downstream of the stop codon (obtained by PCR with the forward 
primer 5’-CTCCTCGAGAGGAAAAAGGCTTCT-3’ and the reves primer 5’-
TAGGTACCCTGTTCTCTCCTACGCAGTTT-3’) into the Sall-Kpnl sites of pYIV3. 
 
The unmodified and placZSERT-modified YAC35D8 were then transformed with Notl-
linearized pYAM4 to amplify YAC DNA. YAC DNA was then purified by pulsed field gel 
electorphoresis and injected into the fertilised eggs of wild-type mice. Transgenic mice were 
identified by PCR using primer pairs for hSERT (exon 1A, 1B, inton 1A and 3’UTR), STS 
markers (D17S2009, D17S2004, D1S1294 and D17S1549) and the YAC vector arms (Shen 
et al., 2000a). 
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Mice from the A102.3 transgenic line previously partially characterised (Loder et al., 2000; 
Jennings et al., 2006; MacLean et al., 2004) were used in this study. This transgenic line was 
chosen as it was considered likely to contain the complete hSERT transgene, expressing all 
hSERT gene coding regions and the STS markers, which are located close to the hSERT 
gene.  The A102.3 transgenic line was found to have 8 copies of the transgene, which 
resulted in a pronounced increase in SERT mRNA (approximately 3-fold) and total SERT 
protein expression levels (approximately 3-fold) in the central nervouse system (Jennings et 
al., 2006; Loder et al., 2000; 2002).  
 
In addition to the human SERT gene (SLC6A4) the transgene present in hSERT OVR mice 
also contains genes coding for a number of other proteins, including that for bleomycin 
hydrolase, the carboxypeptidase D precursor and the golgi SNAP receptor complex member 
1. While the inclusion of these genes in the transge e presents an important limitation when 
considering the possible influence of the transgene o  parameters of serotonergic system 
functioning, at present there is no evidence to suggest that any gene present in the transgene 
other than that for the hSERT is involved in the regulation of 5-HT system functioning. 
 
5.2 Serotonergic characteristics of hSERT OVR mice  
 
An increase in SERT mRNA expression has been confirmed in the CNS of hSERT OVR 
mice from the A102.3 transgenic line by in situ hybridisation. Furthermore, an increase in 
SERT binding site density (2.3-3.5 fold) and an alter ion in the Hill co-efficient, indicative 
of the presence of more than 1 binding site, has also been reported in cortical membranes of 
hSERT OVR as compared to wild-type (Wt) mice (Jennings et al., 2006). This not only 
confirms that SERT expression is increased in the CNS of mice with the hSERT transgene 
but also suggests that these mice express both the murine and human form of the transporter, 
as the rodent and human SERT have differing affinities for the SERT ligands (MacLean et 
al., 2004; Plenge and Mellerup, 1991).  The increased SERT expression in the CNS of 
hSERT OVR mice results in decreased extracellular and tissue 5-HT levels while tissue 5-
HIAA levels are not affected (Jennings et al., 2006). 
 
5.3 Relevance of hSERT OVR mice to Humans  
 
As previously outlined (section 4.6.3) polymorphic variations in the human SERT gene exist 
that lead to a life-long increase in SERT function. For example, the “long”/“L” promoter of 
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the 5-HTTLPR region results in greater transcriptional activity of the hSERT gene in 
comparison to the “short”/“S” promoter and results in higher SERT mRNA expression, 
protein density and 5-HT uptake in lymphoblastoid cells, platelets and the brain (Greenberg 
et al., 1999; Heinz et al., 2000; Lesch et al., 1996; Little et al., 1998). Several studies have 
investigated the possible relationship between the 5-HTTLPR and affective 
psychopathology. However, despite the known influence of the 5-HTTLPR on affective 
functioning, and involvement in the risk of developing affective disorders (as reviewed 
below), the underlying differences in neurobiology and physiology which contribute to these 
effects are unknown. Research into these parameters has been limited by the fact that the 5-
HTTLPR sequence is present in humans and non-human primates but not in rodents (Lesch 
et al., 1996) and that the function of known transcriptional control elements in murine SERT 
are not yet sufficiently well characterised to allow experimental alterations that would drive 
increased SERT expression. However, hSERT OVR mice have a life-long increase in SERT 
function which parallels that observed in “L” allele human individuals as compared to “S” 
allele individuals. These animals, therefore, provide a unique opportunity in which to 
investigate the mechanisms by which a life-long increase in SERT expression may regulate 
affective functioning and the underlying neurobiology. Here, I briefly review evidence from 
clinical studies implicating a role for the 5-HTTLPR in psychopathology. 
 
5.3.1 5-HTTLPR polymorphism and Psychopathology  
 
A role for the 5-HTTLPR in the risk of developing and influencing the severity of several 
psychopathologies has been reported. For example, the “S” allele has been associated with 
increased impulsivity and aggression (Beitchman et al., 2006; Sakado et al., 2003; Steiger et 
al., 2005), is more frequent in anorexia and bulimia patients (Di Bella et al., 2000; Fumeron 
et al., 2001; Matsushita et al., 2004), and is alsomore frequent in migraine sufferers (Gonda 
et al., 2007; Juhasz et al., 2003) as compared to controls. However, an equal number of 
studies have reported no association, or no difference in the frequency of the “S” allele as 
compared to controls in patients with the same disor ers (Baca-Garcia et al., 2004; Patkar et 
al., 2002; Schmidt et al., 2002; Hinney et al., 1997; Sundamurthy et al., 2000; Urwin et al., 
2003; Yilmaz et al., 2001). At present meta-analysis studies have not been completed to 
further investigate the possible relationship betwen any of these disorders and the 5-
HTTLPR polymorphism.  
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The usefulness of meta-analysis studies in considering the effect of the 5-HTTLPR 
polymorphism in psychopathology can be demonstrated by studies investigating the effect of 
the polymorphisms on suicidal behaviour. A possible rol  for the 5-HTTLPR in suicide is 
supported by several studies which have reported an increased frequency of the “S” allele in 
hospitalised violent suicide attempters (Bayle et al., 2003; Bellivier et al., 2000) and suicide 
completers (Bondy et al., 2000). An association betwe n the “S” allele has also been 
reported with a family history of suicide (Joiner et al., 2002; Limosin et al., 2005)  and a  
personal history of suicide attempts (Limosin et al., 2005; Preuss et al., 2001). However, 
numerous others have reported no such association (C urtet et al., 2003; Mann et al., 2000; 
Rujescu et al., 2001; Segal et al., 2006). Furthermore, other studies have demonstrated a 
significantly higher frequency of the “L” allele indepressed suicide victims in comparison to 
non-suicidal controls (Du et al., 1998; 1999). To clarify the relationship between the 5-
HTTLPR and suicide a recent meta-analysis of 25 studies investigating the relationship 
between the 5-HTTLPR and suicide was completed. This has shown that although the “S” 
allele does not increase the risk of suicide, when comparing suicidal individuals to normal 
controls, it did significantly increase the risk of suicide attempts in psychiatric patients with 
the same psychiatric diagnosis and was also associated with an increase in the level of 
violence in the method used to commit suicide (Lin and Tsai, 2004). 
 
Where the “S” allele may confer increased susceptibility to some disorders it is apparent that 
the “L” allele may play a role in determining either the likelihood r clinical severity of other 
disorders. For example, while the 5-HTTLPR polymorphism was not found, by meta-
analysis, to influence susceptibility to the development of schizophrenia (Fan and Sklar, 
2005) a number of studies have associated the “L” allele with an increase in the severity of 
the schizophrenic hallucinations and the schizo-affective symptoms experienced by patients 
(Kaiser et al., 2001; Malhotra et al., 1998).  Furthe more, the “L” allele has been reported to 
be more frequent in autism (Yirmiya et al., 2001) and has been associated with an increase in 
the severity of social and communicative impairments i  autistic individuals (Tordjman et 
al., 2001). In addition, the “L” allele has also been reported to be more frequent in patients 
suffering from OCD (Greenberg et al., 1999). 
 
5.3.2 5-HTTLPR and Anxiety  
 
Since the seminal study by Lesch et al (1996) detailing the influence of the 5-HTTLPR on 
anxiety-related traits (neuroticism scores on the NEO-PI-R) many subsequent studies have 
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replicated the finding that the “S” allele of the 5-HTTLPR is associated with increased 
neuroticism (Greenberg et al., 2000; Osher et al., 2000; Schinka et al., 2004). This 
relationship has also been confirmed in a number of other studies using different measures of 
anxiety-related personality traits, including the harm avoidance scale (of the Tridimensional 
Personality Questionaire (TPQ)) (Heinz et al., 2000; Osher et al., 2000; Tsai et al., 2002) and 
self-rating anxiety and depression questionnaires (Murakami et al., 1999). However, several 
studies have reported no association between the 5-HTTLPR and anxiety traits with the same 
measures (Ebstein et al., 1997; Gustavsson et al., 1999; Lerman et al., 2000; Willis-Owen et 
al., 2005). These inconsistencies may be influenced by the small sample sizes used in some 
studies and the possible interference of other co-morbid disorders in some patient samples. 
However, a recent meta-analysis of 26 studies investigating the possible influence of the 5-
HTTPLR polymorphism on anxiety traits suggests that t e “S” allele does indeed increase 
neuroticism (as detected by NEO) but not harm avoidance or other anxiety-related 
personality traits (Mintun et al., 2004). 
 
Despite the significant influence of the 5-HTTLPR on neuroticism, however, few 
investigations have found evidence for an increase in the frequency of the “S” allele in 
patients with anxiety disorders (You et al., 2005). Indeed, most studies fail to demonstrate 
any significant difference in the frequency of the “S” allele in patients with these anxiety 
disorders (Deckert et al., 1997; Matsushita et al., 1997; Olesen et al., 2005). However within 
these patients a link between the “S” allele and an increase in the severity of some of the 
symptoms of these disorders has often been noted. 
 
5.3.3 5-HTTLPR and Depressive Disorders  
 
As neuroticism is a governing factor in the likelihood of developing depression (Collier et 
al., 1996; Duggan et al., 1995) and neuroticism is influenced by the 5-HTTLPR, research has 
been directed towards investigating the possible influe ce of the 5-HTTLPR in depressive 
disorders. Multiple studies provide evidence for an association between the “S” allele and 
the risk of developing depression, with an increased fr quency of this allele identified in 
patients with MDD (Furlong et al., 1998; Hoefgen et al., 2005; Heils et al., 1997; Mann et 
al., 2000), BPD (Furlong et al., 1998; Rees et al., 1997) and seasonal affective disorder 
(Rosenthal et al., 1998). However, several other studies have found no evidence for a 
significant difference in the frequency of the “S” promoter in depressed patients (Gutierrez et 
al., 1998; Steffens et al., 2002) and no association between the 5HTTLPR polymorphism and 
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MDD (Frisch et al., 1999; Gillespie et al., 2005; Hoehe et al., 1998), BPD (Kirov et al., 
1999; Mellerup et al., 2001) or seasonal affective disorder (Johansson et al., 1997). Possible 
reasons for variability in the findings of these studies include the use of small sample sizes, 
variability in the clinical phenotypes of subjects included in the studies and possible 
interference from coexisting disorders. The relative distribution of male and female 
participants in the sample may also be important (see section 7.2). Despite these contrasting 
results, however, two meta-analysis have confirmed that individuals homozygous for the “S” 
allele (S/S genotype) are at increased risk of suffering from MDD and BPD (Furlong et al., 
1998; Lotrich and Pollock, 2004).  
 
Recent research suggests that the effect of the 5-HTTLPR polymorphism on the likelihood to 
develop depression is directly mediated by its effect on neuroticism (David et al., 2005) 
while others have suggested that the modulatory effect of the 5-HTTLPR on the response to 
life stressors may be central to its influence on the likelihood of developing depression 
(Caspi et al., 2003). However, the close inter-relationship between neuroticism and the 
perception of stress makes it difficult to delineate each of these factors as the primary 
mechanism by which the 5-HTTLPR influences the vulnerability to depression, and it is the 
interaction between these factors which is likely to be most important.  
 
5.3.4 5-HTTLPR and Antidepressant Efficacy  
 
In addition to its influence on the vulnerability to developing affective disorders the 5-
HTTLPR polymorphism has also been found to influence the efficacy of antidepressant 
treatment in these disorders. A number of studies have reported decreased efficacy of 
antidepressant treatment in patients with an “S” allele (S/S or S/L genotype) (Arias et al., 
2003; Pollock et al., 2000; Zanardi et al., 2001) while others have reported decreased 
efficacy in patients homozygous for the “S” allele (S/S genotype) (Smeraldi et al., 1998). 
However, the association between the 5-HTTLPR and the efficacy of antidepressant 
treatment are not always consistent (Smits et al., 2004). The considerations previously noted 
with regard to studies investigating the frequency of the 5-HTTLPR in affective disorders are 
also relevant to these studies. In addition ethnicity may be an important factor in the 
variability observed in these studies. Thus, a number of studies conducted in Asian 
populations have reported that antidepressant efficacy is increased in “S” allele as compared 
to “L” allele patients (Kim et al., 2000; Kim et al., 2006; Yoshida et al., 2002). This is in 
direct contrast to the effect reported by studies in Caucasian populations (Arias et al., 2003; 
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Durham et al., 2004; Joyce, 2003; Serretti et al., 2007) and suggests that ethnicity may 
modulate the ability of the 5-HTTLPR polymorphisms to influence the antidepressant 
response. However, the possible influence of ethnicity requires further investigation as a 
number of more recent studies in Asian populations have reported the same trend as that 
observed in Caucasian samples (Cheetham et al., 1988; Hong et al., 2006). Furthermore, a 
recent meta-analysis of 15 studies investigating the possible effect of the 5-HTTLPR 
polymorphism on SSRI efficacy in depressed patients, which included studies with both 
Asian and Caucasian samples, found that being homozygous for the “S” allele significantly 
reduced the frequency of remission from depressive symptoms, whereas being both 
homozygous or heterozygous for the “S” allele signif cantly delayed the rate of the treatment 
response (Serretti et al., 2007).  
 
Overall, the data from human studies suggest that the “S” allele of the 5-HTTLPR may be 
associated with an increased risk of individuals developing affective disorders, in part 
through its influence on trait anxiety, and that this allele is also associated with the reduced 
efficacy of antidepressant treatment. 
 
5.4 Phenotype of hSERT OVR mice  
 
In comparison to Wt animals hSERT OVR mice display decreased anxiety-related 
behaviour in two behavioural paradigms, the elevated-plus maze (EPM) and the 
hyponeophagia test (Jennings et al., 2006). This suggests that hSERT OVR mice may 
provide a valid model of the decreased trait anxiety observed in humans with the “L” 
5-HTTLPR polymorphism. During these studies we also noted that hSERT OVR 


































Body weight of age-matched male and female Wt and hSERT OVR mice. Data from 
mice used in basal [14C]2-deoxyglucose experiment (saline-treated). ***denotes 
p<0.001 significant gender difference, †denotes p<0.05 significant genotype effect 
(2-way ANOVA). hSERT over-expression results in a significant decrease in body 




6. Importance of Gender in Affective Disorders  
 
Gender represents a significant factor in susceptibility for the development of both 
depressive and anxiety disorders with women approximately twice as likely to develop these 
disorders than men (Kessler et al., 1994) . Clinical evidence also suggests that the severity of 
symptoms is greater and the onset of effective antidepressant treatment delayed in depressed 
women as compared to men (Drevets et al., 2002; Kornstein et al., 2000; Kornstein et al., 
1995). Furthermore, preliminary data also suggest that treatment of GAD with SSRI 
antidepressants may be less effective in women as compared to men (Simon et al., 2006).  
 
The neurobiology and physiology underlying the gender differences in affective disorders is 
largely unknown. However, reported gender differences in 5-HT and HPA axis functioning 
are likely to play a role. In humans gender differences reported in the 5-HT system include 
increased SERT (Arato et al., 1991; Staley et al., 2006), increased 5-HT1A (Arango et al., 
1995; Parsey et al., 2002) and decreased 5-HT2 receptor binding (Biver et al., 1996) along 
with a reduced rate of 5-HT synthesis (Nishizawa et al., 1997) in women as compared to 
men. Several of these sexually dimorphic differences have also been reported in studies 
 45 
using experimental animals (Frankfurt et al., 1993; Little et al., 1998; Rubinow et al., 1998; 
Schiller et al., 2006). Despite these observations, however, there is a relative paucity of data 
on gender differences in 5-HT system function, especially with regard to the other 5-HT 
receptor subtypes and actual receptor functioning in comparison to known receptor binding 
differences. Nevertheless, a central role for the modulation of 5-HT system functioning by 
the gonadal steroids (estrogen and testosterone) is supported by a body of evidence reporting 
on the effects of ovariectomy, castration and hormonal supplementation (for review see 
(Rubinow et al., 1998) on the 5-HT system, highlighting one important mechanisms 
contributing to the gender differences present in the 5-HT system. In addition to the 
regulation of 5-HT system function by gonadal steroids, however, it is also important to note 
that steroids are likely to have an important organis tional effect on the 5-HT system during 
development. Furthermore, there is increasing evidence for primary genetic mechanisms 
governing sexual differentiation (Reisert and Pilgrim, 1991) which are likely to influence the 
5-HT system. 
 
Considering the suggested central role of the HPA axis in the aetiology of depressive and 
anxiety disorders it is of interest that gender differences in HPA axis function have also been 
reported. In the preclinical literature gender differences in HPA axis functioning are 
consistent, with female reported as displaying higher basal corticosterone levels as compare 
to males (Chisari et al., 1995; Griffin and Whitacre, 1991; Kitay, 1961) and greater HPA axis 
activation in response to a number of different stressors (Lesniewska et al., 1990; Rivier et 
al., 1999). These observations are paralleled by evidence for increased feed-forward drive, 
including increased hypothalamic CRH mRNA (Patchev et al., 1995), AVP mRNA (Viau 
and Meaney, 1991) and increased plasma ACTH levels (L mevel et al., 1979) in females as 
compared to males. Gender differences in HPA axis activity are influenced, in part, by the 
differences in gonadal steroids between the sexes with a stimulatory role for oestrogen and 
an inhibitory role for testosterone on HPA axis function (Seale et al., 2004). In addition to 
gender differences in the feed-forward mechanisms of the HPA axis decreased GR and MR 
receptor levels in the CNS of females as compared to males also suggest that the negative 
feed-back regulation of HPA axis activity may be lower in females and the gonadal steroids 
have also been implicated directly in the control of GR and MR function (Turner et al., 1990; 
1997). In addition to the observed differences in HPA axis function between males and 
females evidence suggest that the programming of HPA axis activity, into a secretory pattern 
similar to that observed in the affective disorders, by adverse early-life experiences is more 
sensitive in females than in males (Matthews, 2002; Mccormick et al., 1995; Weinstock et 
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al., 1992). This further supports a role for the HPA axis in determining the gender 
differences in the likelihood of developing affective disorders. 
 
In contrast to preclinical studies evidence from psychosocial stress studies in healthy human 
individuals support enhanced HPA activation by psychosocial stress in males as compared to 
females (Kirschbaum et al., 1999; Kirschbaum et al., 1992; Stoney et al., 1987). 
Furthermore, under basal conditions increased ACTH secretion in men as compared to 
women has also been reported although this is not accompanied by differences in cortisol 
levels (Horrocks et al., 1990; Roelfsema et al., 1993). These observations seem to be in 
direct contradiction to the hypothesis made from preclinical studies that enhanced HPA axis 
activity in females may play a part in their enhanced risk of developing affective disorders. 
However, more recent studies completed in humans using different kinds of stressors have 
shown that while HPA axis activity is greater in males than females during stressful 
challenges based on achieving a goal, females experi nc  a greater degree of HPA axis 
activation in stressful challenges involving social rejection (Stroud et al., 2002). Clearly, 
further research needs to be dedicated to elucidating the gender dependent effects of different 
stressor on HPA axis activity and to understanding how these relate to the real life situations 
experienced by men and women.  
 
6.1 Gender modulation of 5-HTTLPRs influence on aff ective functioning  
 
Despite the known influence of gender in affective disorders and on trait anxiety the possible 
interaction between gender and the influence of the 5-HTTLPR on affective functioning is 
not clear. Several studies indicate that an interacion between these factors may exist, 
although the results from these studies are often contradictory. For example, while Lesch et 
al. (1996) and Greenberg et al. (2000) have shown that the “S” allele is associated with 
increased neuroticism in both male and female samples others have reported that the “S” 
allele only increases neuroticism in males and not i  females (Brummett et al., 2003; Du et 
al., 2000). Furthermore, it has also been reported that the “S” allele has a diametric influence 
on trait anxiety in males (increased) and females (d creased) (Gelernter et al., 1998; Mizuno 
et al., 2006). In addition the “S” allele has been r ported to increase the risk of depressive 
symptoms in young females but decrease them in young males (Sjoberg et al., 2006). Despite 
reports supporting an interaction between gender and the influence of the 5-HTTLPR on 
affective functioning numerous other studies have repo ted no such interaction (Ball et al., 
1997; Ricketts et al., 1998). Furthermore, two recent meta-analyses investigating the possible 
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influence of gender on the association between the 5-HTTLPR and neuroticism have found 
no significant evidence for this (David et al., 2005; Mintun et al., 2004). Gender has also 
been found not to influence the modulatory effect of the 5-HTTLPR on amygdala function in 
response to fearful stimuli (Harari et al., 2002). The reasons for the variability in the results 
of these studies are largely unknown but possible confounding factors include the different 
ethnic backgrounds and ages of participants within e study and the use of small sample 
sizes, which results in low statistical power. Investigating the potential role of gender in 
modulating the effect of a life-long increase in SERT functioning, as affected by the 5-
HTTLPR, on affective and 5-HT system functioning warrants further systematic 
investigation.  
 
7. Aims of Thesis  
 
The studies conducted in this thesis aim to elucidate the alterations in brain function that 
occur as a result of a genetically determined life-long increase in the expression and function 
of SERT, with particular emphasis on the serotonin system and HPA axis function. In these 
studies mice over-expressing the SERT gene were used as a model of the life-long increase 
in SERT function present in humans with the “L” allele of the 5-HTTLPR as compared to 
those with the “S” allele, which were modelled by Wt animals. Alterations in constitutive 
brain functioning in hSERT OVR mice were first assessed by observing local cerebral 
glucose utilisation (LCMRglu) under basal conditions. As the measurement of LCMRglu in 
this thesis involved the use of a novel approach the validity of this method was assessed 
prior to its use. 
 
Possible alterations in serotonin receptor subtype (5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C) 
pharmacology and function were also determined in hSERT OVR mice, not only to 
characterise the influence of a life-long increase of SERT functioning on these receptors but 
to further elucidate their possible involvement in the altered constitutive brain functioning 
observed in hSERT OVR mice. Constitutive brain function and serotonin receptor 
functioning were characterised in both male and femal  animals to further investigate the 
influence of gender on brain and serotonin system function and to further investigate the 




The functional impact of a life-long increase in SERT on HPA axis functioning was also 
addressed by determining levels of circulating ACTH and glucocorticoids under basal 
conditions and in response to acute stress. Possible alterations in serotonergic feed-forward 
drive of the HPA axis in hSERT OVR mice were assessed by characterising thesehormonal 
responses to specific 5-HT receptor agonists. Central MR and GR mRNA expression levels 
were also determined in hSERT OVR mice in order to investigate the possible influence of a 








































Chapter 2- Methods  
 
1. Animal Housing  
All experiments were performed on male and female hSERT OVR mice and their Wt 
littermates aged 1.5-4 months (males: 24g-38g; femal s 16g-28g). Animals were group-
housed (5-6 animals/cage) under strict environmental conditions with a 12-hour light-dark 
cycle (lights on 7.00-19.00) and at a temperature of 21±1oC. Access to food and water was 
ad libitum until the day of the experiment. Access to food was restricted over-night (13-14 
hours prior to experimental manipulation) for animals involved in 2-deoxyglucose imaging 
experiments to reduce the known hyperglycaemic response of specific pharmacological 
challenges. 
 
2.Polymerase Chain Reaction (PCR)  
 
2.1 Theory  
 
The polymerase chain reaction (PCR) is an in vitro technique that allows for the generation 
of multiple copies of a target DNA sequence by repeatedly cycling through three reaction 
steps: DNA denaturation, primer hybridization and DNA polymerase extension. In the first 
step double stranded DNA is denatured into two single strands at high temperature (95oC-
97oC). This subsequently allows other complementary DNA sequences to anneal to it by 
hydrogen bonding in a nucleotide specific manner. In the second step the temperature is 
reduced (approximately 55oC-72oC) to allow primer hybridization with specific sequences 
within the target DNA. Primers are single strands of oligonucleotides, approximately 20 
nucleotides long, which complement a sequence of nucleotides flanking the target DNA. 
Following primer hybridisation a complementary sequnce of nucleotides to those present in 
the target DNA is generated through the extension of each annealed primer by DNA 
polymerase from deoxyribonucleotide trisphosphates (dNTPs) present in the reaction mix. In 
PCR a thermostable polymerase originally isolated from the thermophilus aquaticus 
bacterium, known as Taq polymerase, is used for this extension reaction (optimum 
temperature 72oC). Following the formation of this new single strand of DNA the sequence 
is repeated. Importantly, all previously synthesised DNA products act as templates for new 
primer-extension reactions in each new cycle, thus t e DNA product is synthesised in an 
exponential fashion. After approximately 30 PCR cycles enough (~230) copies of the target 
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DNA sequence are present for it to be visualised, usually by ethidium bromide staining, 
following isolation of the target DNA sequence according to its mass by gel electrophoresis. 
 
2.2 Detection of the hSERT transgene  
 
Genomic DNA was extracted from ear punch tissue samples by digestion with proteinase K 
(600µg/ml) in a lysis buffer (50mM Tris-HCl pH8, 100mM EDTA, 100mM NaCl, 1% SDS) 
overnight at 56oC (500µl per sample). Following digestion samples wre centrifuged (13,000 
rpm for 5 minutes) to remove debris and isolate DNA within the supernatant. The DNA was 
then precipitated from the supernatant in a fresh eppendorf tube containing 300µl of 
isopropanol for 15 minutes at room temperature and the DNA pellet isolated by 
centrifugation (13,000 rpm for 10 minutes). Excess isopropranol was then removed from the 
tube and the DNA pellet washed with 70% ethanol (puse centrifugation) and re-suspended 
in 100µl of TE (10mM Tris-HCl, 1mM EDTA) solution by incubation for 1 hour at 56oC.    
 
1µl of each DNA sample was added to 24µl of the PCR reaction mixture (table 2.1) 
containing primers specific for the hSERT gene (MWG Biotech AG) and was then overlayed 
with a drop of mineral oil. A blank sample was also generated by addition of 1µl deionised 
water to 24µl of PCR solution. Samples then underwent PCR as outlined in table 2.2. 
Following PCR 5µl blue loading gel was added to each sample and the DNA samples were 
separated by electrophoresis (125V for approximately 1 hour) on a 2% agarose gel (with 
12.5ml/112.5ml Tris-Borate-EDTA (TBE, 10x concentrate, Sigma U.K) and 5µl 10mg/ml 
ethidium bromide) in a 1:10 dilution TBE buffer along with a 100 base pair DNA ladder 
(10µl with 5µl blue loading gel, Promega, U.K). Presence of the hSERT gene in transgenic 
hSERT OVR mice was confirmed by observing a single 230 base pair DNA band while this 
product is not present in wild-type animals (Figure 2.2). 
 
Figure 2.1 Primer Sequences  F7 
 
Forward Primer Sequence: 5′-TTC TTT CCT TAC TAA GTT GAG AAC G-3’ 






Table 2.1 PCR reaction mixture  T2 
 
 Volume (per sample) 
Buffer (10x concentrate) 2.5µl 
Magnesium Chloride 1.5µl 
dNTP mix (40mM) 0.5µl 
Forward Primer (200ng/µl) 0.25µl 
Reverse Primer (200ng/µl) 0.25µl 
TAQ polymerase 0.25 µl 
ddH2O 18.75µl 
Total PCR tube volume 24µl 
 
Table 2.2 PCR cycle temperature and duration for hSERT detection  T3 
 
Denature 97oC 2 minutes 
   
5 cycles 94 oC 30 seconds 
 58 oC 30 seconds 
 72 oC 60 seconds 
   
30 cycles 94 oC 30 seconds 
 56 oC 30 seconds 
 72 oC 60 seconds 
   



























Detection of the hSERT gene product (203bp) on 2%agarose gel. First well shows 
the 100bp DNA ladder while the second well shows the result from a blank control 
(no product detected). The third well shows the result given from a hSERT OVR 
mouse (230bp DNA product detected) where the fourth shows the result from a Wt 

























3. Measurement of Local Cerebral Glucose Utilisatio n (LCMRglu)  
 
Under normal physiological conditions the energy requirements of the brain are provided 
almost exclusively by the oxidative catabolism of glucose. Importantly, the functional 
activity within any regions of the CNS is directly linked and intimately related to the energy 
consumption, and so glucose catabolism, within thatregion. As very low levels of glucose 
are stored within the CNS any functionally-related glucose requirements must be met by 
glucose from the cerebral blood. Use of radiolabelled glucose (or oxygen) in 
autoradiographic methods would not give an accurate refl ction of the rate of metabolism 
within a brain region, as during metabolism the isotopes present in these tracers would 
become incorporated into carbon-dioxide (CO2) or water (H2O) which freely diffuse away 
from the brain region of interest (ROI). However, quantification of glucose utilisation as a 
reflection of functional activity in distinct brain regions has been made possible by the 
development of the [14C]-2-deoxyglucose technique (Sokoloff et al., 1977).    
 






2-deoxy-D-glucose (2-DG) is an analogue of glucose with one structural difference, the 
replacement of the hydroxyl group on the second carbon of the hexose ring by a single 
hydrogen atom (Figure 2.3). The structural similarities between these molecules mean that 
they are both transported across the blood brain barrier (BBB) by the same molecular carrier 
and are metabolised to their respective hexose-6-phosphates by the enzyme hexokinase in 
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brain tissue. However, while glucose-6-phosphate can ontinue through the glycolytic 
pathway and tricarboxylic acid (TCA) cycle, being sub equently metabolised into CO2 and 
H2O, deoxyglucose-6-phophate (2-DG-P) can not and remains effectively trapped in the 
tissue. These biochemical characteristics of deoxyglucose mean that radiolabelled 
dexoyglucose may be used in experimental animals to determine tracer accumulation over a 
known time period in a ROI as an accurate reflection of glucose metabolisms and so 
functional activity.  
 
3.1 Mathematical model and Operational Equation for  the Quantitative  
2-deoxyglucose technique  
 
Sokoloff et al. (1977) developed a mathematical model for the accumulation of radiolabelled 
[14C]-2-DG in brain tissue that allows for the determinat on of local cerebral glucose 
utilisation (LCMRglu) in discrete regions of the CNS. This model includes pre-determined 
rate constants for the transport and phosphorylation (by hexokinase) of glucose and 
deoxyglucose (Figure 2.4). From this model and its empirically derived rate constants the 


























Figure 2.4 Theoretical model of 2-deoxyglucose tech nique F10 
 
PLASMA BRAIN TISSUE
































Schematic representation of the theoretical model on which the 2-deoxyglucose technique is 
based. Ci* represents the total 14C present in a single homogenous brain tissue. Cp* and Cp 
represent the concentrations of [14C]-2-DG and glucose present in the arterial plasma, 
respectively. CE* and CE represent their respective concentrations in the pool available for 
hexokinase metabolism. CM* represents the concentration of [14C]-2-DG-P present in the 
tissue. K1*, K2* and K3* represent the constants for the carrier-mediated transport of [14C]-2-
DG from plasma to tissue, tissue to plasma and hexokinase phosphorylation respectively, 
whereas K1, K2 and K3 represent those of glucose for the same processes. The dashed 
arrow represents the possibility of glucose-6-phosphate metabolism by glucose-6-




The operational equation outlines the determination of cerebral glucose use (Ri) following a 
bolus intravenous injection of [14C]-2-DG when the concentrations of arterial plasma [14C]-2-
DG (Cp*) and glucose (Cp), gained from blood samples taken throughout the experimental 
period, and the total [14C] concentration in a brain region, as determined by autoradiography, 
are known. As the concentration of [14C] within a brain region reflects both the 
phosphorylated and unphosphorylated [14C]-2-DG present in the tissue, the operational 
equation includes an integral determined from the art ri l plasma [14C] values along with the 
rate constants for the transportation of DG between tissue and plasma (k1* and k2*) and the 
phosphorylation of DG (k3*) that allows for calculation of the unphosphorylated DG 
present. This allows for the determination of the amount of phosphorylated DG present in the 
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designated brain region which relates directly to the rate of glucose utilisation. The equation 
also contains a “lumped constant” combining six different constants that describe the 
differences in the kinetics and distribution volumes of glucose and [14C]-2-DG. The lumped 
constant and rate constants used in the operational equation have all been previously 
determined by Sokoloff et al. (1977) in separate experiments. In the equation the lumped 
constant is multiplied by the plasma integral for glucose and deoxyglucose determined 
throughout the experiment, and is also corrected for the lag in tissue-plasma equilibration. 
 




Ci*(T)  - k1
*e-(k2* + k3*)T ∫0
T Cp* e(k2* + k3*)t dt
[λ.Vm*.K m/Ф.Vm.Km*]  [ ∫0
T (Cp*/C p) dt – e-(k2*+k3*) T ∫0
T (Cp*/C p)e(k2*+K3*)t dt]
Total 14C in 









Correction for lag in Tissue 
Equilibration with plasma
Integrated precursor 
specific activity in 
tissue
 
For abbreviations see those in legend of figure 2.4. In addition, T represents the time at 
which the experiment is terminated (~45 minutes). In the lumped constant λ represents the 
ratio of the distribution space between [14C]-2-DG to glucose in the tissue, while Φ 
represents the fraction of glucose which continues along the glycolytic pathway. Vm*, Km* 
and Vm, Km represent the Michaelis-Menten kinetic constants of hexokinase for [14C]-2-DG 
and glucose, respectively. 
 
 
In order for the operational equation to give a valid measurement of LCMRglu several 
conditions must be met. Measurements must only be made in localised brain regions in 
which blood flow and the rate of uptake and phosphorylation of 2-DG are constant. The 
concentration of 2-DG and glucose within each element of tissue must be constant, they must 
be present in the same compartment and they must also be free to exchange between the 
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plasma and tissue. In addition, the determined arteri l plasma glucose and 2-DG 
concentrations must accurately represent their cerebral capillary concentrations. Finally, 
[14C]-2-DG and [14C]-2-DG-P must only be present in pharmacologically inactive, tracer 
amounts. 
 
It has previously been acknowledged that there is con iderable imprecision in our knowledge 
of the rate constants (k1*, k2* and k3*) within a single animal  and that the assumption in 
the operational equation that these constants do not change over a given range of 
physiological conditions is erroneous (Orzi et al.,1988). However, the error inherent in the 
rate constants and their influence on Ri can be diminished by used of an long (45 minute) 
experimental time period. As plasma [14C]-2-DG concentration (Cp*) diminishes with time 
the use of a 45 minute experimental end-point minimises the contribution of the rate 
constants to the equation, therefore any error as a re ult of the rate constants is reduced. This 
has been demonstrated experimentally (Sokoloff et al., 1977; Sokoloff, 1978).  
 
As the lumped constant represents a significant contribution to the operational equation any 
alteration in this constant has the potential to induce error. Theoretically, the value of the 
lumped constant may be altered by any factor producing an imbalance between glucose 
supply and utilisation. However, the lumped constant has been shown to remain stable 
during changes in glucose utilisation, cerebral blood flow and during moderate 
hypoglycaemia and hyperglycaemia. However, out-with normoglycaemia the ratio of 
distribution between glucose and [14C]-2-DG may be altered resulting in the inaccurate 
calculation of LCMRglu. For example, in severe hyperglycaemia (plasma glucose in excess 
of 17µmol/ml) decreases in the brain distribution space of [14C]-2-DG and glucose occur, 
leading to a decrease in the ratio of the distribution volumes for glucose and [14C]-2-DG, 
resulting in inaccuracies in the operational equation that lead to an underestimation of 
LCMRglu (Schuier et al., 1990). Conversely, in sever  hypoglycaemia (plasma glucose less 
than 4µmol/ml) the distribution volume of glucose i decreased and that of deoxyglucose is 
increased, leading to a marked increase in the value of the lumped constant and an 
overestimation of LCMRglu (Suda et al., 1990). Stress-induced or drug induced 
hyperglycaemia, therefore, are possible confounding errors in the calculation of LCMRglu. 
Therefore, within this work as several of the drug challenges used were known to induce 
hyperglycaemia animals were routinely fasted over-night in order to maintain 
normoglycaemia during the experiment. It is also important to note that fasting animals in 
this way did not result in severe hypoglycaemia (in saline-treated animals). 
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An additional criticism of the 2-DG technique has been that it does not account for the 
metabolism of 2-DG-P to 2-DG by glucose-6-phosphatase (Hawkins and Miller, 1987). 
However, the activity of glucose-6-phosphatase in cerebral tissue has been found to be low 
and rigorous neurochemical analysis has confirmed that the amounts present are unlikely to 
compromise the 2-DG method (Nelson et al., 1985; 1986; Sokoloff et al., 1977).  
 
3.2 Experimental protocol for quantitative measurem ent of LCMRglu  
 
Polyethene cannulae are surgically inserted into both the femoral arteries and veins of 
anaesthetised animals. Following surgery, animals are secured and lightly restrained by 
means of a plaster cast around the lower torso to a weighted block. Anaesthesis is then 
terminated and animals allowed to recover for 2 hours prior to further manipulation (i.e. 
injection of pharamacological agents) or [14C]-2-DG injection. Measurement of LCMRglu is 
initiated by the intravenous (i.v.) injection of [14C]-2-DG (7.4MBq.kg-1 in 2.5mls.kg-1 sterile 
saline) at a steady rate over 30 seconds. Over the subsequent 45 minutes of the experiment a 
series of 14 blood samples, approximately 0.75mls in volume, are collected into heparinised 
centrifuge tubes at pre-determined time intervals. In order to avoid hypovolaemia each blood 
sample is replaced by a similar volume of saline. The collection of samples is temporally 
distributed in such a way as to ensure full characterisation of the peak in plasma [14C]-2-DG 
concentration during the first 5 minutes of the experiment and the full arterial profile of 
plasma [14C]-2-DG over the course of the whole experimental period. Samples are 
immediately centrifuged and aliquots of plasma removed for the determination of plasma 
glucose and [14C] concentrations by glucose oxidase assay and liquid scintillation analysis, 
respectively. At 45 minutes animals are rapidly killed by i.v. injection of sodium 
pentobarbitone and the brains rapidly dissected out, frozen (isopentane, -40oC) and processed 
for quantitative autoradiography (Chapter 2, section 7.1). The three parameters determined 
by the experiment; the time-course of arterial [14C]-2-DG concentration, time-course of 
arterial plasma glucose concentration and the tissue concentration of [14C], as determined by 







3.3 Semi-quantitative 2-deoxyglucose autoradiograph y 
 
A semi-quantitative (SQ) 2-deoxyglucose method, modified from the fully quantitative 
method, has been applied to determine LCMRglu in tra sgenic mice (Kelly et al., 2002) and 
in mice in response to pharmacological challenge (Jordan et al., 2005). In this method 
measurement of LCMRglu is initiated in freely-moving conscious animals by the 
intraperitoneal (i.p) injection of [14C]-2-DG (5µCi in 0.4mls) at a steady rate over 10 
seconds. 42.5 minutes after the injection of [14C]-2-DG animals are anaethetized in a perspex 
chamber containing halothane (2.5%) in a nitrous oxide:oxygen mixture (70%:30%) for 2.5 
minutes. At exactly 45 minutes after isotope injection mice are rapidly decaptitated and a 
terminal blood sample collected by torso inversion. Terminal blood plasma [14C] and glucose 
concentrations are determined from this sample by the methods previously outlined and the 
brains are processed as outlined for the quantitative 2-DG method. Autoradiographic image 
analysis allows for the determination of the [14C] isotope concentration present in each brain 
ROI. 
 
As the arterial plasma [14C] and glucose concentration profile throughout the experimental 
period in each animal is not determined by this method the original analytical method 
developed by Sokoloff et al. (1977) can not be used to quantitatively define LCMRglu. 
Rather, LCMRglu is estimated as the ratio of the [14C] isotope concentration in each ROI 
relative to that in a proposed control brain region, where LCMRglu is thought to remain 
constant between the experimental conditions. The constancy of LCMRglu in this region 
between experimental groups is implied by the observation of a similar [14C] concentration 
in the standard region between experimental groups when the terminal plasma parameters 
([14C] and glucose concentration) also remain constant between groups. Observation of a 
similar relationship between the [14C] concentration of the selected control region andthe 
plasma [14C]: [glucose] ratio of each animal, as displayed on an X-Y graph, within and 
between groups is also used to further implicate the validity of the standard region as an 
appropriate control. However, the relationship between these factors and any possible 
difference in this relationship between experimental groups is not usually analysed 
statistically by correlation or linear regression analysis, respectively. The control region is, 
however, often selected with reference to previous relevant data gained by the quantitative 2-
DG method in the rat. 
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In these experiments the SQ was further modified from the reported method in two ways; (i) 
as the level of unphosphorylated [14C]-2-DG has been reported to be significantly increased 
in the brain of rats at the experimental end-point following i.p. compared to i.v. injection 
(Kelly and Mcculloch, 1983a) animals in these studies were killed by rapid cervical 
dislocation and decapitation with no anaethesia in order to minimise the possible 
confounding influence of anaesthesia on the [14C]-2-DG levels in the brain (ii) LCMRglu 





























4. Ligand Binding Autoradiography  
 
4.1 Receptor Theory  
 
Ligand binding autoradiography experiments involve th  interaction of a radiolabelled ligand 
with a target binding site to form a reversible ligand-receptor complex governed by the Law 




           Ligand + Receptor   ↔  Ligand-Receptor Complex 
K-1 
 
[L] + [R] ↔ [LR] 
 
The Law of Mass Action states that the rate of a chemical reaction is proportional to the 
product of the effective concentrations of each participating molecule in that reaction. 
Therefore, if the concentration of participating molecules remains constant the reaction will 
eventually reach a state known as equilibrium, when t  forward rate of the reaction is equal 
to the reverse rate of the reaction. In terms of radioligand binding this means that the rate of 
association (K+1) between ligand and receptor becomes equal to the rat  of ligand 
dissociation from (K-1) the ligand-receptor complex. 
 
The product of the above reaction [RL] is more commonly referred to as [B], the amount of 
the radioligand bound to the receptor. When equilibrium is attained the dissociation constant 





Kd = [R].[L]/[B] 
 
Numerically, Kd is equal to the concentration of the ligand that would be required to occupy 
50% of the binding sites at equilibrium and is characteristic of both the ligand and the 
receptor. Therefore, if a ligand has a low Kd for a receptor binding site a low concentration 
of the ligand is required to occupy half of the receptor binding sites and the ligand is said to 
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display high affinity for the receptor. Ligands with low affinity have high Kd values and a 
large concentration is required to occupy 50% of the receptors. 
 
At equilibrium, the total number of receptors present (Bmax) is equal to the number of 
receptors bound by the radioligand and unbound free rec ptors, represented as: 
 
Equation 3 
Bmax = [R] + [B] 
 
Therefore, [R] may be substituted in equation 2 to give: 
 
Equation 4 
Kd = (Bmax – [B]).[L]/[B] 
 
If specific binding follows the Hill-Langmuir equation then the relationship between the 




[B] = Bmax [L]/ [L]+ Kd 
 
Saturation analysis methods can be used in order to determine estimates of both Kd and 
Bmax (Figure 2.6). [B] is a function of the radioligand concentration which increases in a 
rectangular hyperbolic fashion with [L]. As previously mentioned the dissosciation constant 




















Non-specific binding (NSB), the binding of the ligand to components of the tissue other than 
the receptor is non-saturable and displays a linear r l tionship to [L]. Experimentally NSB 
may be determined by the displacement of the radioligand from a binding site by use of a 
non-labelled ligand specific to the site of interest. 
 
Equation 5 may be re-arranged to give: 
 
Equation 6 
[B] / [L] = (Bmax / Kd) + [B] / Kd 
 
Bmax and Kd are more commonly estimated by Scatchard plot analysis of binding data, this 
directly relates to equation 6 and is shown in figure 2.7. In Scatchard analysis the 
concentration of [B]/[L] ligand is plotted directly against [B] giving a straight line with a 
gradient equal to -1/Kd and the intercept of the line with the X-axis is equal to the Bmax 
(Scatchard, 1949). This analysis allows estimation of Bmax by extrapolation and thus avoids 
the need to use saturating concentrations of ligand. This method has been used extensively in 
the calculation of receptor binding kinetics in order to establish protocols for binding with 
each radioligand. The studies employed in this thesis mploy kinetic analysis of ligand 
binding which has been calculated elsewhere (Table 2.3) 
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4.2 Receptor Autoradiography  
 
Ligand binding autoradiography methods were used in order to obtain a complete pattern of 
SERT and serotonin receptor (5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C) binding throughout the 
brain in anatomically discrete regions. The receptor theory principles outlined above apply to 
all receptor autoradiography studies. The technique allows for the determination of the 
concentration of radioligand bound to a specific binding site (receptor/transporter) 
population in discrete brain areas. Brain sections are exposed to a buffer solution containing 
a known concentration of the radioligand until equilibrium is reached giving the total binding 
(TB) concentration of the radioligand in each brain region. Adjacent brain sections are also 
incubated in a solution containing exactly the same concentration of radioligand and under 
the same conditions except for the presence of a saturating concentration of a non-
radiolabelled competitor (or non-specific determinant) for the binding site of interest. This 
allows for the determination of NSB, the concentration of radioligand bound to the section 
which is not directly bound to the binding site of interest. The concentration of radioligand 
bound to the binding site of interest is then calcul ted by subtracting the NSB concentration 




4.2.1 Preparation of brain Sections for in vitro  receptor autoradiography  
 
For in vitro autoradiographic studies mice were killed by cervical dislocation followed by 
decapitation. The brain was then rapidly dissected out and frozen in isopentane at -40oC and 
stored at -80oC until sectioning. Prior to sectioning brains were f ozen onto orientating 
microtome chucks with Lipshaw Embedding matrix and llowed to equilibrate to -20oC in a 
cryostat for 30 minutes. 20µm coronal sections were cut on a Bright cryostat and thaw 
mounted onto Polysine coated slides (VWR, UK). Two sections, mounted onto separate 
slides, were taken for the duplicate determination of TB and the next adjacent section was 
taken on a separate slide for assessment of NSB. Three sections were taken every 60µm in 
the rostral to caudal direction. Sections were allowed to dry at room temperature and were 
then stored at -80oC until the experimental day. 
 
4.2.2 Method  
 
On the day of the experiment tissue sections were rmoved from the freezer and left to 
equilibrate to room temperature for 30 minutes. Allautoradiographic incubations were 
completed in Coplin jars containing 70mls of assay buffer. The specific methodologies for 
each autoradiographic study is outlined in table 2.3. Briefly, sections were pre-incubated in 
assay buffer, then incubated in the presence of the [3H]ligand for determination of TB or in 
the presence of the [3H]ligand and a saturating concentration of ‘cold’ competitor ligand for 
determination of NSB, these incubations were then followed by a series of washes in fresh 
ice-cold (4oC) assay buffer. Sections were then briefly dipped (5 seconds) in ice-cold 
distilled H2O and excess liquid removed from the slide under a vacuum with a fine tipped 
Pasteur pipette then rapidly dried under a stream of warm air. Slides were then mounted onto 
autoradiographic cards and the sections opposed to [3H]-sensitive film (Kodak, SB-5) along 
with pre-calibrated tritium standards ([3H] microscales, Amersham) in light-tight cassettes 
for varying periods of time at -40oC as specified in Table 2.3.
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Table 2.3 Ligand binding autoradiography protocols T4 
 
Target  SERT 5-HT1A 5-HT1B 5-HT2A 5-HT2C 






















Source Amers. Amers. G.E. P-E. Amers. 
 Citalopram 5-HT CP 93,129 DOI DOI 














4 10 1 1 1 
Source S-A. S-A. S-A. S-A. S-A. 
Assay 
Buffer 
50mM Tris (pH 
7.7) + 120mM 
NaCl + 5mM 
KCl 
50mM Tris (pH 
7.4) + 10µM 
pargyline 
50mM Tris 





Tris (pH 7.7) 
Pre-
incubation 
2 x 5 min. (25oC) 2 x 5 min. (37oC) 
1 x 30 min 
(25oC) 
1 x 15 min. 
(25oC) 
1 x 15 min. 
(25oC) 
Incubation 2 hours (25oC) 1 hour (37oC) 
1.5 hours 
(25oC) 
2 hours (25oC) 2 hours (25oC) 
Washes 4 x 30 min. (4oC) 
1 x 2 min. + 1 x 
3min. (4oC) 
3 x 10 min. + 
1 x 5 min. 
(4oC) 
2 x 10 min. 
(4oC) 




















De Souza et al., 
(1987) 
Preece et al., 
(2004) 
Wren (2000) 
Preece et al., 
(2004) 
Laakso et al., 
(1996) 
 
Summary of Lingand binding autoradiography methods. For each target the [3H]ligand, assay buffer 
constituents, non-specific binding (NSB) determinant and incubation protocols are outlined, along with 
appropriate references and additional relevant information for each assay. Abbreviations; Amers: 
Amersham, G.E.: G.E. Healthcare, P-E.: Perkin-Elmer, S-A.: Sigma-Aldrich. ~pKi values were gained 
from quoted references and the IUPHAR receptor database (www.iuphar-db.org, 2007).
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Table 2.4 Representative autoradiograms from ligand  binding studies T5 
 
 [3H]Paroxetine [3H]WAY 100,635 [3H]Ketanserin  [3H]Mesulergine  [3H]GR 125,743 




0.10 – 5.66 0 – 1.52 0.20-12.05 0 1.63 – 13.17 1.23 – 6.74 1.81 – 14.01 1.19 – 5.33 0.83 - 0.36 0 
Prefrontal 
Cortex   
 




     
 
    
Dorsal 
Hippocampus 
       
  
Ventral 
Hippocampus     
 
 
   
Raphé 




Representative autoradiograms showing the distribution of [3H]Paroxetine, [3H]WAY 100,635, [3H]Ketanserin, [3H]Mesulergine and [3H]GR 125,743 binding from 
ligand binding studies. Autoradiograms taken from wild-type male mice. TB represents total binding while NSB represents non-specific binding. Where no image is 
presented TB was not distinguishable from NSB in any brain region at that level. The [3H] concentration range (nCi/mg) for sections exposed to TB and NSB 




5. Enzyme-linked immunosorbent assay (ELISA)  
 
Enzyme-linked immunosorbent assays (ELISA) allow for the detection and quantitative 
analysis of nanomolar (nM) and picomolar (pM) concentrations of proteins, hormones or 
drugs in biological fluids. The technique utilises the specificity of the antigen-antibody 
reaction with the compound of interest being the antige  and at least one of the antibodies 
targeted to the antigen being enzyme linked.  
 
5.1. Detection of ACTH  
 
A commercially available ACTH ELISA kit (Biomerica ACTH ELISA, IDS Ltd UK) was 
used in these studies to detect plasma concentratios of ACTH. This is a two-site ELISA 
designed to quantify the levels of intact (39 amino acid) biologically active ACTH with two 
polyclonal antibodies that recognize two different binding sites at opposite ends of the 
ACTH molecule. One antibody is a goat polyclonal antibody that binds to the carboxy-
terminal of the (34-39 amino acids) ACTH molecule and is biotinyalated. During incubation 
the biotinylated antibody not only binds to ACTH molecules present in the solution but also 
binds the solid phase of the microplate well. The other antibody is a mouse antibody to 
ACTH which binds the mid-region and amino-terminus of ACTH (amino acids 1-24) and is 
conjugated with horseradish peroxidase (HRP). Both antibodies are present in excess of the 
concentration required to bind the ACTH present within the sample. During incubation both 
antibodies react with the ACTH molecules within thesample. However, only intact ACTH 
binds to both antibodies at the same time resulting in the formation of a “sandwich” 
complex. After incubation excess enzyme-linked antibody is removed from the well by 
repeated decanting and washing. Any ACTH bound to the solid-phase antibody remains in 
the well with the enzyme linked anti-body attached to the amino terminus. The “sandwich” 
complex is then incubated with the substrate tetramethylbenzidine (TMB) and the enzymic 
reaction then stopped by the addition of an acidic solution (sulphuric acid) resulting in the 
formation of a coloured product (yellow), the intensity of which is proportional to the 






5.1.1 Method  
 
Plasma samples were stored at -80oC until the day of analysis and were allowed to 
equilibrate to room temperature before use. 6 lyophilized ACTH calibrators of known 
concentration (range 0-515pg/ml ACTH) were reconstituted with distilled water as were two 
reference controls of known ACTH concentration, all of which were included in the kit. 
200µl of each standard, the controls and each unknown plasma sample was added to a 
designated streptavidin coated well. 25µl of the biotinylated ACTH antibody (goat anti 
human ACTH) and 25µl of the enzyme-labelled (mouse monocolonal anti human ACTH) 
antibody solutions were then added to each well. The microplate was then covered with foil 
to avoid light exposure and incubated on an orbital shaker (170 rpm) for 4 hours at room 
temperature. The solution was then decanted from the microplate wells by inversion and 
each plate washed five times with working wash solution (in kit). 150µl TMB solution was 
then added to each well and the enzymatic reaction all w to incubate for 30 minutes at room 
temperature while on an orbital shaker (170rpm). The enzymatic reaction was stopped by the 
addition of 100µl stopping solution (1M sulphuric aid). The absorbance of each well was 
then measured using a microplate reader (Dynex technologies, MRX) at both 450nm and 
405nm against 250µl of distilled water. The concentration of ACTH in each plasma sample 
was determined with reference to the calibration curve (concentration versus absorbance) 
generated by the in kit calibrators. The curve generated at 450nm was used to calculate 
ACTH concentrations up to 150 pg/ml while that at 405nm was used to analyse any ACTH 
concentrations above 150 pg/ml.  
 
5.2 Detection of Corticosterone  
 
A commercially available ELISA kit (IDS Ltd, UK) was used for the determination of 
plasma corticosterone concentrations in these studies. This kit is a competitive 
enzymeimmunoassay which utilised a polyclonal rabbit anti-corticosterone antibody coated 
onto the inner surface of polystyrene microtitre wells. Calibrators, controls and plasma 
samples are incubated for 24 hours with HRP labelled corticosterone. The wells are then 
washed and colour is developed by incubation with the chromogenic substrate TMB. The 
reaction is then stopped by the addition of a stop lution (0.5M hydrochloric acid) and the 
level of corticosterone in each sample is inversely proportional to the intensity of the colour 




5.2.1 Method  
 
Plasma samples were stored at -80oC until the say of the experiment and were allowed to 
equilibrate to room temperature before analysis.  6 lyophilized corticosterone calibrators of 
known concentration (range 0-133ng/ml corticosteron) were reconstituted with 1ml distilled 
water, as were two reference controls of known corti s erone concentration. Each plasma 
sample was diluted 1:10 with buffer (in kit, phosphate buffered saline with horse serum) 
prior to use. 100µl of each calibration standard, the controls and each unknown plasma 
sample was added to a designated antibody coated well. Th  lyophilised enzyme conjugate, 
containing the enzyme labelled corticosterone, was reconstituted with phosphate buffered 
saline (in kit) and then 100µl of the enzyme conjugate solution was then added to each well. 
The microplate was then sealed with an adhesive plat  sealer and incubated for 24 hours at 
4oC. After incubation the solution within the wells was decanted and the wells washed three 
times with wash solution (250µl per well, phosphate buffered saline with tween). After the 
final wash excess solution was removed from each well by inverting the microplate firmly 
on absorbent tissue paper. 200µl TMB solution was then added to each well and the 
incubation completed at room temperature for 30 minutes. The enzymatic reaction was then 
stopped by the addition of 100µl of stop solution (0.5M HCl) to each well. The absorbance 
of each well was then measured at 450nm, with reference to distilled water measured at 
















6. In situ hybridisation  
 
In situ hybridisation (ISH) is a technique in which molecular biology and histochemical 
methods are combined to study gene expression in tissue sections. In brain sections this 
technique is particularly useful as it allows for the detection of gene expression, by detecting 
messenger RNA (mRNA) expression, while also preserving the cellular integrity of the 
tissue. This allows for the quantification of gene expression in distinct neuroanatomical 
localisations within the CNS. 
 
ISH involves the annealing of a nucleic acid probe (in this thesis 35S-radiolabelled riboprobes 
are used) with a sequence complementary to that of the mRNA of interest to the native 
mRNAs present within the tissue. The localisation of the probe can then be visualised, in the 
case of this thesis by autoradiographic methods. The riboprobes are generated by in vitro 
transcription from cloned DNA (cDNA) sequences for the target of interest which have been 
inserted into a transcription vector. In this vector, wo RNA polymerase initiation sites exist 
that allow for the generation of both the anti-sense (complementary) and sense (same 
sequence) probes for the mRNA. As the sense probe has the same nucleotide sequence as 
that of the mRNA of interest it can be used in ISH as a control to detect any binding of the 
probe to the tissue which is not specific to mRNA hybridization. 
 
6.1 Glucocorticoid (GR) and Mineralocorticoid (MR) ISH 
 
For these studies mice were killed by cervical dislocation followed by decapitation. The 
brain was then rapidly dissected out and frozen in isopentane at -40oC and stored at -80oC 
until sectioning. Prior to sectioning brains were fozen onto orientating microtome chucks 
with Lipshaw embedding matrix and allowed to equilibrate to -20oC in a cryostat for 30 
minutes. Coronal sections at the level of the hypothalamic paraventricular nucleus (PVN) 
and dorsal hippocampus were thaw mounted onto poly-L-lysine coated slides and stored at -
80oC until the experimental day. In situ hybridisation studies were conducted as according to 
Seckl et al (1990) and Holmes et al (1995). Tissue ections were fixed in cold 4% 
paraformaldehyde in 0.1M phosphate buffer (pH 7.4) containing 0.02% 
diethylpyrocarbonate for 10 minutes at room temperature. This was followed by 2 x 10 
minute washes in 1 x PBS buffer, one wash in 0.1M triethanolamine (300ml) with 0.75ml of 
acetic anhydride, and a final 5 minute wash in 1 x phosphate buffered saline (PBS). Sections 
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were then dehydrated by sequential 2 minute dehydration in 70%, 80% and 90% ethanol 
washes. 
 
Radiolabeled sense and anti-sense cRNA probes were transcribed from plasmids containing 
template fragments of complementary DNA (cDNA) for the rat GR (673 bp, PstI-EcoR1 
fragment of rat cDNA) and MR (513 bp, EcoR1 fragment of rat cDNA) using 35S-uridine-5’-
trisphosphate (Amersham). 1µl of the required cDNA (1µg/µl) was added to an Rnase-free 
eppendorf with 9.9µl of reaction mix (Table 2.4). T7 RNA polymerase was used to generate 
the GR anti-sense cRNA probe and SP6 RNA polymerase w  used in the generation of the 
anti-sense MR cRNA probe. SP6 and T7 RNA polymerase were used to generate the sense 
cRNA probes for GR and MR, respectively. Reactions using T7 were incubated at 37oC for 
RNA probe generation, while those using SP6 were incubated at 40oC. 1µl Dnase (Rnase 
free) was then added to the reaction mixture and further incubated for 15 minutes at 37oC. 
The cRNA probes were then purified from the reaction mixture by use of a Nick column 
(G.E Healthcare) in 400µl TE buffer, and stored at -20oC until use. The efficiency of probe 
transcription was confirmed by determining the amount of radioactivity in a 1µl sample of 
the probe by liquid scintillation analysis (~4000 cpm). 
 
Table 2.5 GR and MR cRNA probe reaction mixture T 6 
 
 Volume (µl) 
Transcription Buffer (5x concentrate) 2 
1:1:1 ratio ATP, CTP, GTP mix 1 
200mM DTT 0.5 
Rnase Inhibitor 0.4 
cDNA Template (µg/µl) 1 
35S-UTP 4 
RNA Polymerase (T7 / SP6) 1 
Total mixture volume 9.9 
 
To reduce background binding of the radiolabbelled cRNA probe sections were exposed to a 
pre-hybridisation step. Sections were incubated in sealed boxes for 3 hours at 50oC with 
200µl per slide of pre-hybridisation buffer (50% deionised formamide, 1.2M NaCl, 0.02M 
Tris HCl, 2 x Denhardt’s solution, 2µM EDTA, 1mg/ml denatured salmon sperm DNA and 
0.2 µg/ml yeast transfer RNA). 
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Prior to hybridization incubation cRNA probes were d natured by heating to 75oC for 10 
minutes in hybridization mixture (10 x 106 cpm/ml probe concentration; in 50% formamide, 
1.2M NaCl, 0.02M Tris HCl, 2x Denhardt’s solution, 0.2mg/µl denatured salmon sperm 
DNA, 0.2 µg/ml yeast transfer RNA, and 20% dextan sulphate hybridization mixture). 200µl 
per slide of the complete hybridization mixture was then added to the sections which were 
then incubated in sealed boxes over night (~16 hours). Following hybridization sections were 
washed three times in 2x SSC buffer for 5 minutes a room temperature before ribonuclease 
A digestion (0.09 µg/ml final concentration in 0.5M NaCl, 10µM Tris HCl, 1µM EDTA) for 
1 hour at 37oC. Sections were then serially washed in 2x SSC (60 mins, RT), 0.1x SSC (60 
mins at 60oC) and then a final 0.1x SSC wash (60 mins, 60oC at start time and allowed to 
cool to RT) and then dehydrated in 50%, 70% and 90% ethanol in ammonium acetate (2 
minutes for each concentration at RT). After dehydration slides were air dried overnight and 
exposed to autoradiographic film (Kodak, SB-5) for 5 days along with pre-calibrated [14C] 





















7. Experimental Sample Analysis  
 
7.1 14C, 3H and 35S Autoradiography  
 
Radioactive isotopes, such as 3H and 14C and 35S, have unstable nuclei and undergo 
radioactive decay in which they emit subatomic particles in an attempt to become more 
stable. In the case of the isotopes used in these studie  electrons, also known as β rays, are 
emitted from the nucleus. The emission of these particles can be detected with x-ray 
autoradiographic film which has a photographic emulsion consisting of silver halide crystals 
surrounded by a capsule of gelatine. This allows each individual crystal of silver halide to act 
as an independent detector for emitted radioactive particles. Exposure of a silver halide 
molecule to radioactive particles causes a photochemical reaction in which silver ions are 
produced. This produces a stable-latent image on the autoradiographic film which can be 
visualised by chemical development. During the first stage of the development process the 
film is exposed to a reducing agent which converts silver ions into silver metal, while 
unexposed crystals remain as silver halide. During the second stage of the developing 
process the film is exposed to a fixing agent that dissolves silver halide, removing it from the 
film, but not the silver metal. This results in the production of spatially accurate “negative 
image” of the brain section, in which the area of the film exposed to the greatest number of 
radioactive particles has the highest density of opaque silver atoms. The isotope 
concentration in the source of the radiation can then be determined by measuring the optical 
density (O.D) of opaque silver atoms within a defind area. 
 
7.1.1 Densitometric Analysis  
 
Autoradiographic images on x-ray film were analysed using a computer bacsed image 
analysing system (MCID, Imaging Research Inc.). The O.D of pre-caibrated standards 
exposed to the film in concurrence with the brain sections was first measured, which allowed 
for the construction of the calibration curve for isotope concentration against O.D. [3H]-
standards with tissue equivalent [3H] concentrations of 0.1-110 nCi/mg (Amersham 
International, UK) were used in the analysis of the ligand binding autoradiography studies, 
as tritiated ligands were always used. In both the [14C]-2-deoxyglucose and in-situ 
hybridization studies, using [35S], pre-calibrated [14C] standards with tissue equivalent [14C] 
concentrations of 40-1098 nCi/mg (Amersham Internatio l, UK) were used. Use of [14C] 
standards to quantify [35S] concentrations by autoradiographic methods is deemed 
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appropriate due to the linear relationship between th se isotopes of concentration with O.D 
(Miller, 1991). The O.D of discrete brain regions, a  identified with reference to a stereotaxic 
atlas of the mouse brain (Franklin and Paxinos, 1997), were then determined.  
 
For each animal the mean O.D of each discrete brain region was deteremined from a total of 
6 to 12 bilateral measurements, dependent upon the size of the regions being measured, in 3 
to 6 sequential brain sections. For each brain region O.D measurements were detemined in a 
circular field of pre-determined size that fitted easily in to the ROI. The size of the 
measurement field for each ROI was maintained between all experimental groups and 
conferred the advantage of avoiding the possible inf ue ce of any artefacts or tissue damage 
on O.D measurement. The isotope concentration of each discrete brain region was then 
determined from the mean O.D of that region with refer nce to the calibration curve 
generated by the co-exposed standard (isotope concentration versus O.D). Analysis of all 
autoradiograms was completed blind to each animals genotype and/or treatment group.  
 
In [14C]-2-deoxyglucose experiments this data was used within the [14C]-uptake ratio 
operational equation, together with the blood data collected for each animal in order to 
determine the [14C]-uptake ratio in each ROI (Chapter 3, Study 1). In ligand binding 
autoradiography experiments determination of isotope concentration for each brain ROI was 
carried out on consecutive brain sections for the det rmination of TB, in duplicate, and NSB. 
Specific binding could then be calculated by subtracting the value for NSB from that of TB. 
In in-situ hybridisation studies isotope concentrations determined from sense exposed 
sections were subtracted from those of anti-sense expos d sections. 
 
7.2 Liquid Scintillation Analysis  
 
In [14C]-2-deoxyglucose experiments blood plasma [14C] isotope concentration was detected 
by liquid scintillation analysis (LSA), an analytical technique that calculates the kinetic 
energy of nuclear emission from a radiolabelled sample by measuring the rate of light photon 
emission from a liquid sample. A vial containing the radiolabelled sample (20µl plasma) and 
scintillation cocktail (5mls) is placed into a scintillation counter which allows photon 
intensity to be observed. The beta particles emitted from the radioactive isotope first transfer 
their energy to aromatic solvent molecules and then fluor molecules in the cocktail, which 
dissipate this energy by emitting visible light (photons). These photons are detected by 
photonmultiplier tube (PMT) of the scintillation counter, which converts the frequency of 
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photon detection into an electrical impulse. The amplitude of the electrical impulse is 
directly proportional to the number of photons detected within the sample. The amount of 
radioactivity in the sample is then automatically calculated by counting the number of 































8. Specific Experimental Methodology  
 
8.1 Study 1- Validation of semi-quantitative 2-deox yglucose 
autoradiography  
 
The validity of the current (Jordan et al., 2005; Kelly et al., 2002) and a novel analytical 
method for determination of LCMRglu by semi-quantitative [14C]-2-DG was assessed by 
comparison of the results gained by these analytica methods to that of the quantitative 
method. These analyses were completed on data originally obtained by the quantitative 
method investigating the LCMRglu response to 15mg.kg-1 i.p. 3,4-
methylenedioxymethamphetamine (MDMA) in male Dark-Agouti rats in 71 diverse ROI 
(Quate et al, 2004).  
 
8.2 Study 2- Constitutive brain function in hSERT over-expressing mice  
 
The density of SERT in 46 brain ROI was determined i  male and female hSERT OVR mice 
and their Wt littermates (n = 6, each genotype and sex) by quantitative [3H]-paroxetine 
binding autoradiography. Constitutive brain function was assessed by determining LCMRglu 
in 47 ROI in both male and female hSERT OVR mice and their Wt littermates by use of the 
SQ [14C]-2-deoxyglucose autoradiographic technique. Determination of LCMRglu in 
females was spread over the reproductive cycle (4 days) to control for the known impact of 
the cycle on LCMRglu (Nehlig et al., 1985). Each animal received 0.2mls of saline i.p.10 
minutes prior to the injection of [14C]-2-DG i.p. (hSERT OVR; male Wt: n= 11, OVR: n= 
11, female Wt n= 12, OVR n= 12). These groups were derived from those animals used as 
controls in additional LCMRglu experiments investiga ing the effects of the various 
pharmacological challenges on LCMRglu in Wt and hSERT OVR mice.  
 
Statistics 
Data from both the [3H]-paroxetine binding and constitutive LCMRglu studies were analysed 
using 2-way ANOVA with gender (male, female) and genotype (Wt, hSERT) as the 
dependent variables. Within the LCMRglu study a significant genotype effect was analysed 
within gender by 2-way ANOVA with Bonferroni post-hoc correction for multiple 




8.3 Study 3- 5-HT 1A function in hSERT over-expressing mice  
 
5-HT1A binding was assessed in 48 ROI in male and female hSERT OVR mice (n = 6 each 
gender) and their Wt littermates (n = 6 each gender) by quantitative [3H]WAY 100,635 
binding autoradiography. LCMRglu was determined in 47 brain ROI by semi-quantitative 2-
DG autoradiography under basal conditions with [14C]-2-DG injected i.p. 10 minutes after 
saline injection (0.2ml, i.p) in Wt and hSERT OVR mice of both sexes (male: Wt n= 11, 
OVR n= 11; female Wt n= 12, OVR n= 12). 5-HT1A function was assessed in Wt and hSERT 
OVR mice of both sexes by observing the LCMRglu response in the same 47 brain regions 
to 10mg.kg-1 8-OH-DPAT (i.p, 0.2mls), with 2-DG being injected 10 minutes after the acute 
8-OH-DPAT injection (male: Wt n= 9, OVR n= 9, female Wt n= 9, OVR n= 10). The ability 
of this treatment protocol to produce pronounced alter tions in LCMRglu, as assessed by the 
SQ [14C]-2-DG, was determined in a set of initial dose-response experiments (1, 5 and 
10mg.kg-1, n = 4 each treatment group) completed in male and female wild-type male mice. 
In these initial experiments it was decided that [14C]-2-DG would be injected 10 minutes 
after the 8-OH-DPAT (i.p) injection as the behavioural effects of the drug (head-weaving, 
hyperlocomotion and forepaw treading) were fully manifest at this time. In females all [14C]-
2-DG experiments and the harvesting of brains for [3H]WAY100,635 binding studies were 
spread across the reproductive cycle in order to control for the confounding influence of the 
cycle on LCMRglu and 5-HT1A pharmacology and function (Maswood et al., 1995; 
Osterlund et al., 2000; Uphouse et al., 1991). In [14C]-2-DG experiments animals were 
randomly allocated to their treatment group on the day of the experiment. 
 
Statistics 
Data (mean ± s.e.m) from the [3H]WAY 100,635 study were analysed using 2-way ANOVA 
with gender (male, female) and genotype (Wt, hSERT OVR) as the dependent variables. 
Bonferroni post-hoc correction for multiple comparison was applied when analysing for the 
effect of hSERT OVR on binding within gender. LCMRglu data were also analysed using 
ANOVA. The significance of the 8-OH-DPAT response was analysed by 2-way ANOVA 
(within genotype) with Bonferroni post-hoc correction for multiple comparisons. Gender x 
8-OH-DPAT interactions were also analysed by 2-way ANOVA (within genotype). The 
significance of gender x genotype, genotype x 8-OH-DPAT and gender x genotype x 8-OH-




8.4 Study 4- 5-HT 2A/C  receptor function hSERT over-expressing mice  
 
5-HT2A binding was assessed in 50 brain ROI in both male and female hSERT OVR mice (n 
= 6, each sex) and their Wt littermates (n = 6, each sex) by quantitative [3H]Ketanserin 
binding autoradiography. In the same animals 5-HT2C pharmacology was characterised in 43 
ROI by quantitative [3H]mesulergine autoradiography. LCMRglu was determined in 47 brain 
regions by semi-quantitative [14C]-2-DG autoradiography under basal conditions with [14C]-
2-DG injected 15 minutes after saline injection (0.2ml, i.p) in Wt and hSERT OVR mice of 
both sexes (male: Wt n= 11, OVR n= 11; female Wt n= 12, OVR n= 12). 5-HT2A/C function 
was assessed in Wt and hSERT OVR mice of both sexes by observing the LCMRglu 
response to 25mg.kg-1 DOI (i.p, 0.2mls) in the same 47 brain regions, with [14C]-2-DG being 
injected 15 minutes after the acute DOI injection (n= 8 for each genotype and sex). This 
treatment protocol had previously been confirmed to induce alterations in LCMRglu in rats 
(Freo et al., 1991; 1992) in quantitative [14C]-2-DG autoradiography and was confirmed to 
produce pronounced alterations in LCMRglu, as assessed by the SQ [14C]-2-DG method, in 
initial dose-response experiments completed in male and female wild-type mice (dose 2.5, 
10 and 25mg.kg-1; n = 4 animals per group). In females all [14C]-2-DG experiments and the 
harvesting of brains for the ligand binding studies were spread across the reproductive cycle 
in order to control for the confounding influence of the cycle on LCMRglu and 5-HT2A/C 
function and pharmacology (DiazVeliz et al., 1997; Sumner and Fink, 1998). In [14C]-2-DG 




Data for [3H]ketanserin and [3H]mesulergine binding were analysed using 2-way ANOVA 
with gender (male, female) and genotype (Wt, hSERT) as the dependent variables. A 
significant genotype effect on binding was analysed within gender by 2-way ANOVA with 
application of post-hoc Bonferroni correction for multiple comparison. Data from LCMRglu 
studies were also analysed using ANOVA. The DOI effect was analysed by 2-way ANOVA 
(within genotype) with Bonferroni post-hoc correction for multiple comparison. The 
genotype effect, gender x DOI interaction, genotype x DOI interaction and the gender x 





8.5 Study 5- 5-HT 1B function in hSERT over-expressing mice  
 
5-HT1B binding was assessed in 3 ROI in male and female hSERT OVR mice (n = 6 in each 
gender) and their wild-type litter mates (n = 6 in each gender) by quantitative [3H]GR 
125,743 binding autoradiography. LCMRglu was determined by SQ [14C]-2-DG 
autoradiography under basal conditions, with 2-DG injected i.p. 10 minutes after saline 
injection (0.2ml, i.p.), in Wt and hSERT OVR mice of both sexes (male: Wt n= 11, OVR n= 
11; female Wt n= 12, OVR n= 12). 5-HT1B function was assessed in Wt and hSERT OVR 
mice of both sexes by observing the LCMRglu response to 10mg.kg-1 CP 94,253 (0.2mls, 
i.p.) with [14C]-2-DG being injected 10 minutes after the acute CP 94, 253 injection (male: 
Wt n= 9, OVR n= 10, female Wt n= 9, OVR n= 9). The ability of this treatment protocol to 
produce alterations in LCMRglu, as assessed by the SQ [14C]-2-DG, was determined in a set 
of initial dose-response experiments (1, 5 and 10mg.kg-1, n = 4 each treatment group) 
completed in male and female wild-type mice. In females all [14C]-2-DG experiments and 
the harvesting of brains for [3H]GR 125,743 binding studies were spread across the 
reproductive cycle in order to control for the confounding influence of the cycle on 
LCMRglu and the possible influence in 5-HT1B pharmacology and function. In [
14C]-2-DG 




Data from the [3H]GR 125,743 binding study were analysed using 2-way ANOVA. 
LCMRglu data were also analysed using ANOVA. The signif cance of the CP 94,253 effect 
was analysed using 2-way ANOVA (within genotype) with Bonferroni post-hoc correction 
for multiple comparison. Genotype effects and the genotype x CP 94,253 interaction were 
also analysed using 2-way ANOVA (within gender). Gend r x CP 94,253, genotype x CP 
94,253 and the gender x genotype x CP 94,253 interaction were analysed using Univariate 









8.6 Study 6- Stress axis function in male hSERT over-expressing mice  
 
Basal plasma ACTH and corticosterone levels were det rmined in male hSERT OVR (n=8) 
and their Wt (n=8) littermates by radioimmunoassay. Stress axis responsiveness was 
determined in male hSERT OVR (n=8) and Wt mice (n=8) by observing plasma ACTH and 
corticosterone levels 15 minutes after acute saline injection (0.2mls, i.p.). The influence of 
specific 5-HT receptor subtypes on the activity of the HPA axis was assessed in hSERT 
OVR and Wt mice by determining plasma ACTH and corti sterone levels 15 minutes after 
injection with 0.1mg.kg-1 8-OH-DPAT (0.2mls, i.p., Wt: n=8, hSERT OVR n=8), 10mg.kg-1 
CP 94,253 (0.2mls, i.p., Wt n= 8, hSERT OVR n = 8) and 2.5mg.kg-1 DOI (0.2mls, i.p., Wt 
n= 8, hSERT OVR n = 8) to characterised the influence of 5-HT1A, 5-HT1B and 5-HT2A/C 
receptors respectively. The doses of 8-OH-DPAT and DOI used in these studies have 
previously been found to result in peak plasma levels of ACTH and/or corticosterone 
secretion at 15 minutes post-injection (8-OH-DPAT: Li et al., 1999; DOI: Van de Kar et al., 
2001; Bagdy et al., 1996). As no data are available upon the influence of the 5-HT1B agonist 
CP 94,253 on ACTH and corticosterone secretion the dose administered was chosen to 
coincide with that used in our LCMRglu studies (10mg.kg-1). The 15 minute time-point for 
culling was chosen to coincide with available contrls (saline-treated animals) and with the 
knowledge that central 5-HT1B receptor activation results in peak plasma ACTH 
concentrations at this time (Van de Kar et al., 1994). All studies of stress axis function were 
completed between 8.00am-10.30am to limit the influence of circadian variation in plasma 
ACTH and corticosterone levels. All animals were randomly assigned to the respective 
treatment group on the day of the experiment. Hormone levels were detected by enzyme-
linked immunoassay as previously outlined. 
 
Central glucocorticoid (GR) and mineralocorticoid (MR) receptor mRNA levels were 
determined in key brain regions implicated in the control of HPA axis function including the 
PVN and dorsal hippocampus, of male hSERT OVR (n= 6) and wild-type (n= 6) littermates 
by in-situ hybridisation.  
 
Statistics 
ACTH and corticosterone data were analysed using 2-way ANOVA with genotype (Wt, 
hSERT OVR) and treatment (basal, saline, 8-OH-DPAT, DOI, CP 94,253) as the dependent 
variables. Statistical analysis of the effect of acute mild stress (saline injection) was 
completed relative to hormone levels under basal conditi ns, while the effect of acute drug 
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treatment (8-OH-DPAT, DOI, CP 94,253) were analysed r lative to acute saline treated 
animals. GR and MR binding data were analysed using Student’s t-test. Acceptable levels of 















































Chapter 3 - Results  
 
 
1. Study 1- Validation of semi-quantitative 2-deoxy glucose 
autoradiography  
 
1.1 Rationale  
The uptake of radiolabelled 2-deoxyglucose into brain tissue is influenced by a number of 
factors; the metabolic activity of brain cells, whic  constitutes the factor of interest as it 
provides an index on neuronal activity and brain fuction, the amounts of tracer available in 
the blood compartment over the time of the experiment, and the levels of endogenous blood-
borne glucose with which the tracer competes for transport into the brain compartment. 
Thus, the original fully quantitative approach develop d by Sokoloff et al. (1977) requires 
that the animal be prepared surgically to allow for the intermittent sampling of arterial blood 
from which tracer and glucose concentrations can be measured and applied to the operational 
equation. While this fully quantitative approach is undoubtedly very powerful, the 
intravascular cannulation required does impose restrictions upon the experimental design and 
limits the usefulness of the technique. A number of attempts have been made to circumvent 
these limits, either by ignoring the inter-animal vriation in plasma tracer and glucose levels, 
or by generating blood data that give an approximation o plasma histories of tracer and 
glucose concentrations. 
A semi-quantitative (SQ) [14C]-2-DG autoradiographic imaging technique has been proposed 
previously for the measurement of LCMRglu as an index of neuronal function in mice 
(Jordan et al., 2005; Kelly et al., 2002). In contras  to the quantitative technique the SQ 
method involves the intraperitoneal (i.p) rather than intravenous (i.v) injection of [14C]-2-DG 
and the collection of a single terminal blood sample as opposed to the collection of 14 timed 
arterial samples throughout the experimental time period. These modifications were driven 
by the fact that the required cannulation of femoral a teries and veins is technically difficult 
in mice and that the removal of the blood volume required in the quantitative technique may 
induce hypovolaemia in mice, invalidating LCMRglu determination. Furthermore, use of the 
SQ method confers the advantage of allowing behavioural observation during the 
determination of LCMRglu as animals are not restrained during the experimental period.  
In the SQ method the concentration of [14C] and glucose in the terminal blood sample are 
expressed as a ratio ([14C] / [glucose]) for each animal and this is assumed to be an accurate 
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reflection of the plasma [14C] and [glucose] profiles throughout the experimental period. 
Animals in which this ratio can be identified as an “outlier” from the overall group mean can 
be excluded from further analysis. Subsequently, LCMRglu can be estimated in each brain 
region of interest (ROI) by deriving the ratio of [14C] in that ROI relative to that of a selected 
reference region, where the rate of LCMRglu is assumed to be constant both within and 
between the experimental groups. A consistent rate of LCMRglu in the reference region is 
usually implied by the observation of a relatively constant [14C] concentration in this region 
between experimental groups under conditions in which the plasma parameters also remain 
constant. However, many experimental manipulations – physiological, pharmacological or 
pathological – have an effect upon circulating glucose levels that could generate marked 
intergroup differences in the uptake of tracer into the reference brain region. Although an 
element of objectivity can be introduced by examining the relationship between the [14C] 
concentration in the reference region and the terminal plasma [14C] / [glucose] ratio between 
experimental groups, claims that this relationship remains constant between groups have 
never been tested statistically in previous publications. It has been assumed that minor 
individual variations from the overall group and intergroup relationships have only minor 
effects upon the certainty of the data, but again this has never been tested. 
In these initial studies we have investigated the validity of the SQ 2-deoxyglucose methods 
as currently published with particular attention to the assumption of a consistent rate of 
LCMRglu in the selected reference region and the influe ce that the choice of an 
inappropriate reference region could have upon the estimation of LCMRglu when using SQ 
analysis. From these studies we identified limitations in thecurrent SQ analytical method 
and with these in mind developed and tested a novel f rm of analysis, [14C]-uptake ratio 
([14C]-UR) analysis, based upon direct modification of the operational equation used in the 
quantitative method. Use of this novel form of analysis allows for the direct estimation of 
LCMRglu within each brain region by comparing the amount of radioactivity in that region 
(Ci*) to the terminal plasma variables (plasma [
14C]-2-DG (Cp*) and [glucose] (Cp) 
concentrations). This ratio is then adjusted in accordance with the plasma variables of each 




Ci*(T)  - k1
*e-(k2* + k3*)T ∫0
T Cp* e(k2* + k3*)t dt
[λ.Vm*.K m/Ф.Vm.Km*]  [ ∫0
T (Cp*/C p) dt – e-(k2*+k3*) T ∫0
T (Cp*/C p)e(k2*+K3*)t dt]
Total 14C in 









Correction for lag in Tissue 
Equilibration with plasma
Integrated precursor 
specific activity in 
tissue
 
Operational Equation for quantitative 2-deoxyglucose autoradiography. For abbreviations 
see those in legend of figures 2.4 and 2.5.  
The complexity of the operational equation is much reduced by the fact that as the time 
following acute administration of [14C]-2-DG increases, and the concentration of [14C]-2-DG 
in the plasma approaches zero, those factors containing the rate constants (k1*, k2* and k3), 
the correction for lag in the equilibration between tissue and plasma and the concentration of 
unphosphorylated [14C]-2-deoxyglucose in the tissue, also approach zero. Indeed, at infinite 
time these values will become zero but even at 45 minutes following a pulse of [14C]-2-DG 
their contribution is deemed insignificant (Sokoloff et al., 1977). Therefore, we propose that 
for LCMRglu estimation in the SQ method these factors may be removed from the equation 
as long as an appropriately long time period following tracer injection is used. This gives:- 
 
Equation 1 
In the SQ method we do not have the detailed profile  the plasma [14C]-2-DG and [glucose] 




[λ.Vm*.K m/Ф.Vm.Km*]  [ ∫0
T (Cp*/Cp) dt] 
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concentration of these factors in the terminal sample provides an accurate reflection of the 





The lumped constant is proposed to remain the same between all brain regions and animals 
and so this factor may also be removed from the equation in order to further simplify 
analysis. In addition, under normal physiological conditions the values of the lumped and 
rate constants for [14C]-2-DG uptake and metabolism are consistent between animals. 
Therefore, any variability in the plasma [14C]-2-DG and glucose histories between animals is 
the primary factor dictating variability in the levl of [14C] measured in tissues where the 
metabolic rate is constant. This means that adjustment ay be made to the ratio gained from 
equation 2 in accordance with the plasma [14C]-2-DG / [glucose] ratio of each individual 
animal relative to both the other animals within the same experimental group and also 
between experimental groups. This gives the final equation for [14C]-uptake ratio analysis:- 
 
 Operational equation for [14C]-uptake ratio ([14C]-UR) analysis in semi-quantitative 2-
deoxyglucose autoradiography. Ci*(T) represent total tissue [14C] concentration. Cp* 
represents terminal plasma [14C]-2-DG concentration. Cp represents terminal plasma 
glucose concentration. (Cp*/Cp)i represents the plasma ratio within an individual animal, 
whereas µ(Cp*/Cp)g represents the mean plasma ratio of that animals experimental group 
and µ(Cp*/Cp)cg the mean plasma ratio of the chosen control group. For analysis in which 










(Cp*/C p) µ(Cp*/C p)g µ(Cp*/C p)cg 
(Cp*/Cp)i  µ(Cp*/C p)g [ ] [ ] [ ] 
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1.2 Methods  
In order to assess the validity of both our new approach to quantifying LCMRglu and the SQ 
methodology, as applied previously, we examined the effects of 3,4-
methlyendioxymethamphetamine (MDMA) upon LCMRglu in male Dark Agouti (DA) rats 
as measured by these two approaches relative to data generated using the fully quantitative 
method.  The fully quantitative data were obtained from reanalysis of [14C]-2-DG 
autoradiography experiments published previously from this laboratory by Quate et al. 
(2004). Briefly, LCMRglu was determined in 71 ROI in male DA rats treated with saline (n 
= 5) or 15mg.kg-1 i.p MDMA (n = 5). Measurement of LCMRglu was initiated 15 minutes 
after the injection of saline or MDMA. A computer based image analysis system 
(MCID/M5+) was used to determine the local tissue [14C] concentration in each ROI from 
the optical density of autoradiographic brain images r lative to [14C]-standards (Amersham, 
UK). 
 
From the raw experimental data LCMRglu was first deermined quantitatively using the 
operational equation and the complete recorded plasma history profile with the tissue [14C] 
concentration of each brain region generated from reanalysis of the existing autoradiograms 
(Sokoloff et al., 1977). Two approaches to the original SQ analysis were applied to the data, 
the first with a reference region shown by quantitative analysis to have a constant LCMRglu 
between experimental groups (dorsal tegmental nucleus, DTN) and the second with a region 
shown to have significantly increased LCMRglu in MDA-treated animals (corpus 
callosum, CC). This allowed us to both assess the validity of the methods employed in SQ 
analysis to verify the reference region as an appropriate standard, and to determine the 
possible impact of an actual alteration in LCMRglu in the reference region upon SQ 
LCMRglu determination. The validity of each referenc  region as an appropriate control was 
investigated in line with previously reported methods (Kelly et al., 2002), but in addition we 
also applied linear regression and correlation analysis to statistically investigate the 
relationship between the [14C] concentration in the reference region and the plasma ratio 
within and between experimental groups. LCMRglu was then estimated as the ratio of [14C] 
in each ROI to that of the chosen reference region in each animal. The [14C]-uptake ratio 
analysis method outlined above was also applied to the same data set to assess the validity of 
this novel method to estimate LCMRglu.  
 
To investigate the validity of the assumption that terminal plasma [14C] / [glucose] ratios 
provide as accurate estimation of the plasma profile history of any given animal we 
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performed a correlation analysis of the relationship between the terminal plasma ratio in each 
animal and the area under the curve (integral) derived from the 14 times plasma samples. 
Within each animal the [14C] / [gluocose] ratio of each plasma sample was first obtained and 
the integral then determined from the X-Y plot of this ratio against time. Correlation analysis 
was completed on the relationship between the terminal plasma ratio and the integral given 
for the plasma history profile of each animal.  
 
In each form of analysis LCMRglu data (mean ± s.e.m) were analysed using student’s t-test 
with significance set at p<0.05. The validity of each analytical method was assessed by 
comparing the magnitude, directionality, localisation and statistical outcome of alterations in 
LCMRglu detected between saline and MDMA-treated anim ls compared to those detected 
by the quantitative method. 
 
1.3 Quantitative determination of LCMRglu  
 
Quantitative analysis revealed the MDMA produced signif cant changes in LCMRglu in 21 
of the 71 ROI analysed, in comparison to saline controls. Of these 21 alterations 19 
represented significant increases in LCMRglu (range 19% to 88%) and 1 represented a 
significant decrease in LCMRglu, detected in the posterior cingulate cortex (-19%). These 
alterations were consistent with previously reported MDMA-induced alterations in 
LCMRglu (Wilkerson and London, 1987). In quantitative analysis LCMRglu was found to 
be significantly increased in the corpus callosum (+19%) of MDMA-treated animals relative 
to saline controls, whereas LCMRglu in the DTN (-5%) was not significantly altered. 
Detailed data from quantitative analysis are shown in tables 3.1.2 to 3.1.7. 
 
1.4 Semi-quantitative determination of LCMRglu  
 
1.4.1 Validation of the control region  
 
In contrast to the findings from quantitative analysis, the rate of LCMRglu was found to be 
constant in both the DTN and corpus callosum between experimental groups as defined by 
the terms used in SQ analysis as there was no significant difference between any of the 
terminal plasma parameters and no significant difference in the mean [14C] concentration of 
these regions between experimental groups. In addition, linear regression analysis also 
confirmed that the relationship between [14C] concentration in these regions and the plasma 
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ratio was not significantly different between experimental groups in terms of slope, intercept 
or elevation (Table 3.1.1). Furthermore, the [14C] concentration of these regions showed a 
significant correlation with the plasma ratio in both experimental groups (Figure 3.1.1). 
 
Table 3.1.1 Control regions and plasma parameters i n SQ analysis T7 
 
Plasma data and control region validity in saline and MDMA-treated DA rats. Data 


















 Saline MDMA 
Plasma [14C] concentration (nCi/ml)  93.7 ± 20.8 55.2 ± 5.5 
Plasma glucose concentration(mg/ml) 12.2 ± 1.5 11.9 ± 1.4 
Plasma [14C]:[glucose] ratio (nCi/mg) 7.4 ± 1.1 4.8 ± 0.5 
Dorsal Tegmental Nucleus [14C] (nCi/mg) 493.8 ± 63.1 316.8 ± 56.7  
Corpus Callosum [14C] concentration (nCi/mg) 146.5 ± 21.6 126.2 ± 23.5 
Linear regression analysis   
Dorsal Tegmental Nucleus   
Intercept 58.31 ± 92.32 22.66 ± 96.20 
Slope 55.24 ± 11.30 70.30 ± 21.77 
Corpus Callosum   
Intercept 18.22 ± 26.2 27.9 ± 22.4 
Slope 16.6 ± 3.2 17.2 ± 5.1 
Correlation analysis   
Dorsal Tegmental Nucleus R2 0.89* 0.78* 
Corpus Callosum R2 0.89* 0.79* 
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Figure 3.1.1 Control region-plasma ratio relationsh ips F14 
 
(a) Dorsal Tegental Nucleus













































Relationship between tissue [14C] (nCi/mg) concentration in the selected reference 
region (a) dorsal tegmental nucleus (b) corpus callosum, and terminal plasma [14C] / 
[glucose] concentration ratio in saline and MDMA-treated DA rats. In each control 
regions there was no significant difference in the relationship between [14C] 
concentration and the plasma [14C]:glucose ratio between the experimental groups 
(linear regression). 
 
1.4.2 LCMRglu  
 
When the DTN was used as the reference region significa t alterations in LCMRglu were 
detected in 17 of the 71 ROI. All of these significant alterations were also found from 
quantitative analysis and the directionality and magnitude of significant LCMRglu 
alterations was also maintained. However, there were 3 “false- negative” results where this 
approach failed to identify significant alterations i  LCMRglu which were detected by the 
quantitative method. When the corpus callosum was used as the selected reference region the 
magnitude, localisation and directionality of detected LCMRglu alterations was changed in 
comparison to the quantitative method (see Figure 3.1.4 for representative examples). In this 
case significant alterations were found in 27 of the 71 ROI analysed, that is 10 of these 
significant alterations were “false-positives” giving a statistically significant alteration in 
LCMRglu in a ROI which was not found in quantitative analysis. All “false-positives” 
represented significant decreases in LCMRglu (-8% to -32%). A number of “false-negative” 
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(3) results were also found when the corpus callosum was used as the selected reference 
region. 
1.5 [14C]-uptake ratio determination of LCMRglu  
1.5.1 Terminal plasma ratio validity  
The area under the curve (integral) of the complete plasma history for each animal, as 
determined from the [14C] / [glucose] ratio of 14 timed blood samples against the time at 
which the sample was taken, was significantly correlated with the [14C] / [glucose] terminal 
plasma ratio (Figure 3.1.3).   
 
Figure 3.1.2 Plasma history profile in quantitative  2-deoxyglucose 
autoradiography F15 



























562 nCi/ml : 2.01mg/ml
364 nCi/ml : 1.83 mg/ml
304 nCi/ml : 1.71 mg/ml
11.32 nCi/ml : 1.34 mg/ml
7.34 nCi/mg : 1.29 mg/ml
4.61 nCi/ml : 2.07 mg/ml
 
Complete plasma history profile as determined in quantitative 2-deoxyglucose 
autoradiography. Data shown from 3 representative animals. The plasma [14C] and 
[glucose] concentrations for each animal at the peak of isotope infusion and in the 
terminal plasma sample are also shown. Note in particular how the terminal plasma 
[14C]:[glucose] ratio appears to reflect the peak amplitude of the plasma ratio history 
in each animal. This appears to be largely due to the fact that plasma [14C]-2-DG 
concentration in the terminal plasma sample reflects that observed at the peak. This 
suggests that the terminal plasma [14C] concentration, and plasma ratio, may 
provide an accurate reflection of that present at the peak. 
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Correlation between complete plasma [14C] / [glucose] history profile (Area under 
curve (integral)) and terminal plasma [14C] / [glucose] ratio. (R2=0.60, p=0.0087).The 
significant correlation between these parameters suggests that the terminal plasma 
[14C]:[glucose] history provides an accurate reflection of the plasma history 
throughout the experimental time period. 
 LCMRglu  
Changes in LCMRglu induced by MDMA and detected by [14C]-UR analysis were similar in 
magnitude, directionality and localisation to those generated from quantitative analysis (see 
Figure 3.1.4 for representative examples). Of particular note was the fact that both MDMA-
induced increases (in 21 of the 71 ROI) and decreases (in 1 ROI) were detected accurately 
by [14C]-UR analysis with neither false negative nor false positive results being generated. 
The magnitude of the changes, increases ranging between range 20% to 81% and the 
decrease of -19%, were also similar to those found with the fully quantitative approach 




Figure 3.1.4 LCMRglu response to MDMA in quantitati ve, semi-quantitative and [ 14C]-uptake ratio analysis F17 
False-positives












































































LCMRglu responses to acute MDMA as detected by quantitative, semi-quantitative (SQ) and [14C]-uptake ratio ([14C]-UR) analysis. Data shown as % LCMRglu 
response in MDMA-treated animals in comparison to controls (saline-treated). Representative data shown from regions in which the significance of LCMRglu 
responses to MDMA is unaltered by the different analyses and regions in which false-negative and false-positive results are generated by SQ analysis. SQ:DTN 
represents data analysed with the dorsal tegmental nucleus and SQ:CC represents data analysed with the corpus callosum as the selected control region. *denotes 
p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant difference from saline control (t-test). Note how the LCMRglu alterations detected by [14C]-UR 
analysis are similar in magnitude, directionality and significance to those detected by quantitative analysis and that this form of analysis does not generate false-
negative or false-positive results.
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Table 3.1.2 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: cortical regions T8 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-Uptakeratio analysis in cortical regions 
of MDMA-treated and control (saline-treated) rats. Semi-quantitative analysis completed with the corpus callosum and dorsal tegmental nucleus (DTN) 
as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA-treated and control (saline-treated) animals.. *denotes 








Semi-quantitative analysis Quantitative Analysis 
(µmol/100g/min) [14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum 
[14C]-Uptake ratio analysis Cortical Brain Areas 
Saline MDMA % Saline MDMA % Saline MDMA % Saline MD MA % 
Anterior Cingulate 119 ± 3 116 ± 9 -2 1.12 ± 0.07 1.15 ± 0.06 3 3.68 ± 0.19 3.55 ± 0.09 -4 15.07 ± 0.41 14.7 ± 1.13 -2 
Frontal Layer IV 95 ± 3 103 ± 8 9 0.97 ± 0.05 1.05 ± 0.04 9 3.23 ± 0.13 3.08 ± 0.17 -5 12.02 ± 2.22 13.1 ± 0.96 9 
Frontal Layer VI 87 ± 1 86 ± 5 -1 0.91 ± 0.03 0.90 ± 0.02 -2 3.02 ± 0.07 2.62 ± 0.08 -13* 10.99 ±  0.51 10.87 ± 1.01 -1 
Somatosensory Layer IV 114 ± 4 148 ± 7 30** 1.15 ± 0.03 1.44 ± 0.06 25** 3.79 ± 0.10 4.44 ± 0.12 17** 14.46 ± 0.51 18.77 ± 0.86 30** 
Somatosensory Layer VI 83 ± 3 81 ± 7 -3 0.88 ± 0.01 0.84 ± 0.06 -5 2.91 ± 0.07 2.57 ± 0.06 -12 10.57 ± 0.20 10.29 ± 0.89 -3 
Posterior Cingulate 117 ± 5 95 ± 8 -19* 1.18 ± 0.05 0.96 ± 0.07 -18* 3.88 ± 0.16 2.95 ± 0.06 -24** 14.87 ± 0.61 12.05 ± 0.92 -19* 
Parietal Layer IV 94 ± 2 94 ± 8 1 0.95 ± 0.03 0.95 ± 0.06 0 3.18 ± 0.04 2.93 ± 0.07 -8* 11.86 ± 0.28 11.92 ± 0.91 1 
Parietal Layer VI 83 ± 1 83 ± 8 0 0.86 ± 0.03 0.84 ± 0.04 -2 2.87 ± 0.09 2.67 ± 0.08 -7 10.50 ± 0.11 10.50 ± 0.96 0 
Piriform 54 ± 4 71 ± 1 32 0.61 ± 0.04 0.74 ± 0.04 22 2.01 ± 0.12 2.30 ± 0.13 14 6.80 ± 0.53 9.01 ± 0.97 32 
Entorhinal 72 ± 3 81 ± 8 12 0.77 ± 0.03 0.84 ± 0.06 8 2.55 ± 0.08 2.58 ± 0.14 1 9.16 ±0.39 10.30 ± 1.01 12 
Auditory 133 ± 5 150 ± 11 13 1.32 ± 0.66 1.43 ± 0.10 11 4.35 ± 0.19 4.50 ± 0.22 4 16.82 ± 0.67 19.03 ± 1.34 13 
Occipital IV 109 ± 4 107 ± 10 -2 1.10 ± 0.04 1.07 ± 0.08 -3 3.65 ± 0.14 3.29 ± 0.10 -10 13.88 ± 0.54 13.62 ± 1.25 -2 
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Table 3.1.3 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: motor regions T9 
 
 Semi-quantitative analysis 
Motor Brain Areas 
Quantitative Analysis 
(µmol/100g/min) [14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum  
[14C]-Uptake ratio analysis 
 Saline MDMA % Saline MDMA % Saline MDMA % Saline M DMA % 
Striatum             
Medial 93 ± 3 152 ± 10 64*** 0.96 ± 0.03 1.47 ± 0.09 54*** 3.16 ± 0.10 4.56 ± 0.21 44*** 11.77 ± 0.38 19.28 ± 1.24 64*** 
Lateral 103 ± 4 129 ± 9 25* 1.05 ± 0.03 1.27 ± 0.10 21 3.48 ± 0.12 3.90 ± 0.11 12* 13.2 ± 0.49 16.39 ± 1.12 25* 
             
Ventrolateral Thalamus 92 ± 4 111 ± 10 21 0.95 ± 0.03 1.11 ± 0.06 17 3.13 ± 0.09 3.45 ± 0.23 10 11.64 ± 0.50 14.13 ± 1.21 21 
Subthalamic Nucleus 80 ± 3 95 ± 10 20 0.84 ± 0.03 0.96 ± 0.06 14 2.77 ± 0.06 2.97 ± 0.19 7 10.10 ± 0.43 12.08 ± 1.33 20 
Lateral Habenula 109 ± 10 87 ± 6 -20 1.09 ± 0.06 0.89 ± 0.08 -18 3.61 ± 0.25 2.75 ± 0.15 -24* 13.80 ± 1.22 10.98 ± 0.79 -20 
Substantia Nigra             
pars Reticulata 53 ± 3 96 ± 16 81* 0.60 ± 0.02 0.95 ± 0.10 59* 1.98 ± 0.05 2.96 ± 0.34 50* 6.70 ± 0.35 12.13 ± 2.06 81* 
pars Compacta 64 ± 2 95 ± 8 48** 0.70 ± 0.03 0.97 ± 0.09 37* 2.33 ± 0.06 2.98 ± 0.21 28* 8.17 ± 0.21 12.08 ± 0.98 48** 
Cerebellum             
Paramedian Lobule 52 ± 1 67 ± 5 29* 0.59 ± 0.02 0.71 ± 0.04 20* 1.96 ± 0.03 2.20 ± 0.06 12** 6.57 ± 0.07 8.50 ± 0.59 29* 
Copula Pyramis 60 ± 2 96 ± 8 61** 0.66 ± 0.02 0.97 ± 0.06 47** 2.18 ± 0.05 2.99 ± 0.12 37*** 7.56 ± 0.20 12.20 ± 1.05 61** 
Vermis 85 ± 1 138 ± 9 62*** 0.89 ± 0.02 1.34 ± 0.05 50*** 2.94 ± 0.06 4.15 ± 0.14 41*** 10.81 ± 0.17 17.45 ± 1.09 62*** 
             
Red Nucleus 70 ± 2 85 ± 7 21 0.75 ± 0.02 0.87 ± 0.05 15 2.49 ± 0.04 2.68 ± 0.12 8 8.90 ± 0.30 10.73 ± 0.93 21 
Inferior Olive 79 ± 1 103 ± 6 30** 0.83 ± 0.01 1.03 ± 0.06 24* 2.76 ± 0.03 3.19 ± 0.08 16** 10.00 ± 0.18 13.01 ± 0.78 30** 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-uptake ratio analysis in motor  regions of 
MDMA-treated and control (saline-treated) Dark Agouti rats. Semi-quantitative analysis completed with the corpus callosum and dorsal tegmental 
nucleus (DTN) as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA and control. *denotes p<0.05, **denotes 





Table 3.1.4 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: limbic regions T10 
 
 Semi-quantitative analysis 




14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum  
[14C]-Uptake ratio analysis 
 Saline  MDMA % Saline MDMA % Saline MDMA % Saline MDMA % 
Nucleus Accumbens 87 ± 3 118 ± 7 35** 0.91 ± 0.02 1.16 ± 0.05 28** 3.00 ± 0.09 3.62 ± 0.19 21* 11.06 ± 0.37 14.92 ± 0.86 35** 
Septal Nucleus 61 ± 4 83 ± 5 35* 0.68 ± 0.04 0.85 ± 0.06 25* 2.25 ± 0.14 2.63 ± 0.06 17* 7.79 ± 0.49 10.48 ± 0.69 35* 
Anterior Thalamus 105 ± 5 93 ± 7 -11 1.06 ± 0.04 0.95 ± 0.08 -11 3.53 ± 0.19 2.92 ± 0.17 -17* 13.29 ± 0.61 11.82 ± 0.88 -11 
Mediodorsal Thalamus 102 ± 5 118 ± 9 16 1.04 ± 0.05 1.17 ± 0.06 12 3.44 ± 0.16 3.62 ± 0.14 5 12.96 ± 0.63 15.02 ± 1.16 16 
Medial Amygdala 50 ± 5 68 ± 12 37 0.58 ± 0.06 0.71 ± 0.09 23 1.90 ± 0.15 2.16 ± 0.24 14 6.32 ± 0.58 8.63 ± 1.58 37 
Lateral Amygdala 75 ± 2 91 ± 4 21** 0.80 ± 0.03 0.93 ± 0.06 17 2.64 ± 0.10 2.86 ± 0.08 9 9.46 ± 0.31 11.49 ± 0.49 21** 
Ventral Tegmental Area 45 ± 2 57 ± 4 28* 0.53 ± 0.01 0.61 ± 0.02 16* 1.75 ± 0.04 1.96 ± 0.08 12* 5.71 ± 0.26 7.28 ± 0.46 28* 
Mamillary Body 100 ± 4 104 ± 8 3 1.02 ± 0.02 1.04 ± 0.07 2 3.39 ± 0.09 3.21 ± 0.13 -5 12.71 ± 0.49 13.14 ± 1.03 3 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-uptake ratio analysis in limbic brain  
regions of MDMA-treated and control (saline-treated) Dark Agouti rats. Semi-quantitative analysis completed with the corpus callosum and dorsal 
tegmental nucleus (DTN) as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA and control. *denotes p<0.05, 










Table 3.1.5 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: hippocampal regions T11 
 
Semi-quantitative analysis Quantitative 
Analysis 
(µmol/100g/min) [
14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum  
[14C]-Uptake ratio analysis 
Hippocampal Regions  
Saline  MDMA % Saline MDMA % Saline MDMA % Saline MDMA % 
Molecular Layer 87 ± 8 94 ± 8 9 0.91 ± 0.08 0.96 ± 0.07 6 2.98 ± 0.23 2.96 ± 0.18 -1 11.04 ± 1.01 11.97 ± 0.97 9 
Dorsal Subiculum 76 ± 5 84 ± 5 9 0.81 ± 0.05 0.87 ± 0.05 6 2.69 ± 0.17 2.68 ± 0.14 0 9.69 ± 0.59 10.60 ± 0.64 9 
Dentate PO 56 ± 2 60 ± 6 6 0.63 ± 0.02 0.64 ± 0.05 2 2.08 ± 0.08 1.98 ± 0.09 -5 7.10 ± 0.26 7.56 ± 0.77 6 
Dorsal CA1 58 ± 2 75 ± 6 30* 0.64 ± 0.02 0.78 ± 0.03 21** 2.13 ± 0.07 2.43 ± 0.13 14 7.31 ± 0.28 9.51 ± 0.82 30* 
CA2 56 ± 1 62 ± 4 11 0.63 ± 0.02 0.67 ± 0.04 6 2.09 ± 0.04 2.07 ± 0.07 -1 7.15 ± 0.16 7.91 ± 0.53 11 
Ventral CA1 65 ± 3 74 ± 4 15 0.7 ± 0.0.3 0.78 ± 0.05 10 2.32 ± 0.07 2.39 ± 0.07 3 8.19 ± 0.35 9.39 ± 0.52 15 
Ventral Subiculum 64 ± 5 67 ± 6 5 0.70 ± 0.05 0.72 ± 0.05 2 2.32 ± 0.14 2.21 ± 0.09 -5 8.14 ± 0.62 8.55 ± 0.81 5 
CA3 67 ± 2 66 ± 6 -1 0.73 ± 0.01 0.71 ± 0.06 3 2.40 ± 0.04 2.17 ± 0.11 -10 8.50 ± 0.26 8.40 ± 0.75 -1 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-uptake ratio analysis in hippocampal  
regions of MDMA-treated and control (saline-treated) Dark Agouti rats. Semi-quantitative analysis completed with the corpus callosum and dorsal 
tegmental nucleus (DTN) as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA and control. *denotes p<0.05, 










Table 3.1.4 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: sensory regions T12 
 
 Semi-quantitative analysis    




14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum  
[14C]-Uptake ratio analysis 
 Saline  MDMA % Saline MDMA % Saline MDMA % Saline MDMA % 
Superior Olive 113 ± 4 109 ± 8 -3 1.13 ± 0.02 1.09 ± 0.06 -4 3.74 ± 0.10 3.37 ± 0.13 -10 14.28 ± 0.54 13.83 ± 0.96 -3 
Trigeminal Nucleus 61 ± 1 84 ± 8 39* 0.67 ± 0.02 0.85 ± 0.05 27** 2.22 ± 0.04 2.63 ± 0.10 19** 7.71 ± 0.18 10.71 ± 0.97 39* 
Lateral Geniculate 92 ± 3 89 ± 10 -3 0.95 ± 0.02 0.90 ± 0.06 -5 3.14 ± 0.10 2.79 ± 0.15 -11 11.62 ± 0.44 11.31 ± 1.29 -3 
             
Superior Colliculus             
Superficial Layers 109 ± 6 97 ± 10 -11 1.10 ± 0.05 0.98 ± 0.06 -11 3.64 ± 0.13 3.03 ± 0.16 -17* 13.88 ± 0.59 12.33 ± 1.27 -11 
Deep Layers 86 ± 3 102 ± 9 19 0.90 ± 0.04 1.03 ± 0.07 15 2.96 ± 0.11 3.17 ± 0.15 7 10.88 ± 0.35 12.99 ± 1.17 19 
             
Inferior Colliculus 142 ± 5 131 ± 10 -8 1.40 ± 0.05 1.23 ± 0.13 -13 4.65 ± 0.20 3.74 ± 0.27 -19* 18.06 ± 0.66 16.62 ± 1.33 -8 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-uptake ratio analysis in sensory regions 
of MDMA-treated and control (saline-treated) Dark Agouti rats. Semi-quantitative analysis completed with the corpus callosum and dorsal tegmental 
nucleus (DTN) as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA and control. *denotes p<0.05, **denotes 









Table 3.1.7 LCMRglu as determined by quantitative, semi-quantitative and [ 14C]uptake ratio analysis: non-specific regions T13 
 
Semi-quantitative analysis Quantitative 
Analysis 
(µmol/100g/min) [
14C] ROI / [ 14C] DTN [ 14C] ROI / [ 14C] Corpus Callosum  
[14C]-Uptake ratio analysis 
Non-specific Brain Regions  
Saline  MDMA % Saline MDMA % Saline MDMA % Saline MDMA % 
Nucleus Gelatinosus 110 ± 3 117 ± 9 6 1.12 ± 0.05 1.16 ± 0.08 4 3.69 ± 0.14 3.59 ± 0.15 -3 13.98 ± 0.44 14.87 ± 1.17 6 
Cerebellar White 25 ± 1 30 ± 2 21* 0.33 ± 0.01 0.37 ± 0.03 13 1.08 ± 0.03 1.13 ± 0.04 5 3.17 ± 0.16 3.83 ± 0.22 21* 
Corpus Callosum 22 ± 1 26 ± 2 19* 0.30 ± 0.01 0.33 ± 0.02 7 n/a n/a n/a 2.74 ± 0.10 3.27 ± 0.20 19* 
Nucleus Reunines 83 ± 6 95 ± 12 15 0.87 ± 0.04 0.95 ± 0.06 10 2.87 ± 0.17 2.99 ± 0.33 4 10.53 ± 0.82 12.08 ± 1.49 15 
Medial Habenula 78 ± 3 75 ± 4 -4 0.83 ± 0.04 0.78 ± 0.04 -6 2.74 ± 0.11 2.41 ± 0.06 -12* 9.89 ± 0.37 9.46 ± 0.50 -4 
Hypothalamus 54 ± 2 60 ± 4 13 0.61 ± 0.02 0.65 ± 0.03 7 2.01 ± 0.07 2.01 ± 0.04 0 6.80 ± 0.30 7.66 ± 0.53 13 
Internal capsule 26 ± 1 34 ± 3 31 0.34 ± 0.01 0.40 ± 0.03 18 1.11 ± 0.02 1.23 ± 0.05 10 3.30 ± 0.12 4.31 ± 0.43 31 
Pontine Reticular Formation 53 ± 1 62 ± 4 17 0.6 ± 0.02 0.67 ± 0.04 11 1.99 ± 0.05 2.07 ± 0.09 4 6.72 ± 0.16 7.84 ± 0.52 17 
Dorsal Raphe 81 ± 1 85 ± 6 4 0.86 ± 0.02 0.87 ± 0.05 2 2.83 ± 0.06 2.69 ± 0.09 -5 10.32 ± 0.17 10.76 ± 0.80 4 
Median Raphe 90 ± 2 89 ± 7 -1 0.93 ± 0.02 0.09 ± 0.05 -3 3.08 ± 0.06 2.79 ± 0.10 -9* 11.39 ± 0.22 11.26 ± 0.92 -1 
Dorsal Tegmental Nucleus 98 ± 3 93 ± 7 -5 n/a n/a n/a 3.31 ± 0.06 3.13 ± 0.23 -5 12.41 ± 0.43 11.80 ± 0.93 -5 
Nucleus Ambiguus 62 ± 1 86 ± 5 40** 0.68 ± 0.02 0.89 ± 0.04 30** 2.26 ± 0.04 2.75 ± 0.11 22** 7.84 ± 0.13 10.96 ± 0.58 40** 
 
Local cerebral glucose utilisation (LCMRglu) measurements gained by quantitative, semi-quantitative and [14C]-uptake ratio analysis in non-specific  
regions of MDMA-treated and control (saline-treated) Dark Agouti rats. Semi-quantitative analysis completed with the corpus callosum and dorsal 
tegmental nucleus (DTN) as the selected control region. Data shown as mean ± s.e.m and % difference between MDMA and control. *denotes p<0.05, 
**denotes p<0.01 significant difference from saline control (T-test). n/a denotes measurements not available due to form of analysis being applied. 
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1.6 Discussion and Conclusions  
These results suggest that the SQ analytical method as used previously suffers from reduced 
accuracy and reduced validity in comparison to the fully quantitative method. The 
inaccuracies are found in the magnitude, directional ty nd localisation of drug-induced 
changes in LCMRglu and the data are markedly affected by the choice of reference area. The 
DTN meets the criterion for choice as a reference region as LCMRglu was not significantly 
altered by MDMA treatment when analysed using quantitative analysis. However, using this 
reference region resulted in a number of “false-negative” results being generated, suggesting 
that this method has a reduced statistical power in comparison to the quantitative approach. 
While it might be possible to increase statistical power by the simple expedient of increasing 
sample size, it would appear that it cannot be solved by more judicious choice of reference 
region. A more extensive analysis (data not shown) in which a number of other areas of the 
brain were used as the reference region, on the basis that they both fulfilled the required 
criteria as an appropriate reference region by the SQ method and were also confirmed to 
remain unaltered across treatment groups by fully quantitative analysis, it was found that 
most also resulted in the generation of “false-positive” results. This finding, along with the 
observation that the methods employed in SQ analysis are not sufficiently robust to 
appropriately establish if the rate of LCMRglu is constant within a selected reference region 
between experimental groups, considerably weakens the validity of this analytical technique. 
Indeed, we have demonstrated that when a region in which a significant alteration in 
LCMRglu is not detected by the methods used in SQ analysis is used as the selected 
reference region (as exemplified by the corpus callosum in this study) the weaknesses of this 
analytical technique are further compounded. In addition to these problems the requirement 
for consistent plasma parameters and the use of a predetermined reference region in SQ 
analysis also limit the experimental conditions in which the method can be applied, as many 
experimental manipulations result in altered plasma glucose and/ or global alterations in 
LCMRglu.  
The development of the alternative analytical approach to the SQ 2-DG methodology, as 
outlined here, presents several advantages over the approaches used previously. By 
approximating as closely as possible to the original operational equation, there is no need to 
use a reference brain region against which to standardise the regions of interest thus avoiding 
the potentially problematic assumption of stability of this region across treatment groups. As 
a direct consequence of this, our novel approach can be used in a wider variety of 
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experimental conditions where either altered plasma par meters or when global alterations in 
LCMRglu occur. Additionally, our analyses have confirmed that the terminal plasma [14C] / 
[glucose] ratio provides a close approximation to the plasma history profile of these 
parameters within each animal allowing it to be used with a fair degree of certainty in the 
determination of LCMRglu by [14C]-UR analysis. However, it is important to note that for 
valid determination of LCMRglu with [14C]-UR analysis several assumptions are accepted 
that are exactly equivalent to those incorporated in the quantitative technique and it is worth 
considering whether these assumption are at all compr ised by our novel analytical 
method.  
A principal assumption of our novel approach is that t e relationship between the rate of 
[14C]-2-DG incorporation into the cerebral tissue and the plasma [14C] / [glucose] history is 
consistent between experimental groups. This assumption provides the foundation for 
adjustment of the initial ratio in [14C]-UR analysis to accommodate individual animal and 
group plasma ratio variability, and directly parallels the assumption in the fully quantitative 
approach that the rate constants for carrier mediat transport and phosphorylation of [14C]-
2-deoxyglucose, and the lumped constant, are consiste t between different experimental 
groups. However, it is accepted that the certainty of this assumption is likely to diminish if 
the glycaemic state of animals within the different xperimental groups is vastly different. 
Indeed, both the kinetic and lumped constants have been shown to alter under conditions of 
severe hyperglycaemia (Schuier et al., 1981; Sokoloff et al., 1977). The requirement that all 
animals are in the normoglycaemic range for the fully quantitative approach to 2-
deoxyglucose imaging is likely to be even more important for our novel approach. Indeed, it 
is also possible the SQ approach is actually more sensitive to violations of these assumptions 
arising from altered 2-DG kinetics than is the fully quantitative approach. In quantitative 
analysis the contribution of these kinetic values to the operational equation is minimised by 
the relatively long experimental time, by the end of which only low levels of plasma [14C]-2-
DG are present relative to the large peak of plasma [14C]-2-DG a few seconds after i.v bolus 
injection. However, when injected i.p the clearance of [14C]-2-DG from the plasma is 
delayed and higher residual levels are present at the experimental end-point (Kelly and 
McCulloch, 1983a; Meibach et al., 1980) and in terms of impact upon the operational 
equation, the contribution of the factors containing the kinetic constants will be increased 
and any error that results from altered [14C]-2-DG kinetics will be enhanced. The observation 
that unphopshorylated levels of [14C]-2-DG in the CNS are increased following i.p injection 
give some credence to this suggestion. Although some f the uncertainty can be eliminated 
by ensuring that there are no inter-group differences in glycaemic state that will introduce 
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systematic errors into the determination of LCMRglu, the lack of a timed sampling protocol 
to accurately define plasma histories of glucose and tracer in the SQ methodology adds the 
risk of missing any transient alterations in glycaemic state that may interfere with valid 
LCMRglu estimation. 
In many experiments using a modified SQ [14C]-2-DG technique it is assumed that the levels 
of tracer measured in the brain represent phosphorylated 2-DG with levels of 
unphosphorylated [14C]-2-DG so close to zero that they can be ignored. In eed, we have 
made this very assumption in the derivation from the original quantitative operational 
equation of the initial ratio for [14C]-UR analysis. It has previously been demonstrated, 
however, that under some experimental conditions a significant proportion of the total [14C] 
present is in the form of unphosphorylated [14C]-2-DG. Such conditions include the injection 
of tracer by i.p. rather than i.v. routes, when a short (30 minute) experimental time period is 
used, or when animals are hyperglycaemic (Kelly and McCulloch, 1983a). These problems 
can be largely reduced by the use of a longer (45 minute) experimental time period and by 
the intrinsic properties inherent in the [14C]-UR analytical method itself. In addition, if 
similar glycaemic states (within the normoglycaemic range) are maintained as a prerequisite 
in the experimental design then the influence of this factor on LCMRglu determination is 
limited. Furthermore, as LCMRglu is estimated in one experimental group in direct 
comparison to the control group and adjustment is made to the initial ratio in [14C]-UR 
analysis to incorporate the plasma variables for each animal, any potential influence of slight 
variability in the glycaemic state of the animals is controlled for. In order to circumvent the 
possible influence of increased unphosphorylated [14C]-2-DG the brain following i.p 
injection and variation in glycaemic state on LCMRglu determination, brain and plasma 
samples were routinely collected 45 minutes after [14C]-2-DG injection and the glycaemic 
state of animals in all groups was ensured to be within the normoglycaemic range in all 
experiments completed in this thesis. 
In conclusion, the novel analytical approach to theSQ 2-DG approach outlined here 
represents an increase in accuracy that brings data very close to that generated by the fully 
quantitative technique. Any loss in accuracy from the fully quantitative approach is offset by 
the wider experimental design that can be accommodated. The [14C]-UR analytical method 
was used in the determination of LCMRglu in all of the [14C]-2-DG autoradiographic 





2. Study 2 - Constitutive brain function in hSERT over-expressing mice  
 
2.1 Rationale  
 
SERT mRNA levels have been shown to be enhanced in the raphé nuclei of hSERT OVR 
mice (Jennings et al., 2006) supporting the contention hat SERT gene transcription is 
enhanced in the raphè 5-HT neurones of these animals. Furthermore, this enhanced SERT 
gene transcription results in an increased level of SERT protein expression, as detected by 
[3H]paroxetine binding, in membranes from the frontal cortex and brainstem for these 
animals (Loder et al., 2000). However, the possibility that the increased SERT expression 
present in the CNS of hSERT OVR mice may be regionally heterogenous has not been 
addressed. As such heterogeneity may be central to the effects of increase SERT gene 
transcription on affective, cerebral and serotonin system functioning here we use 
[3H]paroxetine binding autoradiography to characterise SERT protein expression in 46 
discrete brain regions in hSERT OVR mice in comparison to their Wt littermates.  
 
In humans the influence of the 5-HTTLPR on affective functioning is greater in females than 
in males. Gender-dependent modulation of the increase in SERT protein expression that 
results from the increased SERT transcription in “long” allele individuals of this 
polymorphisms may represent a primary mechanism by which gender influences the effect 
of the 5-HTTLPR on affective functioning. To assess the possible influence of gender on a 
genetically driven increase in SERT expression here we investigate [3H]paroxetine binding 
in both male and female hSERT OVR and Wt mice. In parallel to the known gender 
influence of the 5-HTTLPR on affective functioning we hypothesise that the magnitude of 
increased SERT expression that results from the enhanced SERT gene transcription in 
hSERT OVR mice will be greater in females than in males. 
 
As a life-long increase in SERT function results in reduced trait anxiety in humans (Lesch et 
al., 1996), and reduced anxiety-like behaviour under normal behavioural conditions in 
hSERT OVR mice (Jennings et al., 2006), alterations n constitutive cerebral functioning are 
likely.  Here we use the SQ [14C]-2-DG to determine LCMRglu in hSERT OVR and Wt 
mice to investigate the effect of a life-long increas  in SERT expression on constitutive 
cerebral function. Increased SERT protein expression present in hSERT OVR mice has been 
shown to result in decreased extracellular 5-HT levels in the CNS (Jennings et al., 2006). 
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The relationship between extracellular 5-HT availability and cerebral metabolism appears to 
be brain-region dependent. In most brain regions an acute enhancement of 5-HT 
neurotransmission is associated with a decrease in c rebral glucose metabolism (McBean et 
al., 1999; Smith et al., 2002a; Smith et al., 2002b). However, results from other studies in 
which 5-HT neurotransmission is pharmacologically enhanced or depleted suggest that 5-HT 
stimulates cerebral metabolism some brain regions, including the orbitofrontal and prefrontal 
cortex (Bremner et al., 1997; Mann et al., 1996). Furthermore, electrical stimulation of raphé 
5-HT neurones has been found to increase cerebral met bolism in a number of other brain 
regions, including the thalamus, mamillary body and components of the basal ganglia 
(Cudennec et al., 1988b). Therefore, we hypothesise that an increase in constitutive cerebral 
metabolism is likely to be present in the majority of brain regions in hSERT OVR mice with 
localised decreases observed in a limited number of b ain regions as a result of the decreased 
synaptic 5-HT levels present in these animals. Furthermore, we hypothesis that in parallel 
with the known influence of gender on the effects of a life-long increase in SERT function 
on affective functioning, constitutive cerebral metabolism with be altered to greater extent in 
female hSERT OVR mice than in males. 
 
2.2 Serotonin transporter binding  
 
The distribution and concentration of [3H]paroxetine binding in this study was similar to that 
reported by others (DeSouza and Kuyatt, 1987; Reader et al., 1998; Sharkey et al., 1991). 
The regional pattern of [3H]paroxetine binding sites was similar between both genders and 
genotypes. There was a strong correlation between all binding data in male and female mice 
(r=0.734, p<0.0001) and Wt and hSERT OVR mice (r=0.837, p<0.0001) indicative of a 
similar SERT expression profile across the genders and genotypes. Figures 3.2.1 and 3.2.2 
demonstrate the correlative nature of [3H]paroxetine binding between genders and 
genotypes, respectively, as shown in 10 representative brain regions. In all animals 
[3H]paroxetine binding was highest in the dorsal and median raphé, the molecular layer of 
the hippocampus, amygdala nuclei, hypothalamus and the substantia nigra. Medium levels of 
binding were evident in subregions of the hippocampus and the nucleus accumbens whereas 
low levels of binding were detected in the striatum and anterior cortical regions (e.g. mPFC, 





Figure 3.2.1 Regional correlation of [ 3H]paroxetine binding between  
male and female mice F18 

































Regional correlation of [3H]paroxetine binding in male and female mice. Data shown 
for 10 selected representative brain regions. 1= ventrolateral thalamus, 2= posterior 
cingulate, 3= dentate PO, 4= anterior cingulate, 5= CA3, 6=orbitofrontal cortex, 7= 
dorsal subiculum, 8= frontal cortex, 9= basolateral amygdala, 10= dorsal raphé. 
Data from both Wt and hSERT OVR mice were included in this analysis which 
showed a strong and significant correlation (r= 0.908, p<0.0001).This suggests that 
















Figure 3.2.2 Regional correlation of [ 3H]paroxetine binding in hSERT 
OVR and Wt mice F19 
 






































Regional correlation of [3H]paroxetine binding in Wt and hSERT OVR animals. Data 
shown for 10 representative brain regions. 1= posterior cingulate, 2= dentate PO, 3= 
ventrolateral thalamus, 4= anterior cingulate, 5= orbitofrontal cortex, 6= CA3, 7= 
dorsal subiculum, 8= frontal cortex, 9= dorsal raphé, 10= basolateral amygdala. 
Data from both male and female mice were included in this representative analysis 
which showed a strong and significant correlation (r= 0.9, p<0.0001). This suggests 
that the regional expression of SERT is similar between hSERT OVR and Wt mice. 
 
 
In the majority of brain regions [3H]paroxetine binding tended to be greater in females than 
in males. Indeed, [3H]paroxetine binding was found to be significantly higher in females as 
compared to males in a 18 of the 42 brain regions analysed. This effect was particularly 
prevalent in cortical regions (including the dorsal mPFC +65%, posterior cingulate  +97%  
and somatosensory cortex +46%), the hippocampus (includi g the dentate PO +53%, CA2 
+30%, ventral CA1 +51%), components of the basal gangli  (medial striatum +27%, globus 
pallidus +70%) and thalamic regions (mediodorsal +47%, ventrolateral +173%) (Figure 
3.2.3). In contrast, there was no evidence for a significant gender difference in 
[3H]paroxetine binding in any of the amygdala or raphé nuclei. See Figures 3.2.3 and 3.2.4 
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for representative regions in which gender influences [3H]paroxetine binding. Detailed 















































Figure 3.2.3 Effect of gender and hSERT over-expression on 










































































































































































































[3H]Paroxetine binding (fmol/mg) in 8 representative brain regions of wild-type and 
hSERT OVR male and female mice. Data were analysed using 2-WAY ANOVA. 
**denotes p<0.01 and ***denotes p<0.001 significant gender effect. #denotes p<0.05 
and ##denotes p<0.01 significant genotype effect. †denotes p<0.05 significant 
gender x genotype interaction. Note in particular the increased [3H]paroxetine 
binding in some brain regions of females as compared to males (e.g. Dorsal mPFC) 
and how hSERT over-expression results in increased binding in some brain regions 
(e.g. somatosensory cortex) but not others (e.g. central amygdala). Furthermore, 
note how the increased [3H]paroxetine binding induced by hSERT over-expression 
is greater in females than in males in some brain regions (e.g. septal nucleus)
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Figure 3.2.4 Gender differences in [ 3H]paroxetine binding F21 
F22 















































Gender differences in [3H]paroxetine binding in representative brain regions of 
diverse functional systems. Data shown as % difference of binding in female 
animals as compared to males, with data gained from both Wt and hSERT OVR 
animals. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender 
difference (2-way ANOVA). Gender differences in some regions appear to be 
extremely large when shown as a % due to the relatively low level of actual 
[3H]paroxetine binding present in these regions (e.g. ventrolateral thalamus 
[3H]paroxetine male:26 fmol/mg  female:47 fmol/mg). 
 110 
In both male and female animals the density of [3H]paroxetine binding tended to be greater 
in hSERT OVR mice compared to Wt animals in the majority of brain areas. Indeed, 
[3H]paroxetine binding was found to be significantly increased in hSERT OVR mice in 20 of 
the 42 brain regions analysed. These significant increases were present in cortical regions 
(range +34% to 59%), multiple hippocampal subfields (range +30 to +36%), components of 
the basal ganglia (range +38% to +42%), thalamic regions (range +25% to 38%) and the 
raphé nuclei (range 38% to 39%). However, [3H]paroxetine binding was not significantly 
altered in hSERT OVR animals in a number of brain regions including the piriform cortex 
(+8%) or any of the amygdala nuclei (range -5% to +8%) indicating that increased SERT 
expression in hSERT OVR mice is regionally heterogenous. See Figures 3.2.3 and 3.2.5 for 
representative examples of how hSERT over-expression alters [3H]paroxetine binding in a 
brain region dependent manner. Detailed data on [3H]paroxetine binding in Wt and hSERT 
OVR mice are shown in Tables 3.2.1 to 3.2.5. 
 
In the majority of brain regions the magnitude of the increase in [3H]paroxetine binding 
present in hSERT OVR animals as compared to Wt animals tended to be greater in females 
than in males (see Figure 3.2.5). This suggests that gender may modulate the ability of 
hSERT OVR to increase SERT protein expression levels and this was confirmed by the 
presence of a significant gender x genotype interacion in two brain regions, the septal 


















Figure 3.2.5 Effect of hSERT over-expression of [ 3H]paroxetine binding  
F23 
 


















































Effect of hSERT over-expression on [3H]paroxetine binding in selected brain 
regions. Data shown as % difference in binding of hSERT OVR mice in comparison 
to Wt mice of the same gender. +denotes p<0.05, ++denotes p<0.01 and +++denotes 
p<0.001 significant genotype effect. †denotes p<0.05 significant gender x genotype 
interaction. Data were analysed using 2-way ANOVA. Note how the presence of the 
hSERT transgene results in significantly increased [3H]paroxetine binding in some 
brain regions (e.g. cortical regions) but not others (e.g. amygdale). Furthermore, 
note how the magnitude of the increase in [3H]paroxetine binding as a result of 
hSERT over-expression is greater in females than in males in a limited number of 
brian regions (dorsal subiculum and septal nucleus). 
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Table 3.2.1 [ 3H]Paroxetine binding in hSERT OVR and Wt mice: cortical regions T14 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Cortex               
Orbitofrontal 52 ± 7 70 ± 6 35### 53 ± 5 76 ± 6 43### 
Frontal 72 ± 9 87 ± 6 21# 66 ± 6 82 ± 6 23# 
Anterior Cingulate 38 ± 6 57 ± 9 52### 50* ± 6 81* ± 7 60### 
Dorsal medial Prefrontal 40 ± 5 55 ± 6 37# 69*** ± 9 84*** ± 6 22# 
Ventral medial Prefrontal 45 ± 5 68 ± 5 50## 73*** ± 5 83*** ± 8 13## 
Somatosensory 56 ± 8 70 ± 9 24## 69** ± 7 118** ± 12 71## 
Temperoparietal 30 ± 8 59 ± 7 99## 53 ± 6 78 ± 7 45## 
Posterior Cingulate 18 ± 5 34 ± 5 94### 31*** ± 6 75*** ± 9 140### 
Piriform 88 ± 9 101 ± 11 14 84 ± 12 86 ± 12 2 
Entorhinal 87 ± 9 88 ± 10 2 72 ± 4 96 ± 8 33 
 
Effect of hSERT over-expression on [3H]Paroxetine binding in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and were 
analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. #denotes p<0.05, ##denotes 








Table 3.2.2 [ 3H]Paroxetine binding in hSERT OVR and Wt mice: basal ganglia T15 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Basal Ganglia               
Medial Striatum 47 ± 6 63 ± 6 34### 55* ± 6 87* ± 9 59### 
Lateral Striatum 34 ± 7 47 ± 9 37## 36* ± 5 68* ± 6 85## 
Globus Pallidus 35 ± 6 58 ± 7 66# 74*** ± 4 86*** ± 9 17# 
Subthalamic Nucleus 42 ± 6 45 ± 9 7 37 ± 5 32 ± 5 -13 
Substantia Nigra pars Reticulata 88 ± 5 102 ± 9 16 113* ± 11 120* ± 12 7 
Substantia Nigra pars Compacta 74 ± 6 91 ± 7 22 90 ± 4 113 ± 12 25 
 
Effect of hSERT over-expression on [3H]Paroxetine binding in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and were 
analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. #denotes p<0.05, ##denotes 
















Table 3.2.3 [ 3H]Paroxetine binding in hSERT OVR and Wt mice: amygdala, thalamic and hypoth alamic regions T16 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean   s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Amygdala               
Medial 86 ± 12 82 ± 7 -5 91 ± 13 103 ± 9 13 
Basolateral 87 ± 12 83 ± 7 -4 99 ± 11 92 ± 7 -7 
Central 83 ± 11 80 ± 7 -4 80 ± 10 96 ± 6 20 
Thalamic Nuclei               
Anterior 56 ± 5 61# ± 6 11 59 ± 8 76# ± 7 28 
Mediodorsal 43 ± 7 51# ± 4 21 56** ± 7 84**# ± 9 51 
Venterolateral 15 ± 5 22 ± 5 5 50*** ± 9 45*** ± 5 -10 
Hypothalamic Nuclei               
Anterior 81 ± 8 88 ± 5 8 93* ± 8 114* ± 11 21 
Venterolateral 69 ± 7 84 ± 5 21 84 ± 9 101 ± 16 19 
 
Effect of hSERT over-expression on [3H]Paroxetine binding in amygdala, thalamic and hypothalamic regions. Data are expressed as mean ± s.e.m and 
% difference between hSERT OVR and Wt animals. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, **denotes p<0.01 











Table 3.2.4 [ 3H]Paroxetine binding in hSERT over-expressing and Wild-type mice: hippocampa l regions T17 
 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m  
% 
difference  
Molecular Layer 103 ± 6 101 ± 7 -2 103 ± 13 105 ± 7 2 
Dorsal Subiculum 63 ± 4 76## ± 9 20 56 ± 9 78## ± 4 40† 
Dentate PO 22 ± 7 36# ± 6 58 38** ± 3 48**# ± 6 27 
Dorsal CA1 48 ± 6 61## ± 5 27 61** ± 5 80**## ± 4 31 
CA2 66 ± 6 70 ± 6 5 85** ± 8 92** ± 8 8 
Ventral CA1 63 ± 8 67 ± 5 6 92*** ± 8 104*** ± 8 13 
Ventral Subiculum 79 ± 7 89 ± 7 13 90 ± 9 96 ± 8 6 
CA3 56 ± 6 64 ± 7 14 63 ± 6 80 ± 6 27 
 
Effect of hSERT over-expression on [3H]Paroxetine binding in hippocampal regions. Data are expressed as mean ± s.e.m and % difference between 
hSERT OVR and Wt animals. Data were analysed using 2-way ANOVA.  **denotes p<0.01, ***denotes p<0.001 significant gender difference. #denotes 










Table 3.2.5 [ 3H]Paroxetine binding in hSERT OVR and wild-type mice: raphé, mesocorticolimb ic and non-specific 
regions T18 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m  
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Raphé               
Dorsal 90 ± 9 107# ± 11 19 74 ± 7 97# ± 4 32 
Median 60 ± 8 84## ± 8 40 59 ± 4 81## ± 7 38 
Paramedian 47 ± 9 58 ± 8 23 53 ± 5 56 ± 4 6 
Mesocorticolimbic System               
Ventral Tegmental Area 30 ± 5 53## ± 7 79 53** ± 5 69**## ± 9 30 
Nucleus Accumbens 57 ± 4 70 ± 3 23 71 ± 5 73 ± 7 3 
Non-specific               
Septal Nucleus 77 ± 8 84## ± 6 8 68 ± 5 101## ± 5 48† 
Bed Nucleus of the Stria Terminalis 55 ± 5 71 ± 9 28 82* ± 6 94* ± 11 15 
Lateral Habenula 52 ± 8 61 ± 6 18 63 ± 5 45 ± 8 -28 
Periaqueductal Grey 68 ± 8 78 ± 7 13 76 ± 12 93 ± 8 22 
 
Effect of hSERT over-expression on [3H]Paroxetine binding in raphé, mesocorticolimbic and non-specific regions. Data are expressed as mean ± s.e.m 
and% difference between hSERT OVR and Wt animals. Data were analysed using 2-way ANOVA. **denotes p<0.01. # denotes p<0.05, ## denotes 
p<0.01 signficant genotype effect. †denotes p<0.05 signficant gender x genotype interaction. 
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2.3 Constitutive LCMRglu  
 
In all brain regions LCMRglu tended to be lower in females than in males and this was 
confirmed by the significant gender effect observed in 34 of the 47 brain regions analysed. 
The most marked difference between the sexes was present in the anterior hypothalamus 
(mean 40% lower in females). LCMRglu was significantly lower in females as compared to 
males in all hippocampal subregions (min. effect -14%, max. effect -26%) as well as in all 
amygdala (min. -23%, max. -26%) and raphé (min. -21%, max. -26%) nuclei. 
 
In both male and female animals hSERT OVR produced a tendency towards decreased 
LCMRglu in the majority of brain regions. However, these observed decreases only reached 
significance in female animals, occurring in 34 of the 47 regions of interest (ROI) analysed. 
In females, hSERT OVR resulted in significantly decreased LCMRglu in all cortical (min. -
31%, max. -44%), raphé nuclei (min. -28%, max -29%), amygdala nuclei (min. -20%, max. -
28%) and all hippocampal subfields (min. -16%, max. -31%) except the dentate PO. There 
was no evidence for a significant effect of hSERT OVR on LCMRglu in any ROI in males. 
This suggested that the ability of hSERT OVR to modify constitutive LCMRglu was 
influenced by gender. Figures 3.2.6 and 3.2.7 show representative examples of how 
constitutive LCMRglu is affected by gender and hSERT over-expression as well as how 
these factors interact. Despite the widespread trend for a modulatory influence of gender on 
the cerebral hypo-metabolism induced by hSERT OVR the conservative nature of 2-WAY 
ANOVA meant that a significant gender x hSERT OVR interaction was only detected in 4 
brain regions; the medial striatum (26% greater reduction in females), globus pallidus (25% 
greater reduction in females), ventrolateral thalamus (32% greater reduction in females) and 
the mammillary body (27% greater reduction in females). In both male and female animals 
there was no correlation between the magnitude of the increased [3H]paroxetine binding 
observed in hSERT OVR animals and the changes observed in constitutive LCMRglu on a 
regional basis. For detailed LCMRglu data in all 47 ROI analysed see Tables 3.2.6 to 3.2.11. 





































































































































Influence of gender and hSERT OVR on constitutive LCMRglu in 6 representative 
brain regions. Data represent mean ± s.e.m. Data were analysed using 2-WAY 
ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender 
effect. †denotes p<0.05, ††denotes p<0.01 significant hSERT OVR effect (within 
gender with Bonferroni correction applied). ‡denotes p<0.05 significant gender x 
hSERT OVR interaction. In several brain regions constitutive LCMRglu is 
significantly decreased in females as compared to males (e.g. dorsal raphé). hSERT 
over-expression significantly decreases constitiutive LCMRglu in several limbic brain 
regions in females but has no effect in males (e.g. mamillary body). 
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Figure 3.2.7 Influence of Gender on hSERT OVR mediated alterations in constitutive LCMRg lu F25 


















LCMRglu (% different from Wt)

















LCMRglu (% difference from Wt)
 
Effect of hSERT OVR on constitutive LCMRglu in male and female mice. Data shown as % difference in the [14C]-Uptake ratio from 
appropriate Wt control. Figures illustrate representative regions for the (A) maxiumum  and (B) minimum  gender difference in the effect 
of hSERT over-expression upon LCMRglu. †denotes p<0.05, ††denotes p<0.01 significant hSERT effect (within gender Bonferroni 
correction). ‡denotes p<0.05 significant gender x hSERT OVR interaction (2-WAY ANOVA). hSERT over-expression results in a 
significantly more pronounced constitutive hypometabolism in females as compared to males in a number of limbic brain regions (e.g. 
somatosensory cortex, globus pallidus and mamillary body).
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Table 3.2.6 Constitutive LCMRglu in hSERT OVR and Wt mice: cortical regions T19 
 
 Male Female % Gender difference 
 Wt hSERT OVR % Wt 
hSERT 
OVR 
% Wt hSERT OVR 
hSERT 
Effect 
Cortex          
Orbitofrontal 58 ± 6 50 ± 5 -14 43 ± 4 31 ± 3 -36† -21** -29** -22 
Frontal 43 ± 5 36 ± 4 -16 44 ± 3 25 ± 2 -44†† -4 -37 -28 
Anterior Cingulate 46 ± 5 38 ± 4 -15 43 ± 3 27 ± 3 -38†† -10 -31 -23 
Dorsal medial Prefrontal 44 ± 6 35 ± 3 -21 37 ± 3 23 ± 2 -39†† -22** -32** -18 
Ventral medial Prefrontal 40 ± 4 31 ± 3 -21 29 ± 2 17 ± 2 -40†† -31*** -33*** -19 
Somatosensory 51 ± 5 46 ± 5 -9 55 ± 5 28 ± 3 -44†† 1 -43 -35‡ 
Temperoparietal 51 ± 5 47 ± 5 -8 44 ± 4 28 ± 2 -35† -19** -28** -27 
Posterior Cingulate 49 ± 5 47 ± 5 -6 48 ± 4 32 ± 3 -34† -5 -27 -28 
Piriform 29 ± 3 24 ± 2 -17 20 ± 2 14 ± 2 -31† -34*** -21*** -14 
Entorhinal 34 ± 3 30 ± 3 -14 30 ± 2 19 ± 2 -35† -14* -26* -21 
 
Constitutive LCMRglu in cortical regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± s.e.m [14C]-Uptake ratio and % 
change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % difference in the effect of hSERT 
OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 
significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant hSERT effect within gender (2-way 




Table 3.2.7 Constitutive LCMRglu in hSERT OVR and W t mice: basal ganglia regions T20 
  




% Wt hSERT OVR % Wt hSERT OVR 
hSERT 
Effect 
Basal Ganglia          
Medial Striatum 41 ± 3 38 ± 4 -7 42 ± 3 25 ± 3 -40†† -4 -32 -33‡ 
Lateral Striatum 46 ± 4 40 ± 4 -12 42 ± 3 26 ± 3 -37†† -13* -30* -25 
Globus Pallidus 30 ± 2 28 ± 3 -9 33 ± 3 18 ± 2 -44†† 1 -37 -35‡ 
Subthalamic Nucleus 46 ± 5 45 ± 5 -2 50 ± 4 30 ± 3 -34† 4 -32 -32 
Substantia Nigra pars Reticulata 29 ± 2 27 ± 2 -7 26 ± 2 17 ± 2 -35† -12* -26* -28 
Substantia Nigra pars Compacta 36 ± 3 33 ± 3 -9 34 ± 3 21 ± 2 -39†† -6* -31* -30 
 
Constitutive LCMRglu in basal ganglia regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± s.e.m [14C]-Uptake ratio 
and % change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % difference in the effect of 
hSERT OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes 
p<0.001 significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant hSERT effect within gender (2-












Table 3.2.8 Constitutive LCMRglu in hSERT OVR and W t mice: amygdala, thalamic and hypothalamic regions T21 
 
 
 Male Female % gender difference 








Amygdala          
Medial 24 ± 2 21 ± 2 -14 18 ± 2 12 ± 2 -32 -30** -23** -18 
Basolateral 33 ± 2 30 ± 3 -9 29 ± 2 18 ± 2 -36† -18** -28** -27 
Central 22 ± 2 19 ± 2 -12 17 ± 2 12 ± 2 -30 -29** -20** -18 
Thalamic Nuclei          
Anterior 47 ± 4 47 ± 5 0 47 ± 5 32 ± 3 -32 -7 -24 -32 
Mediodorsal 54 ± 5 47 ± 4 -14 48 ± 4 29 ± 3 -39†† -17** -32** -25 
Venterolateral 53 ± 5 50 ± 5 -6 56 ± 5 31 ± 3 -46††† 1 -39 -40‡ 
Hypothalamic Nuclei          
Anterior 37 ± 6 34 ± 4 -9 19 ± 3 13 ± 2 -34 -55** -25** -25 
Venterolateral 28 ± 2 27 ± 3 -3 26 ± 2 16 ± 2 -37† -17* -29* -34 
 
Constitutive LCMRglu in amygdala, thalamic and hypothalamic regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± 
s.e.m [14C]-Uptake ratio and % change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % 
difference in the effect of hSERT OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, 
**denotes p<0.01, ***denotes p<0.001 significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant 





Table 3.2.9 Constitutive LCMRglu in hSERT OVR and Wt mice: hippocampal regions T22 
 
 
 Male Female % gender difference 
 Wt hSERT OVR % Wt hSERT OVR % Wt hSERT OVR hSERT Effect 
Hippocampus          
Molecular Layer 41 ± 4 34 ± 3 -16 32 ± 3 21 ± 2 -35† -21** -27** -19 
Dorsal Subiculum 38 ± 3 34 ± 3 -11 38 ± 3 25 ± 3 -34†† -3 -26 -23 
Dentate PO 25 ± 1 22 ± 2 -11 20 ± 2 15 ± 2 -25 -18** -15** -14 
Dorsal CA1 35 ± 3 30 ± 2 -16 28 ± 3 17 ± 2 -38† -21** -31** -22 
CA2 33 ± 3 27 ± 3 -18 26 ± 3 16 ± 2 -38† -22** -31** -20 
Ventral CA1 33 ± 2 28 ± 3 -16 24 ± 2 17 ± 2 -31 -26*** -22*** -15 
Ventral Subiculum 29 ± 2 26 ± 3 -11 23 ± 2 17 ± 2 -26 -21** -16** -15 
CA3 27 ± 2 24 ± 2 -14 21 ± 2 14 ± 2 -34 -25*** -25*** -20 
 
Constitutive LCMRglu in hippocampal regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± s.e.m [14C]-Uptake ratio and 
% change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % difference in the effect of 
hSERT OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes 
p<0.001 significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant hSERT effect within gender (2-







Table 3.2.10 Constitutive LCMRglu in hSERT OVR and Wt mice: raphé and mesocorticolimbic regions T23 
 
 Male Female % gender difference 
 Wt 
hSERT 
OVR % Wt 
hSERT 





Raphé          
Dorsal 36 ± 3 31 ± 3 -14 29 ± 2 18 ± 2 -37† -23*** -29*** -23 
Median 46 ± 5 39 ± 4 -15 39 ± 3 25 ± 3 -36† -19** -28** -21 
Paramedian 45 ± 4 39 ± 4 -13 40 ± 3 25 ± 3 -37† -14** -29** -24 
Mesocorticolimbic System          
Ventral Tegmental Area 36 ± 3 37 ± 5 2 43 ± 4 28 ± 3 -35† 17 -27 -37‡ 
Nucleus Accumbens 43 ± 6 34 ± 3 -21 31 ± 2 19 ± 2 -40† -30** -32** -19 
 
Constitutive LCMRglu in raphé and mesocorticolimbic regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± s.e.m [14C]-
Uptake ratio and % change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % difference in 
the effect of hSERT OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, 
***denotes p<0.001 significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant hSERT effect within 










Table 3.2.11 Constitutive LCMRglu in hSERT OVR and Wt mice: non-specific regions T24 
 
 Male Female % gender difference 
 Wt hSERT OVR % Wt hSERT OVR % Wt hSERT OVR 
hSERT 
Effect 
Septal Nucleus 34 ± 3 29 ± 3 -13 29 ± 2 18 ± 2 -37†† -18** -29** -24 
BNST 27 ± 3 21 ± 2 -21 17 ± 2 11 ± 2 -35 -41* -28* -14 
Corpus Callosum 16 ± 1 13 ± 1 -16 11 ± 2 8 ± 1 -31 -31* -14* -15 
Lateral Habenula 53 ± 5 48 ± 5 -10 55 ± 4 32 ± 3 -41†† 2 -34 -31‡ 
Mamillary Body 52 ± 4 50 ± 5 -3 56 ± 3 34 ± 3 -39†† 4 -31 -36‡ 
Periaqueductal Grey 33 ± 3 26 ± 2 -20 23 ± 3 15 ± 2 -34 -19** -25** -14 
Inferior Colliculus 73 ± 7 71 ± 10 -3 81 ± 7 48 ± 5 -40† 14 -33 -37 
Ventral Tegmental Nucleus 46 ± 4 41 ± 4 -12 43 ± 3 26 ± 2 -40†† -12* -32* -28 
Locus Coeruleus 41 ± 4 36 ± 4 -13 38 ± 3 22 ± 2 -42† -16* -33* -29 
Nucleus Tractus Solitaris 56 ± 9 44 ± 7 -20 37 ± 4 17 ± 1 -52 -30* -31* -32 
 
Constitutive LCMRglu non-specific brain regions of male and female hSERT OVR and wild-type mice. Data shown as mean ± s.e.m [14C]-Uptake ratio 
and % change from appropriate control. The % difference between the genders (female v male) in each genotype, and the % difference in the effect of 
hSERT OVR on LCMRglu (female v male) is also shown. Data were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes 
p<0.001 significant gender effect. ‡denotes p<0.05 significant gender x genotype interaction. †denotes p<0.05 significant hSERT effect within gender (2-
way ANOVA with Bonferroni correction). 
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2.4 Discussion and Conclusions  
 
In this study we found that SERT protein expression was significantly higher in a number of 
functionally diverse brain regions in female as compared to male mice. There is a surprising 
paucity of published data on possible gender differences in SERT expression given the 
known role of gender in affective disorders and the multitude of reported gender differences 
in serotonergic system function (for review see Rubinow et al., 1998). However, evidence 
that the density of the high affinity [3H]imipramine binding site is greater in the brains of 
females rats as compared to males (Ieni et al., 1985) and that β-CIT, which labels both SERT 
and DAT, is higher in human females than males (Staley et al., 2001) provides some support 
to our findings. The sex steroids may be suggested to have a possible role in determining the 
observed gender differences in SERT protein expression. Indeed, oestrogen has been found 
to stimulate both SERT gene transcription and protein expression levels (McQueen et al., 
1997). However, the regional localisation of the gender differences found in our study do not 
correlate with those in which oestrogen increases SERT protein expression. Furthermore, 
testosterone has also been found to stimulate SERT expression in males (McQueen et al., 
1999). Therefore, it seems unlikely that gender differences in SERT expression are directly 
related to the acute regulatory effects of sex steroids. Gender differences in SERT protein 
expression and function are likely to contribute to the reported gender differences in 
affective functioning, anti-depressant efficacy and i  governing some of the other sexual 
dimorphisms reported in 5-HT system functioning. In particular, the enhanced expression of 
SERT in females may be central to the observation of the decreased synaptic 5-HT levels 
reported in females as compared to males (Gundlah et al., 1998; Jones and Lucki, 2005; 
Mitsushima et al., 2006). 
 
Our data suggest that hSERT OVR mice have an increased level of SERT protein expression 
in a number forebrain regions as well as in the midbrain raphé, as detected by 
autoradiography using the selective SERT radioligand [3H]paroxetine. Although the number 
of SERT binding sites was increased in hSERT OVR mice, the pattern of expression showed 
a close correlation to that of Wt animals and also corresponded with other studies using a 
variety of selective SERT radioligands (DeSouza andKuyatt, 1987; Reader et al., 1998; 
Sharkey et al., 1991). Despite the observation that t e expression of both the murine and 
human SERT proteins in hSERT OVR mice results in the presence of more than one binding 
site for SERT ligands (Loder, 2000), presumably dueto the differing affinities of murine as 
compared to the human transporter for these ligands (Plenge and Mellerup, 1991), the use of 
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a saturating concentration of [3H]paroxetine in our studies for both species of SERT proteins 
allows us to conclude that increased SERT protein expression levels (Bmax) rather than 
altered affinity is responsible for our observation f increased [3H]paroxetine binding in 
hSERT OVR mice. Furthermore, as rodent SERT displays higher affinity for SERT ligands 
in comparison to the human transporter increased [3H]paroxetine binding is unlikely to occur 
in hSERT OVR mice as a result of the presence of human SERT if expression levels are 
unaltered. Interestingly, the reported enhanced transcription of SERT mRNA observed in the 
raphé nuclei of hSERT OVR mice (Jennings et al., 2006) does not result in a universal 
increase in SERT protein expression throughout the brain. Rather, SERT expression is 
enhanced in a regionally heterogenous manner with the greatest increase found in anterior 
cortical regions, moderate increases in components of the basal ganglia, hippocampal regions 
and raphé, while in other regions, such as the amygdala nuclei, no increase is observed. 
Furthermore, there was also no correlation between th  level of SERT expression observed 
in Wt animals and the magnitude of the increased SERT expression observed in hSERT 
OVR mice on a region-dependent basis. This suggests tha  the increased SERT protein 
expression in hSERT OVR mice is not directly related to the enhancement of SERT gene 
transcription. Rather, complicated regulatory mechanisms must exist that govern SERT 
protein expression levels as a function of enhance gene transcription and these must operate 
in a brain-region specific manner. As yet the nature of these mechanisms is not understood. 
However, as they directly regulate the outcome of enhanced SERT gene transcription they 
are likely to be central in mediating the effect of enhanced SERT transcription in hSERT 
OVR mice and possibly of the 5-HTTLPR in humans on affective, brain and serotonin 
system functioning.  
 
Another interesting observation is that the approximate 2-fold increase in SERT binding in 
regions of the CNS of hSERT OVR mice shows a striking parallel to the magnitude (also 
approximately 2-fold) to the increase in SERT binding, mRNA expression and 5-HT re-
uptake found in the brain or platelets of human individuals with the l/l genotype as compared 
to those of the s/l or s/s genotype (Greenberg et al., 1999; Heinz et al., 2000; Little et al., 
1998). This adds further credence to the suggestion that hSERT OVR mice provide an 
accurate animal model of the human 5-HTTLPR polymorphism.  However, it is also 
important to note that a number of other studies have reported the lack of an effect of the 5-
HTTLPR on SERT binding in the brain (Parsey et al., 2006; Shioe et al., 2003; Van Dyck et 
al., 2004; Willeit et al., 2001). While it is interesting to speculate, with reference to our 
results, that the regional localisation of the binding measurements made in some of these 
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studies may be responsible for their negative findings it is also likely that the use of small 
sample sizes in some of these studies also contributes to their negative results.  
 
In this study we found that LCMRglu was lower in all regions analysed in females as 
compared to males. This result contrasts to those reported by others using the quantitative 
method in rats which have found no gender difference i  LCMRglu in the majority of brain 
regions (Nehlig et al., 1985) or a significantly increased rate of LCMRglu in females as 
compared to males (Brown et al., 1996). The reason for the disparities in these results is 
largely unknown. However, as Brown et al. (1996) measured LCMRglu in ovariectomised 
female rats with oestrogen replacement and acute administration of estradiol is known to 
increase LCMRglu (Namba and Sokoloff, 1984) the possible contribution of the  enhanced 
plasma oestrogen levels present in these females can not be ruled out. Furthermore, 
prolonged acute stress enhances LCMRglu to a greater x nt in females than in males. 
Therefore, use of restraint during the quantitative determination of LCMRglu in rats may 
also contribute in the apparent sexual dimorphisms of increased LCMRglu in females as 
compared to males. In contrast, the SQ 2-deoxyglucose method used in this study does not 
expose animals to a prolonged period of restraint stres  and so the possible influence of the 
enhanced LCMRglu response to stress in females is negated. In addition, in our own studies 
using the quantitative method in Dark Agouti rats we have also found a generalised 
significant decrease in LCMRglu in females as compared to males in the same brain regions 
analysed within this study (unpublished observations), further supporting our findings in 
mice. As our results in Dark-Agouti rats are divergent from those reported by others in 
Sprague-Dawley rats (Nehlig et al., 1985) this suggests that strain and gender may interact to 
influence constitutive LCMRglu, although this is yet to be adequately investigated.  
 
We also found that a life-long increase in SERT function decreases constitutive cerebral 
metabolism in a number of brain regions and that this effect was only significant in females. 
Interestingly, many of the regions in which a decreased rate of LCMRglu was found in 
hSERT OVR females as compared to Wt animals are strongly implicated in the regulation of 
anxiety. Pharmacological challenges associated withan anxiolytic effect, including acute 
diazepam and phenobarbital treatment, commonly result in decreased LCMRglu in many of 
the regions in which constitutive LCMRglu is decreas d in hSERT OVR mice. These 
regions include the mamillary body, ventrolateral thalamus, septal nucleus, medial striatum 
and globus pallidus (Ableitner and Herz, 1987; Ableitner et al., 1985; Kelly et al., 1986). In 
addition, a number of anxiogenic pharmacological challenges have been reported to elicit 
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increased LCMRglu in these structures (Pratt, 1988; Ableitnet 1987) and chronic prenatal 
treatment with diazepam which produces an anxiolytic phenotype in the “drug-free” adult is 
also associated with reduced LCMRglu in many of the structures (Schroeder, 1997). Overall, 
our data suggest that constitutive cerebral functio is decreased in several brain structures in 
which neuronal activity is positively correlated with anxiety. In addition, elevated LCMRglu 
in the lateral habenula appears to be the most robust correlate of depressive behaviour of rats 
and this hyper-metabolism is reversed, in parallel with the alleviation of depressive-like 
behaviour, by antidepressant treatment (Caldecott-Hazard et al., 1988). Therefore, it is 
notable that LCMRglu is also significantly decreased in the lateral habenula of hSERT OVR 
mice suggesting that hypo-metabolism in this region may contribute to their anti-depressive 
phenotype. Interestingly, the observation of decreased constitutive metabolism in limbic 
structures of female hSERT OVR mice parallels the reported basal fronto-limbic hypo-
metabolism reported in l/l as compared to s/s allele human individuals (Graff-Guerrero et al., 
2005). However, while significant hypo-metabolism was limited to frontal cortical structures 
in l/l human individuals we found evidence for a more widespread effect in hSERT OVR 
female mice, which also included many sub-cortical regions and the raphé nuclei. One 
reason for this disparity may be the lack of sample segregation on the basis of gender in the 
human study, which could lead to the masking of a more widespread hypo-metabolism in l/l 
allele females by the presence of a smaller effect in males. Indeed, it is pertinent that the 
hypo-metabolism reported in l/l human individuals is limited to anterior cortical regions that 
parallel those in which the greatest effect was detect d in hSERT OVR females. 
 
Interestingly, several of the regions in which hypo-metabolism was observed in hSERT OVR 
mice (including the orbitofrontal cortex, thalamus and mamillary body) have been shown to 
display increased metabolism in response to acutely increased 5-HT neurotransmission 
(Bremner et al., 1997; Cudennec et al., 1988b; Mann et al., 1996). This suggests that the 
decreased synaptic availability of 5-HT in hSERT OVR mice may be directly responsible for 
the decreased neuronal activity observed in these rgions. However, electrolytic and 
neurotoxic manipulations that result in a prolonged d crease 5-HT neurotransmission fail to 
reduce LCMRglu in these regions (Cudennec et al., 1988a). Furthermore, a number of brain 
regions shown to be hypo-metabolic in hSERT OVR mice have been shown to display a 
decreased rate of metabolism in response to acutely increased 5-HT neurotransmission 
(McBean et al., 1999; Smith et al., 2002a; Smith et al., 2002b). These results suggest that 
prolonged alterations in synaptic 5-HT availability, such as those in hSERT OVR mice and 
lesioned animals, do not mirror the effects of acutely altered 5-HT levels. This most likely 
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reflects the occurrence of compensatory mechanisms in 5-HT neurotransmission when 5-HT 
availability is chronically altered. Alterations inserotonin receptor expression and function 
are likely to constitute some of these alterations. Therefore, it will be important to 
characterise the possible alterations in serotonin receptor function that may contribute to the 
constitutive hypo-metabolism observed in hSERT OVR mice. 
 
Evidence from both [3H]paroxetine binding and constitutive LCMRglu data suggest that 
gender modulates the influence of hSERT OVR on these parameters, with hSERT OVR 
having a greater effect in females than in males. The greater enhancement of [3H]paroxetine 
binding in the CNS of females as compared to males by hSERT OVR suggests that direct 
gender modulation of the increase in SERT protein expression elicited by the increased 
transcription of the SERT gene may be central to the reported gender differences in the 
influences of the 5-HTTLPR on affective functioning in humans. However, in hSERT OVR 
mice the modulatory influence of gender on increased SERT expression was limited in its 
regional distribution, being significant in the dorsal subiculum and septal nucleus. In 
contrast, the influence of gender on the cerebral hypo-metabolism present in hSERT OVR 
animals was more widespread and did not include either the dorsal subiculum or septum. 
Furthermore, the regions in which LCMRglu was altered by hSERT OVR to a greater extent 
in females than in males do not receive dense innervation from either the dorsal subiculum or 
septum. This may suggest that the influence of gender on the hypo-metabolism in hSERT 
OVR mice may not be directly related to the influenc  of gender on SERT expression levels 
in these animals. However, it is commonly reported that regional alterations in LCMRglu in 
response to pharmacological challenge do not correlate with the regional distribution of 
receptors. This is thought to be due to both the sensitivity of the method, which localises 
metabolic alterations at the synapse rather than cell body, the convergence and contribution 
of multiple neuronal pathways to the observed altertions in LCMRglu and the behavioural 
effects of drug treatment which may also alter LCMRglu (e.g. by increasing locomotor 
activity). Therefore, it is not surprising that the g nder effects of hSERT OVR on SERT 
protein expression do not correlate with those of LCMRglu. However, one other possibility 
is that the gender dependent modulation of secondary responses to the increased SERT 
expression in hSERT OVR animals, rather than of SERT expression itself, may be primarily 
responsible for the gender differences observed in the influence of hSERT OVR on 
LCMRglu. For example, gender modulation of the possible alterations in 5-HT receptor 
functioning that may occur in response the altered SERT function in hSERT OVR animals 
and may contribute to the gender differences noted in LCMRglu. A contention supported by 
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the increased alteration in 5-HT1A receptor function present in SERT KO female animals as 
compared to males (Li et al., 2000). Overall, these data suggest that increased SERT 
transcription modifies constitutive cerebral function to a greater in females than in males. 
While this finding parallels reported gender-differences observed in humans in the effect of 
the 5-HTTLPR on affective functioning the possible g nder difference in anxiety-like 
behaviour in hSERT OVR animals has not been investigated. However, our data suggest that 
hSERT OVR may produce a greater anxiolytic effect in females than in males. 
 
Interestingly, we found that the rate of metabolism in the ventrolateral hypothalamus was 
significantly reduced in hSERT OVR mice. Evidence suggests that neuronal activity in this 
region regulates feeding behaviour as the excitation of neurones within this region with 
excitatory amino acids results in intense feeding behaviour (Stanley et al., 1993). 
Furthermore, the local application of GABA or GABAA agonists into this brain region results 
in decreased feeding (Kelly et al., 1977; 1979). This suggests, therefore, that hSERT OVR 
mice may eat less than Wt mice, which may contribute to their decreased body weight 
(Figure 1.7). Clearly, further research should be dedicated to investigating possible 
alterations in the feeding behaviour of hSERT OVR mice and the possible influence of 
altered hypothalamic neuronal function on the feeding behaviour of these mice. 
 
In summary, the SERT expression and cerebral functio al alterations present in hSERT OVR 
mice parallel those observed in l/l allele in comparison to s/s allele human individuals 
suggesting that hSERT OVR mice provide a good animal model of the 5-HTTLPR 
polymorphism. In addition, alterations in SERT expression and cerebral functioning 
observed in hSERT OVR mice are greater in females than in males which parallels the 
known gender-difference in the influence of the 5-HTTLPR polymorphism on affective 
functioning and the antidepressant response in humans. Alterations in 5-HT receptor 
expression and/or functioning in hSERT OVR animals are likely to occur in response to the 
decreased synaptic 5-HT availability in these animals and may play a role in the constitutive 
hypo-metabolism present in these animals. Possible alterations in 5-HT receptor functioning 







3. Study 3- 5-HT 1A binding and function in hSERT over-expressing mice  
 
3.1 Rationale  
 
Alterations in 5-HT1A receptor function are postulated to play a central role in both affective 
psychopathology and the response to antidepressant trea ment (see section 4.4.1). 
Furthermore, evidence from both human and animal studies supports a central role for 
genetically determined SERT levels in the regulation of 5-HT1A receptor expression and 
function. In humans the ‘s’ polymorphism in the 5-HTLLPR region of the SERT gene, 
resulting in a life-long decrease in SERT functioning, is associated with decreased post-
synaptic 5-HT1A binding whereas 5-HT1A autoreceptor binding in the raphé is unaltered 
(David et al., 2005). Although this suggests that post-synaptic 5-HT1A receptor expression 
may be decreased as a result of a life-long decrease in SERT function the possible effect of 
the polymorphism on 5-HT1A receptor function has not yet been explored. In mice where 
SERT function is knocked-out (KO), however, the most consistent observation has been 
decreased 5-HT1A autoreceptor binding and function. Whereas, observations of reduced post-
synaptic 5-HT1A binding and function in SERT KO mice, despite consistency in their 
directionality, have been inconsistent in their localisation (Fabre et al., 2000a; La Cour et al., 
2001; Li et al., 1999). Mechanistically, it is suggested that the decreased SERT function, 
both in ‘s’ allele humans and SERT KO mice, leads to 5-HT1A receptor desensitisation due to 
increased synaptic 5-HT levels. In line with this suggested mechanism and the findings of 
previous studies it may be hypothesised that 5-HT1A binding and function may be increased 
in hSERT OVR mice as a result of the decreased synaptic 5-HT availability in these animals 
(Jennings et al., 2006). 
 
In order to further understand the alterations in serotonin receptor function that may be 
responsible for the reported alterations in constitutive neuronal functioning in hSERT OVR 
mice here we characterised 5-HT1A binding using [
3H]WAY100,635 and 5-HT1A-mediated 
functional responses, in terms of the LCMRglu respon e to 8-OH-DPAT, in these animals. 
Furthermore, as our previous studies suggest that the ability of hSERT OVR to modify 
neuronal activity is influenced by gender and other studies suggest that the ability of 
genetically determined SERT expression levels to modify 5-HT1A receptor function may be 
greater in females than males (David et al., 2005; Li et al., 2000) we will investigate these 
parameters in animals of both genders. 
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3.2 5-HT1A Receptor Binding  
 
In the majority of brain regions [3H]WAY100,635 binding tended to be greater in females in 
comparison to males. Indeed, [3H]WAY100,635 binding was found to be significantly 
increased in females as compared to males in 23 of the 48 brain regions analysed. This 
gender difference was prevalent in diverse cortical regions (range +21% to +42%), multiple 
hippocampal subfields (range +4% to +36%) and in the dorsal (+26%) and median (+28%) 
raphé. The only region in which [3H]WAY100,635 binding was significantly decreased in 
females as compared to males was in the medial amygdala (-35%). In contrast there was no 
evidence for a significant gender difference in 5-HT1A binding in any of the hypothalamic 
regions analysed. Gender differences in [3H]WAY 100,635 binding for a number of 
representative brain regions are shown in Figures 3.3.1 and 3.3.2. 
 
hSERT OVR produced a trend towards decreased [3H]WAY100, 635 binding in the majority 
of brain regions in males, whereas this trend was more limited in females. In both males and 
females hSERT OVR produced a significant decrease in [3H]WAY100,635 binding in the 
dentate gyrus (males: -39%, females: -17%) and dentate PO (males: -35%, females: -11%). 
Despite the observation that [3H]WAY100,635 binding was reduced to a greater extent in 
males than in females in response to hSERT over-expression in these regions there was no 
significant evidence for a gender x genotype interaction. However, in two other regions, the 
CA2 and VCA1 subfields of the ventral hippocampus, a significant interaction was found 
between genotype and gender indicating that hSERT OVR resulted in a significant decrease 
in [3H]WAY100,635 binding in males (CA2: -20%, VCA1 -22%) but not females (CA2: 
+6%, VCA1 -2%) in these regions (Figures 3.3.1 and 3.3.3). A further significant interaction 
between gender and genotype was identified in the somatosensory cortex where hSERT 
OVR was found to result in a significant increase in [3H]WAY100,635 binding in females 
(+17%) and a non-significant decrease in males (-12%). Detailed data on [3H]WAY100,635 
binding in male and female hSERT OVR animals and their Wt littermates are presented in 






































































































































































[3H]WAY100,635 binding in 6 representative brain regions in male and female 
hSERT OVR and wild-type mice. Data shown as mean ± s.e.m. *denotes p<0.05, 
**denotes p<0.01 and ***denotes p<0.01 significant gender effect. †denotes p<0.05 
significant genotype effect. +denotes p<0.05 significant genotype x gender 
interaction (2-way ANOVA). #denotes p<0.05 significant genotype effect within 
gender (2-way ANOVA with Bonferroni Correction). [3H]WAY 100,635 is significantly 
ihigher in several brain regions in females as compared to males (e.g dorsal raphé, 
medial amygdala). [3H]WAY 100,635 binding is significantly decreased in the 
dentate gyrus of both male and female hSERT OVR mice. In addition 
[3H]WAY100,635 binding is reduced in other hippocampal brain regions (ventral 




Figure 3.3.2 Gender differences in [ 3H]WAY100,635 binding F27 












































Gender differences in [3H]WAY100,635 binding in representative brain regions of 
diverse functional systems. Data shown as % difference in binding in female animals 
as compared to males, with data gained from both Wt and hSERT OVR animals. 
*denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant gender 
difference (2-way ANOVA). [3H]WAY100,635 binding is significantly higher in 








Figure 3.3.3 Gender modulates the influence of hSERT OVR on  
[3H]WAY 100,635 binding i28 
 



















Figure showing regions in which [3H]WAY 100,635 binding is significantly altered in 
hSERT OVR mice. Data shown as % difference in binding from appropriate Wt 
control. Data were analysed using 2-way ANOVA. †denotes p<0.05 significant 
hSERT OVR effect, +denotes p<0.05 significant gender x genotype interaction. 
#denotes p<0.05 significant hSERT effect within gender (2-way ANOVA with 
Bonferroni correction). hSERT OVR significantly increases [3H]WAY100,635 binding 
in the somatosensory cortex, but only in female animals. In contrast 
[3H]WAY100,635 binding is decreased in the dentate gyrus and dentate PO by 
hSERT over-expression in animals of both genders. However, in the ventral CA1 
and ventral subiculum [3H]WAY100,635 binding is only decreased by hSERT over-







Table 3.3.1 [ 3H]WAY100,635 Binding in hSERT over-expressing mice:  cortical regions T25 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Cortex               
Orbitofrontal 70.4 ± 5.5 65.7 ± 2.5 -7 95.5*** ± 6.2 99.2 ± 3.3 4 
Frontal 50.9 ± 2.6 50.9 ± 1.7 0 64.3*** ± 3.9 68.0 ± 2.6 6 
Anterior Cingulate 34.8 ± 1.5 29.0 ± 1.9 -17 43.7*** ± 4.8 46.4 ± 3.5 6 
Dorsal medial Prefrontal 39.5 ± 1.7 35.5 ± 1.4 -10 51.9*** ± 4.7 54.0 ± 2.2 4 
Ventral medial Prefrontal 45.8 ± 1.7 41.8 ± 1.1 -9 59.7** ± 6.6 54.8 ± 2.3 -8 
Somatosensory 44.2 ± 1.5 38.4 ± 1.6 -13+ 51.5*** ± 3.1 60.4 ± 2.6 17+# 
Frontal Piriform 78.9 ± 2.2 80.8 ± 3.0 2 92.4*** ± 3.6 101.4 ± 4.2 -4 
Temperoparietal 30.7 ± 1.3 25.5 ± 1.8 -17 38.6** ± 4.6 4.6 ± 3.1 8 
Posterior Cingulate 23.8 ± 1.8 19.4 ± 2.9 -18 25.9 ± 2.9 28.0 ± 3.8 8 
Piriform 46.2 ± 0.4 36.0 ± 1.6 -22 49.0** ± 3.7 51.6 ± 3.7 5 
Entorhinal 89.0 ± 9.1 55.0 ± 3.1 -38 98.6* ± 9.4 76.1 ± 17.4 -7 
 
Effect of hSERT over-expression on [3H]WAY100,635 binding in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and were 
analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. + p<0.05 denotes significant 
gender x genotype interaction. #denotes significant genotype effect within-sex (2-way ANOVA with Bonferroni correction).  n/s indicates no significant 










Table 3.3.2 [ 3H]WAY100,635 Binding in hSERT over-expressing mice:  basal ganglia T26 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Basal Ganglia               
Medial Striatum 6.6 ± 0.7 3.4 ± 1.2 n/s 3.6 ± 3.0 2.8 ± 3.9 n/s 
Lateral Striatum 5.3 ± 0.7 2.3 ± 1.1 n/s 2.7 ± 2.7 0.1 ± 4.3 n/s 
Globus Pallidus 5.9 ± 0.6 2.8 ± 0.9 n/s 3.4 ± 3.1 1.5 ± 4.1 n/s 
Subthalamic Nucleus 19.9 ± 1.0 17.9 ± 1.0 -10 12.6 ± 4.9 16.1 ± 4.6 27 
Substantia Nigra pars Reticulata 3.9 ± 0.8 1.7 ± 2.1 n/s 1.0 ± 4.4 2.3 ± 3.9 n/s 
Substantia Nigra pars Compacta 5.2 ± 0.9 6.2 ± 1.6 n/s 5.7 ± 4.7 4.7 ± 4.0 n/s 
 
 
Effect of hSERT over-expression on [3H]WAY100,635 binding in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and were 
analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. + p<0.05 denotes significant 
gender x genotype interaction. #denotes significant genotype effect within-sex (2-way ANOVA with Bonferroni correction).  n/s indicates no significant 















Table 3.3.3 [ 3H]WAY100,635 Binding in hSERT over-expressing mice: amygdala, thalamic and h ypothalamic regions T27 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean   s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Amygdala               
Medial 55.0 ± 1.5 59.0 ± 3.3 7 41.7** ± 6.5 31.5 ± 7.2 -25 
Basolateral 13.4 ± 1.1 12.1 ± 2.4 -10 11.5 ± 4.3 5.8 ± 4.2 -50 
Central 18.2 ± 2.3 16.9 ± 2.9 -7 25.8 ± 4.8 19.5 ± 3.0 -25 
Thalamic Nuclei               
Anterior 3.9 ± 0.5 0.9 ± 2.1 n/s 1.1 ± 3.1 0.3 ± 3.9 n/s 
Mediodorsal 5.3 ± 0.9 2.4 ± 2.0 n/s 0.8 ± 2.7 0.1 ± 3.9 n/s 
Venterolateral 4.2 ± 0.6 0.2 ± 2.0 n/s 1.9 ± 3.2 1.6 ± 4.7 n/s 
Hypothalamic Nuclei               
Anterior 20.6 ± 3.2 18.6 ± 3.6 -10 25.8 ± 2.9 26.9 ± 2.4 4 
Paraventricular 30.2 ± 1.8 24.4 ± 2.2 -19 31.6 ± 3.1 28.5 ± 3.4 -10 
Venterolateral 15.9 ± 0.7 14.2 ± 1.7 -11 15.9 ± 3.1 14.6 ± 4.4 -8 
Ventromedial 25.1 ± 0.9 27.0 ± 1.7 8 34.7 ± 4.4 25.3 ± 4.5 -27 
 
Effect of hSERT over-expression on [3H]WAY100,635 binding in amygdala, thalamic and hypothalamic regions. Data are expressed as mean ± s.e.m 
and were analysed using 2-way ANOVA. **denotes p<0.01 significant gender difference.  n/s indicates no significant [3H]WAY100,635 binding in region 










Table 3.3.4 [ 3H]WAY100,635 Binding in hSERT over-expressing mice: hippocampal regions T28 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m  
% 
difference  Mean  s.e.m  Mean  s.e.m  
% 
difference  
Dorsal Hippocampus               
CA1 152.8 ± 4.2 139.5 ± 5.9 -9 159.7 ± 9.3 159.7 ± 6.7 7 
CA2 137.1 ± 2.9 123.1 ± 3.9 -10 151.4** ± 6.5 142.8 ± 5.7 9 
CA3 29.7 ± 0.9 23.4 ± 1.6 -21 30.9 ± 4.9 29.6 ± 4.1 -5 
DG 30.3 ± 1.4 20.1 ± 1.9 -34† 36.5* ± 3.3 30.3 ± 4.1 -17† 
Ventral Hippocampus               
Molecular Layer 85.1 ± 3.3 79.0 ± 4.8 -7 105.0*** ± 2.4 104.5 ± 3.1 -1 
Dorsal Subiculum 58.4 ± 2.9 46.4 ± 2.6 -20 65.6*** ± 3.6 65.2 ± 6.2 -1 
Dentate PO 43.1 ± 1.4 29.3 ± 1.8 -32† 47.9* ± 5.5 42.5 ± 3.9 -11† 
Dorsal CA1 79.0 ± 2.9 75.9 ± 4.5 -4 100.6* ± 7.8 109.0 ± 7.0 8 
CA2 85.1 ± 2.8 71.8 ± 2.9 -16 103.2*** ± 3.2 110.6 ± 6.5 7 
Ventral CA1 87.3 ± 2.9 70.8 ± 3.7 -19#+ 103.6*** ± 4.2 109.5 ± 5.1 6+ 
Ventral Subiculum 101.2 ± 4.8 80.3 ± 2.8 -21#+ 99.5 ± 4.7 98.0 ± 7.1 -2+ 
CA3 49.9 ± 1.0 41.5 ± 2.2 -17 47.1 ± 7.3 47.8 ± 2.8 2 
 
Effect of hSERT over-expression on [3H]WAY100,635 binding in hippocampal regions. Data are expressed as mean ± s.e.m and were analysed using 
2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. †denotes p<0.05 significant genotype effect. 




Table 3.3.5 [ 3H]WAY100,635 Binding in hSERT over-expressing mice: raphé, mesocorticolimbic  and non-specific 
regions T29 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m 
% 
difference  Mean  s.e.m  Mean  s.e.m 
% 
difference  
Raphé               
Dorsal 113.3 ± 4.9 117.3 ± 8.1 4 149.0*** ± 2.9 141.9 ± 5.7 -5 
Median 36.9 ± 1.0 29.7 ± 2.3 -20 41.1** ± 3.9 44.2 ± 2.9 7 
Paramedian 20.8 ± 1.0 13.1 ± 1.7 -37 22.3 ± 3.6 15.7 ± 5.3 -30 
Mesocorticolimbic System               
Ventral Tegmental Area 8.8 ± 0.6 5.1 ± 1.8 n/s 2.7 ± 3.9 5.4 ± 4.3 n/s 
Non-specific               
Dorsal Endopiriform Nucleus 84.0 ± 2.6 78.5 ± 3.1 -7 95.2** ± 5.4 96.6 ± 1.7 2 
Septal Nucleus 95.5 ± 3.6 90.9 ± 3.7 -5 116.3*** ± 4.9 116.6 ± 6.8 0 
Bed Nucleus of the Stria Terminalis 30.8 ± 1.2 31.7 ± 31.7 3 26.7 ± 1.7 31.5 ± 4.8 10 
Lateral Habenula 4.8 ± 1.8 1.3 ± 2.0 n/s 1.4 ± 1.9 0.9 ± 2.3 n/s 
Interpeduncular Nucleus 117.5 ± 3.3 104.9 ± 6.7 7 151.6*** ± 6.5 160.6 ± 8.8 6 
Periaqueductal Grey 25.1 ± 1.5 16.6 ± 1.1 1 28.5* ± 3.4 27.2 ± 3.9 -5 
Inferior Colliculus 23.0 ± 0.7 17.6 ± 3.8 4 31.7 ± 2.8 23.8 ± 5.2 -25 
 
Effect of hSERT over-expression on [3H]WAY100,635 binding in raphé, mesocorticolimbic and non-specific regions. Data are expressed as mean ± 
s.e.m and were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. n/s indicates no 
significant [3H]WAY100,635 binding in region (t-test TB against NSB). 
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3.3 LCMRglu  
 
Acute 10mg.kg-1 8-OH-DPAT produced widespread decreases in LCMRglu in all 
experimental groups. Figure 3.3.4 shows representative utoradiograms demonstrating that 
8-OH-DPAT treatment results in a wide-spread reduction in [14C]-2-DG isotope 
accumulation. These decreases were most extensively observed in cortical regions (male: 
min. effect -28%, max. effect -46%; female: min. -30%, max. -51%), the hippocampus 
(male: min. -31%, max. -51%; female: min. -42%, max. -54%) and the raphé nuclei (male: 
min. -35%, max. -41, female: min. -38%, max. -52%). In Wt males these decreases reached 
significance in 37 of the 47 ROI analysed. In Wt females the LCMRglu decreases produced 
by 8-OH-DPAT in were both more pronounced and widespr ad than those seen in males 
with 44 of the 47 areas reaching significance. This suggested that the response to 8-OH-
DPAT was greater in Wt females as compared to Wt males. Indeed, a significant gender x 8-
OH-DPAT interaction was identified in 5 ROI where the LCMRglu response to 8-OH-DPAT 
was greater in females than in males (see Figures 3.3.5 and 3.3.6 for representative 
examples). A significantly greater response in femal s was noted in the globus pallidus (68 
% greater), lateral habenula (100% greater), ventral tegmental area (181% greater), 
mamillary body (75% greater) and the inferior collicu us (53% greater). This finding is in 
agreement with the enhanced 5-HT1A binding noted in females as compared to males. In 
contrast to the observations made in Wt animals there was no evidence for a significant 
difference in the LCMRglu response to 8-OH-DPAT between male and female hSERT OVR 
mice in any ROI. 
 
In males the LCMRglu response to 8-OH-DPAT appeared to be of a similar magnitude in the 
majority of brain regions in Wt and hSERT OVR animals. In contrast, in females the 
LCMRglu response to 8-OH-DPAT appeared to be reduce in the majority of brain regions 
in hSERT OVR in comparison to Wt animals. hSERT OVR was found to significantly 
reduce, to a similar extent in both males and femals, the LCMRglu response to 8-OH-
DPAT in 4 of the 47 ROI. These areas were the DmPFC (males -7%, females -24%), 
VmPFC (male -13%, female -13%), the nucleus accumbens (male -21%, female -35%) and 











Representative “false-colour” autoradiographic images at the level of the caudate, 
dorsal hippocampus, ventral hippocampus and raphé in saline-treated and 8-OH-
DPAT-treated wild-type male mice. High levels of tissue isotope accumulation are 
shown as “warm” colours (red/orange) whilst low isotope tissue accumulation is 
depicted by “cold” colours (green/blue). Note in particular how 8-OH-DPAT causes a 











Figure 3.3.5 LCMRglu responses to 8-OH-DPAT in Wild -type and hSERT 























































































































LCMRglu responses in 8 representative brain regions in wild-type and hSERT OVR 
male and female mice. Data shown as mean ± s.e.m [14C]-uptake ratio. *denotes 
p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant 8-OH-DPAT effect 
(within genotype 2-way ANOVA with Bonferroni correction). +denotes p<0.05 
significant gender x 8-OH-DPAT interaction (within genotype 2-way ANOVA). 
#denotes p<0.05 significant gender x genotype x 8-OH-DPAT interaction and 
†denotes p<0.05 signficant genotype x 8-OH-DPAT interaction in both males and 
females (Univariate ANOVA). 8-OH-DPAT results in significant decreases in 
LCMRglu in a number of brain regions, in animals of b th gender and genotype. The 
response to 8-OH-DPAT is greater in wild-type females as compared to males in a 
number of brain regions (e.g. lateral habenula). The response to 8-OH-DPAT is 

































































































































Effect of hSERT OVR on the LCMRglu response to 10mg.kg-1 8-OH-DPAT in male 
and female mice. Data for 6 representative brain regions shown as % change in the 
[14C]-Uptake ratio ([14C]-UR) in 8-OH-DPAT-treated animals relative to the 
appropriate saline control. Data analysed using Univariate ANOVA. †denotes p<0.05 
significant hSERT OVR x 8-OH-DPAT interaction. ‡denotes p<0.05 significant sex x 
hSERT OVR x 8-OH-DPAT interaction. *denotes p<0.05, **denotes p<0.01 
significant gender x 8-OH-DPAT interaction (2-WAY ANOVA within genotype). 8-
OH-DPAT effect on LCMRglu was significant in all regions.The LCMRglu response 
to 8-OH-DPAT is significantly greater in wild-type females as compared to males in 
a number of brain regions (e.g. ventral tegmental area, globus pallidus). The 
response to 8-OH-DPAT is significantly reduced by hSERT over-expression in a 
number of brain regions, in both males and females (e.g. Dorsal mPFC, Septal 
nucleus). In some brain regions the LCMRglu response to 8-OH-DPAT is attenuated 
only in females (e.g. lateral habenula). 
 
 146 
In addition, 6 other brain regions were identified in which a significant gender x hSERT 
OVR x 8-OH-DPAT interaction was found. This interaction was observed in functionally 
diverse brain regions which included the lateral habenula, mammillary body, the VTA and 
several components of the basal ganglia (medial stri tum, subthalamic nucleus, and globus 
pallidus). In each of these regions the LCMRglu response to 8-OH-DPAT appeared to be 
reduced in female animals by hSERT over-expression but not in males (Figure 3.3.7 for 
representative regions). In 4 of these regions the LCMRglu response to 8-OH-DPAT was 
previously found to be significantly greater in Wt female animals as compared to Wt males. 
However, in hSERT OVR animals there was no evidence for a greater ff ct of 8-OH-DPAT 
on LCMRglu in females as compared to males in any of these regions. This suggests that 
hSERT OVR reduced the LCMRglu alterations induced by 8-OH-DPAT in these regions in 
females to a similar level as that observed in males. Detailed data on the effects of hSERT 
over-expression on the LCMRglu response to 8-OH-DPAT are shown in Tables 3.3.6 to 
3.3.11. The plasma data for animals involved in this experiment are also shown in Appendix 























Figure 3.3.7 Attenuation of Gender differences in t he LCMRglu 
response to 8-OH-DPAT by hSERT OVRF32 
 



















Fold difference in LCMRglu response
 
hSERT OVR attenuates the enhanced response to 8-OH-DPAT found in wild-type 
females as compared to wild-type males. Data shown as fold difference in the 
LCMRglu ([14C]-Uptake ratio) response to 8-OH-DPAT of females as compared to 
males. Dashed line represents 1.0 fold signifying no gender difference in the 
response to 8-OH-DPAT. **denotes p<0.01 significant gender x 8-OH-DPAT 
interaction (2-way ANOVA within genotype). ‡denotes p<0.05 significant gender x 










Table 3.3.6 LCMRglu response to 8-OH-DPAT in hSERT over-expressing mice: cortical regions T30 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR  
 Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT % 
Cortex             
Orbitofrontal 62 ± 6 39 ± 4 -37* 52 ± 5 33 ± 2 -36* 49 ± 4 30 ± 4 -39*** 33 ± 3 24 ± 3 -30* 
Frontal 46 ± 5 33 ± 3 -28* 38 ± 4 26 ± 2 -31 44 ± 3 25 ± 4 -43*** 26 ± 3 19 ± 2 -29 
Anterior Cingulate 48 ± 5 31 ± 4 -36** 41 ± 5 24 ± 2 -42* 43 ± 3 21 ± 3 -51*** 28 ± 3 17 ± 2 -43** 
Dorsal medial Prefrontal 47± 5 26 ± 3 -44*** 37 ± 4 22 ± 2 -41*† 37 ± 3 18 ± 3 -51*** 24 ± 3 15 ± 2 -39**† 
Ventral medial Prefrontal 42 ± 4 23 ± 2 -46*** 33 ± 3 20 ± 1 -40*† 29 ± 2 15 ± 2 -46*** 18 ± 2 13 ± 1 -33† 
Somatosensory 54 ± 4 43 ± 5 -20 48 ± 5 37 ± 3 -23 55 ± 6 38 ± 7 -30*** 29 ± 3 25 ± 3 -17 
Temperoparietal 54± 4 34 ± 4 -37** 48 ± 5 33 ± 3 -31* 44 ± 4 27 ± 4 -38*** 30 ± 2 22 ± 3 -30* 
Posterior Cingulate 51 ± 4 32 ± 3 -37** 49 ± 5 27 ± 2 -45** 48 ± 4 25 ± 3 -49*** 33 ± 3 20 ± 2 -42** 
Piriform 29 ± 3 18 ± 2 -39 23 ± 2 15 ± 1 -34* 20± 2 16 ± 5 -20 14 ± 2 10 ± 1 -35 
Entorhinal 35 ± 3 24 ± 3 -32* 30 ± 2 20 ± 1 -34* 30 ± 2 18 ± 3 -41*** 21 ± 2 15 ± 2 -33 
 
LCMRglu response to 8-OH-DPAT in cortical brain regions of wild-type and hSERT over-expressing mice. Data shown as mean ± s.e.m and % 
difference in LCMRglu between 8-OH-DPAT treated and control (saline treated) animals of the same gender and genotype. *denotes, p<0.05, ** 
denotes p<0.01 and ***denotes p<0.001 significant DPAT effect (within-genotype 2-way ANOVA with Bonferroni correction). †denotes p<0.05 significant 












Table 3.3.7 LCMRglu response to 8-OH-DPAT in hSERT over-expressing mice: basal ganglia regions T31 
 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR  
 Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT % 
Basal Ganglia             
Medial Striatum 43 ± 3 33 ± 3 -24* 40 ± 5 26 ± 2 -35# 42 ± 3 25 ± 4 -40***+ 26 ± 3 28 ± 2 -28# 
Lateral Striatum 48 ± 4 29 ± 3 -39*** 43 ± 5 25 ± 2 -41* 42 ± 3 22 ± 3 -48*** 28 ± 3 18 ± 2 -38* 
Globus Pallidus 32 ± 3 22 ± 2 -31* 29 ± 3 18 ± 1 -37*# 33 ± 3 16 ± 2 -52***+ 29 ± 3 18 ± 1 -34# 
Subthalamic Nucleus 48 ± 4 33 ± 4 -30 48 ± 5 29 ± 2 -39*# 50 ± 3 25 ± 4 -49** 31± 3 21 ± 2 -36*# 
Substantia Nigra pars Reticulata 29 ± 2 22 ± 2 -24 27 ± 2 19 ± 1 -29 26 ± 2 13 ± 2 -50*** 18 ± 2 13 ± 2 -33 
Substantia Nigra pars Compacta 37 ± 3 27 ± 3 -28* 34 ± 3 23 ± 2 -32 34 ± 3 20 ± 3 -43*** 22 ± 2 16 ± 2 -31 
 
Effect of hSERT over-expression on the LCMRglu response to 8-OH-DPAT in basal ganglia regions. Data shown as mean ± s.e.m and % difference in 
LCMRglu between 8-OH-DPAT-treated and control (saline-treated) animals of the same gender and genotype. ** denotes p<0.01 and ***denotes 
p<0.001 significant 8-OH-DPAT effect (within-genotype 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x 8-OH-DPAT 















Table 3.3.8 LCMRglu response to 8-OH-DPAT in hSERT over-expressing mice: amygdala, thalamic and h ypothalamic 
regions T32 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT % Saline  8-OH-DPAT (%) 
Amygdala             
Medial 25 ± 2 17 ± 2 -34** 22 ± 2 14 ± 1 -38* 18 ± 2 10 ± 1 -45*** 13 ± 2 8 ± 1 -40* 
Basolateral 35 ± 3 26 ± 3 -25* 31 ± 3 22 ± 2 -29 29 ± 2 17 ± 3 -40*** 19 ± 2 15 ± 1 -29 
Central 23 ± 3 17 ± 2 -25 20 ± 2 14 ± 1 -32 17 ± 2 13 ± 3 -22 12 ± 2 8 ± 1 -36 
Thalamic Nuclei             
Anterior 51 ± 5 33 ± 4 -34* 48 ± 5 29 ± 2 -41* 47 ± 5 26 ± 3 -46*** 34 ± 3 21 ± 2 -40* 
Mediodorsal 58 ± 6 33 ± 3 -42*** 48 ± 4 28 ± 2 -41* 48 ± 4 30 ± 3 -43*** 32 ± 2 21 ± 2 -34* 
Venterolateral 56 ± 5 41 ± 5 -27 29 ± 3 19 ± 2 -32 56 ± 5 35 ± 5 -38*** 34 ± 2 28 ± 3 -19 
Hypothalamic Nuclei              
Anterior 43 ± 7 19 ± 2 -55*** 32 ± 4 15 ± 1 -54* 19 ± 3 10 ± 2 -47* 14 ± 2 9 ± 1 -40* 
Venterolateral 31 ± 3 18 ± 2 -40** 29 ± 3 19 ± 2 -32 26 ± 2 13 ± 2 -51*** 32 ± 3 28 ± 3 -39* 
 
Effect of hSERT over-expression on the LCMRglu response to 8-OH-DPAT in amygdala, thalamic and hypothalamic regions. Data shown as mean ± 
s.e.m and % difference in LCMRglu between 8-OH-DPAT-treated and control (saline-treated) animals of the same gender and genotype. ** denotes 












Table 3.3.9 LCMRglu response to 8-OH-DPAT in hSERT over-expressing mice: hippocampal regions T33 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline 8-OH-DPAT % Saline 8-OH-DPAT % Saline 8-OH-D PAT % Saline 8-OH-DPAT % 
Hippocampus             
Molecular Layer 41 ± 4 26 ± 3 -38*** 34 ± 3 22 ± 2 -38* 32 ± 3 17 ± 2 -49*** 21 ± 2 14 ± 2 -40* 
Dorsal Subiculum 38 ± 3 24 ± 3 -39*** 34 ± 3 20 ± 1 -44** 38 ± 3 18 ± 3 -52*** 25 ± 3 14 ± 2 -50*** 
Dentate PO 25 ± 1 15 ± 1 -38*** 22 ± 2 12 ± 1 -47** 20 ± 2 10 ± 2 -53*** 15 ± 2 8 ± 1 -52*** 
Dorsal CA1 35 ± 3 23 ± 7 -36** 30 ± 2 18 ± 1 -41** 28 ± 3 14 ± 2 -52*** 17 ± 2 11 ± 2 -43* 
CA2 33 ± 3 21 ± 2 -36** 27 ± 3 18 ± 2 -40* 26 ± 3 13 ± 2 -51*** 16 ± 2 10 ± 1 -43* 
Ventral CA1 33 ± 2 20 ± 2 -39*** 28 ± 3 18 ± 2 -38* 24 ± 2 12 ± 2 -50*** 17 ± 2 11 ± 1 -42** 
Ventral Subiculum 29 ± 2 20 ± 2 -31** 26 ± 3 18 ± 1 -35* 23 ± 2 12 ± 2 -48*** 17 ± 2 11 ± 1 -43* 
CA3 27 ± 2 15 ± 2 -44*** 24 ± 2 12 ± 1 -51** 21 ± 2 10 ± 2 -54*** 14 ± 2 8 ± 3 -48** 
 
Effect of hSERT over-expression on the LCMRglu response to 8-OH-DPAT in hippocampal regions. Data shown as mean ± s.e.m and % difference in 
LCMRglu between 8-OH-DPAT-treated and control (saline-treated) animals of the same gender and genotype. ** denotes p<0.01 and ***denotes 















Table 3.3.10 LCMRglu response to 8-OH-DPAT in hSERT  over-expressing mice: raphé and mesocorticolimbic 
regions T34 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  8-OH-DPAT % Saline  
8-OH-
DPAT % Saline  
8-OH-
DPAT % Saline  
8-OH-
DPAT % 
Raphé             
Dorsal 36 ± 3 22 ± 2 -40*** 33 ± 3 19 ± 1 -41** 29 ± 2 13 ± 2 -55*** 18 ± 2 13 ± 1 -38** 
Median 46 ± 5 30 ± 3 -37** 41 ± 4 25 ± 2 -40* 39 ± 3 19 ± 3 -52*** 25 ± 3 17 ± 2 -38** 
Paramedian 45 ± 4 30 ± 3 -35** 41 ± 4 25 ± 2 -38* 40 ± 3 19 ± 3 -52*** 25 ± 3 18 ± 2 -38** 
Mesocorticolimbic System             
Ventral Tegmental Area 36 ± 3 31 ± 3 -16 38 ± 4 28 ± 2 -26# 43 ± 4 23 ± 3 -45***++ 28 ± 3 19 ± 2 -38**# 
Nucleus Accumbens 43 ± 6 27 ± 3 -39** 35 ± 3 24 ± 1 -31† 31 ± 2 17 ± 2 -46** 19 ± 2 15 ± 2 -30† 
 
Effect of hSERT over-expression on the LCMRglu response to 8-OH-DPAT in raphé and mesocorticolimbic. Data shown as mean ± s.e.m and % 
difference in LCMRglu between 8-OH-DPAT-treated and control (saline-treated) animals of the same gender and genotype. ** denotes p<0.01 and 
***denotes p<0.001 significant 8-OH-DPAT effect (within-genotype 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x 8-
OH-DPAT interaction (within-genotype 2-way ANOVA). #denotes p<0.05 significant gender x 8-OH-DPAT x genotype interaction and †denotes p<0.05 















Table 3.3.11 LCMRglu response to 8-OH-DPAT in hSERT over-expressing mice: non-specific regions T35 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  8-OH-DPAT % Saline 
8-OH-
DPAT % Saline  
8-OH-
DPAT % Saline  
8-OH-
DPAT % 
Non-specific             
Septal Nucleus 34 ± 3 23 ± 3 -35** 31 ± 3 21 ± 2 -30† 29 ± 2 15 ± 2 -50*** 18 ± 2 13 ± 2 -38*† 
BNST 27 ± 3 16 ± 2 -45** 22 ± 2 14 ± 1 -38* 17 ± 2 10 ± 2 -40** 11 ± 2 9 ± 1 -23 
Corpus Callosum 16 ± 1 10 ± 1 -35 14 ± 1 9 ± 1 -35 11 ± 2 7 ± 1 -35 8 ± 1 8 ± 2 0 
Lateral Habenula 53 ± 5 40 ± 4 -25* 49 ± 5 35 ± 2 -29# 55 ± 4 27 ± 3 -50***+ 36 ± 2 24 ± 3 -33*# 
Mamillary Body 54 ± 4 35 ± 4 -36** 52 ± 5 27 ± 2 -47*# 56 ± 3 20 ± 3 -63***+ 38 ± 2 21 ± 2 -44**# 
Periaqueductal Grey 33 ± 3 22 ± 2 -25** 27 ± 2 17 ± 1 -37* 23 ± 3 10 ± 2 -56** 17 ± 2 10 ± 1 -40* 
Inferior Colliculus 73 ± 7 69 ± 9 -30 74 ± 10 54 ± 5 -27 81 ± 7 44 ± 6 -46**+ 54 ± 4 40 ± 4 -28 
Ventral Tegmental Nucleus 46 ± 4 30 ± 3 -39*** 42 ± 4 26 ± 2 -38* 43 ± 3 19 ± 3 -54** 29 ± 2 20 ± 2 -33* 
Locus Coeruleus 41 ± 4 45 ± 5 -37* 38 ± 4 25 ± 2 -36* 38 ± 3 17 ± 3 -54** 25 ± 2 18 ± 2 -30 
Nucleus Tractus Solitaris 56 ± 9 25 ± 3 -53* 50 ± 6 24 ± 1 -51** 37 ± 4 37 ± 4 -55* 17 ± 1 15 ± 2 -19 
 
Effect of hSERT over-expression on the LCMRglu response to 8-OH-DPAT in non-specific brain regions. Data shown as mean ± s.e.m and % 
difference in LCMRglu between 8-OH-DPAT-treated and control (saline-treated) animals of the same gender and genotype. ** denotes p<0.01 and 
***denotes p<0.001 significant 8-OH-DPAT effect (within-genotype 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x 8-
OH-DPAT interaction (within-genotype 2-way ANOVA). #denotes p<0.05 significant gender x 8-OH-DPAT x genotype interaction and †denotes p<0.05 
significant genotype x 8-OH-DPAT effect in both males and females (Univariate ANOVA). BNST=Bed nucleus of the stria terminalis. 
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3.4 Discussion and Conclusions  
 
The distribution and densities of [3H]WAY100,635 binding identified in this study are in
strong accordance with those previously reported by other investigators (Fabre et al., 2000a; 
Preece et al., 2004). We found that [3H]WAY100,635 binding was significantly increased in 
females as compared to males in the cortex, hippocampus and the raphé. Reports detailing 
gender differences in cortical 5-HT1A receptor binding in rodents are inconsistent, with some 
supporting increased 5-HT1A binding (Schiller et al., 2006) while others report no difference 
(Ferrari et al., 1999; Zhang et al., 1999). Furthermore, gender differences in post-synaptic 5-
HT1A binding in the hippocampus display even greater inconsistency with increases 
(Mendelson and McEwen, 1991), decreases (Li et al., 2000; Schiller et al., 2006) and no 
difference (Ferrari et al., 1999; Zhang et al., 1999) reported in females as compared to males. 
Several factors could contribute to the inconsistencies observed between these studies 
including the use of aged animals, as age-dependent creases in 5-HT1A binding are 
stronger in males than in females (Meltzer et al., 2001; Yamaguchi and Yamagata, 1991). 
Furthermore, lack of appropriate control for the influence of the female reproductive cycle 
on 5-HT1A binding (Biegon et al., 1980; Uphouse et al., 1986) and the use of different 
ligands between studies may also contribute to these inconsistencies. To control for the 
influence of these factors our studies were completed in young animals (4-6 months) and 5-
HT1A binding levels were determined in female animals spread across the reproductive cycle. 
As we used the 5-HT1A antagonist [
3H]WAY100,635 in these studies this may explain some 
of the discrepancies between our data and that reported by others using 5-HT1A agonists, 
such as [3H]-8-OH-DPAT. As an antagonist [3H]WAY100,635 detects both high and low 
affinity 5-HT1A binding sites (Gozlan et al., 1995) whereas agonists bind to only high affinity 
state 5-HT1A receptors directly coupled to their effector G-proteins. This may, in part, 
account for the significantly increased 5-HT1A binding found in our study in the raphé nuclei 
of females as compared to males in contrast to others who have found no significant gender 
difference when using [3H]8-OH-DPAT (Bouali et al., 2003). However, our find g of 
increased 5-HT1A binding in the raphé of females is likely to represent increased binding at 
the 5-HT1A autoreceptor which would be consistent with the repo ted reduced rate of 5-HT 
neuronal firing (Klink et al., 2002) and enhanced 5-HT1A autoreceptor sensitivity (Bouali et 
al., 2003; Maswood et al., 1995) in females as compared to males. 
 
In this study 8-OH-DPAT resulted in a generalised depression in cerebral function in all 
animals, as reflected by widespread significant decreases in LCMRglu. These findings were 
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similar to previously published reports on the metabolic effect of 8-OH-DPAT on cerebral 
function in the rat as determined by the quantitative [14C]-2-DG method (Ferrington et al., 
2005; Kelly et al., 1988; McBean et al., 1991). However, the significant decreases in 
LCMRglu observed in our study were more extensive than those previously reported and 
most likely result from the use of a higher dose of 8-OH-DPAT (10mg.kg-1 versus 1mg.kg-1) 
in this study. This may also account for the fact that we observed no significant increases in 
the LCMRglu in response to 8-OH-DPAT in contrast to the limited number of increases 
reported in other studies. In line with the increased 5-HT1A binding in females we also found 
evidence for increased 5-HT1A functioning, as demonstrated by a significantly enhanced 
LCMRglu response to 8-OH-DPAT, in a number of brain regions in females as compared to 
males. Interestingly, 5 of the 6 regions identified as having an increased response to 8-OH-
DPAT in females have no detectable levels of 5-HT1A receptor binding. The enhanced 
metabolic response to 8-OH-DPAT in these regions likely results from the increased 
functioning of 5-HT1A receptors at sites projecting to these areas as alterations in glucose 
utilisation primarily reflect alterations in energy requirements at the nerve terminal rather 
than cell bodies (McCulloch, 1982a). As all of these regions receive dense innervation from 
multiple brain regions rich in 5-HT1A receptors it is difficult to localise the origin of 
enhanced 5-HT1A receptor functioning responsible this gender difference. One may speculate 
on the possible involvement of enhanced 5-HT1A autoreceptor function in females in these 
responses as electrostimulation of the raphé results in an increased LCMRglu in many of the 
regions in which this gender difference is observed including the lateral habenula, globus 
pallidus and mamillary body (Bonvento et al., 1991; Cudennec et al., 1993; Cudennec et al., 
1988a). Activation of 5-HT1A autoreceptors could plausibly result in decreased LCMRglu in 
these regions as a result of decreased raphé 5-HT neuro al activity. Therefore, enhanced 5-
HT1A autoreceptor function in females, which is also consistent with our findings in 
[3H]WAY100,635 binding in the raphé, could contribute to the gender differences in the 
response to 8-OH-DPAT in these regions. This suggestion is consistent with gender 
differences in 5-HT1A autoreceptor function reported by others (Bouali et al., 2003; 
Maswood et al., 1995). However, given the widespread increase in post-synaptic 5-HT1A 
binding noted in females and the knowledge that each region in which the enhanced response 
to 8-OH-DPAT was observed in females also receive dense innervation from forebrain sites 
rich in post-synaptic 5-HT1A receptors it is impossible to rule out their involvement in the 
sexually dimorphic LCMRglu response to 8-OH-DPAT. While the observed gender 
differences in post-synaptic 5-HT1A binding observed in this study and by others (Mendelson 
and McEwen, 1991; Schiller et al., 2006) are suggestive of enhanced post-synaptic 5-HT1A 
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functioning in females no research to date has specifically characterised gender differences 
in post-synaptic 5-HT1A coupling or function. In future, the utilisation of methodologies such 
as GTPγS autoradiography and electrophysiological techniques may be able to elucidate the 
specific localisation of the enhanced 5-HT1A receptor function in females. 
 
Although our data suggest that 5-HT1A function is increased in females it does not allow us 
to draw conclusion upon the basal level of 5-HT1A receptor activation in females as 
compared to males. It may be suggested that the enhanced 5-HT1A receptor function present 
in females may represent an adaptive upregulation of 5-HT1A receptor function in response to 
the decreased levels of extracellular 5-HT (Gundlah et al., 1998; Jones and Lucki, 2005; 
Mitsushima et al., 2006), governed in part by the enhanced SERT functioning present in 
females (study 2), in order to maintain a similar level of 5-HT1A receptor activation to that 
observed in males. However, we found no significant correlation between the magnitude of 
the gender difference in SERT binding and that of 5-HT1A receptor binding in a region 
dependent basis. This suggests that gender differenc s in SERT function, and so the 
extracellular 5-HT levels governed by this, may notbe the primary mechanism responsible 
for gender differences in 5-HT1A expression. However, it is also possible that differences in 
5-HT1A expression may also not be the primary mechanism by which gender differences in 
5-HT1A function are mediated. In the future it will be important to elucidate if gender 
differences in basal 5-HT1A receptor activity occur as these may contribute to the known 
gender differences in affective disorders. One possible experiment that may be able to clarify 
this point would be to investigate the LCMRglu response to 5-HT1A antagonists in animals of 
both sexes.  
 
In these studies we also found that the life-long icrease in SERT functioning in hSERT 
OVR mice decreased post-synaptic 5-HT1A binding levels in a restricted number of 
hippocampal subfields. In both males and females hSERT OVR reduced 5-HT1A binding in 
the dentate gyrus of the dorsal hippocampus and dentate PO of the ventral hippocampus. 
However, the impact of altered SERT function on post-synaptic 5-HT1A binding was also 
found to be greater in males than in females, as evidenced by the significant reduction in 5-
HT1A binding in the ventral CA1 and ventral subiculum of males but not females. These 
findings are not only diametrically opposed to our riginal hypothesis, that post-synaptic 5-
HT1A binding would increase as a result of the increased SERT functioning present in 
hSERT OVR animals, but also contradicts 5-HT1A binding data in both human (David et al., 
2005) and animal (Li et al., 2000) studies showing that a life-long decrease in SERT 
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function decreases post-synaptic 5-HT1A binding. However, others have also reported that a 
life-long decrease in SERT functioning increases pot-synaptic 5-HT1A receptor binding in 
some cortical regions (Lee et al., 2005). Furthermore, the regional distribution of detected 
alterations in 5-HT1A binding in our study differ from those reported in these previous 
studies. Indeed, in no region in which 5-HT1A receptor expression was reported to be altered 
as a result of decreased SERT functioning did we find evidence for a significant alteration in 
5-HT1A binding in hSERT OVR mice. These regions included the raphé, amygdala nuclei, 
the hypothalamus and many cortical regions. In factthe only region in which we found 
evidence for a significant increase in 5-HT1A binding in hSERT OVR mice was the 
somatosensory cortex. 5-HT1A binding in this region was not reported to be altered in any of 
the previous studies, although a linear relationship between genetically determined SERT 
function and 5-HT1A binding in other cortical regions has been reported (David et al., 2005; 
Li et al., 2000). Interestingly, this effect was only observed in females suggesting that 
alterations in 5-HT1A binding in this region were more sensitive in females than in males to 
alterations in SERT functioning. This finding parallels that of others on the enhanced 
sensitivity of altered 5-HT1A expression in response to genetically determined SERT function 
in females as compared to males (as observed in SERT KO mice) (Li et al., 2000). 
 
The decreased 5-HT1A binding found in hSERT OVR mice was limited to specific 
hippocampal subfield whereas previous studies had reported no alteration in hippocampal 5-
HT1A binding in response to decreased SERT functioning. However, the studies conducted in 
humans may have been unable to detect alterations in binding in specific hippocampal 
subfields due to the low resolution of PET. Indeed, David et al. (2005) reported only on total 
hippocampal 5-HT1A binding levels which may mean that any significant lteration in a 
specific hippocampal subfield may have been obscured by a general trend for no alteration in 
5-HT1A binding in the hippocampus.  However, in agreement with our findings others have 
reported a trend towards increased total hippocampal 5-HT1A [
3H]WAY100,635 binding in 
animals where SERT function is ablated (SERT KO mice) and have confirmed a significant 
increase in 5-HT1A protein levels in the hippocampus with antibody binding in these animals 
(Fabre et al., 2000a). These findings suggest that the regulation of hippocampal 5-HT1A 
binding by genetically determined SERT functioning may not be directly linked to the 
regulation of extracellular 5-HT levels by SERT. A possible alternative mechanism may 
involve the regulation of 5-HT1A receptor binding in the hippocampus by glucocorticids. A 
multitude of evidence suggests that 5-HT1A receptor expression and binding in the 
hippocampus is suppressed by corticosterone (Chalmers et al., 1993; Fernandes et al., 1997; 
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Neumaier et al., 2000; Takao et al., 1997) and thatis mechanism primarily involves 
activation of the mineralocorticoid receptor (MR) (Meijer et al., 1997; Meijer and Dekloet, 
1995). Therefore, it is of great interest that we found MR receptor mRNA levels were 
increased in the hippocampus of hSERT OVR mice (Study 6). This suggests that increased 
activation of hippocampal MR receptors may be involved in the decreased 5-HT1A binding in 
the hippocampus of hSERT OVR mice. Furthermore, decreased hippocampal 5-HT1A 
receptor activation in hSERT OVR mice may be involved in their reduced anxiety phenotype 
as the activation of hippocampal 5-HT1A receptors by the local application of 8-OH-DPAT 
has been shown to have an anxiogenic effect (File et al., 1996). At the present time it is 
unclear if developmental events related to the level of 5-HT1A activation in the hippocampus 
of SERT OVR mice may be involved in determining their anxiolytic behavioural phenotype. 
Evidence from 5-HT1A receptor KO mice suggests that the functional state of forebrain 5-
HT1A receptors during the early postnatal period plays  role in determining anxiety-like 
behaviour (Gross et al., 2002) as the functional reinstatement of these receptors at this time 
reverses the increased anxiety observed in 5-HT1A receptor KO mice. The exact anatomical 
localisation of the 5-HT1A receptors responsible for this behavioural rescue, however, is 
unknown. If hippocampal 5-HT1A receptors are involved in this effect it is plausible that 
developmental events regulated by hippocampal 5-HT1A receptors, which are decreased in 
SERT OVR mice, may contribute to their anxiolytic behavioural phenotype. In the future, 
greater anatomical resolution of 5-HT1A receptor functional reinstatement in 5-HT1A KO 
mice may provide evidence for the importance of hippocampal 5-HT1A receptors in 
determining anxiety levels through developmental mechanisms.  
 
In contrast to our findings of altered post-synaptic 5-HT1A binding in hSERT OVR mice we 
found no evidence for altered 5-HT1A autoreceptor binding in these animals. This is also in 
contrast to reports in which 5-HT1A autoreceptor binding has been found to be decreased in 
animals where SERT function is knocked-out (Li et al., 2000). However, as the number of 5-
HT cell bodies in the raphé of SERT KO mice is reduced this may also contribute to the 
reduced 5-HT1A autoreceptor levels observed in these animals (Lira et al., 2003b). It is not 
yet known if 5-HT neuronal number is altered in hSERT OVR mice. 
 
In parallel to the finding of decreased 5-HT1A receptor binding in the hippocampus of 
hSERT OVR mice we also found evidence for decreased 5-HT1A functioning in these 
animals. Again, however, it is difficult to determine the specific localisation of the decreased 
5-HT1A receptor functioning that may be responsible for the decreased LCMRglu response to 
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8-OH-DPAT in hSERT OVR mice. Furthermore, the contribution of decreased hippocampal 
5-HT1A binding to these functional differences is unclear, especially in light of the fact that 
alterations in 5-HT1A binding in hSERT OVR mice appear to be greater in males than in 
females whereas the opposite gender effect is noted in 5-HT1A-mediated functional 
responses. In addition, evidence from SERT KO mice suggests that hippocampal 5-HT1A 
receptor function is maintained in spite of the reported increase in hippocampal 5-HT1A 
receptor levels in these animals (Fabre et al., 2000a; La Cour et al., 2001). This suggests that 
alterations in hippocampal 5-HT1A binding are unlikely to represent the primary mechanisms 
by which the functional response to 8-OH-DPAT is altered in hSERT OVR mice. The 
localisation and mechanism leading to decreased 5-HT1A functional responses in hSERT 
OVR mice, therefore, remain unclear. However, one suggested mechanism may involve 
decreased G-protein coupling of the 5-HT1A receptor. However, evidence from SERT KO 
mice suggests that the G-protein coupling of post-synaptic and pre-synaptic 5-HT1A receptors 
is not altered in response to genetically determined SERT function. Alternatively, it may be 
suggested that alterations in 5-HT1A autoreceptor rather than post-synaptic receptor function 
may be central to the attenuated responses to 8-OH-DPAT in hSERT OVR mice. In SERT 
KO animals decreased 5-HT1A receptor mediated responses can be attributed to the decreased 
level of 5-HT1A autoreceptor expression in the raphé of SERT KO mice (Li et al., 2000; Li et 
al., 1999) whereas we found no evidence for altered 5-HT1A receptor binding in the raphé of 
hSERT OVR mice. However, as the level of 5-HT1A receptor binding in our study relates to 
the total number of 5-HT1A receptors present, rather than those which are directly coupled to 
G-proteins and in the high affinity state, it is still plausible that the number of functionally 
coupled 5-HT1A autoreceptors is reduced in hSERT OVR mice in the presence of unaltered 
total 5-HT1A receptor levels. Furthermore, physiological respones linked to the activation of 
the 5-HT1A autoreceptor have indeed been shown to be decreased in hSERT OVR mice 
(Jennings et al., 2004). The involvement of 5-HT1A autoreceptors in these responses is also 
consistent with the increased sensitivity of females in the functional adaptation of 5-HT1A 
autoreceptor function to a life-long decrease in SERT activity (Li et al., 2000). Although it is 
interesting to speculate on the possible localisation and mechanisms of 5-HT1A receptor 
alterations that may be involved in the decreased LCMRglu to 8-OH-DPAT in hSERT OVR 
mice it is impossible to make decisive judgements ba ed upon the present data and further 
research is needed. 
 
Mechanistically, one may suggest that decreased 5-HT1A autoreceptor function in hSERT 
OVR mice may reflect a developmental adaptation to the increased level of SERT expression 
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present in these animals. Such a decrease in 5-HT1A autoreceptor function would be likely to 
result in the dis-inhibition of raphé 5-HT neuronal activity as an attempt to maintain normal 
levels of extracellular 5-HT in these animals in the face of increased 5-HT uptake. However, 
if this adaptation does occur it is not sufficient to maintain normal extracellular 5-HT levels 
in these animals (Jennings et al., 2006). 
 
To summarise, we found evidence for enhanced 5-HT1A receptor binding and function in 
females as compared to males. Surprisingly, we also found that 5-HT1A receptor binding was 
decreased in the hippocampus of hSERT OVR mice and suggest that this may be related to 
the enhanced MR function present in the hippocampus of hSERT OVR mice. In addition we 
found that the cerebral metabolic response to 8-OH-DPAT was lower in a number of brain 
regions of hSERT OVR mice and that this effect was greater in females than in males. The 
alterations in 5-HT1A receptor function observed in hSERT OVR mice may contribute to the 
differences noted in constitutive cerebral metabolism n these animals. Furthermore, gender-
dependent alterations in 5-HT1A receptor functioning may relate to the noted gender 





















4. Study 4- 5-HT 2A/C receptor binding and function in hSERT over-
expressing mice  
 
4.1 Rationale  
 
5-HT2A/C receptors have a proposed central role in affectiv psychopathology and the 
antidepressant response (see section 4.5.1 and 4.5.2). Furthermore, 5-HT2A/C receptors are 
widely expressed throughout components of the limbic system and play a prominent role in 
the regulation of 5-HT neurotransmission as both post-synaptic effectors and in the 
regulation of raphé 5-HT neuronal activity. Evidenc from animals in which SERT function 
is completely ablated (SERT KO mice) suggests that genetically determined SERT 
expression may regulate both 5-HT 2A/C receptor expression and function. For example, 5-
HT2A and 5-HT2C receptor binding has been found to be significantly increased in some 
brain regions of SERT KO mice (Li et al., 2003; Rioux et al., 1999). However, the ability of 
altered SERT function to regulate 5-HT2A expression appears to be brain region-dependent 
as 5-HT2A binding was also reported to be significantly decreased in other brain areas. In 
addition, while some hormonal responses mediated by hypothalamic 5-HT2A/C receptors 
suggest enhanced functioning of these receptors in SERT KO mice (Li et al., 2003) the 
function of 5-HT2A/C receptors appears to be attenuated in these animals in most other brain 
regions (Qu et al., 2005). These data suggest that the regulation of 5-HT2A/C receptors by 
genetically determined SERT function is complicated an  occurs in a brain region dependent 
fashion. The finding that 5-HT2A/C receptor binding is increased in SERT KO mice appers 
paradoxical to the observation that synaptic 5-HT leve s are elevated in these animals. This 
suggests that the regulation of extracellular 5-HT by SERT functioning may not be the 
primary mechanism by which SERT regulates 5-HT2A/C receptor expression and that other 
developmental events may be important. However, the functional desensitisation of 5-HT2A/C 
receptors in SERT KO animals is consistent with the increased levels of synaptic 5-HT in 
these animals.  
 
In order to further investigate how genetically determined alterations in SERT may regulate 
5-HT2A/C receptor expression and function here we investigate 5-HT2A and 5-HT2C binding in 
hSERT OVR animals using [3H]ketanserin and [3H]mesulergine ligand binding 
autoradiography, respectively, and investigate the LCMRglu response to DOI in order to 
characterise 5-HT2A/C receptor function. On the basis of data obtained i SERT KO animals 
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we hypothesis that 5-HT2A/C receptor binding will be altered in a brain region specific 
manner and that 5-HT2A/C receptor function will be increased in hSERT OVR animals. As 
our previous data suggest that the ability of hSERT OVR to alter cerebral and 5-HT1A 
receptor functioning is modulated by gender we also hypothesise that the ability of hSERT 
OVR to influence 5-HT2A/C binding and function will also be greater in females than in 
males. 
 
4.2 [3H]Ketanserin Binding  
 
[3H]Ketanserin binding levels were high in the claustr m, endopriform nucleus, orbitofrontal 
and frontal cortex. Medium levels of binding were dtected in many other cortical regions 
and the ventral dentate gyrus of the hippocampus. Lower levels of binding were detected in 
the other hippocampal subfields, the striatum and raphé nuclei. The distribution and relative 
densities of [3H]ketanserin binding in this study is consistent wih that reported by others 
(Ciccocioppo et al., 1999; Pazos et al., 1985; Preece t al., 2004). 
 
[3H]Ketanserin binding tended to be lower in females than in males in all brain regions and 
was significantly lower in 27 of the 49 brain areas analysed. This effect was observed in all 
cortical brain regions (range -63% to -103% lower in females), many subfields of the 
hippocampus (range -46% to -123% lower in females) and multiple hypothalamic nuclei 
(range -89% to -91% lower in females). Figures 3.4.1 and 3.4.2 show representative brain 
regions in which [3H]Ketanserin binding was influenced by gender.   
 
There was no evidence for altered [3H]ketanserin binding in hSERT OVR mice in 
comparison to Wt animals in any of the brain regions a alysed. The was also no evidence for 
a significant gender x hSERT OVR interaction on [3H]ketanserin binding in any brain 




























































































































































[3H]Ketanserin binding in 6 representative brain regions in hSERT OVR and Wt mice 
of both genders. Data shown as mean ± s.e.m and were analysed using 2-way 
ANOVA. Y axis values differ between brain region in accordance with maximum 
binding value. ++denotes p<0.01, +++denotes p<0.01 significant gender effect. 
[3H]Ketanserin binding is significantly lower in females than in males in a number of 
brain regions (e.g. dorsal mPFC and basolateral amygdale) but is not altered by 




Figure 3.4.2 Gender differences in [ 3H]Ketanserin binding F34 










































Gender differences in [3H]Ketanserin binding in a representative selection of diverse 
brain areas. Data shown as % difference in binding between male and female 
animals with data from both Wt and hSERT OVR mice. *denotes p<0.05, **denotes 
p<0.01 and ***denotes P<0.01 significant gender effect (2-way ANOVA). 









Table 3.4.1 [ 3H]Ketanserin binding in hSERT over-expressing mice:  cortical regions T36 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m  Mean  s.e.m 
Cortex             
Orbitofrontal 76.1 ± 3.9 80.6 ± 3.4 11.2*** ± 2.1 13.2 ± 3.0 
Frontal 82.5 ± 3.8 84.4 ± 3.6 10.3*** ± 1.8 16.5 ± 2.0 
Anterior Cingulate 34.9 ± 7.2 35.5 ± 3.8 4.0*** ± 1.5 9.7 ± 1.3 
Dorsal medial Prefrontal 50.3 ± 5.5 57.3 ± 3.7 8.8*** ± 2.1 7.0 ± 2.9 
Ventral medial Prefrontal 19.9 ± 3.7 27.3 ± 3.4 7.2*** ± 2.5 8.2 ± 3.2 
Somatosensory 57.8 ± 4.0 63.8 ± 4.2 2.8*** ± 1.5 8.5 ± 1.3 
Frontal Motor Cortex (Layer V) 56.9 ± 6.8 56.1 ± 5.2 9.9*** ± 1.8 11.2 ± 1.3 
Frontal Motor Cortex (Layer VI) 48.1 ± 6.2 54.0 ± 3.6 11.5*** ± 1.8 11.2 ± 0.9 
Temperoparietal 41.8 ± 3.5 42.1 ± 2.4 8.6*** ± 1.9 13.3 ± 3.0 
Posterior Cingulate 9.0 ± 2.5 9.3 ± 2.1 2.8 ± 1.8 7.8 ± 2.3 
Entorhinal 58.0 ± 3.2 60.8 ± 2.3 6.7*** ± 2.1 7.6 ± 2.3 
Endopiriform 65.0 ± 2.3 70.2 ± 2.2 5.6*** ± 1.4 11.0 ± 1.6 
             
 
Effect of hSERT over-expression on [3H]Ketanserin binding (fmol/mg)  in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and 










Table 3.4.2 [ 3H]Ketanserin binding in hSERT over-expressing mice: basal ganglia T37 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Basal Ganglia             
Medial Striatum 21.2 ± 5.7 24.4 ± 3.8 10.1* ± 1.7 14.1 ± 2.9 
Lateral Striatum 11.4 ± 2.8 6.8 ± 3.3 9.4 ± 1.8 11.4 ± 2.1 
Globus Pallidus 3.7 ± 1.7 6.0 ± 2.3 0 ± 0 1.9 ± 1.1 
Substantia Nigra pars Reticulata 4.8 ± 2.6 5.0 ± 2.1 12.2 ± 2.2 9.0 ± 3.5 
Substantia Nigra pars Compacta 5.3 ± 2.3 2.8 ± 1.9 10.9 ± 1.5 7.7 ± 3.7 
             
 
 
Effect of hSERT over-expression on [3H]Ketanserin binding (fmol/mg)  in cortical and basal ganglia regions. Data are expressed as mean ± s.e.m and 














Table 3.4.3 [ 3H]Ketanserin binding in hSERT over-expressing mice: amygdala, thalamic and h ypothalamic regions T38 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Amygdala             
Medial 21.4 ± 6.5 24.3 ± 2.6 4.8*** ± 1.6 7.9 ± 3.5 
Basolateral 11.3 ± 3.1 12.9 ± 3.8 3.5 ± 1.5 5.9 ± 0.8 
Central 6.2 ± 2.7 6.4 ± 1.8 3.8 ± 0.6 8.6 ± 1.4 
Thalamic Nuclei             
Anterior 0.0 ± 2.0 5.7 ± 1.1 0.2 ± 1.4 5.4 ± 1.4 
Mediodorsal 5.6 ± 2.0 4.8 ± 2.5 2.1 ± 1.7 6.6 ± 2.2 
Venterolateral 4.9 ± 2.3 3.2 ± 2.1 3.7 ± 1.1 6.9 ± 2.3 
Hypothalamic Nuclei             
Anterior 8.6 ± 1.6 11.3 ± 2.2 3.0 ± 1.2 2.9 ± 1.2 
Paraventricular 8.5 ± 3.1 11.6 ± 1.2 0.1** ± 1.3 4.0 ± 2.0 
Ventrolateral 11.9 ± 1.7 11.8 ± 1.9 4.2** ± 1.4 4.9 ± 2.0 
Ventromedial 20.4 ± 5.1 18.9 ± 7.3 1.3* ± 1.5 4.0 ± 1.8 
             
 
Effect of hSERT over-expression on [3H]Ketanserin binding (fmol/mg)  in amygdala, thalamic and hypothalamic regions. Data are expressed as mean ± 









Table 3.4.4 [ 3H]Ketanserin binding in hSERT over-expressing mice: hippocampal regions T39 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Dorsal Hippocampus             
CA1 13.9 ± 3.5 17.4 ± 1.2 9.5** ± 1.3 7.1 ± 2.5 
CA2 12.2 ± 1.2 13.5 ± 0.9 6.7 ± 2.6 7.2 ± 3.2 
CA3 7.5 ± 1.9 9.1 ± 1.4 6.6 ± 1.4 9.2 ± 2.6 
DG 7.5 ± 3.6 5.9 ± 2.5 3.9 ± 2.0 4.2 ± 1.0 
Ventral Hippocampus             
Molecular Layer 15.1 ± 3.0 14.5 ± 1.7 5.7** ± 1.8 5.8 ± 0.6 
Dorsal Subiculum 12.3 ± 1.9 8.8 ± 1.9 8.0 ± 1.9 7.7 ± 2.5 
Dentate PO 21.6 ± 3.3 24.8 ± 2.9 8.8*** ± 1.1 7.0 ± 2.2 
Dorsal CA1 17.0 ± 2.0 17.6 ± 1.8 6.2*** ± 0.7 4.4 ± 1.9 
CA2 11.7 ± 4.3 16.3 ± 1.7 6.2* ± 1.1 7.4 ± 1.9 
Ventral CA1 13.1 ± 1.9 11.5 ± 2.5 6.5** ± 1.0 4.4 ± 1.3 
Ventral DG 61.9 ± 4.6 66.4 ± 2.7 9.9*** ± 1.7 8.2 ± 3.5 
Ventral Subiculum 7.7 ± 1.9 8.4 ± 2.3 6.4 ± 0.9 7.0 ± 1.7 
CA3 13.2 ± 2.3 11.5 ± 1.6 9.6* ± 1.4 5.3 ± 1.0 
             
 
Effect of hSERT over-expression on [3H]Ketanserin binding (fmol/mg)  hippocampal  regions. Data are expressed as mean ± s.e.m and were analysed 





Table 3.4.5 [ 3H]Ketanserin binding in hSERT over-expressing mice:  raphé, mesocorticolimbic and non-specific 
regions T40 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Raphé             
Dorsal 13.6 ± 3.5 14.1 ± 4.3 8.1 ± 1.6 8.6 ± 1.6 
Median 9.7 ± 2.6 8.1 ± 1.6 6.5 ± 1.1 8.5 ± 1.6 
Mesocorticolimbic System             
Ventral Tegmental Area 7.9 ± 1.6 7.5 ± 2.8 1.2 ± 1.1 3.8 ± 1.3 
Nucleus Accumbens 22.8 ± 5.2 34.8 ± 5.9 9.7*** ± 1.2 11.8 ± 2.3 
Non-specific             
Claustrum 100.6 ± 8.5 108.8 ± 4.6 7.6*** ± 1.6 13.8 ± 3.0 
Septal Nucleus 5.7 ± 1.6 2.7 ± 3.8 4.7 ± 2.1 4.3 ± 1.5 
Bed Nucleus of the Stria Terminalis 11.1 ± 2.5 10.7 ± 2.0 5.9** ± 1.9 3.2 ± 0.9 
Lateral Habenula 3.0 ± 1.4 3.6 ± 2.6 1.5 ± 1.1 4.0 ± 1.9 
Periaqueductal Grey 8.0 ± 2.7 9.5 ± 2.9 5.6 ± 1.8 2.6 ± 1.6 
Inferior Colliculus 6.7 ± 1.1 8.2 ± 1.6 3.7 ± 1.0 7.7 ± 2.2 
             
 
Effect of hSERT over-expression on [3H]Ketanserin binding (fmol/mg) raphé, mesocorticolimbic and non-specific brain regions. Data are expressed as 
mean ± s.e.m and were analysed using 2-way ANOVA. *denotes p<0.05, **denotes p<0.01, ***denotes p<0.001 significant gender difference. 
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4.3 [3H]Mesulergine Binding  
 
[3H]Mesulergine binding levels were highest in the choroid plexus and nucleus accumbens, 
whereas medium levels of were detected in the amygdala nuclei, raphé and components of 
the basal ganglia. Low levels of binding were detect d in specific hippocampal subfields and 
cortical regions. The distribution and density of [3H]mesulergine binding was with consistent 
with that previously reported (Kuoppamaki et al., 1994; Laakso et al., 1996; Li et al., 2003).  
 
In the majority of brain regions [3H]mesulergine binding tended to lower in females than in 
males. However, this effect was significant only in the nucleus accumbens (66% lower 
binding in females). In contrast [3H]mesulergine binding was found to be significantly 
increased in the choroid plexus (+13%) of females as compared to males. See Figures 3.4.3 
and 3.4.4 for gender differences in [3H]mesulergine binding in a number of representative 
brain regions. 
 
hSERT OVR significantly increased [3H]mesulergine binding in both the choroids plexus 
(mean +16%) and dorsal mPFC (mean +453%) but significa tly decreased binding in the 
venterolateral hypothalamus (mean -100%) (Figure 3.4.3). In all other brain regions binding 
was unaltered in hSERT OVR mice in comparison to their Wt littermates. In addition, there 
was no evidence for an interaction between gender and hSERT OVR on [3H]mesulergine 
binding in any brain region, suggesting that gender does not influence the ability of hSERT 
OVR to alter [3H]mesulergine binding. Detailed data on [3H]mesulergine binding are shown 



































































































































































[3H]Mesulergine binding in 6 representative brain regions in male and female 
hSERT OVR and Wt mice. Data shown as mean ± s.e.m and were analysed using 
2-way ANOVA. *denotes p<0.05, ***denotes p<0.01 significant hSERT OVR effect. 
+++denotes p<0.01 significant gender effect. [3H]mesulergine binding was 
significantly lower in the nucleus accumbens but significantly higher in the choroids 
plexus in females as compared to males. [3H]Mesulergine binding was significantly 
increased in the dorsal mPFC and choroids plexus but decreased in the 
ventrolateral hypothalamus of hSERT OVR mice of both genders.
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Figure 3.4.4 Gender differences in [ 3H]Mesulergine binding F36 



























Gender differences in [3H]Mesulergine binding in selected brain regions from diverse 
functional systems. Data shown as percentage difference between female relative to 
male mice from both genotypes. % difference between genders appears to be great 
but non-significant in many regions (e.g. ventral CA1) due to low level of binding and 
a relatively high variance in these areas. Whereas, a relatively small % difference is 
significant in the choroids plexus as binding is particularly high in this region. 
***denotes p<0.001 significant gender difference (2-way ANOVA). [3H]mesulergine 
binding was significantly lower in the nucleus accumbens of females as compared to 







Table 3.4.6 [ 3H]Mesulergine binding in hSERT over-expressing mice : cortical regions T41 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Cortex             
Orbitofrontal 2.43 ± 2.37 4.82 ± 2.29 1.00 ± 2.53 1.30 ± 1.58 
Frontal 3.91 ± 1.91 4.22 ± 1.96 3.44 ± 2.37 0.43 ± 2.43 
Anterior Cingulate 8.63 ± 1.07 9.91 ± 2.58 6.28 ± 3.13 3.86 ± 1.73 
Dorsal medial Prefrontal 1.91 ± 2.81 8.39 ± 1.64+ 0.93 ± 1.62 6.17 ± 2.62+ 
Ventral medial Prefrontal 1.75 ± 2.85 7.34 ± 1.32 3.47 ± 1.02 5.11 ± 2.43 
Somatosensory 4.28 ± 2.52 5.50 ± 2.61 5.70 ± 1.67 1.69 ± 2.11 
Temperoparietal 1.33 ± 1.74 0.85 ± 0.49 0.25 ± 3.04 0.6 ± 3.15 
Posterior Cingulate 10.62 ± 1.11 10.03 ± 1.90 10.15 ± 3.29 6.80 ± 1.80 
Piriform 10.01 ± 1.62 12.68 ± 3.67 6.44 ± 1.74 10.38 ± 3.37 
Entorhinal 6.95 ± 1.96 2.14 ± 3.74 2.58 ± 2.31 6.37 ± 3.41 
             
 
Effect of hSERT over-expression on [3H]Mesulergine binding (fmol/mg)in cortical and basal ganglia  regions. Data are expressed as mean ± s.e.m and 











Table 3.4.7 [ 3H]Mesulergine binding in hSERT over-expressing mice : basal ganglia regions T42 
 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Basal Ganglia             
Medial Striatum 9.16 ± 2.89 11.44 ± 3.88 5.85 ± 2.95 6.13 ± 2.53 
Lateral Striatum 9.71 ± 3.42 8.94 ± 3.01 2.83 ± 3.07 2.38 ± 2.64 
Globus Pallidus 3.08 ± 1.62 8.30 ± 1.59 1.79 ± 2.41 0.65 ± 2.40 
Subthalamic Nucleus 7.66 ± 1.34 7.23 ± 1.29 10.09 ± 3.09 0.74 ± 1.38 
Substantia Nigra pars Reticulata 8.83 ± 2.17 10.44 ± 2.01 4.29 ± 4.41 4.70 ± 2.60 
Substantia Nigra pars Compacta 7.4 ± 2.20 8.13 ± 1.52 6.98 ± 4.03 5.96 ± 2.90 
             
 
Effect of hSERT over-expression on [3H]Mesulergine binding (fmol/mg)in cortical and basal ganglia  regions. Data are expressed as mean ± s.e.m and 















Table 3.4.8 [ 3H]Mesulergine binding in hSERT over-expressing mice: amygdala, thalamic and h ypothalamic regions T43 
 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean   s.e.m Mean  s.e.m 
Amygdala             
Medial 13.89 ± 1.89 9.82 ± 1.30 7.93 ± 3.43 8.19 ± 2.74 
Basolateral 11.70 ± 1.62 10.74 ± 1.80 9.06 ± 3.21 4.69 ± 2.54 
Central 10.67 ± 1.92 7.52 ± 1.09+ 10.57 ± 3.72 6.65 ± 2.16+ 
Thalamic Nuclei             
Anterior 1.86 ± 3.09 3.31 ± 1.99 1.52 ± 3.03 1.73 ± 2.48 
Mediodorsal 7.54 ± 2.38 8.43 ± 1.86 8.20 ± 3.40 1.49 ± 1.61 
Venterolateral 1.41 ± 1.49 2.42 ± 1.14 2.79 ± 2.93 -3.32 ± 1.55 
Hypothalamic Nuclei              
Anterior 8.21 ± 2.35 7.51 ± 1.17 6.97 ± 3.42 5.79 ± 2.46 
Venterolateral 7.37 ± 1.46 2.20 ± 1.34+++ 7.66 ± 2.83 0.76 ± 0.97+++ 
             
 
Effect of hSERT over-expression on [3H]Mesulergine binding (fmol/mg )in amygdala ,thalamic and hypothalamic  regions. Data are expressed as mean 










Table 3.4.9 [ 3H]Mesulergine binding in hSERT over-expressing mice: hippocampal regions T44 
 
 
 Male Female  
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m Mean  s.e.m Mean  s.e.m Mean  s.e.m 
Dorsal Hippocampus             
CA1 3.54 ± 2.17 0.74 ± 0.80 1.31 ± 3.54 0 ± 0 
CA2 3.51 ± 1.74 0 ± 0 0 ± 0 0 ± 0 
CA3 3.94 ± 1.67 0 ± 0 1.06 ± 2.58 0 ± 0 
DG 1.35 ± 1.73 0.13 ± 0.84 0.60 ± 3.50 0 ± 0 
Ventral Hippocampus              
Molecular Layer 5.27 ± 2.39 3.64 ± 1.46 0 ± 0 4.34 ± 1.99 
Dorsal Subiculum 5.86 ± 1.86 6.00 ± 2.12 0.12 ± 2.68 2.75 ± 2.49 
Dentate PO 2.60 ± 1.93 0.77 ± 2.19 0.14 ± 1.42 2.47 ± 2.74 
Dorsal CA1 4.42 ± 2.17 4.35 ± 2.19 0 ± 0 2.15 ± 2.26 
CA2 2.96 ± 2.23 6.36 ± 1.06 0 ± 0 0.82 ± 3.13 
Ventral CA1 4.19 ± 1.90 8.02 ± 1.82 0 ± 0 3.73 ± 2.97 
Ventral Suiculum 7.70 ± 1.49 12.94 ± 1.28 1.31 ± 2.15 7.92 ± 3.24 
CA3 2.27 ± 1.65 0.42 ± 1.62 0 ± 0 5.53 ± 2.11 
             
 
Effect of hSERT over-expression on [3H]Mesulergine binding (fmol/mg) in hippocampal brain  regions. Data are expressed as mean ± s.e.m and were 






Table 3.4.10 [ 3H]Mesulergine binding in hSERT over-expressing mice: raphé, mesocorticolimbic  and non-specific 
regions T45 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Mean  s.e.m  Mean  s.e.m  Mean  s.e.m  Mean  s.e.m  
Raphé             
Dorsal 8.90 ± 1.94 5.98 ± 1.97 3.79 ± 2.16 3.71 ± 2.77 
Median 8.12 ± 2.65 8.01 ± 1.78 5.72 ± 2.30 5.47 ± 2.60 
Paramedian 5.80 ± 1.86 8.72 ± 1.87 3.79 ± 3.45 1.81 ± 2.79 
Mesocorticolimbic System             
Ventral Tegmental Area 5.58 ± 0.96 5.54 ± 3.02 1.40 ± 3.62 2.44 ± 1.60 
Nucleus Accumbens 20.25 ± 3.86 24.78 ± 2.88 7.05*** ± 1.49 9.74 ± 2.19 
Non-specific             
Choroid Plexus 125.99 ± 3.27 141.60 ± 5.49++ 145*** ± 3.34 155.57 ± 5.06++ 
Septal Nucleus 10.27 ± 3.88 12.04 ± 4.45 7.94 ± 2.49 3.00 ± 2.18 
Bed Nucleus of the Stria Terminalis 6.80 ± 2.33 4.97 ± 2.54 7.28 ± 2.59 3.98 ± 2.14 
Lateral Habenula 5.01 ± 1.98 7.56 ± 2.83 5.33 ± 3.15 0 ± 0 
Periaqueductal Grey 10.94 ± 1.70 8.56 ± 1.85 5.77 ± 2.77 5.56 ± 2.35 
Inferior Colliculus 2.90 ± 1.93 4.94 ± 1.96 0 ± 0 2.56 ± 2.09 
             
 
Effect of hSERT over-expression on [3H]Mesulergine binding (fmol/mg) in raphé, mesocorticolimbic and non-specific brain  regions. Data are expressed 
as mean ± s.e.m and were analysed using 2-way ANOVA.***denotes p<0.05 significant gender effect ++denotes p<0.01 significant genotype effect. 
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4.4 LCMRglu  
 
In Wt females there was no evidence for a significant LCMRglu response to DOI in any 
brain region. In contrast, DOI resulted in 3 significant increases in LCMRglu in Wt males. 
These were present in the lateral habenula (+52%), ventral tegmental area (+37%) and 
mamillary body (+40%). This suggested that females w re less sensitive to DOI, a finding 
that was replicated in hSERT OVR mice. In addition the LCMRglu response to DOI was 
both more pronounced and prevalent in hSERT OVR as compared to Wt animals. In hSERT 
OVR females DOI significantly increased LCMRglu in 3 regions, the septal nucleus (+34%), 
the BNST (+61%) and the lateral habenula (+50%). Whereas, in hSERT OVR males DOI 
produced significant increases in LCMRglu in 32 of the 47 regions analysed. The most 
marked responses in hSERT OVR males were observed in the lateral habenula (+124%), the 
raphé (median, +76%) and in components of the mesocorticolimbic system (nucleus 
accumbens, +74%; VTA +50%). Increases were also prevalent in component of the basal 
ganglia (medial striatum, +41%; SNR/SNC +54%) and the hippocampus (molecular layer 
+40%, ventral subiculum +43%) of hSERT OVR males. 
 
Evidence from both genotypes suggested that the response to DOI was lower in females as 
compared to males. Indeed, a significant effect of gender on the LCMRglu response to DOI 
was identified in 11 of the 47 brain regions analysed. These included components of the 
mesocorticolimbic system (nucleus accumbens: female +2%, male +36%; VTA: female 
+1%, male +44%), all raphè regions (median: female +16%, male +43%) and the lateral 
habenula (female +22%, male +88%). Figures 3.2.6 and 3.4.7 show representative brain 
regions in which the LCMRglu response to DOI is greater in males than in females. 
 
In both genders hSERT OVR increased the LCMRglu response to DOI with a significant 
effect found in 20 of the 47 brain regions analysed. This was particularly noted in the raphè 
(median: males +65%, females +14% increase response in hSERT OVR), hippocampus 
(molecular layer: males +35%, females +36% increase in hSERT OVR), components of the 
motor system (SNR male, +47%, females +46% in hSERT) and the lateral habenula (males 
+73%, females +55% increase response in hSERT OVR). Figures 3.4.6, 3.4.8 and 3.4.9 




Despite the observation that the enhancement of the response to DOI by hSERT OVR tended 
to be greater in males than in females there was no evidence for a significant gender x 
hSERT OVR x DOI interaction in any brain region. Detailed data on the effects of hSERT 
over-expression on the LCMRglu response to DOI are shown in Tables 3.4.11 to 3.4.16. The 






































Representative “false-colour” autoradiographic images at the level of the caudate, 
dorsal hippocampus, ventral hippocampus and raphé in saline-treated and DOI-
treated wild-type male mice. High levels of tissue isotope accumulation are shown 
as “warm” colours (red/orange) whilst low isotope tissue accumulation is depicted by 
“cold” colours (green/blue). Note in particular how DOI-treatment causes a wide-










Figure 3.4.6 Effect of hSERT OVR on the LCMRglu response to DOI in 











































































































LCMRglu response ([14C]-Uptake Ratio) to 25mg.kg-1DOI in 6 representative brain 
regions of Wt and hSERT OVR mice of both genders. Data were analysed using 
Univariate ANOVA with acceptable levels of significance set at p<0.05.  *denotes 
p<0.05, ***denotes p<0.001 significant DOI response (Bonferroni post-hoc 
correction in comparison of means). +denotes p<0.05, +++denotes p<0.001 
significant sex x DOI interaction.  †denotes p<0.05, ††denotes p<0.01 significant 
hSERT OVR x DOI interaction. The LCMRglu response was significantly greater in 
males than in females in a number of brain regions (e.g. nucleus accumbens and 
median raphé). The response to DOI was significantly enhanced in hSERT OVR 
mice as compared to Wt mice in mice of both genders in a number of functionally 





Figure 3.4.7 Gender differences in the LCMRglu resp onse to DOI F39 
 



















Sunbstantia Nigra pars Compacta



























Influence of gender on the LCMRglu response to 25mg.kg-1 DOI. Data shown as % 
change in [14C]-Uptake Ratio ([14C]-UR) in-DOI treated animals relative to saline 
controls with data included from both Wt and hSERT OVR mice. +denotes p<0.05 
and +++denotes p<0.001 significant gender x DOI interaction (Univariate ANOVA). 
The response to DOI is significantlydecreased in females as compared to males in a 







































































































































LCMRglu response to 25mg.kg-1DOI in 6 representative brain regions of Wt and 
hSERT OVR mice of both genders. Data represented as % change in the [14C]-
Uptake Ratio ([14C]-UR) in DOI-treated animals relative to the appropriate saline 
control. Data were analysed using Univariate ANOVA with acceptable levels of 
significance set at p<0.05.  ∆denotes p<0.05, ∆∆denotes p<0.01, ∆∆∆denotes p<0.001 
significant DOI response (Bonferroni post-hoc correction in comparison of means). 
*denotes p<0.05, ***denotes p<0.001 significant sex x DOI interaction.  ‡denotes 
p<0.05, ‡‡denotes p<0.01 significant hSERT OVR x DOI interaction. The response 
to DOI was significantly increased by hSERT over-expression in mice of both 
genders in a number of brain regions including the lateral habenula, nucleus 























































LCMRglu response (% difference from Wt)
 
Areas in which hSERT OVR has the greatest (A) and least (B) effect upon the LCMRglu response to DOI in male and female mice. Data 
presented as % difference in LCMRglu response to DOI ([14C]-Uptake ratio) between hSERT OVR and wild-type animals. ‡denotes p<0.05, 
‡‡denotes p<0.01 significant hSERT OVR x DOI interaction (Univariate ANOVA). The LCMRglu response to DOI was significantly increased by 
hSERT over-expression in a number of brain regions. Despite the observation that the LCMRglu response to DOI may be enhanced to a 
greater extent by hSERT over-expression in males than in females in some brain regions (e.g. median raphé) this effect was not significant.  
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Table 3.4.11 LCMRglu response to DOI in hSERT over-expressing mice: cortical regions T46 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline DOI % Saline DOI % Saline DOI % Saline DOI %  
Cortex              
Orbitofrontal 58 ± 6 62 ± 4 6 50 ± 5 72 ± 2 49**† 49 ± 4 45 ± 4 -7 31 ± 3 39 ± 4 24† 
Frontal 43 ± 5 42 ± 4 -2 36 ± 4 52 ± 6 44*† 44 ± 3 36 ± 4 -18 25 ± 2 28 ± 3 13† 
Anterior Cingulate 46 ± 5 50 ± 6 10 38 ± 4 41 ± 8 8 43 ± 3 38 ± 4 -12 27 ± 3 32 ± 3 22 
Dorsal medial Prefrontal 44 ± 5 45 ± 5 1 35 ± 3 51 ± 6 45* 37 ± 3 35 ± 4 -6 23 ± 2 28 ± 3 23 
Ventral medial Prefrontal 40 ± 4 38 ± 4 -3 31 ± 3 44 ± 5 40*† 29 ± 2 27 ± 3 -6 17 ± 2 23 ± 2 33† 
Somatosensory 51 ± 5 56 ± 6 9 46 ± 5 58 ± 4 26 55 ± 5 43 ± 4 -14 28 ± 3 35 ± 3 27 
Temperoparietal 51 ± 5 52 ± 4 1 47 ± 5 69 ± 7 48* 44 ± 4 39 ± 5 -12+ 28 ± 2 34 ± 3 21+ 
Posterior Cingulate 49 ± 5 47 ± 4 -5 47 ± 5 55 ± 6 19 48 ± 4 39 ± 5 -20 32 ± 3 33 ± 3 5 
Piriform 29 ± 3 36 ± 7 25 24 ± 2 34 ± 2 43** 20 ± 2 21 ± 2 5 14 ± 2 18 ± 2 32 
Entorhinal 34 ± 3 34 ± 3 0 30 ± 3 49 ± 3 65***†† 30 ± 2 28 ± 3 -8+ 19 ± 2 24 ± 2 24+†† 
 
Effect of hSERT over-expression on the LCMRglu ([14C]-Uptake ratio) response to DOI in cortical regions. Data shown as mean ± s.e.m. and % difference 
between DOI-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 
significant DOI effect (within genotype 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x DOI interaction. †denotes p<0.05, 














Table 3.4.12 LCMRglu response to DOI in hSERT over-expressing mice: basal ganglia regions T47 
 
Brain Region Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline DOI % Saline DOI % Saline DOI % Saline DOI %  
Basal Ganglia             
Medial Striatum 41 ± 3 48 ± 5 19 38 ± 4 53 ± 4 41* 42 ± 3 40 ± 4 -3 25 ± 3 34 ± 4 37 
Lateral Striatum 46 ± 4 51 ± 5 13 40 ± 4 58 ± 6 45* 42 ± 3 38 ± 4 -9 26 ± 3 38 ± 4 26 
Globus Pallidus 30 ± 2 29 ± 6 -6 28 ± 3 38 ± 4 18† 33 ± 3 25 ± 3 -22 18 ± 2 23 ± 2 27† 
Subthalamic Nucleus 46 ± 5 53 ± 5 14 45 ± 5 61 ± 5 35* 45 ± 4 39 ± 4 -14 30 ± 3 36 ± 3 19 
Substantia Nigra pars Reticulata 29 ± 2 31 ± 3 7 27 ± 2 41 ± 5 54**† 26 ± 2 25 ± 3 -4 17 ± 2 24 ± 2 44† 
Substantia Nigra pars Compacta 36 ± 3 42 ± 4 15 33 ± 3 51 ± 4 54**† 34 ± 3 31 ± 3 -9+ 21 ± 2 29 ± 3 36+† 
 
Effect of hSERT over-expression on the LCMRglu response to DOI in Basal Ganglia regions. Data shown as mean ± s.e.m. and % difference between DOI-
treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant DOI 
effect (within gender and genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x DOI interaction. †denotes p<0.05 

















Table 3.4.13 LCMRglu response to DOI in hSERT over- expressing mice: amygdala, thalamic and hypothalami c regions T48 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline DOI % Saline DOI % Saline DOI % Saline DOI %  
Amygdala             
Medial 24 ± 2 25 ± 2 3 21 ± 2 27 ± 2 31 18 ± 2 18 ± 2 3 12 ± 2 15 ± 1 28 
Basolateral 33 ± 2 34 ± 3 5 30 ± 3 37 ± 3 24 29 ± 2 28 ± 2 -2 18 ± 2 23 ± 2 28 
Central 22 ± 2 23 ± 2 7 19 ± 2 25 ± 2 31 17 ± 2 19 ± 2 15 12 ± 2 16 ± 1 36 
Thalamic Nuclei             
Anterior 47 ± 4 46 ± 4 -3 47 ± 5 57 ± 5 21 47 ± 5 40 ± 4 -16 32 ± 3 35 ± 4 10 
Mediodorsal 54 ± 5 51 ± 5 -7 47 ± 4 59 ± 6 25† 48 ± 4 42 ± 4 -13 29 ± 3 35 ± 3 21† 
Venterolateral 53 ± 5 50 ± 5 -5 50 ± 5 61 ± 8 22† 56 ± 5 47 ± 6 -16 31 ± 3 36 ± 3 16† 
Hypothalamic Nuclei             
Anterior 37 ± 6 33 ± 4 -12 34 ± 4 40 ± 6 18 19 ± 3 20 ± 2 3 13 ± 2 19 ± 2 50 
Venterolateral 28 ± 2 33 ± 3 16 27 ± 3 41 ± 3 50** 26 ± 2 27 ± 3 3+ 16 ± 2 24 ± 2 50+ 
 
Effect of hSERT over-expression on the LCMRglu response to DOI in amygdala, thalamic and hypothalamic regions. Data shown as mean ± s.e.m. and % 
difference between DOI-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes 
p<0.001 significant DOI effect (within gender and genotype, 2-way ANOVA with Bonferroni correction). †denotes p<0.05, ††denotes p<0.01 significant 










Table 3.4.14 LCMRglu response to DOI in hSERT over-expressing mice: hippocampal regions T49 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  DOI % Saline DOI % Saline  DOI % Saline DOI % 
Hippocampus             
Molecular Layer 41 ± 4 42 ± 4 4 34 ± 3 48 ± 5 40*† 32 ± 3 31 ± 5 -5 21 ± 2 25 ± 3 20† 
Dorsal Subiculum 38 ± 3 37 ± 3 -2 34 ± 3 42 ± 3 24 38 ± 3 33 ± 5 -13 25 ± 3 24 ± 2 -5 
Dentate PO 25 ± 1 24 ± 2 -3 22 ± 2 27 ± 2 24 20 ± 2 20 ± 3 -2 15 ± 2 16 ± 2 8 
Dorsal CA1 35 ± 3 33 ± 3 -5 30 ± 2 38 ± 2 30*† 28 ± 3 25 ± 4 -10 17 ± 2 20 ± 2 13† 
CA2 33 ± 3 31 ± 3 -7 27 ± 3 36 ± 3 33*† 26 ± 3 23 ± 12 -12 16 ± 2 19 ± 2 20† 
Ventral CA1 33 ± 2 31 ± 3 -6 28 ± 3 38 ± 3 38*† 24 ± 2 23 ± 10 -4 17 ± 2 19 ± 2 14† 
Ventral Subiculum 29 ± 2 33 ± 3 13 26 ± 3 37 ± 3 43** 23 ± 2 24 ± 4 -3 17 ± 2 21 ± 2 21 
CA3 27 ± 2 26 ± 2 4 24 ± 2 32 ± 3 34 21 ± 2 19 ± 3 -8 14 ± 2 16 ± 2 20 
 
Effect of hSERT over-expression on the LCMRglu response to DOI in hippocampal regions. Data shown as mean ± s.e.m. and % difference between DOI-
treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant DOI 
effect (within gender and genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05 significant gender x DOI interaction. †denotes p<0.05 















Table 3.4.15 LCMRglu response to DOI in hSERT over- expressing mice: raphé and mesocorticolimbic region sT50 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  DOI % Saline DOI % Saline  DOI % Saline DOI % 
Raphé             
Dorsal 36 ± 3 45 ± 5 23 31 ± 3 45 ± 4 44* 29 ± 2 28 ± 3 -4+ 18 ± 2 22 ± 2 20+ 
Median 46 ± 5 51 ± 5 11 39 ± 4 69 ± 6 76***† 39 ± 3 42 ± 6 9+ 25 ± 3 30 ± 4 23+† 
Paramedian 45 ± 4 52 ± 4 17 39 ± 4 68 ± 5 76***† 40 ± 3 42 ± 6 6+ 25 ± 3 31 ± 3 23+† 
Mesocorticolimbic System             
Ventral Tegmental Area 36 ± 3 50 ± 6 37* 37 ± 5 56 ± 6 50* 43 ± 4 38 ± 6 -11+ 28 ± 3 33 ± 4 22+ 
Nucleus Accumbens 43 ± 6 42 ± 4 -2 34 ± 3 59 ± 3 74***†† 31 ± 2 30 ± 5 -4+ 19 ± 2 23 ± 2 20+†† 
 
Effect of hSERT over-expression on the LCMRglu response to DOI raphé, mesocorticolimbic and non-specific brain regions. Data shown as mean ± s.e.m. 
and % difference between DOI-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and 
***denotes p<0.001 significant DOI effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes 
















Table 3.4.16 LCMRglu response to DOI in hSERT over- expressing mice: non-specific regions 51 
 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  DOI % Saline DOI % Saline  DOI % Saline DOI % 
Non-specific             
Septal Nucleus 34 ± 3 35 ± 3 3 29 ± 3 44 ± 5 51*† 29 ± 2 31 ± 5 6 18 ± 2 25 ± 3 34***† 
Bed Nucleus of the Stria Terminalis 27 ± 3 24 ± 3 -12 21 ± 2 39 ± 4 82***†† 17 ± 2 20 ± 3 19 11 ± 2 18 ± 2 61*†† 
Corpus Callosum 16 ± 1 14 ± 1 -12 13 ± 1 20 ± 2 50* 11 ± 2 15 ± 2 37 8 ± 1 12 ± 1 54 
Lateral Habenula 53 ± 5 81 ± 10 52* 48 ± 5 107 ± 10 124***†† 55 ± 4 57 ± 9 5+++ 32 ± 3 48 ± 5 50*+++†† 
Mamillary Body 52 ± 4 72 ± 8 40* 50 ± 5 78 ± 5 56** 56 ± 3 53 ± 7 -5+ 34 ± 3 43 ± 5 27+ 
Periaqueductal Grey 33 ± 3 35 ± 1 7 26 ± 2 37 ± 4 40* 23 ± 3 23 ± 3 0 15 ± 2 19 ± 2 25 
Inferior Colliculus 73 ± 7 89 ± 9 22 71 ± 10 105 ± 12 50* 81 ± 7 77 ± 6 -5 48 ± 5 56 ± 7 16 
Ventral Tegmental Nucleus 46 ± 4 58 ± 6 26 41 ± 4 67 ± 5 65*** 43 ± 3 46 ± 6 5 26 ± 2 32 ± 2 14 
Locus Coeruleus 41 ± 4 51 ± 6 24 36 ± 4 62 ± 5 71*** 38 ± 3 38 ± 4 2 22 ± 2 25 ± 2 14 
Nucleus Tractus Solitaris 56 ± 9 58 ± 12 4 44 ± 7 75 ± 13 69 37 ± 4 42 ± 6 17 17 ± 1 24 ± 3 40 
 
Effect of hSERT over-expression on the LCMRglu response to DOI raphé, mesocorticolimbic and non-specific brain regions. Data shown as mean ± s.e.m. 
and % difference between DOI-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and 
***denotes p<0.001 significant DOI effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes 
p<0.001 significant gender x DOI  interaction. †denotes p<0.05, ††denotes p<0.01 significant genotype x DOI interaction (Univariate ANOVA). 
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 4.5 Conclusions and Discussion  
 
In this study we found evidence for a widespread reduction in 5-HT2A receptor binding and a 
reduction in 5-HT2C receptor binding that was limited to the nucleus accumbens of females as 
compared to males. Due to the nature of the binding protocol used in this study, which utilised 
a non-saturating concentration of each radioligand, we are unable to determine if this 
alteration in binding reflects a decrease in the expr ssion level or affinity of these receptors. 
Further research is required to clarify this issue. The gender difference in 5-HT2A binding 
reported in this study parallels that reported in humans (Biver et al., 1996). However, other 
studies have reported no gender difference in humans (Adams et al., 2004) while significantly 
increased 5-HT2A binding in the hippocampus of female rats as compared to males (Zhang et 
al., 1999) has also been reported. The reason for disparities in these results is unclear, but may 
relate to the use of small sample sizes in those studies reporting no gender difference, species 
differences or the use of different radioligands in each study. To the best of our knowledge 
our study is the first to characterise gender differences in 5-HT2C receptor binding. It is of 
particular interest that we found 5-HT2C binding was significantly reduced in the nucleus 
accumbens but significantly increased in the choroid plexus of females as compared to males. 
This suggests that the gender-dependent regulation of 5-HT2C receptor pharmacology involves 
diverse mechanisms that differ in neurones, particularly those of the nucleus accumbens, and 
the epithelial cells of the choroid plexus.  
 
We found that 25mg.kg-1 DOI produced only significant increases in cerebral metabolism. 
These findings contrast to those previously reported by the quantitative 2-DG method in rats, 
where only significant decreases were found in respon e to this dose of DOI (Freo et al., 
1992; Freo et al., 1991). The reason for this dispar ty is unknown. However, the localisation 
of the increased metabolism noted in mice (Wt male: l t ral habenula, ventral tegmental area, 
mamillary body) in response to DOI differs from those in which significant decreases were 
detected in rats. Indeed, in no brain region showing decreased metabolism in response to 
25mg.kg-1 DOI in rats was a response noted in mice with this do e. Furthermore, we found 
that a lower dose of DOI (2.5mg.kg-1) in male Wt mice (unpublished observations) produce  
significant decreases in cerebral metabolism that paralleled those reported in rats (at both 
2.5mg.kg-1 and 25mg.kg-1) (Freo et al., 1991). Therefore, it may be suggested that the 
sensitivity of the 5-HT2A/C receptors responsible for this divergent response to DOI may be 
different between species and may contribute to the div rgent metabolic response to 25mg.kg-
1 DOI between rats and mice.  
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In parallel to our binding data showing that 5-HT2A/C receptor binding is lower in females than 
in males we also found that the cerebral metabolic response to the 5-HT2A/C agonist DOI was 
lower in females than in males. The widespread decrease in 5-HT2A binding reported in 
females is likely to represent a primary mechanism by which 5-HT2A/C functional responses 
are decreased in females as compared to males. However, some caution should be exercised 
when drawing this conclusion as the receptor binding characterised in this study involves the 
use of receptor antagonists that label total receptor levels rather than those in the high affinity 
state coupled to G-proteins. Therefore, it may be possible that total 5-HT2A/C receptor 
expression is different between the genders but the level of those receptors in the high affinity 
state, coupled to G-proteins, may not be different between the genders. This seems unlikely, 
however, given the magnitude of the gender differences reported in 5-HT2A binding in some 
brain regions. However, additional mechanisms including altered coupling efficiency of the 5-
HT2A/C receptors between genders can not be ruled out. Our data not only suggest that 5-
HT2A/C receptor functioning is decreased in females but also that basal levels of 5-HT2A/C 
receptor activation is likely to be lower in females than in males. This seems even more likely 
given that we have found evidence for increased SERT expression in females (study 2), 
suggestive of enhanced 5-HT reuptake, and that others have reported decreased extracellular 
5-HT levels in females as compared to males (Jones a d Lucki, 2005; Mitsushima et al., 
2006).  
 
We found that 5-HT2A binding was not altered in any brain regions in hSERT OVR mice. 
This is in contrast to the reported alterations in 5-HT2A receptor binding in animals where 
SERT function is completely ablated, where both increases and decreases have been reported  
(Li et al., 2003; Rioux et al., 1999). Although the reason for this disparity between these two 
animal models is unknown the differing magnitudes of alteration in extracellular 5-HT levels 
is likely to be a contributory mechanism. In SERT KO animals extracellular 5-HT is 
increased by approximately +420% to +1285% (Shen et al., 2004) whereas in hSERT OVR 
animals it is decreased by a more modest -55% (Jennings et al., 2006). In addition, the 
observation that SERT binding is altered in a heterog neous, brain-regions dependent manner 
in hSERT OVR mice (study 2) suggests that this mouse model does not represent a direct 
diametric reflection of the SERT KO mouse, where SERT expression is completely removed 
in all brain regions. Therefore, complex differences in the regulation of 5-HT system 
functioning in response to the genetically altered SERT expression present in these animal 
models is likely to occur. Our results suggest that alterations in 5-HT2C receptor 
pharmacology may be more sensitive to alterations in SERT functioning than the 5-HT2A 
receptor as we found evidence for localised alterations in [3H]mesulergine binding in hSERT 
OVR mice. 5-HT2C receptor binding was significantly increased in the Dorsal mPFC and 
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choroid plexus in hSERT OVR animals. Surprisingly, an increase in 5-HT2C binding has also 
been reported in the choroid plexus of SERT KO mice (Li et al., 2003). This suggests that 
alterations in 5-HT2C receptor binding in this region may not directly relate to alterations in 
extracellular 5-HT levels and the relevance of thisalteration in receptor function to affective 
behaviour, if any, remains unclear. Furthermore, our st dy also supports the contention that 5-
HT2C receptor pharmacology is altered by genetically determined SERT expression in a brain 
region-dependent manner, as a decrease in 5-HT2C binding found in the ventrolateral 
hypothalamus.  
 
Despite the limited effect of hSERT OVR on 5-HT2A and 5-HT2C receptor binding we found 
that 5-HT2A/C mediated functional responses were significantly increased in the majority of 
brain regions in these animals. As the level of cerebral metabolism following DOI treatment 
in hSERT OVR mice often surpasses that following DOI trea ment in Wt mice it is unlikely 
that the enhanced response to DOI in hSERT OVR mice can be attributed to the constitutive 
hypo-metabolism in these animals and that the response in Wt animals is limited by their 
closer basal proximity to the maximum DOI response (“c iling effect”). Our data, therefore, 
support the contention that 5-HT2A/C functioning is enhanced in hSERT OVR mice. This is 
consistent with the reported enhancement of DOI induce  c-fos expression in hSERT OVR as 
compared to Wt animals (Jennings et al., 2003). Furthermore, this finding is not only 
consistent with an adaptive functional response in these receptors to the decreased 
extracellular 5-HT levels in hSERT OVR mice but also parallels the findings of 5-HT2A/C 
function in SERT KO animals (Qu et al., 2005). Our results suggest that alterations in 5-HT2C 
receptor pharmacology (expression level or affinity) may contribute to some of the alterations 
observed in 5-HT2A/C functional responses. However, as alterations in 5-HT2C receptor 
pharmacology are limited in their distribution and 5-HT2A receptor pharmacology unaltered, 
in contrast to the widespread enhancement of 5-HT2A/C receptor function other mechanisms 
are likely to be important. This may include the enha ced coupling of these receptors to their 
effector G-proteins and down-stream coupling mechanisms. With regard to possible 
mechanisms involving the 5-HT2C receptor, alterations in mRNA editing resulting in the 
presence of different 5-HT2C receptor isoforms that possess different coupling efficiencies to 
G-proteins (Niswender et al., 1999) may contribute to the enhanced 5-HT2A/C functional 
response in hSERT OVR mice. Indeed, there is evidence that prolonged 5-HT depletion 
results in the expression of 5-HT2C receptor isoforms with enhanced coupling (Gurevich et al., 
2002a) suggesting that the decreased extracellular 5-HT levels in hSERT OVR mice may 
result in this. Furthermore, there is some evidence that alternative 5-HT2C receptor mRNA 
editing can alter the binding affinity of these receptors (Fitzgerald et al., 1999). Therefore, 5-
HT2C RNA editing in the prefrontal cortex may contribute to the altered 5-HT2C receptor 
 194 
binding in this brain regions in hSERT OVR mice. These data suggest that the possibility of 
altered 5-HT2C mRNA editing hSERT OVR mice should be explored in the future. 
Furthermore, altered 5-HT2C RNA editing (Gurevich et al., 2002b) consistent wih reduced 
coupling efficiency has been noted in the prefrontal cortex of depressed suicide victims. 
Investigating the possible alteration of 5-HT2C mRNA editing in the prefrontal cortex of 
hSERT OVR mice may be relevant to both the noted alter tions in 5-HT2C binding in this 
region and the affective functioning of these animals. An alternative mechanism that may 
allow for enhanced signal transduction following receptor activation may involve increased 
levels of the G-proteins which couple to these receptors. This would increase the level of the 
high affinity forms of these receptors. However, evid nce from SERT KO mice (Li et al., 
2003) and chronic SSRI studies (Li et al., 1997a) suggest that the altered coupling efficiency 
of 5-HT2A/C receptors following chronic alterations in 5-HT transmission is independent of 
alterations in the expression level of 5-HT2A/C receptor linked G-proteins. 
 
In these studies we found no evidence to suggest that 5-HT2A/C receptor binding or 
functioning was altered to a greater extent by hSERT OVR in females as compared to males. 
Therefore, it is unlikely that the altered functioning of these receptors is involved in the 
gender-dependent effects of hSERT OVR on the constitutive cerebral hypometabolism, where 
the effect is greater in females than in males. Enhanced 5-HT 2A/C receptor function in hSERT 
OVR mice may represent a compensatory mechanism to aintain a similar level of 5-HT2A/C 
receptor signalling in these animals in the presence of reduced extracellular 5-HT levels. 
However, it is still unclear as to whether the enhanced 5-HT2A/C receptor function in these 
animals is sufficient to maintain a normal level of 5-HT2A/C receptor activation. Indeed, the 
finding that 5-HT2A/C mediated functional responses are not significantly enhanced in some 
brain regions argues that the receptors mediating them would be hypo-stimulated in hSERT 
OVR mice under basal conditions. Furthermore, as evidence from both 5-HT2A and 5-HT2C 
receptor KO mice suggests that the activation of these receptors is anxiogenic as both of these 
transgenic lines display decreased anxiety-like behaviour (Weisstraub et al., 2006, Heisler et 
al., 1999; Heisler et al., 2007; Tecott et al., 1996) hypostimulation of these receptors in SERT 
OVR mice wqould be consistent with their anxiolytic behavioural phenotype. Clearly, further 
research should be dedicated to elucidating 5-HT2A/C receptor function under basal condition 
in hSERT OVR mice. Using of selective 5-HT2A and 5-HT2C receptor antagonists would not 
only allow for the assessment of basal 5-HT2A/C receptor function in hSERT OVR mice but 




In summary, we found evidence for sexual dimorphism in both 5-HT2A/C receptor 
pharmacology and function, with females showing lower levels of function than those 
observed in males. In addition we found that a life-long increase in SERT expression altered 
5-HT2C receptor pharmacology, but not 5-HT2A receptor pharmacology, in a brain-region 
dependent manner and resulted in increased 5-HT2A/C receptor function. While these 
functional differences in 5-HT2A/C may relate to the reduced anxiety in hSERT OVR mice it is 
unlikely that they contribute to the gender-dependent modulation of hSERT OVR on cerebral 
functioning, and so the possible interaction between g nder and a life-long increase in SERT 



























Study 5- 5-HT 1B receptor binding and function in hSERT over-expressing 
mice  
 
5.1 Rationale  
 
5-HT1B receptors function as both terminal autoreceptors, inhibiting the release and synthesis 
of 5-HT (Hjorth and Tao, 1991), and  heteroreceptors regulating the release of 
neurotransmitters from non-serotonergic neurones (Sari, 2004). Therefore, 5-HT1B receptors 
have a central role in the regulation of 5-HT neurotransmission and in the integration between 
the 5-HT and other neurotransmitter systems. Evidence from chronic SSRI treatment studies 
support the contention that 5-HT1B autoreceptor function down-regulates in response to 
enhanced synaptic 5-HT levels (Moret and Briley, 1990; Newman et al., 2004; Shalom et al., 
2004). An effect which appears to be independent of alterations in 5-HT1B receptor expression 
levels (Le Poul et al., 2000). However, other have reported that 5-HT1B autoreceptor function 
is not altered by chronic SSRI treatment (Bosker et al., 1995; Gobbi et al., 1997). The 
contradictory evidence for 5-HT1B regulation by extracellular 5-HT appears to by due, in part, 
to the central localisation in which 5-HT1B receptor function is assessed. Hippocampal and 
hypothalamic 5-HT1B autoreceptors do not appear to be regulated by extracellular 5-HT 
whereas those in the frontal cortex are. No study to date has specifically assessed the possible 
regulation of 5-HT1B heteroreceptor function by chronic SSRI treatment or alterations in 
extracellular 5-HT. Evidence from studies using SERT KO mice suggests that 5-HT1B 
receptor function can also be regulated by genetically determined SERT expression levels 
(Fabre et al., 2000b). In these animals 5-HT1B function (as assessed by GTPγS binding) was 
found to be reduced in the substantia nigra. Furthermore, this alteration in 5-HT1B function 
was attributed, in part, to a reduction in 5-HT1B binding in this region. Given the available 
evidence we hypothesis that 5-HT1B function may be up-regulated in hSERT OVR mice in 
response to the decreased synaptic 5-HT levels in these animals. Furthermore, we hypothesise 
that 5-HT1B receptor binding may also be increased in hSERT OVR mice. Assessing 5-HT1B 
receptor function in hSERT OVR mice by use of the [14C]-2-DG imaging technique may 
allow us to further determine the CNS localisation at which 5-HT1B receptor function may be 
regulated by SERT expression and alterations in extracellular 5-HT. Use of the 2-DG 
technique may be particularly appropriate in assessing the localisation of functional 
alterations in 5-HT1B receptor given the synaptic localisation of these receptors, their 
inhibitory effect on neurotransmitter release and the sensitivity of the 2-DG method to 
alterations in metabolic demand at the nerve terminal.    
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The paucity of data regarding possible gender differences in 5-HT1B receptor binding and 
function restricts our ability to form a decisive hypothesis on this matter. However, as the 
behavioural and neurochemical alterations observed in 5-HT1B receptor KO mice appear to be 
greater in females than in males (Jones and Lucki, 2005) this at least suggests that 5-HT1B 
function may be greater in females than in males. Furthermore, enhanced 5-HT1B receptor 
function in females would be consistent with an adaptive response to the reduced extracellular 
5-HT levels observed in females as compared to males (Jones and Lucki, 2005; Mitsushima et 
al., 2006). In order to assess possible gender differences in 5-HT1B receptor function and the 
possibility of an interaction between gender, genetically determined SERT function and the 5-
HT1B receptor we will characterise 5-HT1B receptor binding and function in Wt and hSERT 
OVR animals of both genders. 
 
In summary, we hypothesis that 5-HT1B receptor binding and function may be increased in 
hSERT OVR mice in comparison to Wt animals in an attempt to compensate for the reduced 
synaptic 5-HT levels in these animals. We also hypotheses that 5-HT1B receptor function may 
be greater in females than in males and that any effect of hSERT OVR on 5-HT1B function 
may also be greater in females than males, as our previous studies have shown this gender 
difference in constitutive cerebral metabolism, altera ions in SERT expression levels and in 5-
HT1A receptor function.   
 
5.2 [3H]GR 125,743 Binding  
 
In contrast to the widespread distribution of 5-HT1B receptor binding reported in other studies 
(Fabre et al., 2000b; Le Poul et al., 2000; Mendelson and McEwen, 1992) we found that 
[3H]GR 125,743 binding could only be visualised in 3 brain regions; the ventral pallidum, 
globus pallidus and substantia nigra. These regions are reported to display the highest 5-HT1B 
binding when using other 5-HT1B ligands suggesting that the protocol used for [
3H]GR 
125,743 binding in this study requires further optimisation to measure 5-HT1B binding in 
regions where expression of the receptor is more modest. In particular we note that the wash 
time utilised in this protocol is much longer than that utilised for ligands with a similar 
affinity for other receptors. Therefore, reducing the wash time may allow for determination of 
5-HT1B binding in regions in which expression is moderate or low. 
 
There was no evidence for a significant gender difference in the extent of [3H]GR 125,743 
binding in any of the regions analysed. Furthermore, th re was no evidence for a significant 
effect of hSERT over-expression on [3H]GR 125,743 in any of these brain regions in either 
males or females (Figure 3.5.1). 
 198 





































































[3H]GR 125,743 binding (nCi/mg) in male and female hSERT OVR and wild-type 
mice. Data presented as mean ± s.e.m. There was no evidence for a difference in 








5.3 LCMRglu  
 
In Wt males CP 94,253 produced a general trend towards decreased LCMRglu in the majority 
of brain regions. However, the only region in which a significant decrease was observed in 
the anterior hypothalamus (-33%). Non-significant increases in LCMRglu in response to CP 
94,253 were observed in 4 brain regions. In contrast to Wt males CP 94,253 increased 
LCMRglu in Wt females in a greater number of brain regions (35 out of 47). These increases 
were significant in a number of hippocampal subregions including the dentate PO (+22%), 
ventral subiculum (+25%), ventral CA1 (+27%) and CA3 (+25%). Out-with the hippocampus 
significant increases were observed only in the anterior hypothalamus (+41%) and central 
amygdala (+32%) of Wt females. A trend towards decreased LCMRglu was observed in 12 
brain regions in Wt females but none reached significance. These results suggested that the 
LCMRglu response to CP 94,253 was greater in females than in males and this was confirmed 
by the observation of a significant gender x CP 94,253 interaction in 8 of the 46 brain regions 
analysed (2-way ANOVA within genotype). These significant interactions were most 
widespread throughout the hippocampus and were also present in the piriform cortex and 
anterior hypothalamus. Figures 3.5.2 and 3.5.3 show gender differences in the LCMRglu 
response to CP 94,253 in a representative selection of brain regions. 
 
In hSERT OVR males the LCMRglu response to CP 94,253 was of a similar magnitude and 
distribution to that observed in Wt males and the only region in which a significant response 
was found was a significant reduction (-25%) in LCMRglu following CP 94,253 treatment in 
the anterior hypothalamus. There was no evidence for a significant interaction between 
hSERT OVR and CP 94,253 on LCMRglu any brain region in male mice. In contrast to the 
CP 94,253 response in hSERT OVR males CP 94,253 produced a tendency towards increased 
LCMRglu in all brain regions analysed in hSERT OVR females. Significant increases in 
LCMRglu in response to CP 94,253 were more widespread (20 regions) in female hSERT 
OVR than female Wt mice. Additional significant increases in LCMRglu were observed in 
cortical (orbitofrontal, +34%; somatosensory +38%), mesocorticolimbic (nucleus accumbens, 
+45%; VTA, 54%), motor (medial striatum +53%) and raphè (dorsal, +44%) structures in 
hSERT OVR female mice in comparison to Wt females. Furthermore, in all brain regions 
analysed the LCMRglu response to CP 94,253 tended to be of a greater magnitude in hSERT 
OVR females in comparison to their Wt counterparts. Indeed, a significant hSERT OVR x CP 
94,253 interaction was found in females in 6 brain regions (frontal cortex, medial striatum, 
subthalamic nucleus, ventrolateral thalamus, mediodorsal thalamus and lateral habenula). 
These results suggested that SERT OVR increases the LCMRglu response to CP 94,256 in 
females but not in males. Figure 3.5.4 shows a selection of representative brain regions in 
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which the LCMRglu response to CP 94,253 appears to be modified by hSERT over-
expression to a greater extent in females as compared to males. However, there was no 
evidence for a significant gender x hSERT OVR x CP 94,253 interaction in any brain region 
which would support this conclusion.  
 
As the LCMRglu response to CP 94,253 was enhanced by hSERT OVR in females but not in 
males this meant that evidence for a significant gender x CP 94,253 interaction was more 
widespread in hSERT OVR as compared to Wt mice. This again suggests tha  modification of 
the response to CP 94,253 by hSERT OVR is influence by gender, but we found no 
significant evidence for this. Detailed data on theeffects of hSERT over-expression on the 
LCMRglu response to CP 94,253 are shown in Tables 3.5.1 to 3.5.6. The plasma data for 








































































































Effect of hSERT over-expression on the LCMRglu ([14C]-Uptake ratio; [14C]-UR) 
response to 10 mg.kg-1 CP 94,253 in male and female mice. Data for 3 
representative brain regions shown as mean ± s.e.m. *denotes p<0.05 significant 
hSERT effect (2-way ANOVA within saline animals with Bonferroni correction). 
+denotes p<0.05 and ++denotes p<0.01 significant gender x CP 94,253 interaction (2-
way ANOVA within genotype). †denotes significant hSERT OVR x CP 94,253 
interaction.  ∆denotes p<0.05 and ∆∆denotes p<0.01 significant CP 94,253 effect (2-
way ANOVA within gender with Bonferroni correction). The LCMRglu response to CP 
94,253 appears to be enhanced by hSERT over-expression in female mice but not in 
male mice. Unfortunately, the conservative nature of Univariate ANOVA means that a 
significant gender x hSERT OVR x CP 94,253 interaction was not found in any brain 
regions to support this suggestion.  
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Figure 3.5.3 Gender differences in the LCMRglu resp onse to CP 94,253 F44 
Wild-type





















































































































Gender differences in the LCMRglu response to CP 94,253 in Wt and hSERT OVR mice. Data are shown as % difference in the [14C]-Uptake 
ratio in CP 94,253-treated animals relative to the appropriate saline control and were analysed using 2-way ANOVA completed within 
genotype.+denotes p<0.05, ++denotes p<0.01 and +++denotes p<0.001 significant gender x CP 94,253 interaction.  *denotes p<0.05 and 
**denotes p<0.01 significant CP 94,253 effect (with Bonferroni correction). Note in particular the enhancement of gender differences in the 
response to CP 94,253 in hSERT OVR as compared to Wt mice.
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Figure 3.5.4 Interaction between Gender and hSERT over-expression on 
















































































































Effect of gender and hSERT OVR on the LCMRglu response to 10 mg.kg-1 CP 
94,253  in male and female mice. Data for 6 representative brain regions shown as % 
change in the [14C]-Uptake ratio ([14C]-UR) between CP 94,253-treated animals and 
the appropriate saline control. ∆denotes p<0.05 and ∆∆denotes p<0.01 significant 
hSERT OVR x CP 94,253 interaction (2-way ANOVA within gender). *denotes 
p<0.05, **denotes p<0.01 significant CP 94,253 effect (2-way ANOVA with 
Bonferroni correction). +denotes significant gender x CP 94,253 interaction and 
†denotes significant hSERT OVR x CP 94,253 interaction (Univariate ANOVA). The 
LCMRglu response to CP 94,253 was significantly greater in Wt females as 
compared to Wt males in a number of brain regions (e.g. dentate PO). This gender 
difference in the LCMRglu response to CP 94,253 is present in a greater number of 
brain regions in hSERT OVR mice (e.g. central amygdala, dorsal raphé). The 
response to CP 94,253 is enhanced in female hSERT over-expressing mice in 




Figure 3.5.5 CP 94,253-treatment abolishes the cere bral hypo-metabolism observed in hSERT OVR female mice F46 
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Relationship between the Wt basal [14C]-Uptake ratio ([14C]-UR) and the [14C]-UR in hSERT OVR and CP 94,256-treated animals across all 
brain regions analysed. Dashed black line representsthe level of Wt basal LCMRglu (Unity). Note in particular how hSERT OVR results in a 
pronounced hypo-metabolism throughout the brain in females (hSERT OVR; saline) as compared to Wt basal animals (unity line, saline 
treated) whereas in males (hSERT OVR;saline) this effect appears to be more modest. Also note how CP 94,256-treatment alleviates this 
hypo-metabolism in hSERT OVR females (hSERT OVR; CP 94.253), bringing the level of LCMRglu throughout the brain to the same level as 
observed in Wt animals (Wt;saline group represented by the unity line and the Wt; CP 94,253-treated group). Whereas the level of LCMRglu 
appears to be relatively unaffected by CP 94,253 treatment in males as the level of LCMRglu in hSERT OVR; CP 94,253 treated mice appears 
to be the same as that in hSERT OVR; saline treated mice.  
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Table 3.5.1 LCMRglu response to CP 94,253 in hSERT over-expressing mice: cortical regions T52 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253 % 
Cortex             
Orbitofrontal 63 ± 6 54 ± 5 -13 46 ± 3 46 ± 3 0 49 ± 4 51 ± 2 4 35 ± 2▲▲ 46 ± 3 33*++ 
Frontal 45 ± 5 41 ± 4 -8 33 ± 2 35 ± 2 7 44 ± 3 40 ± 2 -8 27 ± 2▲▲▲ 37 ± 1 35* Φ+ 
Anterior Cingulate 48 ± 5 46 ± 5 -3 35 ± 3 39 ± 2 13 43 ± 3 46 ± 2 8 30 ± 2▲▲ 42 ± 3 42**+ 
Dorsal medial Prefrontal 47 ± 5 39 ± 4 -18 32 ± 2 34 ± 2 7 37 ± 3 38 ± 2 4 25 ± 2▲▲ 34 ± 2 34*+ 
Ventral medial Prefrontal 41 ± 4 39 ± 4 -17 28 ± 2 28 ± 1 0 29 ± 2 31 ± 2 8 19 ± 2▲▲ 28 ± 1 48**++ 
Somatosensory 55 ± 4 47 ± 4 -13 44 ± 3 38 ± 2 -12 50 ± 5 49 ± 2 -1 31 ± 2▲▲▲ 42 ± 3 38*+++ 
Temperoparietal 54 ± 5 43 ± 4 -20 43 ± 4 37 ± 2 -14 44 ± 4 44 ± 2 0 32 ± 2▲ 42 ± 5 34++ 
Posterior Cingulate 52 ± 4 52 ± 6 -1 44 ± 3 44 ± 3 0 48 ± 4 51 ± 3 5 35 ± 2▲ 49 ± 5 38*+ 
Piriform 31 ± 3 24 ± 3 -21 22 ± 1 22 ± 1 0 20 ± 2 24 ± 2 24+ 15 ± 5 23 ± 2 51*++ 
Entorhinal 35 ± 3 31 ± 4 -12 28 ± 2 30 ± 1 6 30 ± 2 35 ± 2 16 22 ± 2▲ 32 ± 3 45*+ 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in cortical regions. Data shown as mean ± s.e.m. and % difference between CP 
94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant 
CP 94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes p<0.001 significant gender 
x CP 94,253 interaction (2-way ANOVA within genotype). Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-
way ANOVA). †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate ANOVA). ▲denotes p<0.05, ▲▲denotes p<0.01 











Table 3.5.2 LCMRglu response to CP 94,253 in hSERT over-expressing mice: basal ganglia regions T53 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253  % 
Basal Ganglia             
Medial Striatum 43 ± 3 41 ± 4 -4 35 ± 3 36 ± 2 4 42 ± 3 44 ± 2 6 28 ± 2▲▲ 43 ± 3 53**++Φ 
Lateral Striatum 48 ± 3 43 ± 4 -12 37 ± 3 37 ± 2 -1 42 ± 3 46 ± 3 9 30 ± 2▲ 45 ± 4 51**++ 
Globus Pallidus 32 ± 2 28 ± 3 -12 26 ± 2 24 ± 1 -7 33 ± 3 30 ± 2 -8 21 ± 2▲▲ 28 ± 3 36+ 
Subthalamic Nucleus 49 ± 5 42 ± 4 -15 43 ± 3 37 ± 2 -15 50 ± 3 45 ± 3 -9 34 ± 8 43 ± 4 28 Φ++ 
Substantia Nigra pars Reticulata 30 ± 2 26 ± 2 -13 25 ± 2 24 ± 1 -5 26 ± 2 28 ± 2 7 19 ± 1▲ 26 ± 2 36+ 
Substantia Nigra pars Compacta 38 ± 3 32 ± 3 -16 31 ± 2 29 ± 2 -6 34 ± 3 36 ± 2 5 24 ± 2▲▲ 33 ± 2 41*++ 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in cortical regions. Data shown as mean ± s.e.m. and % difference between CP 
94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant 
CP 94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes p<0.001 significant gender 
x CP 94,253  interaction (2-way ANOVA within genotype). †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate 
ANOVA). Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-way ANOVA). ▲denotes p<0.05, ▲▲denotes 
















Table 3.5.3 LCMRglu response to CP 94,253 in hSERT over-expressing mice: amygdala, thalamic and h ypothalamic 
regions T54 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253  % 
Amygdala             
Medial 25 ± 2 23 ± 2 -7 19 ± 1 20 ± 1 2 18 ± 2 21 ± 2 20 14 ± 1 20 ± 2 45*+ 
Basolateral 34 ± 3 30 ± 3 -11 28 ± 2 26 ± 1 -5 29 ± 2 31 ± 2 7 20 ± 2▲ 29 ± 3 42*++ 
Central 23 ± 2 25 ± 2 9 18 ± 1 22 ± 1 23 17 ± 2 22 ± 2 32* 13 ± 1 21 ± 2 56*++ 
Thalamic Nuclei             
Anterior 50 ± 4 51 ± 5 2 46 ± 5 47 ± 3 2 47 ± 5 54 ± 3 15 36 ± 3 51 ± 5 43*++ 
Mediodorsal 57 ± 5 47 ± 4 -18 45 ± 3 41 ± 2 -9 48 ± 4 48 ± 2 1 32 ± 2▲▲ 45 ± 4 39* ++Φ 
Venterolateral 56 ± 5 45 ± 4 -19 47 ± 4 43 ± 3 -9 56 ± 5 51 ± 2 -9 34 ± 2▲▲ 46 ± 5 37*++ Φ 
Hypothalamic Nuclei             
Anterior 39 ± 5 26 ± 4 -33** 30 ± 4 23 ± 1 -25* 17 ± 1 24 ± 1 41*+ 14 ± 2▲ 19 ± 1 33++ 
Venterolateral 30 ± 2 30 ± 3 1 26 ± 2 27 ± 2 4 26 ± 2 32 ± 3 25 18 ± 2▲ 27 ± 3 50*+ 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in cortical regions. Data shown as mean ± s.e.m. and % difference between CP 
94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant CP 
94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes p<0.001 significant gender x CP 
94,253  interaction (2-way ANOVA within genotype). †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate ANOVA). 
Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-way ANOVA). ▲denotes p<0.05, ▲▲denotes p<0.01 











Table 3.5.4 LCMRglu response to CP 94,253 in hSERT over-expressing mice: hippocampal regions T55 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253  % 
Hippocampus             
Molecular Layer 42 ± 4 34 ± 4 -20 32 ± 2 30 ± 2 -7 32 ± 3 36 ± 2 11+ 23 ± 2▲ 33 ± 3 42*++ 
Dorsal Subiculum 40 ± 3 39 ± 4 -2 34 ± 3 36 ± 2 7 38 ± 3 41 ± 2 9 28 ± 2 40 ± 3 43*+ 
Dentate PO 25 ± 5 27 ± 3 8 21 ± 1 25 ± 1 20 20 ± 2 24 ± 2 22* 17 ± 2 24 ± 2 42* 
Dorsal CA1 37 ± 3 29 ± 3 -23 29 ± 2 28 ± 2 -3 28 ± 3 33 ± 2 15++ 19 ± 2▲ 30 ± 2 56**++ 
CA2 35 ± 3 29 ± 3 -17 26 ± 2 27 ± 4 8 26 ± 3 30 ± 2 17+ 18 ± 2▲ 29 ± 3 61**+ 
Ventral CA1 34 ± 2 28 ± 3 -18 26 ± 2 27 ± 2 4 24 ± 2 31 ± 2 27*++ 19 ± 1 30 ± 3 58**+ 
Ventral Subiculum 30 ± 2 28 ± 3 -7 24 ± 2 26 ± 2 8 23 ± 2 29 ± 2 25*+ 19 ± 2 30 ± 4 57**+ 
CA3 28 ± 2 27 ± 3 -5 22 ± 1 24 ± 1 11 21 ± 2 26 ± 2 25* 15 ± 1 24 ± 2 53*+ 
 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in cortical regions. Data shown as mean ± s.e.m. and % difference between CP 
94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and ***denotes p<0.001 significant CP 
94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and +++denotes p<0.001 significant gender x CP 
94,253 interaction (2-way ANOVA within genotype). †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate ANOVA). 
Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-way ANOVA). ▲denotes p<0.05, ▲▲denotes p<0.01 













Table 3.5.5 LCMRglu response to CP 94,253 in hSERT over-expressing mice: raphé and mesocorticolim bic regions T56 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253  % Saline CP 94,253  % 
Raphé             
Dorsal 38 ± 3 32 ± 2 -18 30 ± 2 28 ± 1 -7 29 ± 2 30 ± 2 6 20 ± 2▲ 30 ± 2 47*++ 
Median 47 ± 5 39 ± 3 -19 37 ± 3 37 ± 2 -1 39 ± 3 39 ± 2 1 28 ± 2▲ 36 ± 3 30+ 
Paramedian 47 ± 4 39 ± 3 -17 37 ± 3 36 ± 2 -1 40 ± 3 40 ± 2 1 28 ± 2▲ 39 ± 2 38*+ 
Mesocorticolimbic System             
Ventral Tegmental Area 38 ± 3 41 ± 3 6 36 ± 4 40 ± 3 11 43 ± 4 44 ± 3 4 31 ± 23 48 ± 5 56*+ 
Nucleus Accumbens 43 ± 6 38 ± 3 -12 31 ± 2 31 ± 1 0 31 ± 2 34 ± 2 8 21 ± 2▲▲ 31 ± 2 45**++ 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in raphé, mesocorticolimbic and non-specific regions. Data shown as mean ± s.e.m. 
and % difference between CP 94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and 
***denotes p<0.001 significant CP 94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and 
+++denotes p<0.001 significant gender x CP 94,253  interaction. †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate 
ANOVA). Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-way ANOVA). ▲denotes p<0.05, ▲▲denotes 
















Table 3.5.6 LCMRglu response to CP 94,253 in hSERT over-expressing mice: non-specific regions T57 
 
 Male Female 
 Wild-type hSERT OVR Wild-type hSERT OVR 
 Saline  CP 94,253 % Saline  CP 94,253 % Saline CP 94,253  % Saline CP 94,253  % 
Non-specific             
Septal Nucleus 35 ± 3 32 ± 3 -8 28 ± 2 30 ± 2 6 29 ± 2 33 ± 2 14 21 ± 2▲ 32 ± 3 55**+ 
Bed Nucleus of the Stria Terminalis 27 ± 3 21 ± 2 -21 20 ± 1 20 ± 1 0 17 ± 2 21 ± 2 25+ 12 ± 2▲ 21 ± 1 68*++ 
Corpus Callosum 16 ± 1 15 ± 2 -8 13 ± 1 13 ± 1 4 11 ± 2 15 ± 2 36+ 8 ± 1 13 ± 1 52+ 
Lateral Habenula 56 ± 5 46 ± 4 -18 44 ± 3 41 ± 2 -7 55 ± 4 47 ± 2 -14 36 ± 2▲▲ 47 ± 4 30*++ΦΦ 
Mamillary Body 55 ± 4 64 ± 7 16 46 ± 3 51 ± 4 11 56 ± 12 56 ± 4 1 38 ± 2 51 ± 5 56*+Φ 
Periaqueductal Grey 29 ± 4 27 ± 2 -7 25 ± 1 25 ± 1 0 23 ± 2 26 ± 2 13 17 ± 2 26 ± 2 47*+ 
Inferior Colliculus 72 ± 8 69 ± 10 -4 75 ± 8 68 ± 5 -9 81 ± 7 80 ± 4 -2 54 ± 4▲ 73 ± 6 35*+ 
Ventral Tegmental Nucleus 51 ± 4 42 ± 4 -17 39 ± 3 38 ± 3 -3 43 ± 3 43 ± 2 -2 29 ± 2
▲ 42 ± 4 42+ 
Locus Coeruleus 44 ± 4 34 ± 3 -23 35 ± 3 35 ± 2 1 38 ± 3 36 ± 3 -4 25 ± 2▲ 31 ± 2 24 
Nucleus Tractus Solitaris 49 ± 7 31 ± 2 -36 40 ± 4 30 ± 2 -26 37 ± 4 33 ± 2 -11 18 ± 1 29 ± 3 62 
 
 
Effect of hSERT over-expression on the LCMRglu response to CP 94,253 in raphé, mesocorticolimbic and non-specific regions. Data shown as mean ± s.e.m. 
and % difference between CP 94,253-treated and control (saline-treated) animals of the same gender and genotype. *denotes p<0.05, **denotes p<0.01 and 
***denotes p<0.001 significant CP 94,253 effect (within genotype, 2-way ANOVA with Bonferroni correction). +denotes p<0.05, ++denotes p<0.05 and 
+++denotes p<0.001 significant gender x CP 94,253  interaction. †denotes p<0.05, ††denotes p<0.01 significant genotype x CP 94,253 interaction (Univariate 
ANOVA). Φdenotes p<0.05, ΦΦdenotes p<0.01 significant genotype x CP 94,253 interactions (within gender 2-way ANOVA). ▲denotes p<0.05, ▲▲denotes p<0.01 
significant hSERT effect (2-way ANOVA in gender). 
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5.4 Discussion and Conclusions  
 
In contrast to other studies reporting on the ability of genetically altered SERT function to 
alter 5-HT1B binding, specifically in the substantia nigra of SERT KO animals (Fabre et al., 
2000b), we found no evidence for altered 5-HT1B binding in this region or others (ventral 
pallidum and globus pallidus) in hSERT OVR mice. This may directly relate to the different 
magnitudes of altered SERT functioning present in these different animal models. Regulation 
of extracellular 5-HT levels by SERT function likely represents a key mechanism by which 
SERT function regulates 5-HT1B receptor expression in SERT KO animals, especially of the 
post-synaptic 5-HT1B heteroreceptors. In agreement with our finding others have reported on 
the inability of chronic alterations in extracellular 5-HT levels to alter 5-HT1B expression (Le 
Poul et al., 2000).  However, as we could only determine 5-HT1B binding in a limited number 
of brain regions, those which express particularly high levels of the receptor, it is possible that 
5-HT1B receptor binding may be altered in brain regions not measured in our study. 
Furthermore, the conditions used in this study are likely to detect binding not only at the 5-
HT1B receptor but also at the 5-HT1D receptor as [
3H]GR 125,743 has affinity for both of these 
binding sites and the concentration of CP 93,129 used for the determination of NSB binding 
in these studies is likely to occupy a significant percentage of both of these receptor subtypes 
(Bruinvels et al., 1993). Therefore, it is possible that any alteration in 5-HT1B binding may 
have been masked by 5-HT1D binding. This suggestion, along with the fact that only high 
levels of 5-HT1B receptor binding are detected using the present methodology, suggests that 
further optimisation of the ligand binding protocol used in this study is necessary before 
definitive conclusions on 5-HT1B binding can be made in hSERT OVR animals. However, 
overall our data suggest that 5-HT1B/1D receptor binding is not altered by hSERT OVR in 
those 3 brain regions measured in our analysis. 
 
In this study administration of the selective 5-HT1B agonist CP 94,253 resulted in an increase 
in cerebral metabolism that was particularly widespr ad within the hippocampus and also 
present in the central amygdala of Wt female animals. In contrast, CP94,253 did not increase 
cerebral metabolism in Wt males. Infact, a generalised trend towards decreased metabolism 
was observed in Wt males but this only reached significa ce in the anterior hypothalamus. 
Only one other study has reported on the cerebral metabolic impact of 5-HT1B receptor 
activation (Kelly et al., 1988) and the results in our study stand in stark contrast to those 
previously reported. For example, Kelly et al. (1988) found no evidence for significantly 
altered metabolism in the anterior hypothalamus. Furthermore, significant increases in 
LCMRglu were detected in numerous brain regions (including cortical and basal ganglia 
structures) that were not found in our study. One reason for these disparities could be the use 
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of the highly selective 5-HT1B agonist CP 94,253 in this study as compared to use of the non-
selective 5-HT1B agonist RU 24,969, which also possesses 5-HT2A/C affinity. However, as the 
published study also involved measurement of LCMRglu in a greater number of brain areas 
(72), many of which were not included in our analysis, a more comprehensive analysis may 
reveal greater similarity between these studies.       
 
Our results suggest that use of the 2-DG method to e ermine the precise localisation of 
altered 5-HT1B receptor function in the CNS may not be as appropriate as originally thought. 
The regional distribution of LCMRglu responses to CP 94,253 does not accurately reflect that 
of 5-HT1B receptor distribution. Furthermore, observations of increased LCMRglu in response 
to CP 94,253 are unlikely to reflect the activation of 5-HT1B receptors localised within these 
areas.  Activation of terminal 5-HT1B receptors inhibits neurotransmitter release and neuronal 
activity which would decrease metabolic demand at the synapse. Therefore, decreases in 
LCMRglu would be expected to occur as a result of the 5-HT1B receptor activation in each 
brain region. It is likely that increases in LCMRglu following CP 94,253 administration 
reflect the complex integration of decreases in the metabolic demand of nerve terminals 
possessing 5-HT1B receptors in each region, alterations in the synaptic ctivity of inputs into 
that region (which may be modified by “up-stream” 5-HT1B receptor activation) and 
alterations in neuronal activity that result from complex alterations in the availability multiple 
neurotransmitters.  
 
In this study a significant sexually dimorphic LCMRglu response to CP 94,253 was noted in 
multiple regions of the hippocampus, the central amygdala and the anterior hypothalamus of 
Wt animals. In the hippocampus and central amygdala this resulted from a significant 
increase in metabolism in females but not in males. It is difficult to determine what this 
dimorphic response means in terms of gender differences in basal 5-HT1B functioning, in part 
due to the vast difference in base-line LCMRglu between genders. The results may be taken 
to suggest that the 5-HT1B receptors responsible for these responses display lower functional 
activity in males than in females. On the other hand it may be suggested that the level of 
functioning of these 5-HT1B receptors is not different between the genders but that they are 
tonically activated in males, therefore application of the agonist elicits no response, but in 
females they are not. Indeed, there is some evidence to support the tonic activation of both 5-
HT1B autoreceptors (Kikvadze and Foster, 1995) and heteror ceptors (Querejeta et al., 2005) 
in selected brain regions under basal conditions. Furthermore, the increased SERT expression 
(study 1), consistent with enhanced 5-HT re-uptake, nd the decreased level of extracellular 
5-HT (Jones and Lucki, 2005; Mitsushima et al., 2006) found in females as compared to 
males would be consistent with reduced tonic activation of 5-HT1B receptors in females under 
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basal conditions (if 5-HT1B receptor functional levels were the same between gders). 
Furthermore, 5-HT1B hypostimulation in females as compared to males as a result of 
decreased synaptic 5-HT availability would be consistent with the enhancement of gender 
differences in the response to CP 94,253 by hSERT OVR (see later in discussion). However, 
definitive conclusions upon the basal activation of 5-HT1B receptors between genders can not 
be made on the basis of our evidence and further res a ch is required. To further clarify this 
issue it may be of particular interest to characterise dose-response curves for LCMRglu 
following 5-HT1B antagonist application in males and females. If the 5-HT1B receptors 
responsible for these LCMRglu responses are tonically active in males but not in females one 
may expect to find a shift to the left (lower dose required to elicit response) in the LCMRglu 
dose-response curve of 5-HT1B antagonists in males as compared to females. If the activation 
of these receptors between genders was not different under basal conditions one would expect 
to see no difference in the dose-response curve. Whereas, if 5-HT1B function is greater in 
females than in males one may expect to see the dose-response curve of females shifted to the 
left to that of males. 
 
The most profound gender difference in the response to CP 94,253 was noted in the anterior 
hypothalamus where a significant decrease was observed in males (Wt -35%, hSERT OVR -
25%) and significant increases were observed in femal s (Wt +41%, hSERT OVR +33%). 
The limited knowledge on the gender-dependent effects of 5-HT1B receptor activation makes 
identifying the possible mechanisms involved in this dramatic gender difference difficult to 
identify.  
 
Despite the increased amplitude of the cerebral metabolic response to CP 94,253 in hSERT 
OVR females as compared to Wt females in a number of brain regions (Figure 3.5.3) we 
suggest that our data do n t support our original hypothesis; that 5-HT1B receptor function is 
increased in hSERT OVR mice. Rather, we suggest that our data support the contention that 
5-HT1B receptor signalling is hypoactive in hSERT OVR females under basal conditions and 
that this contributes to the constitutive hypo-metabolism observed in these animals.  
 
In females the LCMRglu response to CP 94,253 was significantly increased in 5 brain regions 
in hSERT OVR mice as compared to Wt animals. These regions included the frontal cortex, 
medial striatum, subthalamic nucleus, ventrolateral and mediodorsal thalamus and the lateral 
habenula. Each of these regions displayed a significa t basal hypo-metabolism in hSERT 
OVR females as compared to Wt females. This hypo-metabolism was abolished in hSERT 
OVR mice by treatment with the 5-HT1B agonist CP 94,253, bringing LCMRglu in these 
regions to a level comparable to that observed in Wt animals (Figure 3.5.2 provides 
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representative examples). In Wt females CP 94,253 failed to elicit a significant LCMRglu 
response in any of these regions. This suggests that the 5-HT1B receptors responsible for these 
responses are tonically activated in Wt female animls but are hypo-stimulated in female 
hSERT OVR animals. The normalisation of the basal hypo-metabolism in female hSERT 
OVR animals by CP 94,253 treatment to a level comparable to that of Wt animals was a trend 
observed throughout the entire brain (Figure 3.5.5) This suggests that 5-HT1B hypo-
stimulation in hSERT OVR females directly contributes to the basal hypo-metabolism 
observed in the limbic system of these animals. There was no evidence for 5-HT1B hypo-
stimulation in male hSERT OVR mice as there was no evidence for basal hypo-metabolism or 
an altered response to CP 94,253 in male hSERT OVR as compared to Wt male mice. 
Unfortunately, however, lack of a significant gender x genotype x CP 94,253 interaction in 
any brain region meant that the modulatory influence of gender on hSERT OVR induced 5-
HT1B receptor hypo-stimulation was not confirmed. 
 
Hypo-stimulation of 5-HT1B receptors in hSERT OVR females may result from a lack of a 
compensatory alteration in 5-HT1B receptor function to the decreased levels of extracellular 5-
HT in these animals. Lack of evidence for the hypo-stimulation of 5-HT1B receptors in male 
mice suggests that compensatory alterations in 5-HT1B receptor functioning may occur in 
male hSERT OVR mice. Alternatively, females may be more sensitive to decreases in 5-HT1B 
receptor activation than males as they may be closer to the threshold level of 5-HT1B 
stimulation at which alterations in LCMRglu are observed. This suggestion is supported by 
observations of the decreased extracellular 5-HT availability in females and possibly by our 
own observations of an LCMRglu response to CP 94,253 in Wt females but not Wt males. 
This would mean that alterations in 5-HT availability in hSERT OVR mice may result in 
significant 5-HT1B hypo-stimulation in females but not in males. On the other hand this 
gender difference may be a direct result of the greater enhancement of SERT expression by 
hSERT OVR in females as compared to males (study 1). This would suggest that synaptic 5-
HT levels may be decreased to a greater extent in hSERT OVR females in comparison to 
males in some brain regions. Therefore, the theoretical threshold at which 5-HT1B receptors 
become significantly hypo-simulated in hSERT OVR mice may be achieved in these regions 
in females but not in males.  
 
Unfortunately use of the 2-deoxglucose technique to assess 5-HT1B receptor function does not 
allow us to determine the localisation of the 5-HT1B receptors or the relative importance of the 
autoreceptor versus the heteroreceptor in the basal hypo-metabolism observed in hSERT 
OVR females. However, as enhancement of 5-HT neurotransmission has been shown to 
stimulate metabolism in many of the brain regions which display hypo-metabolism in female 
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hSERT OVR mice (Bremner et al., 1997; Cudennec et al., 1988b; Mann et al., 1996) it seems 
unlikely that 5-HT1B autoreceptor activation, which would further reduced synaptic 5-HT, 
would be responsible for the increase in metabolism in these regions following CP 94,253 
administration. Therefore, we suggest that hypo-stimulation of 5-HT1B heteroreceptors may 
be involved in the hypo-metabolism observed in hSERT OVR females. In particular hypo-
activation of 5-HT1B heteroreceptors localised on GABAergic neurones may be particularly 
important. 5-HT1B heteroreceptor activation decreases the availability of multiple 
neurotransmitters including glutamate (Boeijinga and Boddeke, 1996), acetylcholine (Maura 
and Raiteri, 1986) and GABA (Bramley et al., 2005; Johnson et al., 1992; Stanford and 
Lacey, 1996). As acetylcholine and glutamate are classically excitatory neurotransmitters it 
seems unlikely that the dis-inhibition of cholinergic or glutamatergic neurotransmission (by 
reduced 5-HT1B heteroreceptor activation) could account for the cerebral hypo-metabolism in 
hSERT OVR females. Indeed, treatment with acetylcholine (nicotinic and muscarinic) 
receptor antagonists produces widespread increases in cerebral metabolism (Dowedwards et 
al., 1981; Grunwald et al., 1988; London et al., 1988). Furthermore, glutamate receptor 
activation is associated with widespread increases in cerebral metabolism (Fowler et al., 
2004; Jordan et al., 2005) whereas decreases in glutamatergic neurotransmission (MacKay et 
al., 1994) and glutamate receptor antagonists (Browne and McCulloch, 1994) reduce cerebral 
metabolism. As the primary inhibitory neurotransmitter in the CNS it seems more likely that 
the dis-inhibition of GABAergic neurotransmission (by reduced 5-HT1B stimulation) may 
contribute to the cerebral hypometabolism in hSERT OVR females. Indeed, there are striking 
parallels between the pattern of hypo-metabolism observed in hSERT OVR female mice and 
that induced by GABA receptor agonists (Study 2 discus ion; (Cudennec et al., 1987; Kelly 
and McCulloch, 1982; Kelly and MCculloch, 1983b). Furthermore, evidence from 5-HT1B 
mice supports the suggestion that 5-HT1B heteroreceptors tonically inhibit GABAergic 
neurotransmission, at least in the suprachiasmatic nucleus (Bramley et al., 2005). The 
disinhibition of GABAergic neurotransmission by reduced 5-HT1B heteroreceptor activation 
may represent a common mechanisms contributing to decreased anxiety-like behaviour in 
both 5-HT1B KO (Brunner et al., 1999; Zhaung et al., 1999; Mallaret et al., 1999) and hSERT 
OVR mice (Jennings et al., 2006). Clearly, the possible interaction between 5-HT1B hypo-
stimulation and the function of other neurotransmitter systems in determination of the 
cerebral hypo-metabolism found in hSERT OVR mice warrants further investigation. 
Utilisation of in vivo microdialysis may be particularly useful in assessing these interactions 
and the data from these 2-DG experiments provides a guide to those regions in the CNS 
which may be of particular interest. Measuring neurotransmitter levels under basal conditions 
and in response to application of 5-HT1B agonists would allow the assessment of 5-HT1B 
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autoreceptor (5-HT detection) and heteroreceptor (glutamate, acetylcholine, GABA detection) 
function in female hSERT OVR mice.  
 
To summarise, our data suggest that 5-HT1B/1D receptor binding is not influence by gender or 
by a life-long increase in SERT functioning, at least in a limited number of brain areas. In 
contrast, functional responses to 5-HT1B agonists are greater in females than in males 
although it is unclear as to whether this reflects a gender difference in 5-HT1B activation 
under basal conditions. Furthermore, 5-HT1B receptors appear to be hypo-stimulated as a 
result of a life-long increase in SERT functioning i  females and this may contribute to the 
constitutive decrease in cerebral metabolism noted in these animals. Hypo-stimulation of 5-
HT1B receptors does not appear to result from a life-long increase in SERT functioning in 
males, which parallels the observation of unaltered constitutive cerebral metabolism in 


































Study 6- Hypothalamo-pituitary-adrenal axis functio n in hSERT OVR 
mice  
 
6.1 Rationale  
 
 
The functional activity of the HPA axis has been proposed to have a central role in the 
aetiology of affective disorders and in influencing the efficacy of antidepressant treatment. 
Furthermore, there is a wide body of evidence supporting reciprocal interaction between the 
5-HT system and the HPA axis under both normal conditi s and in disease states. Given the 
widespread evidence for altered 5-HT system functioing in hSERT OVR mice (studies 2-5) 
the possibility that HPA axis activity may also be altered in these animals is of considerable 
interest. In particular, the integration of the 5-HT system and HPA axis in these animals, 
where there is a life-long enhancement of SERT functio , may be particularly relevant to the 
known influence of the 5-HTTLPR on the likelihood of developing affective disorders in 
response to stressful life events. In humans the “long” allele of the 5-HTTLPR is associated 
with a decreased risk in the development of affectiv  disorders. In contrast, individuals who 
carry the “short” allele are more susceptible to the negative effects of stressful life-events 
(Caspi et al., 2003; Kendler et al., 2005). Thus, differential integration between central 
serotonergic systems and the HPA axis between these g notypes, and resultant changes to 
stress responses, may represent one mechanism by which individuals may be differentially 
predisposed to the development of affective disorders. Indeed, evidence from animal studies 
suggests that genetically-determined levels of SERT expression do indeed govern HPA axis 
activity during stressful events (Barr et al., 2004b; Li et al., 1999). 
 
In order to further understand the possible influence of a life-long increase in SERT 
expression on HPA axis function, circulating ACTH and corticosterone levels were measured 
in the following studies under basal conditions (rapid decapitation) and in response to acute 
mild stress (saline injection 15 minutes prior to rapid decapitation) in male Wt and hSERT 
OVR mice. Furthermore, to identify possible alterations in the serotonergic feed-forward 
control of the HPA axis in hSERT OVR mice these hormone levels were measured following 
challenge with specific 5-HT receptor agonists (namely 8-OH-DPAT for 5-HT1A, DOI for 5-
HT2A/C and CP 94,253 for 5-HT1B receptors). Finally, to define possible alterations i  feed-
back mechanisms regulating HPA axis functioning, GRand MR mRNA expression levels 
were measured by in situ hybridisation in areas of the CNS known to be associated with the 




6.2 Circulating stress hormones  
 
Under basal conditions there was no evidence for a significant difference in the level of 
circulating ACTH or corticosterone between Wt and hSERT OVR mice. Acute mild stress 
(saline injection, 0.2ml) produced a significant increase in circulating corticosterone in 
animals of both genotypes (Wt 2.8-fold, hSERT OVR 2.5-fold). Despite a trend towards 
increased ACTH levels in animals of both genotypes following acute stress, the effect was not 
significant. This was possibly due to high variability in the levels of ACTH detected in saline-
treated mice, especially in Wt animals. Circulating levels of ACTH were not altered by 8-OH-
DPAT (1.0 mg.kg-1) in animals of either genotype when these were compared to saline 
injected controls. In contrast, circulating levels of corticosterone were significantly elevated 
in both Wt and hSERT OVR mice in response to the same 8-OH-DPAT treatm nt (Wt 2-fold 
increase, hSERT OVR 1.5-fold increase over saline injected controls), but there was no 
significant difference in the hormonal response to 8-OH-DPAT between the two genotypes. 
 
DOI treatment (2.5 mg.kg-1) produced a significant elevation in plasma ACTH in animals of 
both genotypes (Wt 1.6-fold increase, hSERT 4.4-fold increase) and also resulted in a 
significant increase in corticosterone (Wt 2.0-fold increase, hSERT 1.8-fold increase). 
Although the magnitude of the ACTH response to DOI appeared to be greater in hSERT 
OVR, again there was no evidence for a significant difference in the hormonal response to 
DOI between genotypes. CP 94,253-treatment (10mg.kg-1) produced a trend towards 
decreased ACTH levels in both genotypes in comparison to saline treated animals, but this 
effect was not significant. In contrast, CP 94,253-treatment resulted in a marked elevation of 
circulating corticosterone (3-fold increase) in both genotypes. There was no evidence for a 
significant difference in the hormonal response to CP 94,253 between genotypes. All ACTH 


















































































ACTH levels in Wt and hSERT OVR mice under basal conditions, following acute 
mild stress (saline injection) and treatment with the 5-HT receptor agonists 8-OH-
DPAT (1.0 mg.kg-1), DOI (2.5 mg.kg-1) and CP 94,253(10 mg.kg-1). *denotes p<0.05 
significant drug effect (2-WAY ANOVA with Bonferroni correction). There was no 
evidence for a significant difference in basal ACTH or in the alteration of ACTH 












































































































Corticosterone levels in Wt and hSERT OVR mice under basal conditions, following 
acute mild stress (saline injection) and treatment with the 5-HT receptor agonists 8-
OH-DPAT (1 mg.kg-1), DOI (2.5 mg.kg-1) and CP 94,253 (10 mg.kg-1). ***denotes 
p<0.01 significant drug effect (2-WAY ANOVA with Bonferroni correction). There was 
no significant evidence for a difference between the genotypes in basal 
corticosterone levels, the corticosterone response to mild acute stress or in the 


























6.3 Glucocorticoid and mineralocorticoid receptor m RNA expression  
 
 
The distribution and relative density of GR mRNA expression detected throughout the brain 
in this study was consistent with that previously reported (Chao et al., 1989; Morimoto et al., 
1996; Sousa et al., 1989). GR mRNA expression was highest in the paraventricular nucleus 
(PVN) of the hypothalamus and high levels were alsopresent in subfields of the hippocampus 
(CA1, CA2, DG). More moderate expression was noted in neocortex and thalamus, while low 
levels of expression were detected in the amygdala nuclei and CA3 and CA4 subfields of the 
hippocampus (Figure 3.6.3). The level of GR mRNA expr ssion was found to be significantly 
increased in hSERT OVR as compared to Wt mice in only one brain region, the PVN (Figure 
3.6.5). In all other brain regions analysed there was no evidence for a significant difference, 
or even any trend towards difference, in the level of GR mRNA expression between the 
different genotypes. 
 
The distribution and relative densities of MR mRNA expression detected throughout the brain 
in this study were also consistent with those previously reported (Chao et al., 1989). MR 
mRNA expression was highest in CA3 and DG fields of the hippocampus. Moderate levels of 
expression were detected in other hippocampal subfields (CA1, CA2, CA4) while very low 
levels of expression were found in the amygdala and ventrolateral thalamus (Figure 3.6.3). 
The density of MR mRNA was significantly increased in CA1 and CA2 subfields of the 
hippocampus in hSERT OVR mice (Figure 3.6.4). In all other brain regions analysed there 
was no evidence for a significant difference in MR m NA expression between hSERT OVR 
and Wt mice. Detailed data for both MR and GR in situ hybridisation are shown in Tables 
3.6.1. and 3.6.2. 
 
The specificity of both the GR and MR ‘anti-sense’ RNA probes was demonstrated using the 
appropriate 35S-labelled ‘sense’ probe of similar specific activity, hybridized under identical 
conditions. No specific hybridization signal was detected with either the GR or MR ‘sense’ 
probes and the level of radioactivity in each brain region in ‘sense’ hybridized sections was 



















Representative GR and MR mRNA in situ hybridisation autoradiograms from hSERT OVR 























Figure 3.6.4 Effect of hSERT OVR on MR mRNA expression F50 
 
Dorsal Hippocampus













Effect of hSERT over-expression on mineralocorticoid receptor (MR) mRNA expression 
(nCi/mg) in the dorsal hippocampus. Data shown as mean ± s.e.m. *denotes p<0.05 
significance (Student’s t-test). MR mRNA expression is significantly increased in the CA1 and 



































Figure 3.6.5 Effect of hSERT OVR on GR mRNA expression F51 
 


























Effect of hSERT over-expression on glucocorticoid receptor (GR) mRNA expression. Data 
shown as mean ± s.e.m. *denotes p<0.05 significant difference from wild-type (Student’s t-
test). GR mRNA expression is significantly increased only in the hypothalamic paraventricular 















Table 3.6.1 Mineralocorticoid receptor mRNA express ion in hSERT OVR mice T58 
 
 Wild-type hSERT OVR 
 mean  s.e.m mean  s.e.m 
% 
difference 
Thalamus        
Mediodorsal 1 ± 2 1 ± 4 n/s 
Venterolateral 11 ± 3 14 ± 1 28 
Amygdala        
Medial Amygdala 8 ± 6 10 ± 3 11 
Basolateral Amygdala 35 ± 4 40 ± 6 15 
Central Amygdala 78 ± 6 90 ± 14 16 
Dorsal Hippocampus        
CA1 436 ± 22 507 ± 12 16* 
CA2 365 ± 10 442 ± 23 21* 
CA3 614 ± 15 608 ± 39 -1 
DG 620 ± 33 647 ± 25 9 
CA4 289 ± 8 315 ± 4 13 
 
Effect of hSERT over-expression on mineralocorticoid receptor (MR) mRNA expression (nCi/mg) in the CNS. Data shown as mean ± s.e.m and % difference 














Table 3.6.2 Glucocorticoid receptor mRNA expression  in hSERT OVR mice T59 
 
 Wild-type hSERT OVR 
 Mean  s.e.m mean  s.e.m 
% 
difference 
Hypothalamus        
Paraventricular Nucleus 761 ± 40 915 ± 52 20* 
Ventromedial Hypothalamus 502 ± 32 501 ± 49 0 
Thalamus        
Mediodorsal 427 ± 35 464 ± 45 9 
Venterolateral 505 ± 45 539 ± 48 7 
Amygdala        
Medial Amygdala 337 ± 35 396 ± 25 5 
Basolateral Amygdala 292 ± 24 305 ± 23 4 
Central Amygdala 399 ± 33 435 ± 31 9 
Dorsal Hippocampus        
CA1 588 ± 38 586 ± 36 0 
CA2 675 ± 43 705 ± 38 4 
CA3 315 ± 23 303 ± 14 -4 
DG 616 ± 39 643 ± 27 4 
CA4 390 ± 28 390 ± 20 0 
Cortex        
Somatosensory Cortex 489 ± 36 526 ± 22 8 
Posterior Cingulate 377 ± 26 420 ± 21 11 
Endopiriform 522 ± 51 574 ± 33 10 
 
Effect of hSERT over-expression on glucocorticoid receptor (GR) mRNA expression (nCi/mg) in the CNS. Data shown as mean ± s.e.m and % difference 
between hSERT OVR and wild-type animals. *denotes p<0.05 significant difference from wild-type (t-test). 
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6.4 Discussions and Conclusions  
 
In this study no evidence was found for an effect of genotype (hSERT OVR vs Wt) on HPA 
axis activity. Circulating ACTH and corticosterone levels were similar in both groups under 
basal conditions and in response to a mildly stressful event (handling and saline injection). In 
addition there was no evidence to suggest that the AUC integral in ACTH (Wt: 495, hSERT 
OVR: 299)  and corticosterone (Wt: 1210, hSERT OVR: 1339) secretion from basal levels to 
those observed 15 minutes after acute saline injecton was significantly different between the 
genotypes. This further supports the suggestion that the acute stress response is not altered in 
hSERT OVR mice. These findings contrast with the repo ted decrease in basal corticosterone 
level observed in homozygous SERT KO mice but is in agreement with the finding that basal 
ACTH levels are not significantly altered in these animals (Li et al., 1999). The reason for the 
disparities between these opposing models of genetically altered SERT bioavailabilty may 
directly relate to the magnitude of their respective alterations in SERT function. Indeed, the 
finding that basal ACTH and corticosterone levels were not altered in heterozygous SERT 
KO mice, where SERT function is reduced by ~50%, supports the contention that partial 
depletion of SERT function, as compared to complete loss, may not be sufficient to alter basal 
HPA axis activity. However, the finding that the ACTH response to acute stress was not 
reduced in hSERT OVR mice is surprising given the reported enhancement of ACTH 
secretion following acute stress in both heterozygous and homozygous SERT KO mice (Li et 
al., 1999). In the experiments reported here, however, any difference in ACTH secretion 
following acute stress between the genotypes may have been masked by the high variability 
in plasma ACTH concentrations in saline-treated anim ls. There was also no evidence for 
altered adrenal sensitivity in hSERT OVR mice as the corticosterone : ACTH ratio, under 
both basal conditions and in animals subjected to acute stress, was not significantly different 
between hSERT OVR (basal 0.52 ± 0.13, stress 0.68  ± 0.17) and Wt (basal 1.48 ± 0.57, stress 
1.05 ± 0.22) mice. 
 
No evidence was found to suggest any difference between hSERT OVR and Wt mice in the 
effects on HPA axis activity of manipulating 5-HT1A, 5-HT2A/C or 5-HT1B receptors. Thus 
genotype had no significant effect upon either ACTH or corticosterone levels following 8-
OH-DPAT, DOI or CP 94,253 treatments respectively. In contrast to studies using the same 
treatment protocol (Li et al., 1999) the present studies found that 8-OH-DPAT treatment 
failed to significantly increase ACTH levels above that following saline injection. The reason 
for this disparity is unclear but may relate to differences in the sensitivity of hypothalamic 5-
HT1A receptors or the differential activation of these receptors during mild acute stress 
between different mouse strains. In wild-type animals while 8-OH-DPAT treatment resulted 
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in no significant alterations in ACTH secretion, however, the level of corticosterone was 
significantly increased by the drug. This suggests that 8-OH-DPAT may act within the 
periphery, possibly at the level of the adrenal cortex, to stimulate corticosterone release. This 
suggestion is consistent with the known affinity of 8-OH-DPAT for the 5-HT7 receptor and 
the localisation of this receptor subtype to the adrenal cortex (Contesse et al., 1999), although 
the physiological role of these receptors in corticsterone secretion is yet to be confirmed. 
However, it is also important to note that although we found that 8-OH-DPAT did not result 
in a significant increase in ACTH secretion, numerous ther studies have reported this effect 
in mice (Li et al., 1993; Li et al., 1999; Matsuda et al., 1990). Therefore, it is possible that this 
mechanism did contribute to the enhanced secretion of corticosterone by 8-OH-DPAT in this 
study but that this effect was obscured by the high variability in ACTH measurements, 
especially in saline-treated animals. In either case, these results indicate that 5-HT1A receptor-
mediated regulation of HPA axis activity is not altered in hSERT OVR mice.  
 
In both genotypes DOI produced a significant increase in ACTH that was similar in 
magnitude to that reported by others in wild-type animals (Li et al., 2003). While there was a 
trend towards an increased ACTH response to DOI in hSERT OVR mice, which parallels the 
enhanced LCMRglu response to DOI in these animals (study 4), the effect was not 
significant. The finding that the ACTH response to DOI was not significantly altered in 
hSERT OVR mice is consistent, however, with the lack of alteration in hypothalamic 5-
HT2A/C receptor sensitivity reported in both heterozygous and homozygous SERT KO mice 
(Li et al., 2003). As expected from the observed alter tions in ACTH secretion, DOI also 
produced a significant increase in circulating corti sterone the magnitude of which was 
similar in both genotypes.  
 
In contrast to reports in which 5-HT1B agonists have been shown to increase ACTH secretion 
(Calogero et al., 1990; Vandekar et al., 1994) CP 94,253 treatment did not increase circulating 
ACTH levels measured in the present study. In fact, CP 94,253 produced a trend towards 
decreased ACTH levels in animals of both genotypes, although this effect was not significant. 
While this disparity may be attributed in some insta ces to the activation of other 5-HT 
receptor subtypes by non-selective 5-HT1B receptor ligands (mCPP has both 5-HT1B and 5-
HT1C affinity (Calogero et al., 1990)) others studies have reported the same effect using more 
selective drugs (CP 93,129 is highly selective for the 5-HT1B receptor (Van de Kar et al., 
1994)). Disparities between the effects on ACTH secretion of the equally selective 5-HT1B 
agonists CP 93,129 and CP 94,253 may reflect the route f drug administration or subtle 
differences in the properties of the drugs themselves. In the study by Van de Kar et al. (1994) 
the administration of CP 93,129 via the intracerebroventricular (i.c.v) route is likely to have 
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avoided the activation of peripheral 5-HT1B receptors, particularly as the drug does not readily 
cross the blood brain barrier (BBB). In contrast, in the present study the 5-HT1B agonist CP 
94,253 was administered i.p and as it does readily cross the BBB results in the activation of 
both central and peripheral 5-HT1B receptors. Thus, the observation that CP 94,253 results in 
a robust increase in corticosterone secretion without altering ACTH levels suggests that CP 
94,253 may be acting in the periphery, possibly at the level of the adrenal cortex, to increase 
corticosterone levels. Moreover, this peripheral action CP 94,253 may contribute to the 
observed decrease in ACTH secretion (albeit non-sigificant) via glucocorticoid-mediated 
feedback onto the HPA axis. In addition, the increase in ACTH secretion induced by the mild 
stressor of saline injection may require the activation of post-synaptic 5-HT receptors. In CP 
94,253 treated mice ACTH secretion may also be reduc  in comparison to saline injected 
animals through the inhibition of serotonergic neurotransmission by nerve terminal 
autoreceptors activated by the drug. However, given th  evidence that central 5-HT1B receptor 
activation stimulates rather than attenuates ACTH secretion (Can de Kar et al., 1994) the role 
of enhanced glucocorticoid-mediated feedback in the influence of CP 94,253 on ACTH 
secretion seems the more likely mechanism. 
 
Despite the marked alterations in circulating cortisterone levels produced by 8-OH-DPAT, 
DOI and CP 94,253 there was no evidence that this effect was modified in hSERT OVR mice. 
In addition to the direct importance of this finding with regard to understanding the regulation 
of HPA axis functioning in hSERT OVR mice, it also has important implications i the 
interpretation of data from the LCMRglu studies reported previously in this thesis, and 
supports the suggestion that genotype-dependent differences in LCMRglu responses to these 
drugs cannot be attributed to genotype-dependent effects on circulating corticosterone levels, 
which themselves are known to influence LCMRglu (Doyle et al., 1994). 
 
Although HPA axis activity (as indicated by measurements of circulating ACTH and 
corticosterone) was not altered under basal conditions or in response to mild stress in hSERT 
OVR mice, significant alterations in basal MR and GR mRNA expression levels were found. 
If these were translated directly into similar altera ions in levels of receptor protein 
expression, they might be expected to result in altered HPA axis activity. Specifically, 
enhanced GR and MR receptor expression in hSERT OVR mice may result in enhanced 
glucocorticoid-mediated negative feedback upon the HPA axis which could attenuate the 
stress response or alter the circadian rhythm of the axis. This suggestion warrants further 
systematic investigation.  
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The expression of MR mRNA was significantly increasd in CA1 and CA2 subfields of 
hippocampus in hSERT OVR mice and this may contribute directly to their reduced anxiety 
phenotype. Certainly enhanced forebrain expression of MR has previously been shown to be 
associated with reduced anxiety-like behaviour (Lai et al., 2007; Rozeboom et al., 2007). 
Furthermore, the increased MR mRNA expression observed in hSERT OVR mice also 
parallels that observed following chronic antidepressant treatment (Seckl and Fink, 1992), 
which also results in reduced anxiety-like behaviour. In contrast, the acute activation of 
hippocampal MR appears to be anxiogenic (Bitran et al., 1998; Smythe et al., 1997). Taken 
together, these data suggest that adaptive responses re ulting from a prolonged enhancement 
of hippocampal MR signalling, rather than any acute enhancement, may be necessary to elicit 
an anxiolytic behavioural phenotype. It is of great interest, therefore, that the present studies 
show a paradoxical reduction in hippocampal 5-HT1A receptor binding in hSERT OVR mice 
(study 3) despite the reduced synaptic 5-HT levels in these animals which might be expected 
to result in an up-regulation of post synaptic receptors. As MR signalling in the hippocampus 
has an inhibitory effect on 5-HT1A receptor expression (Meijer et al., 1997; Meijer and 
DeKloet, 1995) it may be the prolonged enhancement of MR receptor signalling in hSERT 
OVR mice that induces the reduced 5-HT1A binding noted in these animals. Futhermore, the 
interaction between hippocampal MR signalling and 5-HT1A receptor expression may 
represent an important mechanism by which SERT expression regulates anxiety, as 5-HT1A 
receptor activation in the hippocampus in anxiogenic (File et al., 1996). Therefore, the 
possible interaction between hippocampal MR and 5-HT1A receptor signalling in hSERT 
OVR mice, and the role of this interaction in the regulation of anxiety behaviour warrants, 
further investigation. 
 
It is interesting that the increased MR mRNA expression observed in hSERT OVR mice also 
parallels that observed following chronic SSRI treatment (Bjartmar et al., 2000; Seckl and 
Fink, 1992; Semont et al., 2000), directly implicatng chronic alterations in extracellular 5-HT 
levels in the control of MR receptor gene expression. Therefore, given that extracellular 5-HT 
levels are chronically reduced in hSERT OVR mice the results of the present studies sem 
somewhat surprising, especially given that others have found that reduced 5-HT 
neurotransmission is associated with reduced hippocampal MR mRNA expression (Seckl et 
al., 1990; Yau et al., 1994). It is likely that developmental alterations may account for the 
observed enhancement of hippocampal MR mRNA expression in hSERT OVR mice despite 
reduced synaptic 5-HT availability. One possible mechanism may involve a compensatory 
up-regulation in post-synaptic 5-HT receptor function which might regulate MR mRNA 
expression. However, while a role has been suggested for 5-HT7 receptors in the regulation of 
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hippocampal GR mRNA expression (Laplante et al., 2002) the identity the 5-HT receptor 
involved in the regulation of hippocampal MR mRNA expression has yet to be elucidated. 
 
Enhanced GR receptor mRNA expression was found to be limited to the PVN of hSERT 
OVR mice. The GR receptor in the PVN is known to play a central role in controlling the 
activity of the HPA axis at times when circulating levels of glucocorticoids are elevated, for 
example during stressful events, through a negative feedback mechanism (Feldman et al., 
1992; Kovacs et al., 1986). The increased expression in hSERT OVR mice might suggests 
that the amplitude of the stress response or its duration may be attenuated in these animals. 
The mechanism by which a life-long increase in SERT function is linked to increased PVN 
GR mRNA expression is unclear, as there is a paucity of data on the regulation of PVN GR 
expression by 5-HT neurotransmission. However, a number of studies investigating the 
regulation of GR in hippocampus supports the suggestion that GR gene transcription can be 
regulated by 5-HT neurotransmission, with 5-HT having a stimulatory effect on GR mRNA 
expression (Bjartmar et al., 2000; Seckl et al., 1990; Seckl and Fink, 1992). Therefore, not 
only does it seem surprising that PVN GR mRNA levels are enhanced in hSERT OVR mice, 
where extracellular 5-HT levels are chronically reduced, but the lack of any alteration in 
hippocampal GR mRNA expression in these mice is also of interest. Compensatory 
alterations in post-synaptic 5-HT receptor function may again allow for the maintenance of 
GR mRNA expression in the hippocampus of hSERT OVR mice. In future studies attempts to  
identify possible alterations in the function of hippocampal 5-HT7 receptors in hSERT OVR 
mice may be of particular interest given the known role of this receptors subtype in the 
regulation of hippocampal GR mRNA expression (Laplante et al., 2002). Clearly, the 
relationship between 5-HT neurotransmission and the regulation of PVN GR mRNA 
expression also warrants further investigation.  
 
Overall these result suggest, therefore, that alterations in basal, or acute stress-induced HPA 
axis activity associated with the 5-HTTLPR in humans, are unlikely to contribute to 
differences in the likelihood of developing affective disorders in response to stressful life 
events between individuals carrying the different polymorphisms. However, it should be 
noted that measurements of basal ACTH and corticoster ne concentrations in the present 
studies were limited to a point in the circadian cycle at which the circulating concentration of 
these hormones is particularly low (circadian nadir). It is possible that the basal activity of the 
HPA axis may be different between hSERT OVR and wild-type mice at other points in the 
circadian cycle, when the concentration of these hormones is higher. This suggestion warrants 
further investigation given the alterations in MR and GR receptor mRNA levels detected in 
hSERT OVR mice in these studies. Furthermore, these r c ptor alterations may be expected 
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to contribute to altered HPA axis activity following stressful events in hSERT OVR mice, 
although such a difference was not detected in this study. One reason for this may be that our 
measurement of stress-induced HPA axis activation was limited to the initial phase of HPA 
axis activation (first 15 minutes after stressor) when feed-forward mechanisms contributing to 
the activity of the HPA axis may predominate. In the future, fuller characterisation of HPA 
axis activity following a stressful event, across a longer time frame, may reveal differences in 
the stress response between genotypes. Given the observed differences in GR and MR 
receptor mRNA expression levels in hSERT OVR mice one might expect that the peak 
amplitude of ACTH/corticosterone secretion or the duration of the stress response may be 
attenuated in hSERT OVR mice, but these were outwith the scope of the present 
investigation. Furthermore, application of a paradigm associated with a greater level of HPA 
axis activation (e.g. prolonged restraint stress) may reveal differences in the stress 
responsiveness of the HPA axis between genotypes. While we found no evidence to suggest 
that adrenal sensitivity was altered in hSERT OVR mice, according to the corticosterone : 
ACTH ratio in basal and stressed (saline treated) anim ls,. Observing adrenal size in hSERT 
as compared to wild-type animals may be of interest in the future as this would give an 
indication of the chronic glucocorticoid status of these animals. 
 
As our previous studies have shown that the alterations in brain function and 5-HT system 
activity that result from a life-long increase in SERT expression are influenced by gender, 
with a greater effect being observed in females than in males, it is also likely that any 
alterations in HPA axis function that results from increased SERT expression will also be 
more pronounced in females than in males. Therefore, inv stigating the parameters observed 
in this study in female animals will be of great interest. This may also be particularly relevant 
given the known interaction between gender and the 5-HTTLPR in the programming of HPA 
axis responsiveness by early-life stressful events (Barr et al., 2004a). 
 
In summary, we found no evidence for altered basal HPA axis activity, differential activation 
of the HPA axis by mild stress, or altered 5-HT1A, 5-HT1B or 5-HT2A/C receptor-mediated 
regulation of the HPA axis as a result of a life-long increase in SERT expression. This suggest 
that alterations in the basal or feed-forward drive activity of the HPA axis may not be a 
central mechanism by which the 5-HTTLPR modifies the risk of affective disorder in 
response to stressful life events in humans. However, evidence was found suggesting that 
central MR and GR receptor function may be modified by a life-long increase in SERT 
functioning. Alterations in these receptors may contribute to the reduced anxiety found in 
hSERT OVR mice, and may modify the activity of the HPA axis during the circadian cycle, 
or in response to stressful events, although these have yet to be confirmed. Therefore, 
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differential expression of the GR and MR receptors in response to genetically determined 
SERT function may play a role in the effect of the 5-HTTLPR on affective functioning, 
antidepressant response and risk of developing affective disorders in response to stressful life 














































Chapter 4- Final Discussion and Conclusions  
 
1. Summary  
 
The data presented in this thesis have characterised the effects of a life-long, genetically-
determined increase in SERT bioavailability upon the pharmacology of the serotonergic 
system (ligand binding), neuronal activity in response to serotonergic challenge (2-
deoxyglucose imaging) and hypothalamo-pituitary-adrenal axis function (hormone analysis 
and in situ hybridisation). Furthermore, the importance of gender in determining aspects of 
neuronal function and serotoninergic pharmacology have been examined in order to further 
elucidate gender differences in general brain functio  and their interaction with a life-long 
increase in SERT. 
 
Gender appears to be an important factor and a number of differences have been found when 
male and female mice are compared. Thus the functional response to 5-HT1A receptor 
challenge has been found to be enhanced in females, in part as a result of altered receptor 
binding; 5-HT1B receptor functioning is also enhanced, despite no difference in receptor 
binding; and 5-HT2A/C receptor function is decreased, in part as a result of altered 5-HT2A and 
5-HT2C binding in females as compared to males. Table 4.1 provides a summary of the gender 
differences in the 5-HT system reported in this thesis, while tables 4.2.1 and 4.2.2 provide a 
more comprehensive summary of the gender differences in 5-HT receptor mediated functional 
responses in different functional systems. Evidence for sexually dimorphic alterations in the 
functional response to serotonergic challenges were pa ticularly prevalent in cortical regions, 
the basal ganglia, mesocorticolimbic system and the raphé, while these dimorphisms were 
much more limited in the hippocampus and amygdala nuclei.  
 
Table 4.1. Gender differences in 5-HT system functi on T60 
 
 Binding Function 
SERT F > M  
5-HT1A F > M F > M 
5-HT1B n/s Hypo-stimulated in F 
5-HT2A F < M 
5-HT2C F < M
1 
F < M 
 







Table 4.2.1 Gender differences in LCMRglu responses  to 5-HT receptor 
agonists T61 
 




















































Cortex            
Orbitofrontal                     
Frontal                     
Anterior Cingulate                     
Dorsal mPFC                     
Ventral mPFC                     
Somatosensory                     
Temperoparietal                     
Posterior Cingulate                     
Piriform                     
Entorhinal                     
Basal Ganglia            
Medial Striatum                     
Lateral Striatum                     
Globus Pallidus                     
Subthalamic nucleus                     
Substantia nigra pars reticulata                     
Substantia nigra pars compacta                     
Amygdala            
Medial                     
Basolateral                     
Central                     
Thalamus            
Anterior                     
Mediodorsal                     
Venterolateral                     
 
Gender differences in the LCMRglu responses and modification of these differences by 
hSERT OVR in cortical, basal ganglia, amygdala and thalamic regions. Red denotes 
significant increase in LCMRglu response in females as compared to males. Blue denotes 
significant decrease in the LCMRglu response in females as compared to males and the 
significant attenuation of the gender difference by hSERT OVR (in hSERT OVR x gender 








Table 4.2.2 Gender differences in LCMRglu responses  to 5-HT receptor 
agonists T62 
 

























































Hypothalamus            
Anterior                     
Venterolateral                     
Hippocampus            
Molecular Layer                     
Dorsal Subiculum                     
Dentate PO                     
Dorsal CA1                     
CA2                     
Ventral CA1                     
Ventral Subiculum                     
CA3                     
Raphè            
Dorsal                     
Median                     
Paramedian                     
Mesocorticolimbic system            
Ventral tegmental area                     
Nucleus accumbens                     
Non-specific            
Septal nucleus                     
BNST                     
Lateral Habenula                     
Mamillary Body                     
Peri-aqueductal Grey                     
Inferior Colliculus                     
Locus Coeruleus                     
 
Gender differences in the LCMRglu responses and modification of these differences by 
hSERT OVR in hypothalamic, hippocampal, raphé, mesocorticolimbic and non-specific 
regions. Red denotes significantly increased LCMRglu response in females as compared to 
males. Blue denotes significant decrease in the LCMRglu response in females as compared 
to males or the significant attenuation of the gender differencein the LCMRglu response  by 








A life-long increase in serotonin transporter function appears to result in a decrease in 
constitutive neuronal activity in several limbic regions (Figure 4.1). Furthermore, this effect 
was more pronounced in females when compared to males. In addition, several alterations in 
neuronal function following pharmacological challeng  to the central serotonin system were 
identified that may contribute to this hypo-metabolism, and to the reduced anxiety behaviour 
reported in hSERT OVR mice (Jennings et al., 2006). Specifically, 5-HT1A receptor function 
was found to be decreased and 5-HT2A/C function increased in response to a life-long increase 
in SERT. Hypo-activation of the 5-HT1B receptor in female hSERT OVR mice appears to be a 
major contributory factor in the cerebral hypo-metabolism measured in these animals.  
 
The alterations in neuronal activity of hSERT OVR mice following challenges to the 
serotonin receptors appear to be widespread throughout t e brain, occurring in all functional 
systems. The contribution of altered 5-HT receptor binding levels to observed changes in the 
functional response to serotonergic challenges in appe rs to be relatively limited. The most 
evident alterations in sertonergic receptor binding in hSERT OVR mice were a generalised 
decrease in 5-HT1A and a more localised increase in 5-HT2C receptor binding. However, there 
was no evidence for any alteration in the binding of the 5-HT1B or 5-HT2A receptors despite 
clear changes in functional activity in the brain when these receptors were challenged. Table 
4.3 provides a summary of the alterations in 5-HT receptor binding and function found in 
hSERT OVR mice, and tables 4.4.1 to 4.4.4 provide a more comprehensive summary of the 
differences in 5-HT receptor mediated functional responses across the different functional 
systems. 
 
Table 4.3 hSERT OVR differences in 5-HT system function T63 
 
 Binding Function 
Gender x hSERT 
interaction 
Constitutive  hSERT < Wt F > M2 
SERT hSERT > Wt  F > M1 
5-HT1A hSERT < Wt hSERT < Wt M>F
1 ; F > M2 
5-HT1B hSERT = Wt Hypo-stimulated in hSERT F > M
2 
5-HT2A hSERT = Wt 
5-HT2C hSERT > Wt 
hSERT > Wt n/s 
 
Interaction denotes relative magnitude of alterations between male and female 
animals.1denotes interaction in binding, 2denotes interaction in function.
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Summary of the influence of hSERT OVR on LCMRglu responses in cortical and basal ganglia regions. Blue denotes a significant decrease in LCMRglu 
or a significant decrease in the LCMRglu response. Red denotes significant increase in LCMRglu or a significant increase in the LCMRglu response. 
Orange represents an increase in the LCMRglu response to a drug bringing LCMRglu to wild-type baseline level. Significance set at p<0.05 throughout. 
Drug Effect  hSERT OVR Effect 



































































































Cortex                       
Orbitofrontal                                         
Frontal                                        
Anterior                                          
Dorsal mPFC                                         
Ventral mPFC                                         
Somatosensory                                         
Temperoparietal                                         
Posterior Cingulate                                         
Piriform                                          
Entorhinal                                         
Basal Ganglia                       
Medial Striatum                                         
Lateral Striatum                                         
Globus Pallidus                                         
Subthalamic Nucleus                                         
Substantia nigra pars compacta                                         
Substantia nigra pars reticulata                                         
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Summary of the influence hSERT OVR on LCMRglu responses in serotonergic challenge in amygdala, thalamic and hypothalamic regions. Blue 
denotes a significant decrease in LCMRglu or a significant decrease in the LCMRglu response. Red denotes significant increase in LCMRglu or a 
significant increase in the LCMRglu response. Orange represents an increase in the LCMRglu response to a drug bringing LCMRglu to wild-type 





Drug Effect  hSERT OVR Effect 
































































































Amygdala                       
Medial Amygdala                                         
Basolateral Amygdala                                         
Central Amygdala                                         
Thalamic                       
Anterior                                         
Mediodorsal                                         
Venterolateral                                         
Hypothalamus                       
Anterior                                         





Table 4.4.3 Effect of hSERT on LCMRglu responses: hippocampal regions T66 
 
Drug Effect  hSERT OVR Effect 































































































Hippocampus                       
Molecular Layer                                         
Dorsal Subiculum                                         
Dentate PO                                         
Dorsal CA1                                         
CA2                                         
Ventral CA1                                         
Ventral Subiculum                                         
CA3                                         
 
Summary of the influence of hSERT OVR on the LCMRglu response to serotonergic challenge in hippocampal regions. Blue denotes a significant 
decrease in LCMRglu or a significant decrease in the LCMRglu response. Red denotes significant increase in LCMRglu or a significant increase in the 
LCMRglu response. Orange represents an increase in the LCMRglu response to a drug bringing LCMRglu to wild-type baseline level. Significance set 







Table 4.4.4 Effect of hSERT on LCMRglu responses: raphé, mesocorticolimbic  and non-specific regions T67 
 
Drug Effect  hSERT OVR Effect 































































































Raphè                       
Dorsal                                         
Median                                         
Paramedian                                         
Mesocorticolimbic                       
Ventral tegmental area                                         
Nucleus Accumbens                                         
Non-specific                       
Septal Nucleus                                         
BNST                                         
Corpus Callosum                                         
Lateral Habenula                                         
Mamillary Body                                         
Peri-aqueductal Grey                                         
Inferior Colliculus                                         
 
Summary of the influence of hSERT OVR on LCMRglu responses to serotonergic challenge in raphé, mesocorticolimbic and non-specific brain regions. 
Blue denotes a significant decrease in LCMRglu or asignificant decrease in the LCMRglu response. Red denotes significant increase in LCMRglu or a 
significant increase in the LCMRglu response. Orange represents an increase in the LCMRglu response to a drug bringing LCMRglu to wild-type 
baseline level. Significance set at p<0.05 throughout. 
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hSERT over-expression results in significant constitutive hypometabolism in multiple components of the limbic system. Blue shaded areas represent 
those regions in which a significant hypometabolism  observed in hSERT OVR female, in which the effect was more pronounced than in males,  as 
compared to wild-type mice. Red outlined regions represent those components outlined in the original Papez circuit, proposed to be involved in the 
regulation of emotion (Papez, 1937). Other components included in the diagram are also known to be involved in the regulation of emotion and are 
components of the “limbic system” (for a review see Rajmohan and Mohandas., 2007). The raphé nuclei innvervate all components of the limbic 
system. Abbreviations: BLA: Basolateral amygdala, BNST: Bed Nucleus of the Stria Terminalis, CeA: Central Amygdala, DR: Dorsal raphé, 
Entorhinal Ctx: Entorhinal cortex, LH; Lateral Habenula, MeA: Medial Amygdala, MD Thalamus: Mediodorsal Thalamus, MR: Median Raphé, Nuc. 
Acc.: Nucleus Accumbens,OFCTX: Orbitofrontal Cortex, Piriform Ctx: Piriform Cortex, PMR: Paramedian raphé, VLH: venterolateral hypothalamus, 
VTA: Ventral Tegmental Area.  
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This thesis provides clear evidence to suggest that the effects of altered SERT bioavailability 
upon brain function and serotonergic pharmacology are more extensive in female mice than 
in males. A major contributory mechanism to this is likely to involve the greater 
enhancement of SERT protein expression in female hSERT OVR mice, as shown by 
radioligand binding, despite an identical SERT genotype between the genders. The effects of 
a life-long increase in SERT upon constitutive cerebral function were also more pronounced 
in females than in males. These differences were not d in discrete components of multiple 
functional systems including the ventral tegmental area, thalamic nuclei, components of the 
basal ganglia, the lateral habenula and mammillary body. Gender-dependent modulation of 
the alterations in SERT protein expression, 5-HT1A receptor function and the degree of 5-
HT1B receptor hypo-activation as a result of a genetically driven increase in SERT gene 
expression may be particularly important in determining this gender difference in brain 
function. 
 
Measurements of circulating levels of corticosteron and ACTH provided no evidence for 
altered basal activity, stress-induced activation or serotonin receptor mediated regulation of 
HPA axis function in male hSERT OVR. There were, however, profound alterations in 
hypothalamic GR and hippocampal MR mRNA expression levels which are suggestive of 
enhanced negative-feedback regulation of the HPA axis in hSERT OVR mice.   
 
2. Relevance of Present Work  
 
The increased susceptibility of human females to the development of affective disorders, 
may relate to some of the sexual dimorphisms identifi d n both genotypes in these studies, 
many of which are consistent with a relative serotonergic hypo-function in females as 
compared to males. This is consistent with previous findings of decreased 5-HT turnover in 
human females (Nishizawa et al., 1997) and decreased extracellular 5-HT levels the 
forebrain of female rodents (Gundlah et al., 1998; Jones and Lucki, 2005) when compared to 
males. Such gender-related differences would be expected to add to the decreased post-
synaptic 5-HT2A/C receptor binding and function found in these studies, making it even more 
likely that serotonergic hypo-function would be generated in females. Furthermore, the 
increased 5-HT1A autoreceptor binding and function in females, found both here and by 
others (Bouali et al., 2003; Maswood et al., 1995), suggests that enhanced 5-HT1A 
autoreceptor-mediated inhibition of 5-HT neuronal activity may also contribute to this 
proposed serotonergic hypo-function in females. The decreased availability of forebrain 
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extracellular 5-HT in females appears to be compensat d for by an up-regulation in post-
synaptic 5-HT1A binding and so this serotonergic hypo-function is unlikely to involve this 
receptor mechanism. 
 
However, while in male mice pharmacological challeng  aimed at the 5-HT1B receptor has no 
effect upon brain function, suggesting that these receptors appear to be tonically activated 
under basal conditions, the same challenge produces marked increases in functional activity 
in female mice. This observation further supports the idea of serotonergic hypo-function in 
females.  
 
These 5-HT receptor differences are not only likely to contribute to an enhanced risk of 
affective disorders in females but may also contribu e to the decreased efficacy of 
antidepressant treatment. Antidepressant (SSRI) treatment produces an increase in 
extracellular 5-HT that is self-limited through feedback activation of 5-HT1A autoreceptors. 
Therefore, gender differences in the balance of 5-HT receptor function found in these studies 
support the contention that the effects of SSRI treatm nt on neuronal functioning will be 
smaller in females than in males. For example, it might be expected that the increased 
sensitivity of 5-HT1A autoreceptors identified here could present a mechanism by which the 
increase in extracellular 5-HT following SSRI treatment will be more limited in females. 
Furthermore, post-synaptic 5-HT receptor functioning (e.g. 5-HT2A/C) is also lower in 
females, providing a further mechanism to restrict the post-synaptic response during SSRI 
treatment.  
 
Despite uncertainties in the literature the overwhelming body of evidence implicates a role 
for genetically-determined SERT function in the aetiology of affective disorders and the 
response to antidepressants in humans (see introduci n section 6.3). The work presented 
here has identified profound alterations in cerebral serotonergic systems and HPA axis 
functioning as a result of a life-long increase in SERT bioavailability. These alterations may 
provide the mechanism by which genetically altered SERT levels influence affective 
functioning and the antidepressant response. Furthermor , the observation that the effects of 
a life-long increase in SERT function are greater in females than in males is consistent with 
the finding that the 5-HTTLPR polymorphism has a greater effect on affective functioning 
(Brummett et al., 2003; Du et al., 2000) in human females as compared to males.  
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While extracellular levels of 5-HT are likely to be lower in ‘L’ as compared to ‘S’ allele 
individuals, as a result of enhanced SERT function, our results suggest that compensatory 
alterations in 5-HT receptor function are likely to occur. In particular, 5-HT1A autoreceptor 
function is likely to be decreased whereas post-synaptic 5-HT2A/C receptor function is likely 
to be enhanced. However, it would appear that the compensatory increase in 5-HT neuronal 
activity resulting from 5-HT1A autoreceptor down-regulation is insufficient to maint in the 
same level of extracellular 5-HT availability in response to a lifelong increase in SERT 
functioning.  
 
While our data suggest that compensatory alterations in the function of some post-synaptic 
(e.g. 5-HT2A/C) receptors occur in response to increased SERT bioavailabilty a paradoxical 
decrease in post-synaptic 5-HT1A receptor expression was found in the hippocampus. This 
paradoxical alteration in hippocampal 5-HT1A receptor expression may be a response to the 
increased MR function in this region of hSERT OVR mice, rather than a result of altered 
extracellular 5-HT levels. Furthermore, decreased hippocampal 5-HT1A activity may directly 
contribute to the reduced anxiety in ‘L’ as compared to ‘S’ 5-HTTLPR individuals, as it has 
been shown that hippocampal 5-HT1A receptor activation increases anxiety-like behaviour n 
animal models (File et al., 1996). While this mechanism may be primary in the regulatory 
influence of the 5-HTTLPR in males, our studies suggest that other mechanisms may also 
have a role in females. In particular, the hypo-stimulation of the 5-HT1B receptor subtype in 
females appears to be directly responsible for the constitutive decrease in neuronal activity in 
the limbic system of these animals. Therefore, it may be plausible that in humans the 5-
HTTLPR mediates its effects on anxiety in males and females via divergent mechanisms. 
 
The increased efficacy of SSRI antidepressant treatm nt in humans with the ‘L’ as compared 
to the ‘S’ variant of the 5-HTTLPR may relate to the differential sensitivity of the 5-HT1A 
autoreceptors between these genotypes. This is supported by the findings in this thesis 
(Study 3) and by those of others (Jennings et al., 2006). The desensitisation of 5-HT1A 
autoreceptors during chronic SSRI treatment has been proposed to have a central role in 
determining the efficacy of these drugs in depression. When SSRIs are administered acutely 
the blockade of SERT results in increased levels of extracellular 5-HT. However, the 
concomitant activation of 5-HT1A autoreceptors by this acute increase in extracellular 5-HT 
levels inhibits the activity of 5-HT neurones, limiting any rise in extracellular 5-HT 
(Gartside et al., 1995; Malagie et al., 1996). During chronic SSRI treatment, in contrast, the 
down-regulation of 5-HT1A autoreceptor function is proposed to alter the balance between 5-
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HT neuronal activity and SERT blockade, resulting i the increase of extracellular 5-HT 
levels that is the purpose of the therapy (Kantor e al., 2001). It is at this point that SSRIs are 
proposed to begin demonstrating their anti-depressant action in depressed patients (Hjorth et 
al., 2000). If the decreased sensitivity of 5-HT1A autoreceptors exists as a result of the life-
long increase in SERT function in human individuals with the ‘L’ allele, one may expect that 
the balance between SERT blockade and 5-HT1A autoreceptor activation during SSRI 
treatment is altered in such a way as to allow an eve  greater enhancement of extracellular 5-
HT. Alternatively, the balance between 5-HT1A autoreceptor function and SERT blockade 
following SSRI administration may mean that the activity of 5-HT neurones in ‘L’ allele 
human individuals is closer to the threshold at which extracellular 5-HT is therapeutically 
increased following SSRI treatment. Therefore, a smaller degree of 5-HT1A autoreceptor 
down-regulation may be required in ‘L’ allele individuals in order to achieve enhanced, 
therapeutic extracellular 5-HT levels. This suggestion would be consistent with the finding 
that the delay in the onset of antidepressant efficacy is reduced in ‘L’ allele individuals with 
depression (Serretti et al., 2007). In humans the administration of 5-HT1A receptor 
antagonists has been found to increase the efficacy of SSRI treatment in depression, 
presumably by blocking the SSRI-induced activation of 5-HT1A autoreceptors (Artigas et al., 
1996; Olver et al., 2000). Therefore, our results may suggest that this form of dual treatment 
may be particularly effective at increasing the efficacy of SSRIs in ‘S’ allele human 
individuals. The enhanced function of 5-HT1A autoreceptors in ‘S’ allele human individuals 
may also contribute to a serotonergic hypo-function that would be consistent with the 
increased risk of depressive disorders in these individuals. 
 
Due to the inefficacy of conventional antidepressant  (SSRIs and TCAs) in the treatment of 
affective disorders in some patients and the delay in the onset of their therapeutic effects 
alternative pharmacological treatments are being sought. Many of these new treatments 
target components of the serotonin system other than SERT, including some of the 5-HT 
receptors investigated in this thesis. The altered functioning of 5-HT receptors by a life-long 
increase in SERT functioning observed in this study suggests that humans with the different 
variants of the 5-HTTLPR may display differential sen itivity to these future therapies. As 
previously noted, our data suggest that humans with the ‘S’ allele, whom it is proposed have 
enhanced 5-HT1A autoreceptor function, may represent good candidates for the augmentation 
of SSRI treatment by 5-HT1A autoreceptor antagonists, but this approach is unlkely to be as 
effective in ‘L’ allele individuals. Furthermore, in our studies we also found that 5-HT2A/C 
mediated functional effects were enhanced in response to a life-long increase in SERT 
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function. At present a number of 5-HT2A/C antagonists have been found to decrease anxiety-
like behaviour in preclinical models (Griebel et al., 1997). If 5-HT2A/C receptor antagonists 
ever become used as anxiolytics in a clinical context he efficacy of these drugs may be 
influenced by the 5-HTTLPR. Overall, these data suggest that it may be imperative for 
clinical studies to separate patient samples on the basis of the 5-HTTLPR when assessing the 
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Table A1.1 Plasma variables in constitutive [ 14C]-2-deoxyglucose experiments T68 
 
 Male Female 
 Wt hSERT OVR Wt hSERT OVR 
Plasma Glucose (mg/ml) 9.03 ± 0.61 7.28 ± 0.80 6.52 ± 0.44* 7.68 ± 0.49 
Plasma [ 14C] (nCi/ml) 77.47 ± 4.53 75.69 ± 8.55 96.05 ± 13.57* 138.48 ± 18.12* 
Plasma [ 14C]:[glucose] ratio (nCi/mM)  8.41 ± 0.65 11.89 ± 1.95 15.34 ± 2.11* 18.02 ± 2.41** 
 
Plasma variables in Wt and hSERT OVR mice from constitutive [14C]-2-deoxyglucose experiments. Data expressed as mean ± s.e.m. *denotes 
p<0.05, **denotes p<0.01 significant difference from males of same genotype (t-test with Bonferroni correction). There was no significant effect of 










Table A1.2 Plasma variables in mice from 8-OH-DPAT [14C]-2-deoxyglucose experiments T69 
 
 Male 
 Saline 8-OH-DPAT 
 Wt hSERT OVR Wt hSERT OVR 
Glucose (mg/ml) 9.03 ± 0.61 7.28 ± 0.80 6.74 ± 0.40* 4.76 ± 0.28* 
[14C] (nCi/ml) 77.47 ± 4.53 75.69 ± 8.55 53.64 ± 4.39 32.2 ± 3.94*  
[14C]:[glucose] ratio (nCi/mg) 8.41 ± 0.65 11.89 ± 1.95 8.05 ± 0.73 6.67 ± 0.73* 
 
 Female 
 Saline 8-OH-DPAT 
 Wt hSERT OVR Wt hSERT OVR 
Glucose (mg/ml) 6.52 ± 0.44 7.68 ± 0.49 7.89 ± 0.31* 7.51 ± 0.45 
[14C] (nCi/ml) 96.05 ± 13.57 138.48 ± 18.12 53.49 ± 9.06* 68.04 ± 9.16* 
[14C]:[glucose] ratio (nCi/mg) 15.34 ± 2.11 18.02 ± 2.41 5.66 ± 1.12** 9.75 ± 1.54 ** 
 
Plasma data from male and female hSERT over-expressing and wild-type mice from LCMRglu response to 8-OH-DPAT study. *denotes p<0.05, 









Table A1.3 Plasma variables in mice from DOI  [ 14C]-2-deoxyglucose experiments T70 
 
 Male 
 Wild-type hSERT OVR 
 Saline DOI Saline DOI 
[14C] (nCi/ml) 71.2  ± 5.4 76.4 ± 9.6 71.2 ± 8.6 67.6 ± 9.1 
Glucose (mg/ml) 9.4 ± 1.1 8.2 ± 1.2 8.2 ± 1.0 6.17 ± 0.7 
[14C]:[glucose] ratio (nCi/mg) 8.2 ± 0.6 9.6 ± 0.8 10.0 ± 1.6 11.1 ± 1.3 
 
 Female 
 Wild-type hSERT OVR 
 Saline DOI Saline DOI 
[14C] (nCi/ml) 96.0 ± 13.5 117.2 ± 22.3 154.6 ± 25.5 143.5 ± 21.2 
Glucose (mg/ml) 6.5 ± 0.4 7.4 ± 0.4 7.7 ± 0.5 7.68 ± 0.5 
[14C]:[glucose] ratio (nCi/mg) 14.8 ± 2.0 16.8 ± 3.8 19.9 ± 2.5 19.9 ± 2.5 
 
Plasma data from male and female hSERT OVR and Wt mice from LCMRglu response to DOI study. There was no significant difference in any 











Table A1.4 Plasma variables from animals in CP 94,2 53  [14C]-2-deoxyglucose experiments 71 
 
 Male 
 Saline 8-OH-DPAT 
 Wt hSERT OVR Wt hSERT OVR 
Glucose (mg/ml) 9.03 ± 0.61 7.28 ± 0.80 7.56 ± 0.58 6.03 ± 0.23 
[14C] (nCi/ml) 77.47 ± 4.53 75.69 ± 8.55 52.32 ± 5.89 42.96 ± 2.80  
[14C]:[glucose] ratio (nCi/mg) 8.41 ± 0.65 11.89 ± 1.95 7.21 ± 0.93 7.20 ± 0.53 
 
 Female 
 Saline 8-OH-DPAT 
 Wt hSERT OVR Wt hSERT OVR 
Glucose (mg/ml) 6.52 ± 0.44 7.68 ± 0.49 6.56 ± 0.21 6.61 ± 0.42 
[14C] (nCi/ml) 96.05 ± 13.57 138.48 ± 18.12 130.62 ± 14.52 143.52 ± 21.17 
[14C]:[glucose] ratio (nCi/mg) 15.34 ± 2.11 18.02 ± 2.41 20.22 ± 2.53 22.74 ± 3.83  
 
Plasma data from hSERT over-expressing and wild-type animals in CP 94,253 LCMRglu study. Data shown as mean ± s.e.m. There was no 
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ALTERED CEREBRAL GLUCOSE METABOLISM IN THE RESPONSE TO DOI 
IN SEROTONIN TRANSPORTER OVER-EXPRESSING MICE 
 
N. Dawson, L. Ferrington, H.J. Olverman, A.J. Harmar and P.A.T Kelly, Division of 
Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ. 
 
Genetic variation leading to altered serotonin transporter (SERT) expression is a 
predisposing factor in mood disorders (Pezawas et al., 2005). Previous studies have 
used a novel strain of genetically engineered mice, which over-express human SERT 
(Jennings et al., 2003), to explore the role of theransporter in determining 
serotonergic neuronal function. In this study we have used the same transgenic strain 
and applied the 2-deoxyglucose autoradiographic imaging technique to further 
investigate altered postsynaptic 5-HT2 receptor function in these animals when 
challenged with DOI.  
 
Wild-type and transgenic, CBAxC57Bl6, male mice (27g-39g) were injected i.p. 
with DOI (25mg.kg-1, n = 7 from each genotype) or saline (wild-type, n = 11; 
transgenic, n = 12). Local cerebral glucose utilisaon (LCMRglu) was measured 15 
min. later by semi-quantitative [14C]-2-deoxyglucose autoradiography in 48 brain 
regions of interest (ROI) (Kelly et al., 2002). Data (mean ± s.e.m) were analysed 
using t-test with Bonferroni correction (p<0.05).  
 
Following acute saline there was no significant difference in LCMRglu, in any of the 
48 ROI observed, between wild-type and transgenic am ls. In wild type animals 
DOI produced widespread increases in LCMRglu (range 11% to 89%), which 
because of high intrinsic variability were significantly different from control in only 
6 of the 48 regions analysed. In contrast, there was no evidence for increased 
LCMRglu in DOI-treated transgenic mice. Indeed, in 5 brain regions DOI produced 
significant decreases in LCMRglu. Only one region, the lateral habenula, showed a 
non-significant increase in LCMRglu (20%). Following DOI, LCMRglu was 
consistently lower in transgenic animals when compared to wild type animals in 
every ROI analysed (range -22% to -50%), and was significantly lower in 15 of the 
48 ROI observed. 
 
These results suggest that a life-long increase in SERT expression alters the normal 
functional response of the endogenous serotonin systems to the 5-HT2 agonist DOI. 
A decrease in 5-HT2 functional activity is suggested, as LCMRglu altera ions are 
attenuated, in SERT over-expressing mice. 
 
Jennings, K. et al. (2003) Br. J. Pharmacol. 138, 176P. 
Kelly, S. et al. (2002). European Journal of Neuroscience 15, 945-952. 
Pezawas, L. et al (2005) Nature Neurosci. 8, 828-834. 
This work was funded by EC Grant LSHM-CT-2004-503474. 
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EVIDENCE FOR ALTERED 5-HT2, BUT NOT 5-HT1A, RECEPTOR FUNCTION 
IN MICE OVER-EXPRESSING THE HUMAN SEROTONIN TRANSPORTER 
 
N. Dawson, L. Ferrington, H.J. Olverman, A.J. Harmar and P.A.T Kelly, Division of 
Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ. 
 
Polymorphic variation in the human serotonin transporter (hSERT) gene, influencing 
SERT expression, is a predisposing factor in mood disor ers (Pezawas et al., 2005). 
Mice over-expressing hSERT have been used to explore the role of SERT in 
determining serotonergic neuronal function (Jennings et al 2003). Here we examine 
the effects of selective agonists for 5HT1A (8-OH-DPAT) and 5HT2 (DOI) receptors 
upon local cerebral glucose utilisation (LCMRglu) in this transgenic strain. 
 
Wild-type (Wt) and transgenic (Tg) (CBAxC57Bl6, male, 25g-39g) mice were 
injected i.p. with saline (n=11 Wt, 12 Tg), DOI (25mg.kg-1, both n=7) or 8-OH-
DPAT (10mg.kg-1, n=8 Wt, 7 Tg). LCMRglu was measured (15min post-DOI; 
10min post-8-OH-DPAT) by semi-quantitative [14C]-2-deoxyglucose imaging in 48 
brain regions of interest (ROI). Data (mean ± s.e.m) were analysed using t-test with 
Bonferroni correction (p<0.05). 
 
Following acute saline there was no significant difference in LCMRglu between Wt 
and Tg animals. In Wt animals 8-OH-DPAT produced 8 significant increases in 
LCMRglu, with increases (5%-78%) evident in every ROI. In Tg animals 8-OH-
DPAT produced a larger number (19) of significant increases, with increases (3%-
75%) evident in all ROI, but comparison of Wt and Tg animals revealed no 
significant difference in the LCMRglu response to 8-OH-DPAT. 
 
In Wt animals DOI produced significant increases in LCMRglu in 6 ROI, with 
increases (11%-89%) observed in all ROI. However, no significant increases in 
LCMRglu occurred in DOI-treated Tg mice. In fact, DOI produced significant 
decreases (-33% to -44%) in 5 ROI and LCMRglu was lower in Tg animals than Wt 
animals in every region (–22% to -50%) being significantly lower in 15 ROI . 
These results suggest that a life-long increase in SERT expression alters 5-HT2 but 
not 5-HT1A receptor function. 
 
Jennings, K. et al. (2003) Br. J. Pharmacol. 138, 176P 
Pezawas, L. et al (2005) Nature Neurosci. 8, 828-34 
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THE ACUTE CEREBRAL METABOLIC RESPONSE TO SEROTONIN 
TRANSPORTER TARGETING DRUGS IS ALTERED IN MICE OVER-
EXPRESSING THE HUMAN SEROTONIN TRANSPORTER 
 
L. Ferrington, N. Dawson, H.J. Olverman, A.J. Harmar and P.A.T Kelly, Division of 
Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ. 
 
Polymorphic variation in the human serotonin transporter (hSERT) gene alters SERT 
expression and the efficacy of antidepressant drugs (Smeraldi et al., 1998), although 
the exact causal linkage is unclear. In this study we have examined the acute effects 
of drugs targeted at SERT (citalopram and MDMA) in hSERT over-expressing mice 
(Jennings et al., 2003) in order to determine the link between SERT and general 
brain function as reflected by local cerebral glucose utilisation (LCMRglu).  
 
Wild-type (Wt) and transgenic (Tg)(CBAxC57Bl6, male, 25g-38g) mice were 
injected i.p. with saline (n=11 Wt, 12 Tg), citalopram (10mg.kg-1, n=6 Wt, 8 Tg) or 
MDMA (30mg.kg-1, n=8 Wt, 10 Tg). LCMRglu was measured (10min post-
citalopram; 15min post-MDMA) by semi-quantitative [14C]-2-deoxyglucose imaging 
in 48 brain regions of interest (ROI). Data (mean ± s.e.m) were analysed using 2-
way-ANOVA with Bonferroni correction (p<0.05). 
 
There was no significant difference in LCMRglu betwen saline-treated Wt and Tg 
animals. Despite a trend toward increased LCMRglu in citalopram-treated Wt mice 
(max 38%) there was no significant difference from control. However, in Tg mice 
citalopram produced significant increases in 29 ROI (max 70%), although no 
significant drug x transgene interaction was found for any ROI. 
 
Despite trends for both increases (max 22%) and decreases (max -20%) in MDMA-
treated Wt mice there was no significant difference from control. In Tg mice, 
however, MDMA produced 27 significant increases (max 81%) and no decreases in 
LCMRglu. The LCMRglu response to MDMA was consistently higher in Tg 
compared to Wt mice (5%-38%), with a significant drug x transgene interaction in 7 
ROI. 
 
These results suggest that a life-long increase in SERT expression alters the 
functional response to drugs which acutely alter SERT activity. 
 
Smeraldi E, et al. (1998) Molecular Psychiatry. 3, 508-511. 
Jennings K, et al. (2003) Br. J. Pharmacol. 138,176P. 
 
This work was funded by EC Grant LSHM-CT-2004-503474. Mr N. Dawson is 








Dawson et al (2007) British Neuroscience Assoc. Abstr., 19, P28.07 
 
HIPPOCAMPAL 5-HT1A RECEPTOR BINDING IS DECREASED IN MICE 
OVER-EXPRESSING THE HUMAN SEROTONIN TRANSPORTER 
 
N. Dawson, L. Ferrington, H.J. Olverman, A.J. Harmar and P.A.T Kelly, Division of 
Neuroscience, University of Edinburgh, Edinburgh, EH8 9JZ. 
 
Polymorphic variation in the human serotonin transporter (hSERT) gene, influencing 
SERT expression, is a predisposing factor in mood disor ers (Pezawas et al., 2005).  
Previous studies using a novel strain of genetically engineered mice, which over-
express hSERT, suggest that 5-HT1A receptor function may be altered in these 
animals (Jennings et al., 2004). Here we use the same strain of mice to further 
investigate the effect of increased SERT expression on 5-HT1A receptor 
pharmacology using [3H]WAY 100,635 radioligand binding autoradiography.  
 
5-HT1A receptor binding was characterised in 6 wild-type (Wt) and 6 transgenic (Tg) 
mice (CBAxC57Bl6 background, male, 25g-39g) using 3nM [3H]WAY100,635 
(Preece et al., 2004). Binding was measured in 48 brain regions of interest (ROI) and 
data (mean ± s.e.m) were analysed using t-test (p<0.05).  
 
[3H]WAY100,635 binding was significantly decreased in subfields of the dorsal 
(CA3, -16%; dentate gyrus, -30%) and ventral (dentat  PO,-19%) hippocampus in Tg 
compared to Wt animals. Binding was not significantly different between Tg and Wt 
animals in any other ROI. 
 
These results suggest that a life-long increase in SERT expression alters 5-HT1A 
binding in specific hippocampal subfields. Our data lso suggest that the previously 
reported alteration in 5-HT1A autoreceptor function (Jennings et al., 2004) in these 
animals is not due to altered 5-HT1A autoreceptor pharmacology, as 5-HT1A binding 
was unaltered in the raphé of these animals. 
 
Jennings, K. et al (2004) Proc. of the BPS ( pA2online) 2, 010P 
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Preece, M.A. et al (2004) Neuroscience 123, 725-732. 
 
This work was funded by EC Grant LSHM-CT-2004-503474. Mr N. Dawson is 
funded by an MRC studentship. 
 
 
 
 
 
 
